

3F



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication: **19.02.2003 Bulletin 2003/08**
 (51) Int Cl.7: **C12Q 1/68, A01K 67/027**
 (21) Application number: **02255229.3**
 (22) Date of filing: **26.07.2002**

<p>(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR Designated Extension States: AL LT LV MK RO SI</p> <p>(30) Priority: 27.07.2001 GB 0118354 07.02.2002 GB 0202883</p> <p>(71) Applicant: WARNER-LAMBERT COMPANY Morris Plains, New Jersey 07950 (US)</p> <p>(72) Inventors: • Brooksbank, Robert Alan Cambridgeshire, CB1 3AW (GB)</p>	<ul style="list-style-type: none"> • Dixon, Alistair Kerr, Cambridgeshire, CB1 2LL (GB) • Lee, Kevin, c/o Pfizer Limited UK Sandwich, Kent CT13 9NJ (GB) • Pinnock, Robert Denham, Pfizer Global Res. and Dev Ann Arbor, MI 48105 (US) <p>(74) Representative: Hayles, James Richard et al UK Patent Department, Pfizer Limited, Ramsgate Road Sandwich, Kent CT13 9NJ (GB)</p>
--	--

(54) **Identification and use of molecules implicated in pain**

(57) The invention relates to the use of:

- (a) an isolated gene sequence that is down-regulated in the spinal cord of a mammal in response to mechanistically distinct first and second models of neuropathic or central sensitization pain;
- (b) an isolated gene sequence comprising a nucleic acid sequence of any of Tables I to VI;
- (c) an isolated gene sequence having at least 80% sequence identity with a nucleic acid sequence of any of Tables I to VI;
- (d) an isolated nucleic acid sequence that is hybridizable to any of the gene sequences according to (a), (b) or (c) under stringent hybridisation conditions;
- (e) a recombinant vector comprising a gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (f) a host cell containing the vector according to (e);
- (g) a non-human animal having in its genome an introduced gene sequence or nucleic acid sequence or a removed or down-regulated gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (h) an isolated polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence encoded by a nucleotide sequence according to any one of (a) to (d), or a variant polypeptide thereof with sequential amino acid deletions from the C terminus and/or the N-terminus;
- (i) an isolated polypeptide encoded by a nucleotide sequence according to any one of (a) to (d); or
- (j) an isolated antibody that binds specifically to a polypeptide according to (h) or (i);

in the screening of compounds for the treatment of pain, or for the diagnosis of pain.

The invention also relates to the use of naturally occurring compounds such as peptide ligands of the expression products of the above gene sequences and their associated signal transduction pathways for use in the treatment of pain.

EP 1 284 298 A2

Description**FIELD OF THE INVENTION**

[0001] The present invention relates to nucleic acids, their expression products and pathways involved in pain, and their use in screening for molecules that can alleviate pain. The invention further relates to methods for the assay and diagnosis of pain in patients.

BACKGROUND TO THE INVENTION

[0002] Pain is currently classified into four general types. Post-operative acute pain can be successfully treated with existing pain medications of e.g. the opioid and non-steroidal anti-inflammatory (NSAID) types, and is usually short-term and self-limiting. A second type of pain, present e.g. in cancer and arthritis, is also responsive to medication initially with a NSAID and in its later stages with opioids. Neuropathic pain arises from damage to the central or peripheral nerve systems, and is more effectively treated with antidepressants or anticonvulsants. A fourth type of pain called central sensitization results from changes in the central nervous system as a result of chronic pain, these changes often being irreversible and difficult to treat. Nerve pain from shingles or diabetes falls into this and the neuropathic category. Changes occur where pain is at first poorly controlled and gradually progress to the point where a person is sensitive to stimuli which would not normally cause pain, for example a light touch. People with pain of this kind often describe a widening of the pain area to include areas which had originally not been injured or which were thought not to be involved in pain. This classification is, however based on clinical symptoms rather than on the underlying pain mechanisms.

[0003] Opiates such as morphine belong to a traditional class of pain-relieving compounds that are now recognized as binding to opiate receptors. Naturally occurring polypeptides have also been found to have opiate-like effects on the central nervous system, and these include β -endorphin, met-enkephalin and leu-enkephalin.

[0004] Salicin was isolated at the beginning of the 19th century, and from that discovery a number of NSAIDs such as aspirin, paracetamol, ibuprofen, flurbiprofen and naproxen were developed. NSAIDs are by far the most widely used pain-relieving compounds, but can exhibit side effects, in particular irritation of the GI tract that can lead to the formation of ulcers, gastrointestinal bleeding and anemia.

[0005] Interest in the neurobiology of pain is developing: see a colloquium sponsored by the US National Academy of Sciences in December 1998 concerning the neurobiology of pain and reviewed in *The Scientist* **13**[1], 12, 1999. Many pain mechanisms were discussed including the role of the capsaicin receptors in pain, (M.J. Caterina *et al.*, *Nature*, **389**, 816-824, 1997). Large dosages of capsaicin were reported to disable that receptor, (W.R. Robbins *et al.*, *Anesthesia and Analgesia*, **86**, 579-583, 1998). Additionally, a tetrodotoxin-resistant sodium channel found in small diameter pain-sensing neurons (PN3) was discussed (A.N. Akopian *et al.*, *Nature*, **379**, 257-262, 1986) and L. Sanguameswaran *et al.*, *Journal of Biological Chemistry*, **271**, 953-956, 1996). Its involvement in transmission and sensitization to pain signals has been reported, (S.D. Novakovic *et al.*, *Journal of Neuroscience*, **18**, 2174-2187, 1998). A further tetrodotoxin-resistant sodium channel has been reported (S. Tate *et al.*, *Nature Neuroscience*, **1**, 653-655 1998).

[0006] Second messenger systems have also been shown to be important since knockout-mice lacking protein kinase C (PKC) γ were reported to respond to acute pain e.g. from a hot surface, but not to respond to neuropathic pain when their spinal nerves are injured (Malmberg *et al.*, *Science*, **278**, 279-283 (1997).

[0007] Present methods for identifying novel compounds that relieve pain of one or more of the types indicated above suffer from the defect that they are dependent either on the relatively limited number of receptors known to be involved in pain or on the empirical identification of new receptors which is an uncertain process. In relation to known receptors, for example the opioid receptor, research directed to improved compounds offers the possibility of screening compounds that have a better therapeutic ratio and fewer side effects. This does not lead naturally to compounds for different pain receptors that have new modes of action and new and qualitatively different benefits. Even when newly identified additional receptors are taken into account, known receptors revolve around tens of gene products. However, there are between 30,000 and 40,000 genes in the genome of an animal and more of them are concerned with nervous system function than with peripheral function. We therefore concluded that a large number of receptors and pathways are important to the transduction of pain, but up to now have remained unknown.

SUMMARY OF THE INVENTION

[0008] It is an object of the invention to provide sequences of genetic material for which no role in pain has previously been disclosed, and which are useful, for example, in:

- identifying metabolic pathways for the transduction of pain

- identifying from said metabolic pathways compounds having utility in the diagnosis or treatment of pain
 - producing proteins and polypeptides with a role in the transduction of pain;
 - producing genetically modified non-human animals that are useful in the screening of compounds having utility in the treatment or diagnosis of pain.
- 5 • Identifying ligand molecules for receptors involved in said metabolic pathways and having utility in the treatment of pain.

[0009] It is yet a further object of the invention to provide research tools, for example non-human animals and microorganisms, that can be used in screening compounds for pharmacological activity, especially pain-reducing activity.

10 [0010] The present invention is based on sequences that are down-regulated in two models of chronic pain, namely streptozocin-induced diabetes and chronic constrictive injury (CCI) to a nerve leading to the spine, for example the sciatic nerve.

[0011] In one aspect, the invention relates to the use in the screening of compounds that are effective in the treatment of pain, or in the diagnosis of pain, of:

15 (a) an isolated gene sequence that is down regulated in the spinal cord of a mammal in response to first and second models of pain, for example in response to streptozocin-induced diabetes and in response to a chronic constrictive injury to a nerve leading into the spine;

20 (b) an isolated gene sequence having at least 80% sequence identity with any of the nucleic acid sequences of Tables I - VI, preferably 85% sequence identity, more preferably 90%, increasingly preferably 95%, most preferably 99%.

25 (c) an isolated nucleic acid sequence comprising a sequence that is hybridizable to any of the gene sequences according to (a) or (b) under stringent hybridisation conditions;

30 (d) a recombinant vector comprising any of the gene sequences according to (a) to (c);

35 (e) a host cell containing the vector according to (d);

40 (f) a non-human animal, for use in the screening of compounds that are effective in the treatment of pain, or in the diagnosis of pain, having in its genome an introduced gene sequence or a removed or down-regulated nucleotide sequence, said sequence becoming down-regulated in the spinal cord of a mammal in response to first and second models of pain, particularly neuropathic or sensitisation pain, for example in response to streptozocin-induced diabetes and in response to a chronic constrictive injury to a nerve leading into the spine;

45 (g) an isolated polypeptide containing an amino acid sequence at least 90% identical to an amino acid sequence encoded by a nucleotide sequence according to any one of (a) to (d), or a variant thereof with sequential amino acid deletions from the C terminus and/or the N-terminus; or

50 (h) an isolated antibody that binds specifically to the isolated polypeptide according to (g).

55 [0012] The invention further provides a compound that is useful in the treatment or diagnosis of pain and that modulates the action of an expression product of a gene sequence that becomes down-regulated in the spinal cord of a mammal in response to first and second models of pain, for example being down-regulated both in response to streptozocin induced diabetes and in response to chronic constrictive injury to a nerve leading into the spine.

60 [0013] The invention also relates to the use of naturally occurring compounds such as peptide ligands of the expression products of the above gene sequences and their associated signal transduction pathways for the treatment of pain.

DESCRIPTION OF PREFERRED EMBODIMENTS

65 DEFINITIONS

[0014] Within the context of the present invention:

- 70 "Comprising" means consisting of or including. Thus nucleic acid comprising a defined sequence includes nucleic acid that may contain a full-length gene or full-length cDNA. The gene may include any of the naturally occurring regulatory sequence(s), such as a transcription and translation start site, a promoter, a TATA box in the case of eukaryotes, and transcriptional and translational stop sites. Further, nucleic acid comprising a cDNA or gene may include any appropriate regulatory sequences for the efficient expression thereof *in vitro*.
- 75 "Isolated" requires that the material be removed from its original environment (e.g. the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or a peptide present in a living animal is not isolated, but the same polynucleotide or peptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide can be part of a vector and/or such polynucleotide or peptide can

be part of a composition, and still be isolated in that the vector or composition is not a part of its natural environment.

- "Mechanistically distinct" in relation to pain models implies that the pain is induced by mechanisms that differ in kind rather than being variants of a similar pain model. Thus diabetic pain and chronic constrictive pain models are mechanistically distinct, whereas spinal nerve ligation models and sciatic nerve ligation models which both work by ligation are not.

- "Purified" does not require absolute purity; instead it is intended as a relative definition. Purification of starting materials or natural materials from their native environment to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

- "Nucleic acid sequence" or "gene sequence" means a sequence of nucleotides or any variant or homologue thereof, or truncated or extended sequence thereof, and is preferably indicated by a Genbank accession number. Also within the scope of the present invention are down-regulated nucleic acid sequences which encode expression products which are components of signaling pathways. This invention also includes any variant or homologue or truncated or extended sequence of the down-regulated nucleotide sequence. Also within the scope of the present invention, the term "nucleic acid(s) product", or "expression product" or "gene product" or a combination of these terms refers without being biased, to any, protein(s), polypeptide(s), peptide(s) or fragment(s) encoded by the down-regulated nucleotide sequence.

- "Operably linked" refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or an enhancer is operably linked to a coding sequence if it regulates the transcription of the coding sequence. In particular, two DNA molecules (such as a polynucleotide containing a promoter region, and a polynucleotide encoding a desired polypeptide) are said to be "operably linked" if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation and (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide.

"Gene product" refers to polypeptide - which is interchangeable with the term protein - which is encoded by a nucleotide sequence and includes single-chain polypeptide molecules as well as multiple-polypeptide complexes where individual constituent polypeptides are linked by covalent or non-covalent means. Polypeptides of the present invention may be produced by synthetic means (e.g. as described by Geysen *et al.*, 1996) or by recombinant means.

The terms "variant", "homologue", "fragment", "analogue" or "derivative" in relation to the amino acid sequence for the polypeptide of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant polypeptide has the native gene product activity. In particular, the term "homologue" covers homology with respect to structure and/or function. With respect to sequence homology, there is at least 90%, more preferably at least 95% homology to an amino acid sequence encoded by the relevant nucleotide sequence shown in Tables I - VI, preferably there is at least 98% homology.

Typically, for the variant, homologue or fragment of the present invention, the types of amino acid substitutions that could be made should maintain the hydrophobicity/hydrophilicity of the amino acid sequence. Amino acid substitutions may include the use of non-naturally occurring amino acid analogues.

In addition, or in the alternative, the protein itself could be produced using chemical methods to synthesize a polypeptide, in whole or in part. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g. Creighton (1983) *Proteins Structures and Molecular Principles*, WH Freeman and Co., New York, NY, USA). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g. the Edman degradation procedure).

Direct peptide synthesis can be performed using various solid-phase techniques (Roberge JY *et al* *Science* Vol 269 1995 202-204) and automated synthesis may be achieved, for example, using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Additionally, the amino acid sequence of a gene product, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with a sequence from other subunits, or any part thereof, to produce a variant polypeptide.

In another embodiment of the invention, a gene product natural, modified or recombinant amino acid sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of libraries for compounds and peptide agonists and antagonists of gene product activity, it may be useful to encode a chimeric gene product expressing a heterologous epitope that is recognised by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a gene product sequence and the heterologous protein sequence, so that the gene product may be cleaved and purified away from the heterologous moiety.

The gene product may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals (Porath J, Protein Expr Purif Vol 3 1992 p263-281), protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, WA, USA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego, CA, USA) between the purification domain and the gene product is useful to facilitate purification.

- "Pain" includes chronic pain, neuropathic pain, pain arising from central sensitisation, and in particular diabetic pain.
- "Stringent hybridization conditions" is a recognized term in the art and for a given nucleic acid sequence refers to those conditions which permit hybridization of that sequence to its complementary sequence and closely homologous sequences. Conditions of high stringency may be illustrated in relation to filter-bound DNA as for example 2X SSC, 65°C (where SSC = 0.15M sodium chloride, 0.015M sodium citrate, pH 7.2), or as 0.5M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1mM EDTA, at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds, 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons Inc., New York, at p. 2. 10.3). Hybridization conditions can be rendered highly stringent by raising the temperature and/or by the addition of increasing amounts of formamide, to destabilize the hybrid duplex of non-homologous nucleic acid sequence relative to homologous and closely homologous nucleic acid sequences. Thus, particular hybridisation conditions can be readily manipulated, and will generally be chosen depending on the desired results.
- "Variants or homologues" include (a) sequence variations of naturally existing gene(s) resulting from polymorphism (s), mutation(s), or other alteration(s) as compared to the above identified sequences, and which do not deprive the encoded protein of function (b) recombinant DNA molecules, such as cDNA molecules encoding genes indicated by the relevant Genbank accession numbers and (c) any sequence that hybridizes with the above nucleic acids under stringent conditions and encodes a functional protein or fragment thereof.

IDENTIFIED SEQUENCES

[0015] The inventors have identified nucleotide sequences that give rise to expression products listed in Tables I - VI, that become differentially expressed in the spinal cord in response to two distinct chronic pain stimuli, for example neuropathic and/or central sensitization pain stimuli, and that are believed to be involved in the transduction of pain. In Tables I - VI, * denotes more preferred nucleic acid sequences and ** denotes most preferred nucleic acid sequences. These nucleic acid sequences have not previously been implicated in the transduction of pain.

[0016] The validity of the present experimental procedure was confirmed by the fact that nucleotide sequences were obtained as a result of the investigation whose function in the transduction of pain has been previously confirmed and established. These nucleic acid sequences are not part of this invention. Any of the nucleic acid sequences and expression products can be used to develop screening technologies for the identification of novel molecules for the prevention or treatment of pain. These screening technologies could also be used to ascribe new pain therapeutic indications to molecules that have not previously been identified as being useful for the prevention or treatment of pain. Furthermore, the said nucleic acid sequences can be used as diagnostic tools and for the development of diagnostic tools.

Table I -

Sequences whose expression products are kinases					
Expression product or name (Reference)	Rat Accession Number	Mouse accession number	Human Accession Number	Reaction	Assay
Pyruvate kinase, M1 and M2 subunits (Refs : 1 - 2)	M24359 (SEQ ID No's 1-3)	X97047	X56494	Tissue-specific promoter; Carbohydrate kinase	Kinase

Table II -

Sequences whose expression products are receptors					
Expression Product or Name (Reference)	Rat Accession Number	Mouse accession Number	Human Accession Number	Reaction	Assay
Dopamine receptor D.sub. 1** (Ref : 3)	I58000 (SEQ ID NO 4)			Dopamine receptor	Receptor
Putative GABA-B1a receptor** (Ref : 4)		AF114168 (SEQ ID No's 5-6)		GABA-B Receptor	Receptor

Table III -

Sequences whose expression products are transporters					
Expression Product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Differentiation-associated Na-dependent inorganic phosphate cotransporter (Ref : N/A)	AF271235(SEQ ID NO's 7-8)			Trans-membrane phosphate transport	Transporter
Putative vacuolar assembly protein VSP41 gene (Ref : N/A)	U87309		AAM47563. 1 (SEQ ID No 9)	Vacuolar assembly and traffic	Transporter

Table IV -

Sequences whose expression products are G-protein coupled receptor proteins					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Function	Assay
Git1 (G-protein-coupled receptor kinase-interactor 1 ; GPCR kinase-associated ADP-ribosylation factor) (Ref : 5)	AF085693 (SEQ ID NO 10-11)			Regulation of activity of ARF6 in phosphatidylinositol 3-kinase signalling pathways ; β 2 adrenergic receptor regulation	Ligand binding

Table V -

Sequences whose expression products are DNA-binding proteins					
Expression Product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Putative histone H3.3A (Ref: 6)		X91866	M11354 (SEQ ID NO 12-13)	DNA binding	DNA binding

Table VI -

Sequences whose expression products are other enzymes					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
3-Hydroxy 3-methylglutaryl coenzyme A synthase, cytosolic * (Ref: 7)	X52625 (SEQ ID No's 14-15)			Cholesterol biosynthesis	Ligase
Acyl-CoA synthetase II, brain (Ref : N/A)	D360666 (N/A)			Fatty acid metabolism	Ligase
Farnesyl diphosphate synthase ** (Ref : 8)	M34477 (Seq ID No's 16-17)			Isoprene biosynthesis	Ligase
Bendless protein (Ref : N /A)	AB032739 (Seq ID No's 18-19)		E12457	Protein degradation	Ligase
fatty acid synthase (Ref: 9)	X62888 (SEQ ID No's 20-21)			Fatty acid synthesis	Ligase
Glutamine synthetase (EC 6.3.1.2) ** (Ref : 10)	M91652 (SEQ ID NO's 22-23)			Amino acid metabolism	Ligase
Putative seryl-tRNA synthetase (Ref No : 11)			X91257 (SEQ ID NO's 24-25)	Ligase	Ligase
Enolase, alpha alpha, non-neuronal (NNE) (REF NO 12)	X02610	X52379	M14328 (SEQ ID NO's 26-27)	Glycolysis	Lyase
Aldose reductase, lens (AREC 11.1.21) (REF : 13)	X05884 (SEQ ID NO's 28-29)			Reduces carbonyl	Oxidoreductase
Cytochrome-c oxidase I, mitochondrial (Ref : 14)	S79304 (SEQ ID NO's 30-31)			Mitochondrial energy metabolism	Oxidoreductase

EP 1 284 298 A2

Table VI - (continued)

Sequences whose expression products are other enzymes					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Lactate dehydrogenase-B (LDH-B) (Ref : 15)	U07181 (SEQ ID NO's 32-33)	X51905	Y00711	Glycolysis	Oxidoreductase
Putative cytochrome c oxidase VIB (EC 1.9.3.1) (Ref : 16)			X13923 (SEQ ID NO's 34-35)	Mitochondrial energy metabolism	Oxidoreductase
Putative NADH: ubiquinone oxidoreductase PG IV subunit (Ref : 17)			AF044953 (SEQ ID No's 36-37)	Mitochondrial energy metabolism	Oxidoreductase
Putative succinate dehydrogenase flavoprotein (Ref: N/A)		AF095938 (SEQ ID No's 38-39)	AF171022	TCA cycle	Oxidoreductase
Putative ubiquinol-cytochrome-c reductase (EC 1.10.2.2) core protein II (REF: 18)			J04973 (SEQ ID No's 40-41)	Mitochondrial energy metabolism	Oxidoreductase
Stearoyl-coA desaturase 2 * (Ref: N/A)	AB032243 (SEQ ID NO's 42-43)	M26270		Fatty acid biosynthesis	Oxidoreductase
Ribophorin I * (Ref: 19)	X05300 (SEQ ID No's 44-45)			Glycosylation	Transferase
Sulfotransferase-like protein (REF : 20)	AF188699 (SEQ ID No's 46-47)			Transferase	Transferase
ATP synthase, H+, alpha subunit, mitochondrial (EC 3.6.1.34) (Ref: N/A)	X56133 (SEQ ID No's 48-49)			Mitochondrial energy metabolism	Hydrolase
F1Fo ATPase delta subunit (REF : 21)	U00926 (SEQ ID No's 50-51)			Mitochondrial energy metabolism	Hydrolase
Putative dihydropyrimidinase related protein * (REF: 22)			D78013 (SEQ ID NO's 52-53)	Pyrimidine degradation	Hydrolase
Heat shock protein 90 (REF : 23)	S45392 (SEQ ID NO's 114-115)	M18186	M16660	Cell protection	Hydrolase

Table VI - (continued)

Sequences whose expression products are other enzymes					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Myelin basic protein S (MBP S) (REF :24)	K00512 (SEQ ID No 54)			Myelin structural protein	Ligand binding
Transferrin (Ref 25)	D38380 (SEQ ID No's 55-56)			Iron transport	Ligand binding
Neurofilament, light molecular weight (NF-L) (Ref : 26)	AF031880 (SEQ ID No's 57-58)			Cytoskeleton	Ligand binding
Myelin-associated glycoprotein (MAG) (Ref : 27)	M1680 (SEQ ID No's 59-60)	M31811		Cell adhesion molecule for postnatal neural development	Ligand binding
NF-M middle molecular weight neurofilament protein (Ref : 28)	M18628 (SEQ ID No's 61-62)			Cytoskeleton	Ligand binding
Neuro-degeneration associated-protein 1 (Ref: 29)	D32249 (SEQ ID No's 63-64)			Protein sorting; synaptic communication and plasticity	Ligand binding
S-100 protein β -subunit (REF: 30)	X01090 (SEQ ID No 65)			Zinc and calcium binding	Ligand binding
Microtubule-associated protein 1b (Map 1b) (Ref: 31)	X60370 (SEQ ID No's 66-67)		L06237	Cytoskeleton protein, neuronal growth/regeneration; microtubule binding protein	Ligand binding
Putative cdc 37 homolog (Ref: 32)	D26564 (Seq ID No's 68-69)			Cell signalling ; cell cycle protein	Ligand binding
Putative ras-related protein Rab-5c (Ref : 33)			U11293 (SEQ ID No's 70-71)	Small GTP binding protein	Ligand binding
Putative gelsolin (Ref: 34)		J04953 (SEQ ID No's 72-73)		Cytoskeleton protein	Ligand binding
Cd81 antigen (target of antiproliferative antibody 1) (Ref : 35)	U19894 (SEQ ID No's 74-75)	X59047	M33680	Regulator for neuron-induced astrocyte differentiation; microglial effector functions	Ligand binding

Table VI - (continued)

Sequences whose expression products are other enzymes					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Mobp81 (Myelin-associated/Oligodendrocytic basic protein 81) (Ref : 36)	X87900 (SEQ ID No's 76-77)			Myelin compaction	Ligand binding
Syntaxin binding protein n-sec1, sec1 homolog (Ref : N/A)			BC002869 (Seq ID No's 78-79)	Neuro-transmission	Ligand binding
Alpha-internexin (Ref: 37)	M73049 (SEQ ID No's 80-81)			Cytoskeleton protein; neuronal intermediate filament that can self-assemble	Ligand binding
Putative β -sarcoglycan A3b (Ref: N/a)		AB024921 (SEQ ID No's 82-83)		Cytoskeleton protein	Ligand binding
CGI-78 protein (Ref: 38)	AF151835		AF151835 (SEQ ID No's 84-85)	Unknown	Ligand binding
KIAA0143 (Ref: 39)			D63477 (SEQ ID NO's 86-87)	Transmembrane protein	Ligand binding
Septin 2 (KIAA0128 ; Ref 39)			D50918 (SEQ ID No's 88-89)	GTPase; cytokinesis	Ligand binding
Nucleobindin (Ref: 40)	Z36277 (SEQ ID No's 90-91)			Unknown	Ligand binding
Myelin protein SR13 (Ref: 41)	M69139 (SEQ ID NO's 92-93)	S55427		Myelin structural protein	Ligand binding
B-Actin, cytoplasmic (Ref: 42)	V01217 (SEQ ID NO's 94-95)	X03672		Structural protein	Ligand binding
Ly6/neurotoxin (Lynx1) homolog (Ref: 43)		AF141377 (SEQ ID No's 96-97)		Neuro-transmitter modulator	Ligand binding
Astrocytic phosphoprotein; PFA 15 gene (Ref: N/A)	AJ243949 (SEQ ID NO's 98-99)	X86694		PKC substrate	Ligand binding
PLIC-1 (Ref: N/A)		AF177345 (SEQ ID NO 100-101)		Cytoskeleton interaction	Ligand binding
Nfx1 (tip associating protein (TAP) gene) (Ref: N/A)	AF093139 (SEQ ID NO's 102-103)	AF093140		Unknown	Logand binding

Table VI - (continued)

Sequences whose expression products are other enzymes					
Expression product or Name	Rat Accession Number	Mouse Accession Number	Human Accession Number	Reaction	Assay
Alpha-Crystallin B (Ref N/A)	U04320 SEQ ID NO's 104-105)	M73741	M28638	Stress response ; heat shock element	Ligand binding
Heat shock-like protein 70 kD (Ref : 44)	X70065 (SEQ ID No's 106-107)	U73744	Y00371	Stress response	Ligand binding
Tau microtubule-associated protein (Ref : 45)	X79321 (SEQ ID NO's 108-109)			Microtubule associated protein expressed in neurons	Ligand binding
Myelin, Schwann cell, Peripheral (P-0) (Ref : 46)	K03242 (SEQ ID No's 110-111)			Myelin structural protein	Ligand binding
B-Tubulin class 1 (Ref: 47)	AB011679 (SEQ ID NO's 112-113)	X04663	AF14139	Structural protein	Ligand binding
Putative ribonuclease III (Ref : N/A)			AF116910 (SEQ ID NO's 116-117)	RNA hydrolysis	Hydrolase

PRODUCTION OF POLYPEPTIDES AND NUCLEIC ACIDS

Vectors

[0017] Recombinant expression vectors comprising a nucleic acid can be employed to express any of the nucleic acid sequences of the invention. The expression products derived from such vector constructs can be used to develop screening technologies for the identification of molecules that can be used to prevent or treat pain, and in the development of diagnostic tools for the identification and characterization of pain. The expression vectors may also be used for constructing transgenic non-human animals.

[0018] Gene expression requires that appropriate signals be provided in the vectors, said signals including various regulatory elements such as enhancers/promoters from viral and/or mammalian sources that drive expression of the genes or nucleic acid sequences of interest in host cells. The regulatory sequences of the expression vectors used in the invention are operably linked to the nucleic acid sequence encoding the pain-associated protein of interest or a peptide fragment thereof.

[0019] Generally, recombinant expression vectors include origins of replication, selectable markers, and a promoter derived from a highly expressed gene to direct transcription of a downstream nucleotide sequence. The heterologous nucleotide sequence is assembled in an appropriate frame with the translation, initiation and termination sequences, and if applicable a leader sequence to direct the expression product into the periplasmic space, the extra-cellular medium or cell membrane.

[0020] In a specific embodiment wherein the vector is adapted for expressing desired sequences in mammalian host cells, preferred vectors will comprise an origin of replication from the desired host, a suitable promoter and an enhancer, and also any necessary ribosome binding sites, polyadenylation site, transcriptional termination sequences, and optionally 5'-flanking non-transcribed sequences. DNA sequences derived from the SV40 or CMV viral genomes, for example SV40 or CMV origin, early promoters, enhancers, and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

[0021] A recombinant expression vector used in the invention advantageously also comprises an untranscribed poly-

nucleotide region located at the 3' end of the coding sequence (ORF), this 3'-UTR (untranslated region) polynucleotide being useful for stabilizing the corresponding mRNA or for increasing the expression rate of the vector insert if this 3'-UTR harbours regulation signal elements such as enhancer sequences.

[0022] Suitable promoter regions used in the expression vectors are chosen taking into account the host cell in which the nucleic acid sequence is to be expressed. A suitable promoter may be heterologous with respect to the nucleic acid sequence for which it controls the expression, or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted. Preferred promoters are the LacI, LacZ, T3 or T7 bacteriophage RNA polymerase promoters, the lambda PR, PL and Trp promoters (see EP-0 036 776), the polyhedrin promoter, or the p10 protein promoter from *baculovirus* (kit Novagen; Smith *et al.*, (1983); O'Reilly *et al.* (1992)).

[0023] Preferred selectable marker genes contained in the expression recombinant vectors used in the invention for selection of transformed host cells are preferably dehydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicin or ampicillin resistance in *E. coli*, or Levamsaccharase for *Mycobacteria*, this latter marker being a negative selection marker.

[0024] Preferred bacterial vectors are listed hereafter as illustrative but not limitative examples: pQE70, pQE60, pQE-9 (Quiagen), pD10, phagescript, psiX174, p.Bluescript SK, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIA express).

[0025] Preferred bacteriophage recombinant vectors of the invention are P1 bacteriophage vectors such as described by Sternberg N.L. (1992;1994).

[0026] A suitable vector for the expression of any of the pain associated polypeptides used in the invention or fragments thereof, is a baculovirus vector that can be propagated in insect cells and in insect cell-lines. A specific suitable host vector system is the pVL 1392/1393 *baculovirus* transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N°CRL 1711) that is derived from *Spodoptera frugiperda*.

[0027] The recombinant expression vectors of in the invention may also be derived from an adenovirus. Suitable adenoviruses are described by Feldman and Steig (1996) or Ohno *et al.* (1994). Another preferred recombinant adenovirus is the human adenovirus type two or five (Ad 2 or Ad 5) or an adenovirus of animal origin (Patent Application WO 94/26914)

[0028] Particularly preferred retrovirus for the preparation or construction of retroviral *in vitro* or *in vivo* gene delivery vehicles include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, and Ross Sarcoma Virus. Other preferred retroviral vectors are those described in Roth *et al.* (1996), in PCT Application WO 93/25234, in PCT Application WO 94/06920, and also in Roux *et al.* (1989), Julian *et al.* (1992) and Nada *et al.* (1991).

[0029] Yet, another viral vector system that is contemplated is the Adeno Associated Viruses (AAV) such as those described by Flotte *et al.* (1992), Samulski *et al.* (1989) and McLaughlin *et al.* (1996).

Host cells expressing pain associated polypeptides

[0030] Host cells that endogenously express pain associated polypeptides or have been transformed or transfected with one of the nucleic acid sequences described herein, or with one of the recombinant vector described above, particularly a recombinant expression vector, can be used in the present invention. Also included are host cells that are transformed (prokaryotic cells) or are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

[0031] Preferred host cells used as recipients for the expression vectors used in the invention are the following:

(a) prokaryotic host cells: *Escherichia coli*, strains. (i.e. DH5- α , strain) *Bacillus subtilis*, *Salmonella typhimurium* and strains from species like *Pseudomonas*, *Streptomyces* and *Staphylococcus* for the expression of up and down-regulated nucleic acid sequence modulated by pain, characterized by having at least 80% sequence identity with any of the nucleic acid sequences of Tables I - VI. Plasmid propagation in these host cells can provide plasmids for transfecting other cells.

(b) eukaryotic host cells: HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), Cv 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL 1650; N°CRL 1651), Sf-9 cells (ATCC N°CRL 1711), C127 cells (ATCC N°CRL-1804), 3T3 cells (ATCC N°CRL-6361), CHO cells (ATCC N°CCL-61), human kidney 293 cells (ATCC N° 45504; N°CRL-1573), BHK (ECACC N°84100 501; N°84111301), PC12 (ATCC N° CRL-1721), NT2, SHSYSY (ATCC N° CRL-2266), NG108 (ECACC N°88112302) and F11, SK-N-SH (ATCC N° CRL-HTB-11), SK-N-BE(2) (ATCC N° CRL-2271), IMR-32 (ATCC N° CCL-127). A preferred system to which the nucleic acids of the invention can be expressed are

neuronal cell lines such as PC12, NT2, SHSY5Y, NG108 and F11, SK-N-SH, SK-N-BE(2), IMR-32 cell lines, COS cells, 3T3 cells, HeLa cells, 292 cells and CHO cells. The above cell lines could be used for the expression of any of the nucleic acid sequences of Tables I - VI.

[0032] When a nucleic acid sequence of any of Tables I - X is expressed using a neuronal cell line, the sequence can be expressed through an endogenous promoter or native neuronal promoter, or an exogenous promoter. Suitable exogenous promoters include SV40 and CMV and eukaryotic promoters such as the tetracycline promoter. The preferred promoter when pain associated molecules are endogenously expressed is an endogenous promoter. A preferred promoter in a recombinant cell line is the CMV promoter.

[0033] In a specific embodiment of the host cells described above, these host cells have also been transfected or transformed with a polynucleotide or a recombinant vector for the expression of a natural ligand of any of the nucleic acid sequences of any of Tables I - VI or a modulator of these expression products.

PROTEINS, POLYPEPTIDES AND FRAGMENTS

[0034] The expression products of the nucleic acid sequences of Tables I - VI or fragment(s) thereof can be prepared using recombinant technology, from cell lines or by chemical synthesis. Recombinant methods, chemical methods or chemical synthetic methods can be used to modify a gene in order to introduce into the gene product, or a fragment of the gene product, features such as recognition tags, cleavage sites or other modifications. For efficient polypeptide production, the endogenous expression system or recombinant expression system should allow the expression products to be expressed in a manner that will allow the production of a functional protein or fragment thereof which can be purified. Preferred cell lines are those that allow high levels of expression of polypeptide or fragments thereof. Such cell lines include cell lines which naturally express the nucleic acid sequence of Tables I - VI or common mammalian cell lines such as CHO cells or COS cells, etc, or more specific neuronal cell lines such as PC12. However, other cell types that are commonly used for recombinant protein production such as insect cells, amphibian cells such as oocytes, yeast and prokaryotic cell lines such as *E. coli* can also be used.

[0035] The expression products of Tables I - VI or fragments thereof can be utilized in screens to identify potential therapeutic ligands, either as a purified protein, as a protein chimera such as those produced in phage display, as a cell membrane (lipid or detergent) preparation, or in intact cells.

[0036] The invention also relates generally to the use of proteins, peptides and peptide fragments for the development of screening technologies for the identification of molecules for the prevention or treatment of pain, and the development of diagnostic tools for the identification and characterization of pain. These peptides include expression products of the nucleic acid sequences of Tables I - VI and purified or isolated polypeptides or fragments thereof having at least 90%, preferably 95%, more preferably 98% and most preferably 99% sequence identity with the any of the expression products of nucleic acid sequences of Tables I - VI. Expressed peptides and fragments of any of these nucleic acid sequences can be used to develop screening technologies for the identification of novel molecules for the prevention or treatment of pain. These screening technologies could also be used to ascribe new pain therapeutic indications to molecules, which have not previously been ascribed for the prevention or treatment of pain. Furthermore the said expressed peptides and fragments can be used as diagnostic tools and for the development of diagnostic tools.

SCREENING METHODS

[0037] As discussed above, we have identified nucleic acid sequences whose expression is regulated by pain, particularly chronic pain and more particularly diabetic pain. The expression products of these nucleic acids can be used for screening ligand molecules for their ability to prevent or treat pain, and particularly, but not exclusively, chronic pain. The main types of screens that can be used are described below. The test compound can be a peptide, protein or chemical entity, either alone or in combination(s), or in a mixture with any substance. The test compound may even represent a library of compounds.

[0038] The expression products of any of the nucleic acid sequences of Tables I - VI or fragments thereof can be utilized in a ligand binding screen format, a functional screen format or invivo format. Examples of screening formats are provided.

A) Ligand binding screen

[0039] In ligand binding screening a test compound with is contacted with an expression product of one of the sequences of Tables I - VI, and the ability of said test compound to interact with said expression product is determined, e.g. the ability of the test compound(s) to bind to the expression product is determined. The expression product can be a part of an intact cell, lipidic preparation or a purified polypeptide(s), optionally attached to a support, such as

beads, a column or a plate etc.

[0040] Binding of the test compound is preferably performed in the presence of a ligand to allow an assessment of the binding activity of each test compound. The ligand may be contacted with the expression product either before, simultaneously or after the test compound. The ligand should be detectable and/or quantifiable. To achieve this, the ligand can be labelled in a number of ways, for example with a chromophore, radioactive, fluorescent, phosphorescent, enzymatic or antibody label. Methods of labelling are known to those in the art. If the ligand is not directly detectable it should be amenable to detection and quantification by secondary detection, which may employ the above technologies. Alternatively the expression product or fragment thereof can be detectable or quantifiable. This can be achieved in a similar manner to that described above.

[0041] Binding of the test compound modifies the interaction of the ligand with its binding site and changes the affinity or binding of the ligand for/to its binding site. The difference between the observed amount of ligand bound relative to the theoretical maximum amount of ligand bound (or to the ligand bound in the absence of a test compound under the same conditions) is a reflection of the binding ability (and optionally the amount and/or affinity) of a test compound to bind the expression product.

[0042] Alternatively, the amount of test compound bound to the expression product can be determined by a combination of chromatography and spectroscopy. This can be achieved with technologies such as Biacore (Amersham Pharmacia). The amount of test compound bound to the expression product can also be determined by direct measurement of the change in mass upon compound or ligand binding to the expression product. Alternatively, the expression product, compound or ligand can be fluorescently labelled and the association of expression product with the test compound can be followed by changes in Fluorescence Energy Transfer (FRET).

[0043] The invention therefore includes a method of screening for pain alleviating compounds, comprising:

- a) contacting a test compound or test compounds in the presence of a ligand with an expression product of any of the nucleic acid sequences of Tables I - VI or with a cell expressing at least one copy of the expression product or with a lipidic matrix containing at least one copy of the expression product;
- b) determining the binding of the test compound to the expression product, and
- c) selecting test compounds on the basis of their binding abilities.

[0044] In the above method, the ligand may be added prior to, simultaneously with or after contact of the test compound with the expression product. Non limiting examples and methodology can be gained from the teachings of the *Molecular Probes handbook* and references therein (Molecular Probes, Inc., 4849 Pitchford Ave, Eugene, USA), *Methods in neurotransmitter receptor analysis* (Yamamura H., Enna, S.J., and Kuhar, M.J., Raven Press New York, the *Glaxo Pocket Guide to Pharmacology*, Dr. Michael Sheehan, Glaxo Group Research Ltd, Ware, Herts SG12 0DP), *Bylund DB and Murrin LC* (2000, Life Sciences, 67 (24) 2897-911), *Owricki JC* (2000, *J. biomol Screen* (5) 297-306), *Alberts et al* (1994, *Molecular Biology of the Cell*, 3rd Edn, Garland Publication Inc), *Butler JE*, (2000 *Methods* 22(1):4-23, *Sanberg SA* (2000, *Curr Opin Biotechnol* 11(1) 47-53), and *Christopoulos A* (1999, *biochem Pharmacol* 58(5) 735-48).

B) Functional screening

(a) Kinase assays

[0045] The expression product of any of the nucleic acid sequences of Tables I - VI which encode a kinase, and in particular the nucleic acid sequence listed in Table I, is amenable to screening using kinase assay technology.

[0046] Kinases have the ability to add phosphate molecules to specific residues in ligands such as binding peptides in the presence of a substrate such as adenosine triphosphate (ATP). Formation of a complex between the kinase, the ligand and substrate results in the transfer of a phosphate group from the substrate to the ligand. Compounds that modulate the activity of the kinase can be determined with a kinase functional screen. Functional screening for modulators of kinase activity therefore involves contacting one or more a test compounds with an expression product of one of the nucleic acid sequences of Tables I - VI which encodes a kinase, and determining the ability of said test compound to modulate the transfer of a phosphate group from the substrate to the ligand.

[0047] The expression product can be part of an intact cell or of a lipidic preparation or it can be a purified polypeptide (s), optionally attached to a support, for example beads, a column, or a plate. Binding is preferably performed in the presence of ligand and substrate to allow an assessment of the binding activity of each test compound.

[0048] The ligand should contain a specific kinase recognition sequence and it should not be phosphorylated at its phosphorylation site. The ligand and/or substrate may be contacted with the kinase either before, simultaneously or after the test compound. Optionally the substrate may be labelled with a kinase transferable labelled phosphate. The assay being monitored by the phosphorylation state of the substrate and/or the ligand. The ligand should be such that its phosphorylation state can be determined. An alternative method to do this is to label the ligand with a phosphor-

ylation-state-sensitive molecule. To achieve this, the ligand can be labelled in a number of ways, for example with a chromophore, radioactive, fluorescent, phosphorescent, enzymatic or antibody label. If the ligand is not directly detectable it should be amenable to detection and quantification by secondary detection, which may employ the above technologies. Such technologies are known to those in the art.

[0049] Binding of the test compound to the kinase modifies its ability to transfer a phosphate group from the substrate to the ligand. The difference between the observed amount of phosphate transfer relative to the theoretical maximum amount of phosphate transfer is a reflection of the modulatory effect of the test compound. Alternatively, the degree of phosphate transfer can be determined by a combination of chromatography and spectroscopy. The extent of phosphorylation of the ligand peptide or dephosphorylation of the substrate can also be determined by direct measurement.

This can be achieved with technologies such as Biacore (Amersham Pharmacia).

[0050] The invention also provides a method for screening compounds for the ability to relieve pain, which comprises:

- (a) contacting one or more test compounds in the presence of ligand and substrate with an expression product of any of the sequences of Tables I - VI which is a kinase or with a cell containing at least 1 copy of the expression product or with a lipidic matrix containing at least 1 copy of an expression product;
- (b) determining the amount of phosphate transfer from the substrate to the ligand; and
- (c) selecting test compounds on the basis of their capacity to modulate phosphate transfer.

[0051] Optionally ligand, substrate and/or other essential molecules may be added prior to contacting the test compound with expression product of step (a) or after step (a). Non limiting examples and methodology can be gained from the teachings of the *Molecular Probes handbook* and references therein (Molecular Probes, Inc., 4849 Pitchford Ave, Eugene, USA), *Methods in Molecular Biology* 2000; 99: 191-201, *Oncogene* 2000 20; 19(49): 5690-701, and *FASAB Journal*, (10, 6, P55, P1458, 1996, Pocius D Amrein K *et al*).

b) Receptor assays

[0052] An expression product of any of the nucleic acid sequences of Tables I - VI which encodes a receptor, and in particular any of the nucleic acid sequences listed in Table II, is amenable to screening using receptor assay technology.

[0053] Receptors are membrane associated proteins that initiate intracellular signalling upon ligand binding. Therefore, the identification of molecules for the prevention and treatment of pain can be achieved with the use of a ligand binding assay, as outlined above. Such an assay would utilize an endogenous or non-endogenous ligand as a component of the ligand binding assay. The binding of this ligand to the receptor in the presence of one or more test compounds would be measured as described above. Such is the nature of receptors that the assay is usually, but not exclusively performed with a receptor as an intact cell or membraneous preparation.

[0054] The invention therefore includes a method of screening for pain alleviating compounds, comprising:

- a) contacting a test compound or test compounds in the presence of a ligand with a cell expressing at least one copy of the expression product of any of the sequences of Tables I - VI which is a receptor or with a lipidic matrix containing at least one copy of the expression product;
- b) determining the binding of the test compound to the expression product, and
- c) selecting test compounds on the basis of their binding abilities.

c) Transporter protein assays

[0055] An expression product of any of the nucleic acid sequences of Tables I - VI which encodes a transporter protein, and in particular any of the nucleic acid sequences listed in Table III, is amenable to screening using transporter protein assay technology. Non limiting examples of technologies and methodologies are given by *Carroll FI, et al* (1995, Medical Research Review, Sep15 (5) p419-444), *Veldhuis JD and Johnson MI* (1994, Neurosci. Biobehav Rep., winter 18(4) 605-12), *Hediger MA and Nussberger S* (1995, Expt Nephrol, July-Aug 3(4) p211-218, *Endou H and Kanai Y*, (1999, Nippon Yakurigaku Zasshi, Oct. 114 Suppl 1:1p-16p), *Olivier B et al* (2000, Prog. Drug Res., 54, 59-119), *Braun A et al* (2000, Eur J Pharm Sci, oct 11, Suppl 2 S51-60) and *Molecular Probes handbook and references therein* (Molecular Probes, Inc., 4849 Pitchford Ave, Eugene, USA).

[0056] The main function of transporter proteins is to facilitate the movement of molecules across a cellular membrane. Compounds that modulate the activity of transporter proteins can be determined with a transporter protein functional screen. Functional screening for modulators of transporter proteins comprises contacting at least one test compound with an expression product as aforesaid which is a transporter protein and determining the ability of said test compound to modulate the activity of said transporter protein. The expression product can be part of an intact cell,

or lipidic preparation, optionally attached to a support, for example beads, a column or a plate. Binding is preferably performed in the presence of the molecule to be transported, which should only be able to pass through a cell membrane or lipidic matrix with the aid of the transporter protein. The molecule to be transported should be able to be followed when it moves into a cell or through a lipidic matrix. Preferably the molecule to be transported is labelled to aid in characterization, e.g. with a chromophore, radioactive, fluorescent, phosphorescent, enzymatic or antibody label. If the molecule to be transported is not directly detectable it should be amenable to detection and quantification by secondary detection, which may employ the above technologies. The molecule to be transported may be contacted with the transporter protein before, simultaneously with or after the test compound. If binding of the test compound to the transporter protein modifies its ability to transport molecules through a membranous or lipidic matrix, then the difference between the observed amount of transported molecule in a cell/or through a lipidic matrix relative to the theoretical maximum amount is a reflection of the modulatory effect of the test compound.

[0057] The invention further provides a method for screening compounds for their ability to relieve pain, comprising

- a) contacting at least one test compound in the presence of transporter molecules with a cell containing at least one copy of an expression product of any of the sequences of Tables I - VI which is a transporter protein or with a lipidic matrix containing at least one copy of the expression product;
- c) measuring the movement of transported molecules into or from the cell, or across the lipidic matrix; and
- d) selecting test compounds on the basis of their ability to modulate the movement of transported molecules.

d) G-protein coupled receptor protein assays

[0058] An expression product of any of the nucleic acid sequences of Tables I - VI that encodes a G-protein coupled receptor protein, and in particular any of the nucleic acid sequences listed in Table IV, is amenable to screening using G-protein coupled receptor protein assay technology.

[0059] G-protein coupled receptor proteins (GPCRs) are membrane associated proteins whose main function is to transduce a signal through a cellular membrane. Upon ligand binding, GPCRs undergo a conformational change that allows complexing of the GPCRs with a G-protein. G-proteins possess a GTP/GDP binding site. The formation of the G-protein/ligand complex allows exchange of GTP for GDP, resulting in a conformational change of the G-protein. This conformational change initiates signal transduction.

[0060] Functional screening for modulators of GPCRs comprises contacting at least one test compound with an expression product as aforesaid which is a G-protein coupled receptor protein, and assessing the ability of the test compound(s) to modulate the exchange of GTP for GDP or the modulation of the GPCR signal transduction pathway. The expression product can be part of an intact cell or lipidic preparation, optionally attached to a support, for example beads, a column or a plate. Binding is preferably performed in the presence of a ligand, G-protein and GTP/GDP to allow an assessment of the binding activity of each test compound. Alternatively components of the signaling pathway are also included. In particular, in a preferred embodiment, a labeled GTP is used and the ability of the test compound(s) to modulate the exchange of GTP to GDP is determined. A further optional characteristic of the assay can be the inclusion of a reporter molecule that enables monitoring the regulation of the signaling pathway. The ligand may be contacted with the GPCR before, simultaneously with, or after the test compound. Binding of the test compound to the GPCR modifies its ability to modulate the exchange of GTP for GDP and hence the modulation of signal transduction. The difference between the observed amount of GTP exchanged for GDP relative to the theoretical maximum amount of GTP is a reflection of the modulatory effect of the test compound. Likewise the relative activities of signal transduction reporter molecules are also a reflection of the modulatory effect of the test compound. Non limiting examples of technologies and methodologies can be found in *Molecular Probes handbook* and references therein (Molecular Probes, Inc., 4849 Pitchford Ave, Eugene, USA), *Glaxo Pocket Guide to Pharmacology*, (Michael Sheehan, Pharmacology Division staff, Glaxo Group Research Ltd., Ware, Herts SC12 0DP) and *Xing et al* (2000, J. Recept. Signal. Transduct. Res. 20(40 189-210).

[0061] The invention provides a method of screening compounds for their ability to relieve pain, comprising:

- a) contacting at least one test compound in the presence of a ligand, GTP/GDP, G-protein with a cell containing at least one copy of an expression product of a sequence of Tables I - VI as aforesaid which is a G-protein coupled receptor protein or with a lipidic matrix containing at least one copy of the expression product;
- b) measuring the exchange of GTP for GDP, and
- c) selecting test compounds on the basis of their ability to modulate said exchange.

In the above method, the ligand, GTP/GDP, G-protein and other essential molecules can be added before, simultaneously with or after the contacting of the test compound(s) with the cell line or lipidic matrix in step (a).

e) DNA-binding protein assays

[0062] An expression product of any of the nucleic acid sequences of Tables I - VI that encodes a DNA-binding protein, and in particular any of the nucleic acid sequences listed in Table V, is amenable to screening using DNA-binding protein assay technology.

[0063] DNA binding proteins are proteins that are able to complex with DNA. The complexing of the DNA binding protein with the DNA in some instances requires a specific nucleic acid sequence. Screens can be developed in a similar manner to ligand binding screens as previously indicated and will utilise DNA as the ligand. DNA-binding protein assays can be carried using similar principles described in ligand binding assays as described above. Non limiting examples of methodology and technology can be found in the teachings of *Haukanes BI and Kvam C* (Biotechnology, 1993 Jan 11 60-63), *Alberts B et al* (Molecular Biology of the Cell, 1994, 3rd Edn., Garland Publications Inc, *Kirigiti P and Machida CA* (2000 Methods Mol Biol, 126, 431-51) and *Molecular Probes handbook* and references therein (Molecular Probes, Inc., 4849 Pitchford Ave., Eugene, USA).

[0064] The invention therefore includes a method of screening for pain alleviating compounds, comprising:

a) contacting a test compound or test compounds in the presence of a plurality of nucleic acid sequences with an expression product of any of the nucleic acid sequences of Tables I - VI which is a DNA binding protein or with cells expressing at least one copy of the expression product or with a lipidic matrix containing at least one copy of the expression product;

b) determining the binding of the test compound to the expression product, and

c) selecting test compounds on the basis of their binding abilities.

In the above method, the plurality of nucleic acid sequence may be added prior to, simultaneously with or after contact of the test compound with the expression product.

f) Assays using other enzymes

[0065] Expression products of any of the nucleic acid sequences of Tables I - VI that encode other enzymes, e.g. ligases, lyases, oxidoreductases, transferases and hydrolases, and in particular any of the nucleic acid sequences listed in Table VI, is amenable to screening using appropriate assay technology.

[0066] Each class of enzyme has a defined function. Ligases have the property of being able to splice molecules together. This is achieved with the conversion of ATP substrate to AMP. Therefore, the activity of a ligase can be followed by monitoring the conversion of ATP to AMP. Such technologies are known to those in the art. Non limiting examples and methodologies are illustrated by *Ghee. T. Tan et al* (1996, Biochem J. 314, 993-1000, *Yang SW et al* (1992, 15: 89(6) 2227-31 and references therein, and in *Molecular Probes handbook* and references therein (Molecular Probes, Inc., 4849 Pitchford Ave, Eugene, USA).

[0067] The invention also provides a methods of screening for pain alleviating compounds, comprising:

a) contacting one or more test compounds in the presence of ATP with an expression product of any of the sequences of Tables I - VI which is a ligase or with a cell expressing at least 1 copy of a expression product or with a lipidic matrix containing at least 1 copy of an expression product which is a ligase;

b) determining the amount of ATP converted to AMP, and

c) selecting test compounds on the basis of their ability to modulate said conversion.

[0068] Lyases are enzymes which catalyse the cleavage of by reactions other than hydrolysis. These enzymes can be grouped into seven groups according to type of bond cleaved. These groups are carbon-carbon lyases (E.C. No 4.1), carbon-oxygen lyases (E.C. No 4.2), carbon-nitrogen lyases (E.C. No 4.3), carbon-sulphur lyase (E.C. No 4.4), carbon-halide lyases (E.C. No 4.5), phosphorous-oxygen lyases (E.C. No 4.6) and other lyases (E.C. No 4.99) (Analytical Biochemistry 3rd Edn, David J. Holme and Hazel Peck, Longman press). The enzyme commission number (E.C.) of the International Union of Biochemistry relates to the type of reaction catalysed by the enzyme. Further teachings on how to develop assays and screens for lyases can be obtained from *Methods in Enzymology* (Academic Press).

[0069] Oxidoreductases are enzymes that catalyse the transfer of hydrogen or oxygen atoms or electrons. These enzymes can be sub-grouped into twenty categories according to their specific mode of action. These groups are oxidoreductases acting on the CH-OH group of donors (E.C. No 1.1 oxidoreductases acting on the aldehyde or oxo group of donors (E.C. No 1.2), oxidoreductases acting on the CH-CH group of the donor (E.C. No 1.3), oxidoreductases acting on the CH-NH₂ group of donors (E.C. 1.4), oxidoreductases acting on the CH-NH group of donor (E.C. 1.5), oxidoreductases acting on the NADH or NADPH (E.C. No 1.6), oxidoreductases acting on other nitrogen compounds as donors (E.C. No 1.7), oxidoreductases acting on a sulphur group of donors (E.C. No 1.8), oxidoreductases acting on a haem group of donors (E.C. No 1.9), oxidoreductases acting on diphenols and related substances as donors (E.

C. 1.10), oxidoreductases acting on hydrogen peroxide as acceptor (E.C. No 1.11), oxidoreductases acting on hydrogen as donor (E.C. No 1.12), oxidoreductases acting on single donors with incorporation of molecular oxygen (E.C. No 1.13), oxidoreductases acting on paired donors with incorporation of molecular oxygen (E.C. No 1.14), oxidoreductases acting on superoxide radicals as acceptors (E.C. 1.15), oxidoreductases oxidizing metal ions (E.C. No 1.16), oxidoreductases acting on -CH₂ groups (E.C. No 1.17), oxidoreductases acting on reduced ferredoxin as donor (E.C. No 1.18), oxidoreductases acting on reduced flavodoxin as donor (E.C. No 1.19) and other oxidoreductases (E.C. No 1.97) (Analytical Biochemistry 3rd Edn, David J. Holme and Hazel Peck, Longman Press). The enzyme commission number (E.C.) of the International Union of Biochemistry relates to the type of reaction catalysed by the enzyme. Further teachings on how to develop assays and screens for oxidoreductases can be obtained from *Methods in Enzymology* (Academic Press) with special reference to volume 249.

[0070] Transferases are enzymes that catalyse the transfer of specific groups. They are classified into eight sub groups according to function, transferring one-carbon group (E.C. No 2.1), Transferring aldehyde or ketonic residues (E.C. No 2.2), Acetyltransferases (E.C. 2.3), glycosyltransferases (E.C. No 2.4), transferring alkyl or aryl groups other than methyl groups (E.C. No 2.5), transferring nitrogenous groups (E.C. No 2.6), transferring phosphorous-containing groups (E.C. No 2.7) and transferring sulphur-containing groups (E.C. No 2.8) (Analytical Biochemistry 3rd Edn, David J. Holme and Hazel Peck, Longman Press). The enzyme commission number (E.C.) of the International Union of Biochemistry relates to the type of reaction catalysed by the enzyme. Further teachings on how to develop assays and screens for transferases can be obtained from *Methods in Enzymology* (Academic Press).

[0071] Hydrolases are enzymes that catalyse hydrolytic reactions and are sub-grouped into eleven classes according to the type of reaction they carry out. Hydrolases acting on ester bonds (E.C. No 3.1), hydrolases acting on glycosyl compounds (E.C. No 3.2), hydrolases acting on ether bonds (E.C. No 3.3), hydrolases acting on peptide bonds (E.C. No 3.4), hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (E.C. No 3.5), hydrolases acting on acid anhydrides (E.C. No 3.6), hydrolases acting on acid anhydrides (E.C. No 3.6), hydrolases acting on carbon-carbon bonds (E.C. No 3.7), hydrolases acting on halide bonds (E.C. No 3.8), hydrolases acting on phosphorous-nitrogen bonds (E.C. No 3.9), hydrolases acting on sulphur-nitrogen bonds (E.C. No 3.10) and hydrolases acting on carbon-phosphorous bonds (Analytical Biochemistry 3rd Edn, David J. Holme and Hazel Peck, Longman Press). The enzyme commission number (E.C.) of the International Union of Biochemistry relates to the type of reaction catalysed by the enzyme. Further teachings on how to develop assays and screens for hydrolases can be obtained from *Methods in Enzymology* (Academic Press) with special reference to volume 249.

C) In vivo functional screen

[0072] Any of the nucleotide sequences described in Tables I - VI or homologues thereof may be inserted by means of an appropriate vector into the genome of a lower vertebrate or of an invertebrate animal or may be inactivated or down regulated in the genome of said animal. The resulting genetically modified animal may be used for screening compounds for effectiveness in the regulation of pain. The invertebrate may, for example, be a nematode e.g. *Caenorhabditis elegans*, which is a favourable organism for the study of response to noxious stimuli. Its genome sequence has been determined, see *Science*, **282**, 2012 (1998), it can be bred and handled with the speed of a micro-organism (it is a self-fertilizing hermaphrodite) and can therefore be used in a high throughput screening format (WO 00/63424, WO 00/63425, WO 00/63426 and WO 00/63427), and it offers a full set of organ systems, including a simple nervous system and contains many similarly functioning genes and signaling pathways to mammals. A thermal avoidance model based on a reflexive withdrawal reaction to an acute heat stimulus has been described by Wittenburg *et al*, *Proc. Natl. Acad. Sci. USA*, **96**, 10477-10482 (1999), and allows the screening of compounds for the treatment of pain with the modulation of pain sensation as an endpoint.

[0073] The genome of *C. elegans* can be manipulated using homologous recombination technology which allows direct replacement of nucleic acids encoding *C. elegans* with their identified mammalian counterpart. Replacement of these nucleic acids with those nucleic acids outlined above would allow for the direct screening of test compound(s) with their expression products. Any of the pain-related genes described above may be ligated into a plasmid and introduced into oocytes of the worm by microinjection to produce germline transformants. Successful plasmid injection into *C. elegans* and expression of inserted sequences has been reported by Devgen B.V., Ghent, Belgium. It is also possible to produce by routine methods worms in which the target sequences are down-regulated or not expressed (knock-out worms). Further non limiting examples of methodology and technology can be found in the teachings of Hazendonk *et al* (1997, Nat genet. 17(1) 119-21), Alberts *et al*, (1994, Molecular Biology of the Cell 3rd Ed. Garland Publishing Inc, *Caenorhabditis elegans* is anatomically and genetically simple), Broverman S *et al*, (1993, PNAS USA 15;90(10) 4359-63) and Mello *et al* (1991, 10(12)3959-70).

[0074] A further method for screening compounds for ability to modify response to pain, e.g. relieve pain, comprises:

(a) contacting one or more test compounds with at least one *C. elegans* containing at least one copy of a sequence

as set out above;

(b) subjecting the *C. elegans* to a nociceptive stimulus;

(c) observing the response of the *C. elegans* to said stimulus; and

d) selecting test compounds on the basis of their ability to modify the response of *C. elegans* to said stimulus.

DIAGNOSTIC TOOLS AND KITS

Affinity peptides, ligands and substrates

[0075] Pain associated polypeptides and fragments thereof can be detected at the tissue and cellular levels with the use of affinity peptides, ligands and substrates, which will enable a skilled person to define more precisely a patient's ailment and help in the prescription of a medicament. Such affinity peptides are characterized in that firstly they are able to bind specifically to a pain associated polypeptide, and secondly that they are capable of being detected. Such peptides can take the form of a peptide or polypeptide for example an antibody domain or fragment, or a peptide/polypeptide ligand or substrate, or a polypeptide complex such as an antibody.

[0076] The preparation of such peptides and polypeptides are known to those in the art. Antibodies, these may be polyclonal or monoclonal, and include antibodies derived from immunized animals or from hybridomas, or derivatives thereof such as humanized antibodies, Fab or F(ab')₂ antibody fragments or any other antibody fragment retaining the antigen binding specificity.

[0077] Antibodies directed against pain-associated gene product molecules may be produced according to conventional techniques, including the immunization of a suitable mammal with the peptides or polypeptides or fragment thereof. Polyclonal antibodies can be obtained directly from the serum of immunized animals. Monoclonal antibodies are usually produced from hybridomas, resulting from a fusion between splenocytes of immunized animals and an immortalized cell line (such as a myeloma). Fragments of said antibodies can be produced by protease cleavage, according to known techniques. Single chain antibodies can be prepared according to the techniques described in US 4,946,778. Detection of these affinity peptides could be achieved by labeling technologies which allow detection of peptides, such as enzymatic labeling, fluorescence labeling or radio-labeling are well known to those in the art. Optionally these affinity peptides, ligands and substrates could themselves be detected with the use of a molecule that has specific affinity to the peptides, ligands and substrates and is itself labeled.

[0078] The invention further provides a kit comprising;

(a) affinity peptide and/or ligand and/or substrate for an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain; and

(b) a defined quantity of an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal both in response to first and second models of neuropathic or central sensitization pain,

for simultaneous, separate or sequential use in detecting and/or quantifying an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain.

Complimentary nucleic acids

[0079] Pain associated nucleic acid sequences can be characterized at the tissue and cellular levels with the use of complimentary nucleic acid sequences. Detection of the level of expression of pain associated nucleic acid sequences can help in the prognosis of a pain condition and the prescription of a medicament. These complimentary nucleic acids are characterized in that they can hybridize to a pain associated nucleic acid sequence and their presence can be detected through various techniques. Such techniques are known to those in the art and may include detection by polymerase chain reaction or detection by labeling of complimentary nucleic acid sequences by enzymatic labeling, affinity labeling fluorescent labeling or radio labeling. Complimentary strand nucleic acid sequences of this invention are 10 to 50 bases long, more preferably 15 to 50 bases long and most preferably 15 to 30 bases long, and hybridize to the coding sequence of the nucleic acid sequence.

[0080] A further aspect of this invention is a kit that comprises:

(a) nucleic acid sequences capable of hybridization to a nucleic acid sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain; and

(b) a defined quantity of one or more nucleic acid sequences capable of hybridization to a nucleic acid sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or

central sensitization pain, for simultaneous, separate or sequential use in detecting and/or quantifying a gene sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain.

IDENTIFICATION AND VALIDATION

[0081] Subtractive hybridization enables the identification of nucleic acid sequences whose expression profiles are modified by a stimulus. Upon stimulation of a system (in the case of this invention a nociceptive stimulus on an animal model) all observed changes in the level of nucleic acid sequence expression are due to the reaction of the system to the stimulus. Characterization of these changes in expression by way of identification of nucleic acid sequence and level of expression is both identification and validation.

[0082] The inventors have developed a four step process which allows for the simultaneous identification and validation of nucleic acid sequences whose expression are regulated by a pain stimulus, preferably a chronic pain stimulus, and more preferably a diabetic pain stimulus. This process may comprise the following steps:

- (a) induction of a nociceptive stimulus in test animals;
- (b) extraction of nucleic acids from specific neuronal tissue of test and control animals;
- (c) selective amplification of differentially expressed nucleic acid sequences; and
- (d) identification and characterization of differentially expressed gene products that are modulated by a nociceptive stimulus.

[0083] The above process is described in more detail below.

(a) Induction of nociceptive stimulus

[0084] The effect of the selected nociceptive stimulus on the test animal needs to be confirmable. The test subjects are therefore a species that has a "developed" nervous system, preferably similar to that of humans, most preferably rats or mice. Advantageously, the nociceptive stimulus is analogous to known pain paradigms in humans. One such paradigm of pain is the pain associated with diabetes, which can be induced in rodents with the use of streptozotocin (STZ). The present application requires the sequences to be down-regulated in two pain models which may be, but are not limited to models of neuropathic pain and/or central sensitization, and in which diabetic pain provides the first model and mechanical damage e.g. to a nerve leading into the spine can provide an appropriate second model.

[0085] Streptozotocin (STZ) induces hyperglycemia and Type 1 diabetes mellitus in rats. In particular, STZ contains a glucose analogue that allows it to be taken up by the glucose transporter 2 present on the surface of pancreatic β cells, the site of insulin synthesis. Once inside the cell, STZ causes a reduction in the level of nicotinamide adenine dinucleotide (NAD^+). The decrease in NAD^+ levels eventually leads to necrosis of the pancreatic β cell, causing a reduction in insulin levels and then diabetes, leading to neuropathy (diabetic) and neuropathic pain (R. B. Weiss, *Cancer Treat. Rep.*, **66**, 427-438 1982, Guy *et al*, *Diabetologica*, **28**, 131-137 1985; Ziegler *et al*, *Pain*, **34**, 1-10 1988; Archer *et al*, *J. Neural. Neurosurgeon. Psychiatry*, **46**, 491-499 1983). The diabetic rat model has been shown to be a reliable model of hyperalgesia. We have used an STZ-induced diabetic rat model to create a state of hyperalgesia that can be compared with control animals (Courteix *et al*, *Pain*, **53**, 81-88 1993).

[0086] Three models of neuropathic and/or central sensitization pain in rats, which involve nerve injury, may be used, see Ralston, DD (1998) Present models of neuropathic pain. *Pain Rev.* **5**: 83-100. The injuries are caused by (1) loosely tying four chromic gut sutures around the sciatic nerve (CCI model developed by Bennett, GJ and Y-K Xie, A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, *Pain* **33**: 87-107 (1988), (2) tightly ligating one third to one half of the fibers in the sciatic nerve (model developed by Seltzer, Z, R Dubner, Y Shire, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury, *Pain* **43**: 205-218, 1990), and (3) tightly ligating the dorsal spinal nerve of a rat at the L5 or L5 and L6 levels (L5 model developed by Kim, SH and JM Chung, An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, *Pain* **50**:355-363, 1992).

(b) Extraction of nucleic acids from neuronal tissue of test and control animals

[0087] The inventors have determined that RNA extraction of whole spinal cord nervous tissue would provide a way of identifying nucleic acid sequences whose expression in spinal tissue is modulated by streptozotocin induced diabetes or by a mechanical nerve damage model for neuropathic and/or central sensitization pain e.g. CCI. Test (subjected to the nociceptive stimulus) and control animals were sacrificed, and the tissue to be studied e.g. neural tissue separated. Techniques for so doing vary widely from animal to animal and will be familiar to skilled persons.

[0088] A cDNA library can be prepared from total RNA extracted from neural tissue of the test and control animals. Where possible, however, it is preferred to isolate the mRNA from the total RNA of the test and control animals, by affinity chromatography on oligo (dT)-cellulose, and then reverse transcribe the mRNA from the test and control animals to give test and control cDNA. Converting mRNA from the test and control animals to corresponding cDNA may be carried out by any suitable reverse transcription method, e.g. a method as described by Gubler & Hoffman, *Gene*, 25, 263-269 (1983). If desired a proprietary kit may be used e.g. the CapFinder PCR cDNA Library Construction Kit (Life Technologies) which is based on long-distance PCR and permits the construction of cDNA libraries from nanograms of total RNA.

(c) Selective amplification of differentially expressed nucleic acids

[0089] The reverse transcribed cDNA of the test and control animals is subjected to subtractive hybridisation and amplification so that differentially expressed sequences become selectively amplified and commonly expressed sequences become suppressed, so as to over-produce DNA associated with said nociceptive stimulus. A wide range of subtractive hybridisation methods can be used, but the preferred method is so-called suppression subtractive hybridisation, see US-A-5565340 and Diatchenko *et al*, *Proc. Nat. Acad. Sci. USA*, 93, 6025-6030 (1996), the disclosures of which are herein incorporated by reference. Kits for carrying out this method are available from CLONTECH Laboratories, Inc.

(d) Cloning and Sequencing the differentially expressed cDNA

[0090] The differentially expressed cDNA is ligated into a cloning vector, after which cells of *E. coli* are transformed with the vector and cultured. Positive clones are selected and lysed to release plasmids containing the cDNA insert. The plasmids are primed using forward and reverse primers to either side of the cloning site and the cDNA insert is sequenced. Vector and adaptor sequences are then removed from the output data from the sequencer, leaving only the nucleotide sequence of the differentially expressed gene. The sequence is then checked against data held in a database for homology to known nucleotide sequences and genes, including expressed sequence tags (ESTs) and coding sequences for proteins.

(e) Validation of the above method

[0091] The importance of the sequences that we have identified in pain is confirmed by the fact that genes have been identified using this method that represent nucleic acid sequences which have previously been implicated in pain, including Calmodulin (pRCM1, Genebank X13933), Enkephalin (Genebank Y07503) and Neurotensin receptor type 2 (Genebank X97121).

[0092] The inventors have identified nucleic acid sequences of the MAP kinase pathway, a previously non pain-associated biological pathway. The inventors have subsequently shown that intra-spinal injection of a MEK inhibitor (MEK is part of the MAP kinase pathway) produces a powerful inhibition of pain (Patent application No US 60/144292). Subsequently, it has been shown that the MAP kinase is also implicated in acute inflammatory pain (Woolf *et al*, *Nature Neuroscience* 1999).

[0093] The invention will now be further described in the following Example.

EXAMPLE

Induction of diabetes

[0094] Diabetes was induced in adult (150-200g) male Sprague-Dawley rats (n=6) as described by Courteix *et al* (*supra*). Animals were injected intraperitoneally with streptozotocin (STZ) (50 mg/kg) dissolved in distilled water. Control or sham animals (age-matched animals, n=6) were injected with distilled water only.

Chronic Constrictive Injury (CCI)

[0095] Rats were anaesthetized with i.p. sodium phenobarbital, after which the common left sciatic nerve was exposed at the level of the middle of the thigh by blunt dissection through the biceps femoris and proximal to the sciatic trifurcation. Four ligatures (4.0 braided silk) were tied loosely around it with about 1mm spacing. The muscle was closed in layers and two wound clips were applied to close the skin incision. The wound was then covered with topical antibiotics.

Nociceptive testing

[0096] Static allodynia (a form of hyperalgesia) was measured using a method described by Chaplan *et al*, "Quantitative assessment of tactile allodynia in the rat paw", *J. Neurosci. Methods*, 53, 55-63 (1994). A series of von Frey filaments of different buckling weight (i.e. the load required for the filament to bend) were applied to the plantar surface of the right hand paw. The starting filament had a buckling weight of 20g. Lifting of the paw was taken to be a positive result, in which case a filament with the next lowest buckling weight was used for the next measurement. The test was continued until a filament was found for which there was an absence of response for longer than 5 seconds whereas a re-test with the next heaviest filament gave a positive response. Animals were considered hyperalgesic if their thresholds were found to be <4g of those of comparable untreated rats, see Calcutt & Chaplan, "Spinal pharmacology of tactile allodynia in diabetic rats", *British J. Pharmacol*, 122, 1478-1482 (1997).

Tissue Extraction

[0097] STZ-treated, CCI-treated and control animals were anaesthetized with 4% halothane and perfused with ice-cold 0.9% saline containing 1% citric acid (pH adjusted to 7.4 with NaOH). The animals were decapitated and the lumbar spinal cord exposed. A 2-centimetre length of spinal cord ending at L6 (lumbar-6 forward) was removed from the spinal column. Attached dorsal root ganglia and contaminating spinal connective tissues were removed. The spinal cord tissue was snap frozen in dry ice and isopentane. In the experiments that follow, procedures on the streptozocin-treated and control groups of animals are disclosed. It will be understood that for identification of CCI-treated animals the same experiments are performed, but using tissues from the CCI-treated animals and from control animals.

Total RNA Extraction

[0098] Total RNA was extracted from the pooled male rat tissues of the streptozocin-treated and control groups using the TRIzol Reagent Kit (Life Technologies). Briefly, tissue samples were homogenised fully using a Polytron homogenizer in 1ml of TRIzol reagent per 50-100mg of tissue. Homogenized samples were then incubated at room temperature for 5 minutes and phase separated using 0.2ml chloroform per 1ml TRIzol reagent followed by centrifugation at 3,000g. The aqueous phase was transferred to a fresh tube and the RNA precipitated with an equal volume of isopropyl alcohol and followed by centrifugation at 10,000g. The RNA pellet was washed in 75% ethanol and re-centrifuged. The pellet was then air dried and re-suspended in water.

mRNA Extraction

[0099] In contrast to ribosomal RNA and transfer RNA, the vast majority of mRNAs of mammalian cells carry tracts of poly(A⁺) at their 3' termini. mRNAs can therefore be separated from the bulk of cellular RNA by affinity chromatography on oligo (dT)-cellulose. mRNA was extracted from Total RNA using the MESSAGEMAKER Kit (Life Technologies) in which mRNA (previously heated to 65°C in order to disrupt secondary structures and so expose the poly (A⁺) tails) was bound to oligo(dT) cellulose under high salt concentrations (0.5M NaCl) in a filter syringe. Unbound RNA was then washed away and the poly(A⁺) mRNA eluted in distilled water. A tenth of the volume of 7.5 M Ammonium Acetate, 50µg of glycogen/ml mRNA sample and 2 volumes of absolute alcohol were then added to the samples which were placed at -20°C overnight. Following precipitation, the mRNA was spun down at 12,000g for 30 minutes at 4°C. RNAase free water was used to re-suspend the pellets, which were then and stored at -80°C.

PCR SELECT

[0100] The technique used was based on that of the CLONTECH PCR Select Subtraction Kit. The following protocol was performed using STZ-treated lumbar spinal cord Poly A⁺ RNA as the 'Tester' and Sham lumbar spinal cord poly A⁺ RNA as the 'Driver' (Forward Subtraction). A second subtraction experiment using the Sham lumbar spinal cord mRNA as the 'Tester' and STZ treated lumbar spinal cord mRNA as the 'Driver' (Reverse Subtraction) was performed in parallel using the same reagents and protocol. As a control for both experiments, the subtraction was also carried out using human skeletal muscle mRNA that had been provided by the manufacturer.

First-Strand cDNA Synthesis

[0101] 2 µg of PolyA⁺ RNA and 1 µl of cDNA synthesis primer (10 µM) were combined in a 0.5ml Eppendorf tube and sterile H₂O was added where necessary to achieve a final volume of 5 µl. The contents were mixed gently and incubated in a thermal cycler at 70°C for 2 min. The tubes were then cooled on ice for two minutes, after which 2 µl of

5X First-strand buffer, 1 µl of dNTP mix (10 mM each), sterile H₂O and 1 µl of AMV reverse transcriptase (20 units/µl) was also added. The tubes were then placed at 42°C for 1.5 hr in an air incubator. First-strand cDNA synthesis was terminated by placing the tubes on ice. (the human skeletal muscle cDNA produced by this step was used as the 'control driver' in later steps).

Second-Strand cDNA Synthesis

[0102] 48.4 µl of Sterile H₂O, 16.0 µl of 5X Second-strand buffer, 1.6 µl of dNTP mix (10 mM) and 4.0 µl of 20X Second-strand enzyme cocktail were added to each of the first-strand synthesis reaction tubes. The contents were then mixed and incubated at 16°C in a thermal cycler for 2 hr. 6 units (2 µl) of T4 DNA polymerase was then introduced and the tubes were incubated for a further 30 min at 16°C. In order to terminate second-strand synthesis, 4 µl of 20X EDTA/glycogen mix was added. A phenol:chloroform extraction was then carried out using the following protocol:-

[0103] 100 µl of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the tubes which were then vortexed thoroughly and centrifuged at 14,000 rpm for 10 min at room temperature. The top aqueous layer was removed and placed in a fresh tube. 100 µl of chloroform:isoamyl alcohol (24:1) was then added to the aqueous layer and the tubes were again vortexed and centrifuged at 14,000 rpm for 10 min. 40 µl of 4 M NH₄OAc and 300 µl of 95% ethanol were then added and the tubes centrifuged at 14,000 rpm for 20 min. The supernatant was removed carefully, then 500 µl of 80% ethanol was added to the pellet. The tubes were centrifuged at 14,000 rpm for 10 min and the supernatant was removed so that the pellet could be air-dried. The precipitate was then dissolved in 50 µl of H₂O. 6 µl was transferred to a fresh microcentrifuge tube. The remainder of the sample was stored at -20°C until needed.

Rsa I Digestion

[0104] All products of the above procedures were subjected to a restriction digest, using the restriction endonuclease *Rsa* I, in order to generate ds cDNA fragments that are short and thus are optimal for subtraction hybridisation due to the standard kinetics of the hybridisation. Also, as *Rsa* I makes a double stranded cut in the middle of a recognition sequence, 'blunt ends' of a known nucleotide sequence are produced allowing ligation of adaptors onto these ends in a later step. The following reagents were added to the 6 µl product of the second hybridisation (see above): 43.5 µl of ds cDNA, 5.0 µl 10X *Rsa* I restriction buffer and 1.5 µl of *Rsa* I (10 units/µl). The reaction mixture was incubated at 37°C for 1.5 hr. 2.5 µl of 20X EDTA/glycogen mix was used to terminate the reaction. A phenol:chloroform extraction was then performed as above (second-strand cDNA synthesis section). The pellet produced was then dissolved in 5.5 µl of H₂O and stored at -20°C until needed. The preparation of the experimental 'Driver' cDNAs and the control skeletal muscle cDNA was thus completed.

Adaptor Ligation

[0105] The adaptors were not ligated to the driver cDNA.

[0106] 1 µl of each *Rsa* I-digested experimental cDNA (from the *Rsa* I Digestion above) was diluted with 5 µl of sterile water. Preparation of the control skeletal muscle tester cDNA was then undertaken by briefly centrifuging the tube containing control DNA (*Hae* III-digest of φX174 DNA [3 ng/µl]) and diluting 2 µl of the DNA with 38 µl of sterile water (to 150 ng/ml). 1 µl of control skeletal muscle cDNA (from the *Rsa* I Digestion) was then mixed with 5 µl of the diluted φX174/ *Hae* III DNA (150 ng/ml) in order to produce the control skeletal muscle tester cDNA.

Preparation of the adaptor-ligated tester cDNA

[0107] A ligation master mix was prepared by combining 3 µl of sterile water, 2 µl of 5X ligation buffer and 1 µl T4 DNA ligase (400 units/µl) per reaction. 2 µl of adaptor 1 (10 µM) was then added to 2 µl of the diluted tester cDNA. To this, 6 µl of the ligation master mix was also added. The tube was therefore labeled Tester 1-1. In a separate tube, 2 µl of the adaptor 2R (10 µM) was mixed with 2 µl of the diluted tester cDNA and 6 µl of the master mix. This tube was named Tester 1-2.

[0108] 2 µl of Tester 1-1 and 2 µl of Tester 1-2 were then placed into fresh tubes. These would later be used as the unsubtracted tester control. The remainder of the contents of Tester 1-1 and Tester 1-2 tubes were then centrifuged briefly and incubated at 16°C overnight. The ligation reaction was stopped by adding 1 µl of EDTA/glycogen mix and the samples were heated at 72°C for 5 min in order to inactivate the ligase. In doing so, preparation of the experimental and control skeletal muscle adaptor-ligated tester cDNAs was complete.

[0109] 1 µl from each unsubtracted tester control was then removed and diluted into 1 ml of water. These samples were set aside as they were to be used later for PCR (see below). All of the samples were stored at -20°C

Analysis of Ligation efficiency

[0110] 1 µl of each ligated cDNA was diluted into 200 µl of water and the following reagents were then combined in four separate tubes:

Component	Tube:	1	2	3	4
Tester 1-1 (ligated to Adaptor 1)		1	1	-	-
Tester 1-2 (ligated to Adaptor 2R)		-	-	1	1
G3PDH 3' primer (10 µM)		1	1	1	1
G3PDH 5' primer (10 µM)		-	1	-	1
PCR primer 1 (10 µM)		1	-	1	-
Total volume µl		3	3	3	3

[0111] A master mix for all of the reaction tubes plus one additional tube was made up by adding 18.5 µl of sterile H₂O, 2.5 µl of 10X PCR reaction buffer, 0.5 µl of dNTP mix (10 mM), and 0.5 µl of 50X Advantage cDNA Polymerase Mix, per reaction, into a fresh tube. 22 µl of this master mix was then aliquotted into each of the 4 reaction tubes prepared above. The contents of the tubes were overlaid with 50 µl of mineral oil. The reaction mix was incubated in a thermal cycler at 75°C for 5 min in order to extend the adaptors. The following protocol was then carried out immediately in a thermal cycler (Perkin-Elmer GeneAmp PCR Systems 2400): 94°C for 30 sec (1 cycle), 94°C 10 sec, 65°C 30 sec and then 68°C 2.5 min (25 cycles)

First Hybridisation

[0112] 1.5 µl of the Adaptor 1-ligated Tester 1-1 was combined with 1.5 µl of the *Rsa* I-digested driver cDNA, prepared earlier and 1 µl of 4X Hybridisation buffer. This process was then repeated combining the Adaptor 2R-ligated Tester 1-2 with the *Rsa* I-digested driver cDNA and 4X hybridisation buffer. The samples were incubated in a thermal cycler at 98°C for 1.5 min followed by incubation at 68°C for 8 hr.

Second Hybridisation

[0113] 1 µl of Driver cDNA (i.e. the *Rsa* I-digested cDNA (see above)), 1 µl 4X Hybridisation buffer and 2 µl Sterile H₂O were all combined in a fresh tube. 1 µl of this mix was then removed and placed in a new tube, overlaid with 1 drop of mineral oil and incubated at 98°C for 1.5 min in order to denature the driver. The following procedure was used to simultaneously mix the driver with hybridisation samples 1 and 2 (prepared in the first hybridisation), thus ensuring that the two hybridisation samples were mixed together only in the presence of freshly denatured driver: A micropipettor was set at 15 µl. The pipette tip was then touched onto the mineral oil/sample interface of the tube containing hybridisation sample 2. The entire sample was drawn partway into the tip before it was removed from the tube in order to draw a small amount of air into the tip. The pipette tip was then touched onto the interface of the tube containing the freshly denatured driver (i.e. the tip contained both samples separated by a small pocket of air) before the entire mixture was transferred to the tube containing hybridisation sample 1. The reaction was then incubated at 68°C overnight. 200 µl of dilution buffer was added to the tube, which was then heated in a thermal cycler at 68°C for 7 min. The product of this second hybridisation was stored at -20°C.

PCR Amplification

[0114] Seven PCR reactions were set up: (1) The forward-subtracted experimental cDNA, (2) the unsubtracted tester control (see preparation of the adaptor ligated tester cDNA), (3) the reverse-subtracted experimental cDNA, (4) the unsubtracted tester control for the reverse subtraction, (5) the subtracted control skeletal muscle cDNA, (6) the unsubtracted tester control for the control subtraction, and (7) the PCR control subtracted cDNA (provided in the kit). The PCR control subtracted cDNA was required to provide a positive PCR control as it contained a successfully subtracted mixture of *Hae* III-digested ϕ X174 DNA.

[0115] The PCR templates were prepared by aliquotting 1 µl of each diluted cDNA (i.e., each subtracted sample from the second hybridisation and the corresponding diluted unsubtracted tester control produced by the adaptor ligation see above) into an appropriately labeled tube. 1 µl of the PCR control subtracted cDNA was placed into a fresh tube. A master mix for all of the primary PCR tubes, plus one additional reaction, was then prepared by combining 19.5 µl of sterile water, 2.5 µl of 10X PCR reaction buffer, 0.5 µl of dNTP Mix (10 mM), 1.0 µl of PCR primer 1 (10 µM)

and 0.5 µl of 50X Advantage cDNA Polymerase Mix. 24 µl of Master Mix was then aliquotted into each of the 7 reaction tubes prepared above and the mixture was overlaid with 50 µl of mineral oil, before being incubated in a thermal cycler at 75°C for 5 min in order to extend the adaptors. Thermal cycling was then immediately started using the following protocol: 94°C 25 sec (1 cycle), 94°C 10 sec, 66°C 30 sec and 72°C 1.5 min (32 cycles).

[0116] 3 µl of each primary PCR mixture was then diluted in 27 µl of H₂O, 1 µl of each of these dilutions was then placed into a fresh tube.

[0117] A master mix for the secondary PCRs, (plus an additional reaction) was set up by combining 18.5 µl of sterile water, 2.5 µl of 10X PCR reaction buffer, 1.0 µl of Nested PCR primer 1 (10 µM), 1.0 µl of Nested PCR primer 2R (10 µM), 0.5 µl of dNTP Mix (10 mM) and 0.5 µl of 50X Advantage cDNA Polymerase Mix per reaction. 24 µl of this Master Mix was then added into each reaction tube containing the 1 µl diluted primary PCR mixture. The following PCR protocol was then carried out: 94°C 10 sec, 68°C 30 sec and 72°C 1.5 min (12 cycles). The reaction products were then stored at -20°C.

Ligation into a Vector/ Transformation & PCR

[0118] The products of the PCR amplification (enriched for differentially expressed cDNAs) were ligated into the pCR2.1-TOPO vector using a T/A cloning kit (Invitrogen), transformed into TOPO One Shot competent cells according to the manufacturers protocol and grown up on LB (Luria-Bertani) Agar plates overnight at 37°C. 1,000 colonies were then individually picked (using fresh sterile tips) and dipped into 5 µl of sterile water which had been aliquotted previously into 96 well PCR plates. The water/colonies were heated in a thermal cycler at 100°C for 10 minutes in order to burst the cells, thus releasing the plasmids containing a differentially expressed cDNA insert. The 5 µl of water/plasmid was then used as a template in a PCR reaction (see below) using M13 Forward and Reverse primers (10 ng/µl), complementary to the M13 site present on either side of the cloning site on the vector. 5 µl of the PCR product was then run on a 2% agarose gel and stained by ethidium bromide. PCR products of an amplified insert were identified and 5 µl of the remainder of the PCR product (i.e. from the 15 µl that had not been run on the gel) was diluted 1/10 with water. 5 µl of the diluted PCR product was then used as a template in a sequencing reaction.

Sequencing

[0119] A sequencing reaction containing M13 primer (3.2 pmol/µl), 'BigDye' reaction mix (i.e. AmpliTaq® DNA polymerase, MgCl₂ buffer and fluorescent dNTPs [each of the four deoxynucleoside triphosphates is linked to a specific fluorescent donor dye which in turn is attached to a specific acceptor dye]) and cDNA template (diluted PCR product) was set up. The reaction was carried out on a thermal cycler for 25 cycles of 10 seconds at 96°C, 20 seconds at 50°C and 4 minutes at 60°C. Each reaction product was then purified through a hydrated Centri-Sep column, and lyophilised. The pellets were resuspended in Template Suppression Reagent and sequenced on an ABI Prism 310 Genetic Analyser. The analyser uses an ion laser to excite the specific donor dye that transfers its energy to the acceptor dye, which emits a specific energy spectrum that can be read by the sequencer.

[0120] The differentially expressed genes of the streptozocin-induced diabetes experiment and of the CCI experiment were sequenced at Parke-Davis, Cambridge and at the applicant's core sequencing facility in Ann Arbor, MI, USA.

Bioinformatics

[0121] The sequencing results were analysed using the computer program CHROMAS in which the vector and adaptor sequences were clipped off, leaving only the nucleotide sequence of the differentially expressed gene. Each sequence was then checked for homology to known genes, Expressed Sequence Tags (ESTs) and Proteins using various Basic Local Alignment Search Tool (BLAST) searches against the Genbank sequence database at the National Centre for Biotechnology Information, Bethesda, Maryland, USA (NCBI).

[0122] Lists were derived called STZup and STZdown and CClup and CClidown that contain the nucleic acid sequences from the forward and back subtracted libraries respectively. In each list there are given accession numbers and descriptions for the known rat genes identified, and where available corresponding mouse or human genes. Sequences that are considered to be of interest and that are down-regulated both in a streptozocin-induced diabetes model and in a chronic constrictive injury pain model are identified in Tables I - VI above and are listed below.

[0123] References have been given where available for the sequences that have been found, and sequence listings have been given in the form in which they currently appear in publicly searchable databases e.g. the NCBI database (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, MD 20894, USA, www.ncbi.nlm.nih.gov). These sequence listings are given for the purposes of identification only. The invention includes the use of subsequently revised versions of the above sequences (which may incorporate small differences to the version set out herein) and homologous sequences or similar proteins in other species as

determined by a high percentage identity (e.g. above 50%, preferably above 90%), length of alignment and functional equivalence.

1. Noguchi, T., Inoue, H. and Tanaka, T., The M-1- and M-2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing, *J. Biol. Chem.* **261**, 13807-13812 (1986).

2. Takenaka, M., Noguchi, T., Inoue, H., Yamada, K., Matsuda, T. and Tanaka, T., Rat pyruvate kinase M gene: Its complete structure and characterization of the 5'-flanking region, *J. Biol. Chem.* **264**, 2363-2367 (1989).

3. Zhou, Q.Y., Grandy, D.K., Thambi, L., Kushner, J.A., Van Tol, H.H., Cone R., Pribnow, D., Salon, J., Bunzow, J. R. and Civelli, O., Cloning and expression of human and rat D1 dopamine receptors, *Nature*, **347** (6288), 76-80 (1990)

4. Sullivan, R., Chateaufneuf, A., Coulombe, N., Kolakowski, L.F. Jr., Johnson, M.P., Hebert, T.E., Ethier, N., Belley, M., Metters, K., Abramovitz, M., O'Neill, G.P. and Ng, G.Y.K., Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GABA (B) heterodimer as the functional receptor, *J. Pharmacol. Exp. Ther.* **293** (2), 460-467 (2000)

5. Premont, R.T., Claing, A., Vitale, N., Freeman, J.L., Pitcher, J.A., Patton, W.A., Moss, J., Vaughan, M. and Lefkowitz, R.J., beta2-Adrenergic receptor regulation by G1T1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein, *Proc. Natl. Acad. Sci. U.S.A.*, **95** (24), 14082-14087 (1998).

6. Welis, D. and Kedes, L., Structure of a human histone cDNA: evidence that basally expressed histone genes have intervening sequences and encode polyadenylated mRNAs, *Proc. Natl. Acad. Sci. U.S.A.*, **82** (9), 2834-2838 (1985).

7. Ayle, J., Gil-Gomez, G. and Hegardt, F.G., Nucleotide sequence of a rat liver cDNA encoding the cytosolic 3-hydroxy-3-methylglutaryl coenzyme A synthase, *Nucleic Acids Res.*, **18** (12), 3642 (1990).

8. Teruya, J.H., Kutsunai, S.Y., Spear, D.H., Edwards, P.A. and Clarke, C.F., Testis-specific transcriptional initiation sites of rat farnesyl pyrophosphate synthetase mRNA, *Mol. Cell. Biol.*, **10**, 2315-2326 (1990).

9. Beck, K.F., Schreglmann, R., Stathopoulos, I., Klein, H., Hoch, J. and Schweizer, M., The fatty acid synthase (FAS) gene and its promoter in *Rattus norvegicus*, *DNA Seq.*, **2** (6), 359-386 (1992).

10. Mill, J.F., Mearow, K.M., Purohit, H.J., Haleem-Smith, H., King, R. and Freese, E., Cloning and functional characterization of the rat glutamine synthetase gene, *Brain Res. Mol. Brain Res.*, **9** (3), 197-207 (1991).

11. Vincent, C., Tarbouriech, N. and Hartlein, M., Genomic organization, cDNA sequence, bacterial expression, and purification of human seryl-tRNA synthase, *Eur. J. Biochem.*, **250** (1), 77-84 (1997).

12. Giallongo, A., Feo, S., Moore, R., Croce, C.M. and Showe, L.C., Molecular cloning and nucleotide sequence of a full-length cDNA for human alpha enolase, *Proc. Natl. Acad. Sci. U.S.A.*, **83** (18), 6741-6745 (1986).

13. Carper, D., Nishimura, C., Shinohara, T., Dietzchold, B., Wistow, G., Craft, C., Kador, P. and Kinoshita, J.H., Aldose reductase and p-crystallin belong to the same protein superfamily as aldehyde reductase, *FEBS Lett.* **220** (1), 209-213 (1987).

14. Ku, C.Y., Lu, Q., Ussuf, K.K., Weinstock, G.M. and Sanborn, B.M., Hormonal regulation of cytochrome oxidase subunit messenger RNAs in rat Sertoli cells, *Mol. Endocrinol.* **5** (11), 1669-1676 (1991).

15. Tsuji, S., Qureshi, M.A., Hou, E.W., Fitch, W.M. and Li, S.S.-L., Evolutionary relationships of lactate dehydrogenases from mammals, birds, an amphibian, fish, barley, and bacteria: LDH cDNA sequences from *Xenopus*, pig and rat, *Proc. Natl. Acad. Sci. U.S.A.* **91**, 9392-9396 (1994).

16. Taanman, J.W., Schrage, C., Ponne, N., Bolhuis, P., de Vries, H. and Agsteribbe, E., Nucleotide sequence of cDNA encoding subunit VIb of human cytochrome c oxidase, *Nucleic acids research.* **17** (4), 1766 (1989).

17. Triepels, R., van den Heuvel, L., Loeffen, J., Smeets, R., Trijbels, F. and Smeitink, J., The nuclear-encoded human NADH: ubiquinone oxidoreductase NDUFA8 subunit: cDNA cloning, chromosomal localization, tissue distribution, and mutation detection in complex-I-deficient patients, *Hum. Genet.* **103** (5), 557-563 (1998).

18. Hosokawa, Y., Suzuki, H., Toda, H., Nishikimi, M. and Ozawa, T. Complementary DNA encoding core protein II of human mitochondrial cytochrome bc-1 complex: Substantial diversity in deduced primary structure from its yeast counterpart, *J. Biol. Chem.* **264**, 13483-13488 (1989).

19. Harnik-Ort, V., Prakash, K., Marcantonio, E., Colman, D.R., Rosenfeld, M.G., Adesnik, M., Sabatini, D.D. and Kreibich, G. Isolation and characterization of cDNA clones for rat ribophorin I: complete coding sequence and in vitro synthesis and insertion of the encoded product into endoplasmic reticulum membranes, *J. Cell Biol.* **104**(4), 855-863 (1987).

20. Falany, C.N., Xie, X., Wang, J., Ferrer, J. and Falany, J.L., Molecular cloning and expression of novel sulpho-transferase-like cDNAs from human and rat brain, *Biochem. J.* **346** Pt 3, 857-864 (2000).

21. Pan, W., Ko, Y.H. and Pedersen, P.L., Delta subunit of rat liver mitochondrial ATP synthase: molecular description and novel insights into the nature of its association with the F1-moiety, *Biochemistry* **37** (19), 6911-6923 (1998).

22. Hamajima, N., Matsuda, K., Sakata, S., Tamaki, N., Sasaki, M. and Nonaka, M., A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution, *Gene* **180** (1-2), 157-163 (1996).

23. McGuire, J.A., Poellinger, L., Wikstrom, A.C. and Gustafsson, J.A., Cloning and regulation by glucocorticoid receptor ligands of a rat hsp90 *J. Steroid Biochem. Mol. Biol.* **42** (8), 813-822 (1992).

24. Roach, A., Boylan, K.B., Horvath, S., Prusiner, S.B. and Hood, L.E., Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain of shiverer mutant mice, *Cell* **34**, 799-806 (1983).

25. Hoshino, A., Hisayasu, S. and Shimada, T., Complete sequence analysis of rat transferrin and expression of transferrin but not lactoferrin in the digestive glands, *Comp. Biochem. Physiol. B* **113**, 491-497 (1996).

26. Chin, S.S. and Liem, R.K., Expression of rat neurofilament proteins NF-L and NF-M in transfected non-neuronal cells, *Eur. J. Cell Biol.* **50** (2), 475-490 (1989).

27. Lai, C., Brow, M.A.D., Nave, K.-A., Noronha, A.B., Quarles, R.H., Bloom, F.E., Milner, R.J. and Sutcliffe, J.G., Two forms of IB236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing, *Proc. Natl. Acad. Sci. U.S.A.* **84**, 4337-4341 (1987).

28. Napolitano, E.W., Chin, S.S.M., Colman, D.R. and Liem, R.K.H., Complete amino acid sequence and in vitro expression of rat NF-M, the middle molecular weight neurofilament protein, *J. Neurosci.* **7**, 2590-2599 (1987).

29. Nakayama, M., Miyake, T., Gahara, Y., Ohara, O. and Kitamura, T., A novel RING-H2 motif protein downregulated by axotomy: its characteristic localization at the postsynaptic density of axosomatic synapse, *J. Neurosci.* **15** (7 Pt 2), 5238-5248 (1995).

30. Kuwano, R., Usui, H., Maeda, T., Fukui, T., Yamanari, N., Ohtsuka, E., Ikehara, M. and Takahashi, Y., Molecular cloning and the complete nucleotide sequence of cDNA to mRNA for S-100 protein of rat brain, *Nucleic Acids Res.* **12** (19), 7455-7465 (1984).

31. Zauner, W., Kratz, J., Staunton, J., Feick, P. and Wiche, G., Identification of two distinct microtubule binding domains on recombinant rat MAP 1B, *Eur. J. Cell Biol.* **57** (1), 66-74 (1992).

32. Ozaki, T., Irie, K. and Sakiyama, S., Molecular cloning and cell cycle-dependent expression of a novel gene that is homologous to cdc37, *DNA Cell Biol.* **14** (12), 1017-1023 (1995).

33. Albertsen, H.M., Smith, S.A., Mazoyer, S.S., Fujimoto, E., Stevens, J., Williams, B., Rodriguez, P., Cropp, C. S., Slijepcevic, P. and Carlson, M., A physical map and candidate genes in the BRCA1 region on chromosome

17q12-21, *Nature Genet.* **7** (4), 472-479 (1994).

34. Dieffenbach, C.W., SenGupta, D.N., Krause, D., Sawzak, D. and Silverman, R.H., Cloning of murine gelsolin and its regulation during differentiation of embryonal carcinoma cells, *J. Biol. Chem.* **264**, 13281-13288 (1989).

35. Geisert, E.E. Jr., Murphy, T.P., Irwin, M.H. and Larjava, H., A novel cell adhesion molecule, G-CAM, found on cultured rat glia, *Neurosci. Lett.* **133** (2), 262-266 (1991); Irwin, M.H. and Geisert, E.E. Jr., The upregulation of a glial cell surface antigen at the astrocytic scar in the rat, *Neurosci. Lett.* **154** (1-2), 57-60 (1993); Geisert, E.E. Jr., Yang, L. and Irwin, M.H., Astrocyte growth, reactivity, and the target of the antiproliferative antibody, TAPA, *J. Neurosci.* **16** (17), 5478-5487 (1996).

36. Holz, A., Schaeren-Wiemers, N., Schaefer, C., Pott, U., Colello, R.J. and Schwab, M.E., Molecular and developmental characterization of novel cDNAs of the myelin-associated/oligodendrocytic basic protein, *J. Neurosci.* **16** (2), 467-477 (1996).

37. Ching, G.Y. and Liem, R.K.H., Structure of the gene for the neuronal intermediate filament protein alpha-internexin and functional analysis of its promoter, *J. Biol. Chem.* **266**, 19459-19468 (1991).

38. Lai, C.H., Chou, C.Y., Ch'ang, L.Y., Liu, C.S. and Lin, Wc., Identification of novel human genes evolutionarily conserved in *Caenorhabditis elegans* by comparative proteomics, *Genome Res.* **10** (5), 703-713 (2000).

39. Nagase, T., Seki, N., Tanaka, A., Ishikawa, K. and Nomura, N., Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (K1AA0121-K1AA0160) deduced by analysis of cDNA clones from human cell line KG-1, *DNA Res.* **2** (4), 167-174 (1995).

40. Wendel, M., Sommarin, Y., Bergman, T. and Heinegard, D., Isolation, characterization, and primary structure of a calcium-binding 63-kDa bone protein, *J. Biol. Chem.* **270** (11), 6125-6133 (1995).

41. Welcher, A.A., Suter, U., De Leon, M., Snipes, G.J. and Shooter, E.M., A myelin protein is encoded by the homologue of a growth arrest-specific gene, *Proc. Natl. Acad. Sci. U.S.A.* **88**, 7195-7199 (1991).

42. Nudel, U., Zakut, R., Shani, M., Neuman, S., Levy, Z. and Yaffe, D., The nucleotide sequence of the rat cytoplasmic beta-actin gene, *Nucleic Acids Res.* **11** (6), 1759-1771 (1983).

43. Miwa, J.M., Ibanez-Tallon, I., Crabtree, G.W., Sanchez, R., Sali, A., Role, L.W. and Heintz, N., lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS, *Neuron* **23** (1), 105-114 (1999).

44. Rothmel, E., Detzler, E., Walter, L., Leyan, G. and Gunther, E., Characterization and mapping of a highly conserved processed pseudogene and an intron-carrying gene of the heat shock cognate protein 70 (Hsc70) gene family in the rat, *Mamm. Genome* **6** (9), 602-606 (1995).

45. Sadot, E., Marx, R., Barg, J., Behar, L. and Ginzburg, I., Complete sequence of 3'-untranslated region of Tau from rat central nervous system. Implications for mRNA heterogeneity, *J. Mol. Biol.* **241** (2), 325-331 (1994).

46. Lemke, G. and Axel, R., Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin, *Cell* **40**, 501-508 (1985).

SEQUENCE LISTING

5 <110> Warner-Lambert Company
 Lee, Kevin
 Dixon, Alistair
 Brooksbank, Robert
 Pinnock, Robert

10 <120> Identification and Use of Molecules Implicated in Pain
 <130> WL-A-018199
 <150> GB 0118354.0
 <151> 2001-07-27

15 <160> 117
 <170> PatentIn Ver. 2.1

20 <210> 1
 <211> 531
 <212> PRT
 <213> Rattus norvegicus

25 <220>
 <223> Pyruvate kinase M1 subunit

30 <400> 1
 Met Pro Lys Pro Asp Ser Glu Ala Gly Thr Ala Phe Ile Gln Thr Gln
 1 5 10 15
 Gln Leu His Ala Ala Met Ala Asp Thr Phe Leu Glu His Met Cys Arg
 20 25 30
 Leu Asp Ile Asp Ser Ala Pro Ile Thr Ala Arg Asn Thr Gly Ile Ile
 35 35 40 45
 Cys Thr Ile Gly Pro Ala Ser Arg Ser Val Glu Met Leu Lys Glu Met
 50 55 60
 Ile Lys Ser Gly Met Asn Val Ala Arg Leu Asn Phe Ser His Gly Thr
 40 65 70 75 80
 His Glu Tyr His Ala Glu Thr Ile Lys Asn Val Arg Ala Ala Thr Glu
 85 90 95
 Ser Phe Ala Ser Asp Pro Ile Leu Tyr Arg Pro Val Ala Val Ala Leu
 45 100 105 110
 Asp Thr Lys Gly Pro Glu Ile Arg Thr Gly Leu Ile Lys Gly Ser Gly
 115 120 125
 Thr Ala Glu Val Glu Leu Lys Lys Gly Ala Thr Leu Lys Ile Thr Leu
 50 130 135 140
 Asp Asn Ala Tyr Met Glu Lys Cys Asp Glu Asn Ile Leu Trp Leu Asp
 145 150 155 160
 55 Tyr Lys Asn Ile Cys Lys Val Val Glu Val Gly Ser Lys Ile Tyr Val
 165 170 175

EP 1 284 298 A2

Asp Asp Gly Leu Ile Ser Leu Gln Val Lys Glu Lys Gly Ala Asp Tyr
 180 185 190
 5 Leu Val Thr Glu Val Glu Asn Gly Gly Ser Leu Gly Ser Lys Lys Gly
 195 200 205
 Val Asn Leu Pro Gly Ala Ala Val Asp Leu Pro Ala Val Ser Glu Lys
 210 215 220
 10 Asp Ile Gln Asp Leu Lys Phe Gly Val Glu Gln Asp Val Asp Met Val
 225 230 235 240
 Phe Ala Ser Phe Ile Arg Lys Ala Ala Asp Val His Glu Val Arg Lys
 245 250 255
 15 Val Leu Gly Glu Lys Gly Lys Asn Ile Lys Ile Ile Ser Lys Ile Glu
 260 265 270
 Asn His Glu Gly Val Arg Arg Phe Asp Glu Ile Leu Glu Ala Ser Asp
 275 280 285
 20 Gly Ile Met Val Ala Arg Gly Asp Leu Gly Ile Glu Ile Pro Ala Glu
 290 295 300
 Lys Val Phe Leu Ala Gln Lys Met Met Ile Gly Arg Cys Asn Arg Ala
 305 310 315 320
 25 Gly Lys Pro Val Ile Cys Ala Thr Gln Met Leu Glu Ser Met Ile Lys
 325 330 335
 Lys Pro Arg Pro Thr Arg Ala Glu Gly Ser Asp Val Ala Asn Ala Val
 340 345 350
 30 Leu Asp Gly Ala Asp Cys Ile Met Leu Ser Gly Glu Thr Ala Lys Gly
 355 360 365
 Asp Tyr Pro Leu Glu Ala Val Arg Met Gln His Leu Ile Ala Arg Glu
 370 375 380
 35 Ala Glu Ala Ala Val Phe His Arg Leu Leu Phe Glu Glu Leu Ala Arg
 385 390 395 400
 40 Ala Ser Ser Gln Ser Thr Asp Pro Leu Glu Ala Met Ala Met Gly Ser
 405 410 415
 Val Glu Ala Ser Tyr Lys Cys Leu Ala Ala Ala Leu Ile Val Leu Thr
 420 425 430
 45 Glu Ser Gly Arg Ser Ala His Gln Val Ala Arg Tyr Arg Pro Arg Ala
 435 440 445
 Pro Ile Ile Ala Val Thr Arg Asn Pro Gln Thr Ala Arg Gln Ala His
 450 455 460
 50 Leu Tyr Arg Gly Ile Phe Pro Val Leu Cys Lys Asp Ala Val Leu Asp
 465 470 475 480
 Ala Trp Ala Glu Asp Val Asp Leu Arg Val Asn Leu Ala Met Asn Val
 485 490 495
 55 Gly Lys Ala Arg Gly Phe Phe Lys Lys Gly Asp Val Val Ile Val Leu

EP 1 284 298 A2

	500	505	510
	Thr Gly Trp Arg Pro Gly Ser	Gly Phe Thr Asn Thr	Met Arg Val Val
	515	520	525
5	Pro Val Pro		
	530		
10	<210> 2		
	<211> 531		
	<212> PRT		
	<213> Rattus norvegicus		
15	<220>		
	<223> Pyruvate kinase M2 subunit		
20	<400> 2		
	Met Pro Lys Pro Asp Ser Glu Ala Gly Thr Ala Phe Ile Gln Thr Gln		
	1 5 10 15		
	Gln Leu His Ala Ala Met Ala Asp Thr Phe Leu Glu His Met Cys Arg		
	20 25 30		
25	Leu Asp Ile Asp Ser Ala Pro Ile Thr Ala Arg Asn Thr Gly Ile Ile		
	35 40 45		
	Cys Thr Ile Gly Pro Ala Ser Arg Ser Val Glu Met Leu Lys Glu Met		
	50 55 60		
30	Ile Lys Ser Gly Met Asn Val Ala Arg Leu Asn Phe Ser His Gly Thr		
	65 70 75 80		
	His Glu Tyr His Ala Glu Thr Ile Lys Asn Val Arg Ala Ala Thr Glu		
	85 90 95		
35	Ser Phe Ala Ser Asp Pro Ile Leu Tyr Arg Pro Val Ala Val Ala Leu		
	100 105 110		
	Asp Thr Lys Gly Pro Glu Ile Arg Thr Gly Leu Ile Lys Gly Ser Gly		
	115 120 125		
40	Thr Ala Glu Val Glu Leu Lys Lys Gly Ala Thr Leu Lys Ile Thr Leu		
	130 135 140		
	Asp Asn Ala Tyr Met Glu Lys Cys Asp Glu Asn Ile Leu Trp Leu Asp		
	145 150 155 160		
45	Tyr Lys Asn Ile Cys Lys Val Val Glu Val Gly Ser Lys Ile Tyr Val		
	165 170 175		
	Asp Asp Gly Leu Ile Ser Leu Gln Val Lys Glu Lys Gly Ala Asp Tyr		
	180 185 190		
50	Leu Val Thr Glu Val Glu Asn Gly Gly Ser Leu Gly Ser Lys Lys Gly		
	195 200 205		
	Val Asn Leu Pro Gly Ala Ala Val Asp Leu Pro Ala Val Ser Glu Lys		
	210 215 220		
55	Asp Ile Gln Asp Leu Lys Phe Gly Val Glu Gln Asp Val Asp Met Val		

EP 1 284 298 A2

	225		230		235		240									
	Phe	Ala	Ser	Phe	Ile	Arg	Lys	Ala	Ala	Asp	Val	His	Glu	Val	Arg	Lys
					245					250					255	
5	Val	Leu	Gly	Glu	Lys	Gly	Lys	Asn	Ile	Lys	Ile	Ile	Ser	Lys	Ile	Glu
				260					265					270		
	Asn	His	Glu	Gly	Val	Arg	Arg	Phe	Asp	Glu	Ile	Leu	Glu	Ala	Ser	Asp
10			275					280					285			
	Gly	Ile	Met	Val	Ala	Arg	Gly	Asp	Leu	Gly	Ile	Glu	Ile	Pro	Ala	Glu
			290				295					300				
	Lys	Val	Phe	Leu	Ala	Gln	Lys	Met	Met	Ile	Gly	Arg	Cys	Asn	Arg	Ala
15			305			310					315					320
	Gly	Lys	Pro	Val	Ile	Cys	Ala	Thr	Gln	Met	Leu	Glu	Ser	Met	Ile	Lys
					325					330					335	
	Lys	Pro	Arg	Pro	Thr	Arg	Ala	Glu	Gly	Ser	Asp	Val	Ala	Asn	Ala	Val
20				340					345					350		
	Leu	Asp	Gly	Ala	Asp	Cys	Ile	Met	Leu	Ser	Gly	Glu	Thr	Ala	Lys	Gly
			355					360					365			
	Asp	Tyr	Pro	Leu	Glu	Ala	Val	Arg	Met	Gln	His	Leu	Ile	Ala	Arg	Glu
25			370				375					380				
	Ala	Glu	Ala	Ala	Ile	Tyr	His	Leu	Gln	Leu	Phe	Glu	Glu	Leu	Arg	Arg
						390					395					400
30	Leu	Ala	Pro	Ile	Thr	Ser	Asp	Pro	Thr	Glu	Ala	Ala	Ala	Val	Gly	Ala
					405					410					415	
	Val	Glu	Ala	Ser	Phe	Lys	Cys	Cys	Ser	Gly	Ala	Ile	Ile	Val	Leu	Thr
				420					425					430		
35	Lys	Ser	Gly	Arg	Ser	Ala	His	Gln	Val	Ala	Arg	Tyr	Arg	Pro	Arg	Ala
			435					440					445			
	Pro	Ile	Ile	Ala	Val	Thr	Arg	Asn	Pro	Gln	Thr	Ala	Arg	Gln	Ala	His
			450				455					460				
40	Leu	Tyr	Arg	Gly	Ile	Phe	Pro	Val	Leu	Cys	Lys	Asp	Ala	Val	Leu	Asp
					470						475				480	
	Ala	Trp	Ala	Glu	Asp	Val	Asp	Leu	Arg	Val	Asn	Leu	Ala	Met	Asn	Val
				485					490					495		
45	Gly	Lys	Ala	Arg	Gly	Phe	Phe	Lys	Lys	Gly	Asp	Val	Val	Ile	Val	Leu
				500					505					510		
	Thr	Gly	Trp	Arg	Pro	Gly	Ser	Gly	Phe	Thr	Asn	Thr	Met	Arg	Val	Val
50			515					520					525			
	Pro	Val	Pro													
			530													
55	<210>	3														
	<211>	11788														

<212> DNA
 <213> *Rattus norvegicus*

<220>
 <223> Pyruvate kinase

5

10

15

20

25

30

35

40

45

50

55

```

<400> 3
cccgggagcgag cgccgggagg gtggagagtc accgggaggg gctggaggaa tgtccgggac 60
ctataaatct gggcaacgcc ctggtaggcc agggcagatg gggcacctgg gcagaattcc 120
aaaatgggat tatgtagcct ctgagggtcct aaagcaacag gtggcggacc acccggggat 180
ctaggggtg tggcggcggt ggaccgcagg gcggggtcctg cctcctcacc acttccccat 240
tggccatcag aalgacccat gcgcaatttt gggttgcaat gtccttcgc caggaaggt 300
agtccccctc aaaaggga cctgcttgct ccgcctaccc tgcgactctc tcagaaggtg 360
cgggtgcctg ttgagaggcg gggctctgct agctgctgcc cggattgggc gaggggagg 420
gctgcggagg gattgcggcg gcccgcagca gtgataacct tgaggcccag tctgcgcagc 480
cccgcacagc agcgacccgt cctaagtcga cagacgtcct ctttaggtat tgcaacagga 540
tctgaagtac gcccagggtg agcggggaga acotttgcca tctgtggcc cagagccaat 600
gcatagttgg atcactagtg ggtggctgca atgtcagggt gcagagccag gcttgggtgc 660
atgttcttta ggtatccaga aaagccgatg tccagggtag agtgcgggtc tttgggaagg 720
cagggaagag caaggagatg tggagtgcag gctgtgtgct caggagtgtg aaaggagcct 780
cgtggcctga aaattgattc aagtctctgg tattctgtga ggtacatccc aggttctcgc 840
ttactcagcc aactatccag ctacgtagtg gcttagctgt aagtcgtaat aaagtaaaag 900
caaaggtcag gacagctgtt gggattgtga cctgggtgat taattgcctg gaacagatgt 960
tcagactact gtgtcgtggt ccctatcaga cagagaagga gactctagat agccagaact 1020
ggggctggga aagctgggtc taatgtcagc tcttgggaag agtagtgact ttcaaggtca 1080
acctcggttg cactagtgat ttcaggccag catagactag ctactgtgtg tgattccatc 1140
tcctaggtta ctgaagactc cttgggtgagg ttgtaatgac tttggagcca tttcaatgtc 1200
cttgtgcaaa atttgctttg tgtgtcttgt acatggtgct gcttttttgc ttcttgtcca 1260
gaaaaaaact tgttgctgtt aatttggacc ttattcctgt gtcggataga ggctaaggaa 1320
tacatttagg tgatacctca aacctaggac tttaaaaaga aaggacttgg gacagggttc 1380
gtctcttggc agcaggatcg tttagggtcat gggaacatg ataaaggagg tatgtcagtg 1440
ccaaagcagg tttgacattg tcgtgatagg cttcccagat gttcgtgtgc tgacacatta 1500
gctacgtgct ctgcaggagt ggggaggttt ccttgtgtgg gaaggatagt tctctctagg 1560
gttggtgtga agctcttcaa tagatggcag ccgttgtaag aagctctgct taaactggca 1620
gccagggtgt gtatgtgcac tgggaaggaa gctacttttg ttcaccaagg tctttgctgt 1680
tcgttcatag tcacaggagc cttttgcca atttgagtag taccacata accagcacgt 1740
gccaggcctc tgagtgactt gtgcacaaag cagtcttatt gggttaatgt gtaagcggga 1800
gacagtctcc tatgccaaat ggttcattaa gcaactgccta gtctaattga actcttcaaa 1860
tctccgggat ccaggatctc agaaaccatg cccaagccag acagcgaagc agggactgcc 1920
ttcattcaga cccagcagct ccatgcagcc atggctgaca ccttccctga acacatgtgc 1980
cgcttgagca ttgactccgc acccatcag gcccgaaca ctgggatcat ctgtaccatt 2040
ggtagtgag tgtggcccc ttgcagggtc tctgtcctgg tttgaaaggc gtaataacca 2100
ttgcagggtc aacctagggt ctgagagaca tgtccacact tttagaggaa cgtattgggtg 2160
tacttcttct gcacttggtg aggttcaggg tggctctagt gcctttgcag gagtayttca 2220
gggacttcag atctttttcc tgtgctgtca ctccactttc tgcagaattt atagaaaatg 2280
atagtgtcct tccttacata taaattaaga gagtccctcc ttacatataa atcaagagag 2340
ttgactagca cagttagtct tctggacttt ggaagacct tctctaaat ttgtggaggt 2400
attaaaaaca agggacaagg agttgccttt gatagtagca gatttcatat actttcctac 2460
ctgagaatca tgattttctt cctgtggctc taaatgtttc ttggtaggcc ctgcttcccg 2520
atctgtggag atgtgaagg agatgattaa gtctgggatg aatgtggctc ggctgaattt 2580
ctctcatgga acccatgagg tgagtggcag cttgatccag gaggttcggg acttgcctgt 2640
gctgtgtctc aggtctctca gtgaatggac gttgctctac ttacatttag atccccctc 2700
tccctcttcc cctctggcca acttcattgg catcaacaac ctgcctgctt tgcgcgggc 2760
caggttatcc ctaccatcaa gcttcaccag ggctttctta tctatgtgc accttcgatg 2820
aggggctgtg gctgtctglt ttggatgagg ggctgtggct gtctgtcttg gttttaacca 2880
ttcctggaga cgggtggaatg aatcgtagct ccctcgagct cttggcctaa ttgatcatct 2940
ttggctccag ggtggctcag ggcatgggaa ctggacttgg gtgtggagaa cacctacctg 3000
tcaatctccc cttcttctc tccagtacca tgcagagact atcaagaatg tccgtgcagc 3060
cacagaaagc tttgcatctg atcccattct ctaccgacct gttgcgggtg ctctggatac 3120
aaagggacct gagatccgga ctggactcat caaggcggtg agtatccagg agtttaggtc 3180
tttaaatgag aatatttttc atctgcctgg taggaattat tatagatgca catttttggg 3240

```

	atgtgaataa	cataacttaag	tctcactctg	gggacctggt	ttgttgtttg	ttttgtttgt	3300
	ttccctcaat	aaacaaattc	aggattttaca	gaaaggtgat	cggtttcttg	gggctttgag	3360
	ccagagtttg	agcgcccgcca	tcagggtgtt	ggcgctccaca	gtcacacgcc	tctgtgtgtc	3420
5	ttaatctaga	gcggcaccgc	agaggtggag	ctgaagaagg	gagccacact	gaagatcacc	3480
	ctggacaacg	cctacatgga	gaagtgcgac	gagaacatcc	tgtggctgga	ctataagaac	3540
	atctgcaagg	tgggtggagg	gggcagcaag	atctacgtgg	acgatgggct	catctccctg	3600
	cagggtgaagg	agaaaggat	gtgtgggtga	cagtcacagg	cccaatgcca	ctcccatccc	3660
	cagaactctg	gtaagcactt	aacctagcat	gtatgaattg	gtctcccaag	gtcaaaagtt	3720
	taaggtgggt	gttgggtctg	atccctggcc	tgtctgaaac	actgcctgag	aaaaaataga	3780
10	caaataacct	acaaaggcct	atgtgtacac	ctgtaccctt	tagttccagc	actcggaat	3840
	cagcaggtgt	gtgagttctc	atgtgttaagg	actactcctg	tatgcctaga	atgagtctag	3900
	agttctcttg	gcttctcaca	aactgagata	gatggctctg	atccctttca	cacaggtgct	3960
	gactacctgg	tgacagaagt	ggaaaalgg	ggctccctgg	gcagcaagaa	gggcgtgaac	4020
	ctgcctgggt	ctgctgtgga	cctccctgct	gtgtcagaaa	aggacatcca	ggacctgaag	4080
	tttgggggtg	agcaggacgt	ggacatggtg	tttgcgtctt	tcatccgcaa	ggcggctgac	4140
15	gtgcatgagg	ttaggaaggt	cctgggagag	aaggggcaaga	acatcaagat	catcagcaaa	4200
	atcgagaacc	atgaaggtgt	ccgcaggtga	aggtccactc	ctaccgtgtg	cctgggggtgt	4260
	ggccttgagg	gcacctctgt	cagggcccag	gaaagctctg	tccattcttt	ggttgtactt	4320
	cctgtttctat	agcatctttc	tttttatcag	gtttgtagag	attttggagg	ccagcgatgg	4380
	aatcatggta	gctcgtgggt	acctggggcat	tgagattccg	gcagagaagg	tcttctctagc	4440
20	tcagaagatg	atgattggac	gatgcaaccg	agctgggaag	ccagtcactc	gcgccaccca	4500
	ggcatgtgct	atcccttctc	tctgtgttct	ccacctagga	gacctgggtc	tgacctggcc	4560
	tttaggtaca	cgtacccgca	catagctatg	actgcgtac	ctgtgcaagc	ttcggggaa	4620
	tgcctggaa	tcatactctg	agatgtcctg	ctcttccatt	athtagtgac	tttcattttag	4680
	cggtgggtctc	ttacttaata	aaaacccttg	tttgtccctc	cctagatgct	ggagagcatg	4740
	atcaagaagc	cacgccccac	ccgtgctgaa	ggcagtgacg	tggccaatgc	agtcctagat	4800
25	ggagctgact	gcacatgct	gtccggagaa	acagccaaag	gggactaccc	tctggagggt	4860
	gttcgcatgc	agcacctggt	gagtaagtcc	tcagagtcc	ggggtagaag	agctctgctg	4920
	gagaggcctc	tgtccagtct	tgttacattg	ctcccgtcac	agcaaggaga	gtgagggttg	4980
	tggagtgctg	ttgagtttca	ttgtgctttc	actgcctgca	cctgcccctt	tgtcctgctc	5040
	tggggattac	ataggccaca	tctggctaaa	atatcaaggt	cctaggatgc	agtcaaggga	5100
	tgccttccct	gtggacaccc	agagggcctg	ggtacctcta	ttctaaagga	gccaaagttt	5160
30	tgttcagcta	ttcgccttgt	tacctctcat	tttgtctcct	gtggtctgcc	catgggcaat	5220
	gcttctctcc	actgcagctg	tagccatact	gagctgcttt	aagctggccg	tgcatgggtg	5280
	ctgtgacatg	ggacttctc	ccttgctgtg	ccagacccaa	ctcggggcta	caaatagctc	5340
	tgggggtggg	gaatgggtgc	taatttagca	ggttctgtct	ggtctaggaa	ttataaagac	5400
	ttctcaggca	tattatgtgc	tcttttgatt	aagcttctct	gtttcagtaa	gatagggtct	5460
35	ggcgcaagct	tgtaattcca	acaatcaaat	caagcctgcg	gcaggaagat	ggcttgagat	5520
	taggctggac	tagaatgaga	catctttag	aagcaacagg	cgtcagtgac	ctgtccctgc	5580
	ggactttcca	cccaggcctc	cgtcttctgt	gttctgctcc	agaacttctt	ccggagcaga	5640
	acaattatct	ggggcatcag	ttagggaccg	ttgcctgata	aaggcatggt	ggattagctt	5700
	tttgggggtt	ttctattccc	tttccagcca	acaaagaacc	acagtatctt	ttgtggctcc	5760
	agtttcccac	aagccccccc	aaacttaaga	caagtgaag	aaaagaagga	agccccctct	5820
40	gggttaggca	tcttaccttg	cttttatatgt	atatgagagt	tgagtagatt	ccatgatctt	5880
	tccatggatt	tatctgaatt	atagctgtag	ccagatgttt	gcctatatgt	aaacagacca	5940
	gcgctttgac	tccgctgggt	atgacctgtt	ctgattggaa	ttgtgactgg	tcctcatagc	6000
	ttctcatagc	tgcaggcatt	ctctcccaga	agacttttcc	cttccctcaa	tctccccac	6060
	agtagctgcc	ttcctgggtt	acacccaaac	cccttttcta	cttacctggc	ctcacagtgg	6120
	tcagggaacag	gactttgacc	aggtattcta	aagcatgtag	tcacataaat	gtatttttgg	6180
45	atagctcaag	aagaccttgc	ccaaagtggc	ggttgatgag	attaattaca	attaattata	6240
	tgtgtatgag	ttagtttttg	gtctctgctc	ttttctcatg	ccctgggtctt	tcctatgaac	6300
	agacacctta	gaacctcgag	gctgggattg	catggccctg	ctcagaagat	gagtcacaga	6360
	gtccgggtta	gactgtggct	acccccctcag	ggatacaaat	ttctctatca	gttaaacatt	6420
	aggacagctt	ctcccccttc	tttatctggt	tgtgttttcc	tcctgtgtct	aactgattca	6480
50	gttcaaaaacc	tgtaattaaa	agctagacat	ccagctgtgt	gttgcttctc	gtccatgcct	6540
	cttgtctctt	gggcttgctt	gcattccatg	cttaaccaaa	agattacttt	ccacttgcaa	6600
	atctgctaata	gctaccaata	aaatcgagtg	ctggtttcat	atcattctctg	gaattgcaact	6660
	ctctaaaaact	ttatttcttt	atttctaattg	cttggtttta	cttgaacagg	tggctctgat	6720
	ataacacatt	tgctalccctg	laaccgtttt	aattattgca	gtttgaatct	gtgtcttgaa	6780
	aggcctgtgt	gctttcccag	cctcacatgg	ctgttcagtg	taccgtgttc	taccgtgttc	6840
55	aagtgaagcca	gtcgaccact	gttctgttta	gaacttgtgc	actgcaactt	tggctctttt	6900
	gacctcacc	cccagctttc	agagctgccc	gagtgcttcc	actgtaagcc	aagtgaagcc	6960

EP 1 284 298 A2

	gctcactctt	gtgtgtaggc	ggagttggat	gccttgtaac	cacatagcca	tgtgaggagg	7020
	ggacgccttt	ttcttcctgt	aagctgtgtc	aggaggcagt	gtggtcaagc	ggaagtgtag	7080
	ttggctccac	cttggcatct	ttccatgcc	gggtcccttt	ctcagcttta	atcaaaaaca	7140
5	aaagaaatga	tggatgggtg	atgcctagca	cttgggaggc	tgaggcaaaag	aaaatagtg	7200
	tgttttgagg	ctgaccatgg	caagttcaag	gccagtaggt	gctatggtaa	gacctaact	7260
	caaacctgtg	tggggttgag	aattggcttt	tttggtttgt	ttgttttttag	aaacaggaaa	7320
	tcccaaaagg	atactatctt	tccagaagg	aaggaaggat	ctgtccgtgt	gttgaacag	7380
	aaaagagagc	cacccaaaat	cccacatata	ataccattcc	aggctttgac	catcctgcct	7440
	ctgtatctgc	atggagaaga	aaagattaac	ctaagagttc	cttcctctca	ttagttccct	7500
10	gtctttccat	gtgttgtctc	ttgtttttgc	cttcattcct	cttccttata	cttcctaccc	7560
	ttaaaccctac	agatagctcg	agaggctgag	gcagccgtgt	tccaccgcct	gctgtttgaa	7620
	gagcttgccg	gagcctccag	tcaatccaca	gacccctgg	aggccatggc	catgggcagc	7680
	gtggaggcct	cttataaatg	tttagcagca	gctttgtag	ttctgacgga	gtccggcagg	7740
	tagggccctg	agggcaggta	tcattataag	ataaccagct	tctcacacaa	ctagggccca	7800
	ctgtgtgcct	gagcctgggc	atagcctctc	ccctgcagga	aggcagccaa	ggaggtcacg	7860
15	atagggcagg	accaaaggat	tccctagtgg	gtacagtgg	agtcacaggc	actgggtcag	7920
	gatgggtccc	tgtggagttt	ctaactcttc	tcaagtttca	gaaacgtgtt	agtgaactca	7980
	tctttctcct	ggctttttgt	gccaggaca	tgttcccttc	cagttgcctg	tgactcttct	8040
	ccttcatttt	tgacaaagct	ctgacaaagc	cctgtccccc	ttcctcgtcc	ctctggacgg	8100
	atgtttgctc	ctagattgc	ccgagaggca	gaggctgcca	tctaccactt	gcagttattc	8160
20	gaggaactcc	gccgcctggc	gccattacc	agcgacccca	cagaagctgc	cgccgtgggt	8220
	gccgtggagg	cctccttcaa	gtgctgcagt	ggggccatta	tcgtgctcac	caagtctggc	8280
	aggtaggagg	cggcagtgcc	tccctgggga	tcccagagca	actctgggct	gattttaaga	8340
	ccctgggctg	ccatcaaagg	actccaggaa	gcactccag	gtacatcaga	ttaggtggct	8400
	ccagtgcag	tcagtgcagg	cctgcctcag	ggcctgaagc	atatatacag	ttttgcttag	8460
	ttacgggtgtg	gaagctgggc	atgggtacat	gccttttaac	ctccagcat	tcgggcagaa	8520
25	gaggtgggca	aalgtctgca	ttcglggaca	gtgctggtct	acaaagcaag	ttccaggaca	8580
	gagccctagc	tcacaaaaat	taactcagct	ggtaaaact	acttgctaca	ccaagttaga	8640
	cggatggagg	agggagaaaag	gtaacttagc	aagcgtgccc	aaggacatat	acagtaaac	8700
	ttttttctcat	cccacttgga	gggagctcaa	tggataaagt	gttggcaatc	tggatttgg	8760
	tctggcacct	gtgggttttt	gttgtttgtt	gggtttttgt	tttttttttt	ttttttaagt	8820
	cacctggaga	agtaagtttag	gccttttagga	gcattggggt	ttggttttta	agatttattt	8880
30	attatatatg	aactacactc	tccctatctt	cagtcgcacc	agaagagggt	gattacagat	8940
	gattgtgtaa	gccaccatgt	ggttgctggg	agttgaactc	aggacctctg	gaagagcagt	9000
	tagtgctctt	aaccactgag	ccatctctcc	agccagcact	gttctttcag	aagcccaaca	9060
	catacatgac	agctcacact	atctaactgc	agtcctgggg	ggaatcta	gccctcttct	9120
	aacttccagc	cgtacatggt	tatatgatgc	atgtggtcag	gataccca	cagctggagg	9180
35	gaaaggaagg	tgcccaacac	acctgtgtgc	ctgtaatccc	agcactcatg	gtacagagg	9240
	agaaagatca	caagataggt	ctaactctgag	caaattctgc	aacagcctag	atacagaaag	9300
	ccaaacacat	aaaaatcagt	gtgggctgag	gatgttgacc	tttgtgtgaa	ttggccatga	9360
	acattgtatg	cagctggaag	caagggatgg	gggtgctgaa	aatggggacc	ttaaaaacta	9420
	ttttctgaag	tcctgaagtt	tcgagagctc	caagatacaa	gttctatgct	aatcctggac	9480
	tttctctgaa	gagttcctgg	ttccttcaaa	gcccatgtag	gccagctaga	agcagggtat	9540
40	tttctgcctg	tggaaatggc	acatccccta	ataccttggt	tgtcctcaag	atgcctagtt	9600
	aattcagtaa	gcctgaaaca	gatctgatag	aagtaaacat	atcattttgt	atcggtttag	9660
	gagagagggg	ctccctacat	tcccaaaagg	tcttgattgg	ccagatatta	accatgcctg	9720
	gtcacaccta	gattttccaa	aaaaccatag	aaattcagag	gtttctttta	gcaccaagtt	9780
	cagctgataa	gactcccaaa	ggagcagtat	agtactctct	ggcaataact	gtccactcca	9840
	gggtctctgc	agataccaga	agtcaggagc	taggcacatg	gtgcttggat	tgtaaaagtt	9900
45	gctggcagct	acaggatggg	tctgggtgaga	ttagggcaga	gctgcctcac	tgccctgatg	9960
	aagggttcac	agtgtgggag	ggatcctgcc	agccgtgggt	ctatgggact	gccacactg	10020
	agatcaggac	aatgagttaa	aaaggacagg	acaggtctga	gggggtggcc	aggcactaaa	10080
	cagtaattgt	aagtgggcaa	acctgtggcc	tagagggtgaa	ttagagggtg	ctcctttggc	10140
	tgaactgaaag	ggtctcgtga	cacaatggcc	attcttccca	ccttctcagg	agtgtctcac	10200
50	aagtggcccg	gtaccgcccc	agggctccta	tcattgtgtg	gacacgcaat	cccagacag	10260
	cccgccaggc	ccatctgtac	cgtggcatct	tccctgtgct	gtgtaaggat	gccgtactgg	10320
	atgcctgggc	tgaggacgtt	gatcttctgt	tgaacttggc	catgaatgtt	ggtatgtagc	10380
	tgggaagcaag	ggatgggggtg	ctgggaaatg	gggagcctaa	aactaccatt	tcctgaagcc	10440
	ctcaccacat	tttgggcccc	aggcaaaatt	aattgcctca	ttaggctctt	gtaagattaa	10500
	ttggagctac	tgcctgtggg	ggtggggcac	acaagctgtt	gtggcttttg	ttcctatata	10560
55	aggttgagata	tcaagagaca	aggaagcagc	tgaccctgaa	cttgggcaag	gctggccact	10620
	ctagagtcta	aactgaatgg	tgtccaaagg	tccctgcagt	ctgagttttg	cctcagccct	10680

EP 1 284 298 A2

5
10
15
20
25
30
35
40
45
50
55

tggttaagct aggagacttg caccaccttg tggtaaaaag aagtaactgg caacctgctc 10740
tcctacctga attagaagca atagggcatt tggtatcctg cctgggttagg cttgtgtctg 10800
ggctgggaga aagcaccacc ttgtggtagg agagagtact ggttgctcag ttaggactgg 10860
gtagggcttt gcagttatcc ccaagtgtta tatacctcta ctcaccaacc tccttctccc 10920
ctcaggcaag gcccagggtt tcttcaagaa gggagatgtg gtcattgtgc tgactggatg 10980
gcgccctggc tctggcttca ccaacaccat gcgtgtagtg cctgtacat gatgatctc 11040
tggagcttct cttctagccc ctgtcccttc ccctccccta tcctatccat taggccagca 11100
acgttgtagt gctcactctg ggccatagtg tggcgctggg gggctgggac accaggaaaa 11160
attaatgcct ctgaacatg caatagagcc cagctatctt tcattggcct acttgagcca 11220
ggggtgaagg aggaatgcag gattggaaac cctctgactt tatcacagaa gggcagcatt 11280
atctctgtgt tctttgctcc ttagaagaat tttccagaga attcccagcc ctggcctgga 11340
atcaggagac agcaagaaca gaggtctggg gccaggggtt cccatgtaga tgacttttgg 11400
ccctgtccct gacttgcttt cccaacagct ttggcctctc tcctcgtgca ctccactgct 11460
gtccctgcag atgttccact ctccacctcg tactctgcag cgtctccagg cctgttgcta 11520
tagtgcctac ctgaatgtca ataaacagca gcggaacgac ctgtgttctt ttcttctctg 11580
ggggcgctgt tgaggctatc ctctgagcag tcgaaaatga caaccggcct aaaggctcag 11640
cctggagccg agtatatagg ttgcctctc caacagcacc aagtggggct atctatgtgt 11700
tggaagctc actgttttat ttcaggacag actggaaagg tctgggacag gttcagctag 11760
cacctgtaat ggtgggtaga cggagggg 11788

<210> 4
<211> 446
<212> PRT
<213> Rattus norvegicus

<220>
<223> Dopamine receptor D1

<400> 4
Met Ala Pro Asn Thr Ser Thr Met Asp Glu Ala Gly Leu Pro Ala Glu
1 5 10 15
30 Arg Asp Phe Ser Phe Arg Ile Leu Thr Ala Cys Phe Leu Ser Leu Leu
20 25 30
35 Ile Leu Ser Thr Leu Leu Gly Asn Thr Leu Val Cys Ala Ala Val Ile
35 40 45
40 Arg Phe Arg His Leu Arg Ser Lys Val Thr Asn Phe Phe Val Ile Ser
50 55 60
40 Leu Ala Val Ser Asp Leu Leu Val Ala Val Leu Val Met Pro Trp Lys
65 70 75 80
Ala Val Ala Glu Ile Ala Gly Phe Trp Pro Phe Gly Ser Phe Cys Asn
85 90 95
45 Ile Trp Val Ala Phe Asp Ile Met Cys Ser Thr Ala Ser Ile Leu Asn
100 105 110
Leu Cys Val Ile Ser Val Asp Arg Tyr Trp Ala Ile Ser Ser Pro Phe
115 120 125
50 Gln Tyr Glu Arg Lys Met Thr Pro Lys Ala Ala Phe Ile Leu Ile Ser
130 135 140
Val Ala Trp Thr Leu Ser Val Leu Ile Ser Phe Ile Pro Val Gln Leu
145 150 155 160
55 Ser Trp His Lys Ala Lys Pro Thr Trp Pro Leu Asp Gly Asn Phe Thr
165 170 175

EP 1 284 298 A2

	Ser	Leu	Glu	Asp	Thr	Glu	Asp	Asp	Asn	Cys	Asp	Thr	Arg	Leu	Ser	Arg	
				180					185					190			
5	Thr	Tyr	Ala	Ile	Ser	Ser	Ser	Leu	Ile	Ser	Phe	Tyr	Ile	Pro	Val	Ala	
			195					200					205				
	Ile	Met	Ile	Val	Thr	Tyr	Thr	Ser	Ile	Tyr	Arg	Ile	Ala	Gln	Lys	Gln	
		210					215					220					
10	Ile	Arg	Arg	Ile	Ser	Ala	Leu	Glu	Arg	Ala	Ala	Val	His	Ala	Lys	Asn	
		225				230					235					240	
	Cys	Gln	Thr	Thr	Ala	Gly	Asn	Gly	Asn	Pro	Val	Glu	Cys	Ala	Gln	Ser	
					245					250					255		
15	Glu	Ser	Ser	Phe	Lys	Met	Ser	Phe	Lys	Arg	Glu	Thr	Lys	Val	Ile	Lys	
				260					265					270			
	Thr	Leu	Ser	Val	Ile	Met	Gly	Val	Phe	Val	Cys	Cys	Trp	Leu	Pro	Phe	
			275					280					285				
20	Phe	Ile	Ser	Asn	Cys	Met	Val	Pro	Phe	Cys	Gly	Ser	Glu	Glu	Thr	Gln	
		290					295					300					
	Pro	Phe	Cys	Ile	Asp	Ser	Ile	Thr	Phe	Asp	Val	Phe	Val	Trp	Phe	Gly	
25		305				310					315					320	
	Trp	Ala	Asn	Ser	Ser	Leu	Asn	Pro	Ile	Ile	Tyr	Ala	Phe	Asn	Ala	Asp	
					325					330					335		
	Phe	Gln	Lys	Ala	Phe	Ser	Thr	Leu	Leu	Gly	Cys	Tyr	Arg	Leu	Cys	Pro	
30				340					345					350			
	Thr	Thr	Asn	Asn	Ala	Ile	Glu	Thr	Val	Ser	Ile	Asn	Asn	Asn	Gly	Ala	
			355					360					365				
	Val	Val	Phe	Ser	Ser	His	His	Glu	Pro	Arg	Gly	Ser	Ile	Ser	Lys	Asp	
35			370				375					380					
	Cys	Asn	Leu	Val	Tyr	Leu	Ile	Pro	His	Ala	Val	Gly	Ser	Ser	Glu	Asp	
		385				390					395					400	
	Leu	Lys	Lys	Glu	Glu	Ala	Gly	Gly	Ile	Ala	Lys	Pro	Leu	Glu	Lys	Leu	
40				405					410					415			
	Ser	Pro	Ala	Leu	Ser	Val	Ile	Leu	Asp	Tyr	Asp	Thr	Asp	Val	Ser	Leu	
				420					425					430			
45	Glu	Lys	Ile	Gln	Pro	Val	Thr	His	Ser	Gly	Gln	His	Ser	Thr			
			435					440					445				
	<210> 5																
	<211> 960																
50	<212> PRT																
	<213> Mus musculus																
	<220>																
	<223> GABA-Bla receptor																
55	<400> 5																

EP 1 284 298 A2

	Met	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Phe	Leu	Arg	Pro	Leu	Gly	Ala		
	1				5				10					15			
5	Gly	Gly	Ala	Gln	Thr	Pro	Asn	Val	Thr	Ser	Glu	Gly	Cys	Gln	Ile	Ile	
				20					25					30			
	His	Pro	Pro	Trp	Glu	Gly	Gly	Ile	Arg	Tyr	Arg	Gly	Leu	Ile	Arg	Asp	
			35					40					45				
10	Gln	Val	Lys	Ala	Ile	Asn	Phe	Leu	Pro	Val	Asp	Tyr	Glu	Ile	Glu	Tyr	
		50					55					60					
	Val	Cys	Arg	Gly	Glu	Arg	Glu	Val	Val	Gly	Pro	Lys	Val	Arg	Lys	Cys	
	65					70					75					80	
15	Leu	Ala	Asn	Gly	Ser	Trp	Thr	Asp	Met	Asp	Thr	Pro	Ser	Arg	Cys	Val	
					85					90					95		
	Arg	Ile	Cys	Ser	Lys	Ser	Tyr	Leu	Thr	Leu	Glu	Asn	Gly	Lys	Val	Phe	
				100					105					110			
20	Leu	Thr	Gly	Gly	Asp	Leu	Pro	Ala	Leu	Asp	Gly	Ala	Arg	Val	Asp	Phe	
			115					120					125				
	Arg	Cys	Asp	Pro	Asp	Phe	His	Leu	Val	Gly	Ser	Ser	Arg	Ser	Ile	Cys	
			130				135						140				
25	Ser	Gln	Gly	Gln	Trp	Ser	Thr	Pro	Lys	Pro	His	Cys	Gln	Val	Asn	Arg	
	145					150					155					160	
	Thr	Pro	His	Ser	Glu	Arg	Arg	Ala	Val	Tyr	Ile	Gly	Ala	Leu	Phe	Pro	
					165					170					175		
30	Met	Ser	Gly	Gly	Trp	Pro	Gly	Gly	Gln	Ala	Cys	Gln	Pro	Ala	Val	Glu	
				180					185					190			
	Met	Ala	Leu	Glu	Asp	Val	Asn	Ser	Arg	Arg	Asp	Ile	Leu	Pro	Asp	Tyr	
			195					200					205				
35	Glu	Leu	Lys	Leu	Ile	His	His	Asp	Ser	Lys	Cys	Asp	Pro	Gly	Gln	Ala	
		210					215					220					
	Thr	Lys	Tyr	Leu	Tyr	Glu	Leu	Leu	Tyr	Asn	Asp	Pro	Ile	Lys	Ile	Ile	
	225					230					235					240	
40	Leu	Met	Pro	Gly	Cys	Ser	Ser	Val	Ser	Thr	Leu	Val	Ala	Glu	Ala	Ala	
					245					250					255		
	Arg	Met	Trp	Asn	Leu	Ile	Val	Leu	Ser	Tyr	Gly	Ser	Ser	Ser	Pro	Ala	
				260					265						270		
45	Leu	Ser	Asn	Arg	Gln	Arg	Phe	Pro	Thr	Phe	Phe	Arg	Thr	His	Pro	Ser	
			275					280					285				
	Ala	Thr	Leu	His	Asn	Pro	Thr	Arg	Val	Lys	Leu	Phe	Glu	Lys	Trp	Gly	
		290					295					300					
50	Trp	Lys	Lys	Ile	Ala	Thr	Ile	Gln	Gln	Thr	Thr	Glu	Val	Phe	Thr	Ser	
	305					310					315					320	
	Thr	Leu	Asp	Asp	Leu	Glu	Glu	Arg	Val	Lys	Glu	Ala	Gly	Ile	Glu	Ile	
					325					330					335		
55																	

EP 1 284 298 A2

	Thr	Phe	Arg	Gln	Ser	Phe	Phe	Ser	Asp	Pro	Ala	Val	Pro	Val	Lys	Asn	
				340					345						350		
5	Leu	Lys	Arg	Gln	Asp	Ala	Arg	Ile	Ile	Val	Gly	Leu	Phe	Tyr	Glu	Thr	
			355					360					365				
	Glu	Ala	Arg	Lys	Val	Phe	Cys	Glu	Val	Tyr	Lys	Glu	Arg	Leu	Phe	Gly	
		370					375					380					
10	Lys	Lys	Tyr	Val	Trp	Phe	Leu	Ile	Gly	Trp	Tyr	Ala	Asp	Asn	Trp	Phe	
	385					390					395					400	
	Lys	Thr	Tyr	Asp	Pro	Ser	Ile	Asn	Cys	Thr	Val	Glu	Glu	Met	Thr	Glu	
				405						410					415		
15	Ala	Val	Glu	Gly	His	Ile	Thr	Thr	Glu	Ile	Val	Met	Leu	Asn	Pro	Ala	
				420					425					430			
	Asn	Thr	Arg	Ser	Ile	Ser	Asn	Met	Thr	Ser	Gln	Glu	Phe	Val	Glu	Lys	
			435					440					445				
20	Leu	Thr	Lys	Arg	Leu	Lys	Arg	His	Pro	Glu	Glu	Thr	Gly	Gly	Phe	Gln	
	450						455					460					
	Glu	Ala	Pro	Leu	Ala	Tyr	Asp	Ala	Ile	Trp	Ala	Leu	Ala	Leu	Ala	Leu	
	465					470					475					480	
25	Asn	Lys	Thr	Ser	Gly	Gly	Gly	Gly	Arg	Ser	Gly	Val	Arg	Leu	Glu	Asp	
					485					490				495			
	Phe	Asn	Tyr	Asn	Asn	Gln	Thr	Ile	Thr	Asp	Gln	Ile	Tyr	Arg	Ala	Met	
				500					505					510			
30	Asn	Ser	Ser	Ser	Phe	Glu	Gly	Val	Ser	Gly	His	Val	Val	Phe	Asp	Ala	
			515					520					525				
	Ser	Gly	Ser	Arg	Met	Ala	Trp	Thr	Leu	Ile	Glu	Gln	Leu	Gln	Gly	Gly	
		530					535					540					
35	Ser	Tyr	Lys	Lys	Ile	Gly	Tyr	Tyr	Asp	Ser	Thr	Lys	Asp	Asp	Leu	Ser	
	545					550					555					560	
	Trp	Ser	Lys	Thr	Asp	Lys	Trp	Ile	Gly	Gly	Ser	Pro	Pro	Ala	Asp	Gln	
				565					570						575		
40	Thr	Leu	Val	Ile	Lys	Thr	Phe	Arg	Phe	Leu	Ser	Gln	Lys	Leu	Phe	Ile	
				580					585					590			
	Ser	Val	Ser	Val	Leu	Ser	Ser	Leu	Gly	Ile	Val	Leu	Ala	Val	Val	Cys	
			595					600					605				
	Leu	Ser	Phe	Asn	Ile	Tyr	Asn	Ser	His	Ala	Arg	Tyr	Ile	Gln	Asn	Ser	
		610				615						620					
50	Gln	Pro	Asn	Leu	Asn	Asn	Leu	Thr	Ala	Val	Gly	Cys	Ser	Leu	Ala	Leu	
	625					630					635					640	
	Ala	Val	Val	Phe	Pro	Leu	Gly	Leu	Asp	Gly	Tyr	His	Ile	Gly	Arg	Ser	
					645					650					655		
55	Gln	Phe	Pro	Phe	Val	Cys	Gln	Ala	Arg	Leu	Trp	Leu	Leu	Gly	Leu	Gly	

EP 1 284 298 A2

	660	665	670
5	Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His 675 680 685		
	Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu 690 695 700		
10	Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp 705 710 715 720		
	Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr 725 730 735		
15	Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser 740 745 750		
	Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp 755 760 765		
20	Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile 770 775 780		
	Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp 785 790 795 800		
25	His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu 805 810 815		
	Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala 820 825 830		
30	Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu 835 840 845		
	Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu 850 855 860		
35	Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn 865 870 875 880		
	Asn Asn Glu Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu 885 890 895		
40	Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg 900 905 910		
	His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro 915 920 925		
45	Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro 930 935 940		
	Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys 945 950 955 960		
50			
55	<210> 6 <211> 4365		

<212> DNA
<213> Mus musculus

<220>
<223> GABA-B1a receptor

5

<400> 6

10

15

20

25

30

35

40

45

50

55

```

taacttgctgc cgcgcgtcgc cccggggaag gagagacggg ggtgggggtt gcgggtagcg 60
atcgcgaaagg ggagagagccc cggccgggct ggagcctgga ttcctgtgga agaagaacag 120
ggggaggggga agctggagga cgggagggga gaacggggag ccgcggccgg gcctgggccc 180
ttgagggcccg gggagagccg cggagcgggg cggccgcccg agatgctgct gctgctgctt 240
ctgcttctct tcctccgcc cctgggcgct ggcggggctc agaccccca cgtcacctcg 300
gaaggttgcc agattatata tccgccttgg gaaggtggca tcaggtaccg tggcttgatt 360
cgcgaccagg tgaaggccat caatttcctg cctgtggact atgagattga atatgtgtgc 420
cggggcgaac gcgaggtggt ggggcccagg gtgcgcaagt gcctggccaa cggctccttg 480
acggatatgg acacaccagg tcgctgtgtc cgaatctgct ccaagtctta tttgaccttg 540
gaaaatggga aggttttctt gacgggtggg gacctcccag ctctggatgg agccgggtg 600
gatttccgat gtgacctga cttccatctg gtgggcagct cccggagcat ctgtagtcag 660
ggccagtgga gcaccccca gcccactgc caggtaatc gaacgccaca ctcagaacgg 720
cgtgcagtat acatcggggc gctgtttccc atgagcgggg gctggccggg gggccaggcc 780
tgccagcctg cgttgagat ggcgctggag gacgttaaca gccgcagaga catcctggcg 840
gactacgagc tcaagcttat ccaccacgac agcaagtgcg acccagggca agccaccaag 900
tacttgatg aactactcta caacgacccc atcaagatca tcctcatgcc cggctgcagc 960
tctgtgtcca cactggtagc cgaggctgcc cggatgtgga acctattgt gctctcatat 1020
ggctccagct caccagcctt gtcaaaccca cagcggttcc caacgttctt tcggacacat 1080
ccatccgcca cactccacaa tcccacccgg gtgaaaactc tcgaaaagtg gggctggaag 1140
aagattgcca ccattccagca gactaccgag gtcttcacct caacactgga tgacctggag 1200
gagcgagtga aagaggctgg gattgagatc acttttcgac agagtctctt ctccagatcca 1260
gctgtgcctg ttaaaaacct gaagcgtcaa gatgctcgaa tcctcgtggg acttttctat 1320
gagaccgaag cccggaaagt tttttgtgag gtctataagg aacggctctt tgggaagaag 1380
tatgtctggt ttctcatcgg ttggtatgct gacaactggt tcaaaaaccta tgacctgca 1440
atcaattgta cagtagaaga gatgactgag gcggtggagg gccatatcac caccgagatt 1500
gtcatgtgga accctgccaa caccgaagc atttccaaca tgacatcaca ggaatttctg 1560
gagaaactaa ccaagcggt gaaaagacac cctgaggaga ctggaggctt ccaggaggca 1620
ccactggcct atgatgctat ttgggccttg gctttggcct tgaacaagac ctctggagga 1680
gggtggcgtt caggagtgcg cctggaggac ttttaactaca acaaccagac cattacagac 1740
caaactctac gggccatgaa ctctctctcc tttgagggtg ttcttgccca cgtggctctt 1800
gatgccagcg gctcccggat ggcattggag cttatcgagc agctacaggg cggcagctac 1860
aagaagatcg gctactacga cagcaccaag gatgatcttt cctgggtccaa aacagacaag 1920
tggtatcgag ggtctcccc agccgaccag accttggcca tcaagacatt ccgtttcttg 1980
tcacagaaac tctttatctc cgtctcagtt ctctccagcc tgggcattgt tcttctgtgt 2040
gtctgtctgt cctttaacat ctacaactcc cagctcgtt atatccagaa tccccagccc 2100
aacctgaaca atctgactgc tgtgggotgc tactggcac tggctgttgt ctccctctc 2160
gggctgyaly gttaccacat agggagaagc cagttccgt ttgtctgcca ggcccgctt 2220
tggctcttgg gcttgggctt tagtctgggc tatggctcta tgttaccaca gatctggtg 2280
gtccacacag tcttcacgaa gaaggaggag aagaaggagt ggaggagac cctagagccc 2340
tggaactct atgccactgt gggcctgctg gtgggcatgg atgtcctgac tcttgccatc 2400
tggcagattg tggacccctt gcaccgaacc attgagactt ttgccaagga ggaaccaaag 2460
gaagacatcg atgtctccat tctgccccag ttggagcact gcagctccaa gaagatgaat 2520
acgtggcttg gcattttcta tggttacaag gggctgctgc tgcgtgctgg aatctttctt 2580
gcttacgaaa ccaagagcgt gtccactgaa aagatcaatg accacagggc cgtgggcatg 2640
gctatctaca atgtcgcggt cctgtgtctc atcactgctc ctgtgacct gatcctttcc 2700
agtcagcagg acgcagcctt tgcctttgccc tctctggcca tctgttctc ttcctacatc 2760
actctggttg tgctctttgt gcccaagatg cgcaggctga tcacccgagg ggaatggcag 2820
tctgaaacgc aggacacat gaaaacagga tcattccacca acaacaacga ggaagagaag 2880
tcccgaactg tggagaagga aaaccgagaa ctggaagaaga tcctcgctga gaaagaggag 2940
cgcgtctctg aactgcgcca tcagctccag tctcggcagc aactccgctc acggcgccac 3000
cccccaacac cccagatcc ctctccaggg gacctctga gccccctgac 3060
cggcttagct gtgatgggag tcgagtacat ttgctttaca agtgaggggg catggagaag 3120
gatcaagcca gtaggggagg gaagggtctg ggaagagggt gggggcctgg gaggagggtg 3180
aggactccta tctccaacct ggagagcaca cgctccaatc cccctcttat aaatacatgt 3240

```

EP 1 284 298 A2

5
10
15

```

cgctctgtgc atctgggggtt atttgggtct ccagtactct gggaaacaga ctgttttctt 3300
tctccctat aattttatat ctccacttca caggttttgt ttgaacctg cttggagtta 3360
ttattcactc atggctccag aggggcatct catttttctc cggtagcctg tcttgtagag 3420
ttaccacagc aactcctgtc atttcagcag caggggtctt cctacactag caggggtctc 3480
gctctctcca tttttcagcc tcagaatctc cttccattat tcttctcctt ctacatgtct 3540
ccatggcttc ctctcccagg ggactcgttc tacacacata cacacacaca cacacacaca 3600
cacacacaca cacacacaca cacacccgc atcctgccct ctccaggca gctgcatgtc 3660
gtcctgtaca aatgtgtctg cttctgagtg ctttgtgcgg ccgttcactt gtgctgtctg 3720
cataagctgc gtctgtgagt gcacgggtgt ttgtgggtgc gtgaagtggc atgctccggg 3780
aggtgtgtgt gtgtgtgccc acgcgtgcgc ccgtgtgcat gcgttcgtgt tgccctgact 3840
ggctgtctca gccttctgag taattgggat tccagttgtc tgtctagctc atgtcctgtc 3900
ttcttccagt agagccgtga acaccaaca cacacagtta atcgggctcc cccaggtcca 3960
tgttttctga gccatccaaa aactctcctt ggccttaggt tcatctgcaa atgttccctc 4020
tggtctttgc tctcgtgcgt ccaccttcat tctcttcagt catttctcag atctgctgcg 4080
tcgtgggttc ctttccttca ttatcatcgt cattattttt cagaacttaa gggaaaaaga 4140
aatggggaca ggttggaggc tgtttccagt ggaatagtgg gtgcgcgtcc tgaccaaagt 4200
aaggcacgga cagatggact gacggggcgg gaggcggcgt ccctttcaca ccgtgggtgc 4260
tcttgggggg gaaggatctc cctgaatctc aataaagcag tgaacagtaa aaaaaaaaaa 4320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 4365

```

20
25

```

<210> 7
<211> 582
<212> PRT
<213> Rattus norvegicus

<220>
<223> Differentiation-associated Na-dependent inorganic phosphate
cotransporter

```

30
35
40
45
50
55

```

<400> 7
Met Glu Ser Val Lys Gln Arg Ile Leu Ala Pro Gly Lys Glu Gly Ile
  1             5             10             15

Lys Asn Phe Ala Gly Lys Ser Leu Gly Gln Ile Tyr Arg Val Leu Glu
          20             25             30

Lys Lys Gln Asp Asn Arg Glu Thr Ile Glu Leu Thr Glu Asp Gly Lys
          35             40             45

Pro Leu Glu Val Pro Glu Lys Lys Ala Pro Leu Cys Asp Cys Thr Cys
          50             55             60

Phe Gly Leu Pro Arg Arg Tyr Ile Ile Ala Ile Met Ser Gly Leu Gly
          65             70             75             80

Phe Cys Ile Ser Phe Gly Ile Arg Cys Asn Leu Gly Val Ala Ile Val
          85             90             95

Asp Met Val Asn Asn Ser Thr Ile His Arg Gly Gly Lys Val Ile Lys
          100            105            110

Glu Lys Ala Lys Phe Asn Trp Asp Pro Glu Thr Val Gly Met Ile His
          115            120            125

Gly Ser Phe Phe Trp Gly Tyr Ile Ile Thr Gln Ile Pro Gly Gly Tyr
          130            135            140

Ile Ala Ser Arg Leu Ala Ala Asn Arg Val Phe Gly Ala Ala Ile Leu
          145            150            155            160

```

EP 1 284 298 A2

	Leu	Thr	Ser	Thr	Leu	Asn	Met	Leu	Ile	Pro	Ser	Ala	Ala	Arg	Val	His	
					165					170					175		
5	Tyr	Gly	Cys	Val	Ile	Phe	Val	Arg	Ile	Leu	Gln	Gly	Leu	Val	Glu	Gly	
				180					185					190			
	Val	Thr	Tyr	Pro	Ala	Cys	His	Gly	Ile	Trp	Ser	Lys	Trp	Ala	Pro	Pro	
			195					200					205				
10	Leu	Glu	Arg	Ser	Arg	Leu	Ala	Thr	Thr	Ser	Phe	Cys	Gly	Ser	Tyr	Ala	
		210					215					220					
	Gly	Ala	Val	Ile	Ala	Met	Pro	Leu	Ala	Gly	Ile	Leu	Val	Gln	Tyr	Thr	
	225					230					235					240	
15	Gly	Trp	Ser	Ser	Val	Phe	Tyr	Val	Tyr	Gly	Ser	Phe	Gly	Met	Val	Trp	
					245					250					255		
	Tyr	Met	Phe	Trp	Leu	Leu	Val	Ser	Tyr	Glu	Ser	Pro	Ala	Lys	His	Pro	
				260					265					270			
20	Thr	Ile	Thr	Asp	Glu	Glu	Arg	Arg	Tyr	Ile	Glu	Glu	Ser	Ile	Gly	Glu	
			275					280					285				
	Ser	Ala	Asn	Leu	Leu	Gly	Ala	Met	Glu	Lys	Phe	Lys	Thr	Pro	Trp	Arg	
		290					295					300					
25	Lys	Phe	Phe	Thr	Ser	Met	Pro	Val	Tyr	Ala	Ile	Ile	Val	Ala	Asn	Phe	
	305					310					315					320	
	Cys	Arg	Ser	Trp	Thr	Phe	Tyr	Leu	Leu	Leu	Ile	Ser	Gln	Pro	Ala	Tyr	
					325					330					335		
30	Phe	Glu	Glu	Val	Phe	Gly	Phe	Glu	Ile	Ser	Lys	Val	Gly	Met	Leu	Ser	
				340				345						350			
	Ala	Val	Pro	His	Leu	Val	Met	Thr	Ile	Ile	Val	Pro	Ile	Gly	Gly	Gln	
			355					360					365				
35	Ile	Ala	Asp	Phe	Leu	Arg	Ser	Lys	Gln	Ile	Leu	Ser	Thr	Thr	Thr	Val	
		370					375					380					
	Arg	Lys	Ile	Met	Asn	Cys	Gly	Gly	Phe	Gly	Met	Glu	Ala	Thr	Leu	Leu	
40	385				390					395					400		
	Leu	Val	Val	Gly	Tyr	Ser	His	Thr	Arg	Gly	Val	Ala	Ile	Ser	Phe	Leu	
				405					410						415		
	Val	Leu	Ala	Val	Gly	Phe	Ser	Gly	Phe	Ala	Ile	Ser	Gly	Phe	Asn	Val	
45			420					425					430				
	Asn	His	Leu	Asp	Ile	Ala	Pro	Arg	Tyr	Ala	Ser	Ile	Leu	Met	Gly	Ile	
			435				440						445				
	Ser	Asn	Gly	Val	Gly	Thr	Leu	Ser	Gly	Met	Val	Cys	Pro	Ile	Ile	Val	
50		450				455					460						
	Gly	Ala	Met	Thr	Lys	Asn	Lys	Ser	Arg	Glu	Glu	Trp	Gln	Tyr	Val	Phe	
	465				470					475					480		
	Leu	Ile	Ala	Ala	Leu	Val	His	Tyr	Gly	Gly	Val	Ile	Phe	Tyr	Ala	Leu	
55					485					490					495		

EP 1 284 298 A2

Phe Ala Ser Gly Glu Lys Gln Pro Trp Ala Asp Pro Glu Glu Thr Ser
500 505 510

5 Glu Glu Lys Cys Gly Phe Ile His Glu Asp Glu Leu Asp Glu Glu Thr
515 520 525

Gly Asp Ile Thr Gln Asn Tyr Ile Asn Tyr Gly Thr Thr Lys Ser Tyr
530 535 540

10 Gly Ala Thr Ser Gln Glu Asn Gly Gly Trp Pro Asn Gly Trp Glu Lys
545 550 555 560

Lys Glu Glu Phe Val Gln Glu Ser Ala Gln Asp Ala Tyr Ser Tyr Lys
565 570 575

15 Asp Arg Asp Asp Tyr Ser
580

<210> 8
 20 <211> 3982
 <212> DNA
 <213> Rattus norvegicus

<220>
 25 <223> Differentiation-associated Na-dependent inorganic phosphate
 cotransporter

<400> 8

30 agacagtaag gttcttttgc ttttttccct tacacaagga ttcgatgacg tttttgggtca 60
 atctgattaa aagacagcgg atttggttgc gtttaagactt caaaaccggg aattttacgtt 120
 gtttttcggg gaggtgactt ccagaacggg gactcatcag caccgcgcca aataccacgg 180
 cactgcgcgc gccctcggcc accggatcct ccccttccaa tgagactttg tgactgtgtg 240
 taccaattct cctattagga aaccgcgtgg ctgaatgcag ctattccgtt gtactctctt 300
 tctcgctctc cctccctctt ccaactcaca gccttgctga aaagctcatc tctgctgaga 360
 agaaaacggt ctaccttaac ctattaagac tatgcgagaa actcgccttt catagccatc 420
 35 acaattttaa tctggtaagg ctggacacga gtctttacaa gaatggagtc ggtaaaacaa 480
 aggattttgg ccccggggaa agaggggata aagaattttg ctggaaaatc cctcggacag 540
 atctacaggg tgctggagaa gaagcaggat aaccgagaga ccatcgagct gacagaggac 600
 ggcaagcccc tggagggtgc tgagaagaag gctccgctat gcgactgtac gtgcttcggc 660
 ctgcccgcgc gctacatcat agccatcatg agcggcctcg gcttctgcat ctccttttgt 720
 40 atccgctgta acctgggtgt ggccatttgt gacatggtca acaacagcac catccaccgg 780
 ggtggcaaaag ttatcaagga gaaagccaag tttaactggg accccgagac tgtggggatg 840
 attcacgggt cgttcttctg ggcctatata atcacgcaga ttccggggcg atacatcgca 900
 tcgcgactgg ctgctaaccg ggtcttttgg gctgccatac tgcttacctc taccctcaat 960
 atgctgatcc catctgcagc cagagtgcag tatggatgcg tcactcttct tagaatattg 1020
 caaggacttg tggagggcgt cacctaccca gcctgtcacg ggatatggag caagtggggc 1080
 45 cctccttttg agaggagtag gttggctacc acctccttct gtggttccta tgctggagca 1140
 gtcattgcaa tgcccctagc tggatatcct gtgcagaca ctggatgggt ttcagtattt 1200
 tacgtatatg gaagcttttg tatggtctgg tatatgtctt ggcttctggt gtcttacgag 1260
 agccccgcaa agcatccaac cataacagac gaagaacgta ggtacataga agagagcatc 1320
 ggggagagcg caaatctgtt agggagcaat gagaaattca agaccccatg gaggaagttt 1380
 50 ttcacatcca tgcccgtcta tgcgataatt gttgcaaact tctgcaggag ttggactttt 1440
 tatttactgc tcatcagtc accagcttat ttcgaggagg tttttggatt tgaaatcagc 1500
 aaggttgcca tgttgtctgc ggtccacac ctggtcatga caatcattgt gcctatcggg 1560
 gggcaaattg cagactttct aaggagcaag caaattcttt caacaactac agtgcgaaag 1620
 atcatgaact gggggggttt tggcatggaa gccacactgc ttctggttgt tggctactct 1680
 cactactagag ggggtggcat ctcttcttgc gtgcttgcag tgggattcag tggatttgc 1740
 55 atctctggtt tcaatgtgaa ccacttggat attgccccga gatatgccag tatcttaatg 1800
 ggcatttcaa atggtgttgg cacgctgtcg ggaatggtct gcccgatcat tgttgggtgca 1860

EP 1 284 298 A2

atgacgaaga acaagtcccg tgaagaatgg cagtatgtct tctcatcgc tgcactgggc 1920
 cactatgggtg gagtcataatt ttatgcacta ttgacctcag gagagaagca accttggggca 1980
 gaccttgagg aaacaagcga agaaaagtgt ggcttcattc atgaagatga actgggatgaa 2040
 5 gaaacggggg acatcactca gaattacata aattacggta ccaccaaata ctacggcgcc 2100
 acctcacagg agaacggagg ctggcctaac ggctgggaga aaaaggaaga atttgtgcaa 2160
 gaaagtgcgc aagacgcgta ctctataag gaccgagatg attattcata acgaagctag 2220
 ttgctggatt cctttgtagt gtttgtgatt aaattaattg tgattgcaca aaatcatttt 2280
 aagaaatgtg gtgtaaacat gtaaacacat caaccaagca agtcttgctg ttcaaaaaat 2340
 aataataata tgaattcaaa acagaccgtg agagtcccat caagtgcaat ctgtggcgcc 2400
 10 agtcacgtga cgccatttcc attcaggcca ttcgtccttt tcgtttgtga tttaaagggt 2460
 tctgttagaa ataagtaggt attcgttggg tccatcacca cgtagagag tacaactaca 2520
 acagttggca catgtcatcc tacggaagtt aggaagccaa agctactgga ttatgtgaac 2580
 lgcatttatt latllallac actggactgc aaaatatccc agggaaatcc tgtctagaga 2640
 catagtagaa ctggaaagat ggctagattg ggtactgacg ataatacattg tgtgtatatc 2700
 atggagtggc tatatctttt aattggagaa ctatattgta tagctagcaa aattgtactg 2760
 15 aattattact aggagtgcac agtgtgtgat attttgtgat ctccaaaag cttatcttgc 2820
 agtgttttgt gaaacgcttg ggcacaaaca cttattttta tgaacaagag cttgtaaagg 2880
 gagtagtag ctccatgctc tccattcac tacctgacag tatcaaacct tcacatttca 2940
 atgaaatcca acgtccatgt aacatatcac atgacttttt ttgcaaaaaa gaatataaga 3000
 agaaatagac ttcaatgtat tttttattac aaactttgtac tggttgtaac ttgcattagg 3060
 aaaaatgatt aatatatgta taatcgtaaa gaatctaata aaaatttact atgaagatat 3120
 20 agcccttaaa atgcaatatt aacaacaaaa atatatagaa aatttagata atcttccttg 3180
 ataactagag actatatgga actcacacca caaagctata tataatatga aaagataaac 3240
 aatagagatt gtatatgtag acgattttat gacctaattg cccatttaag aggtatttgt 3300
 cttgagtata tagtacaag tatattaaaa ttatatctac atccctgtat atcttataca 3360
 tatccactca cacaaacata acaaatactt ttcacacaga accaaaaaca agcatacacc 3420
 25 taatgttggg tttggggatt gcaatttcta cttcataga gtcatagaat ttagatggg 3480
 aaaaaaaaag gcattttgct cgtcatttct taatataatt aattcaacag gaactgcaac 3540
 atttgtgtac caagcaataa gtgcgaagca taaacctgct gtgtgtaaac tatccccata 3600
 ctgcttgtgg tagcactgat ttctttcttt taaagaactt aacatcggag ctctttacaa 3660
 tgttttgcgc tgataagaat gcacatccca atttaacgca aagtgtcacc tgggtgtgtt 3720
 30 acctgtctgt tttgggtatt tggctctgtt ggtgtcctgt gctcttgact ggaggccctg 3780
 ctactgcgaa tataaaacgt gaagtttgtt tctaaatgca aaccactcct gaccttaaga 3840
 aactaaagtc cctctctgct ttgtgtctcc aagtactatc atgtgaccat aacccttgc 3900
 gtgctgagta aaaagatgtg aactgtcatt ttgttgctgc gaagcaagtg ttaataaaat 3960
 gttctattta aaaaaaaaaa aa 3982

35 <210> 9
 <211> 854
 <212> PRT
 <213> Homo sapiens

40 <220>
 <223> vacuolar assembly protein VSP41 gene

45 <400> 9
 Met Ala Glu Ala Val Glu Gln Glu Thr Gly Ser Leu Glu Glu Ser Thr
 1 5 10 15
 Asp Glu Ser Glu Glu Glu Glu Ser Glu Glu Glu Pro Lys Leu Lys Tyr
 20 25 30
 50 Glu Arg Leu Ser Asn Gly Val Thr Glu Ile Leu Gln Lys Asp Ala Ala
 35 40 45
 Ser Cys Met Thr Val His Asp Lys Phe Leu Ala Leu Gly Thr His Tyr
 50 55 60
 55 Gly Lys Val Tyr Leu Leu Asp Val Gln Gly Asn Ile Thr Gln Lys Phe
 65 70 75 80

EP 1 284 298 A2

	Asp	Val	Ser	Pro	Val	Lys	Ile	Asn	Gln	Ile	Ser	Leu	Asp	Glu	Ser	Gly	
					85					90					95		
5	Glu	His	Met	Gly	Val	Cys	Ser	Glu	Asp	Gly	Lys	Val	Gln	Val	Phe	Gly	
				100					105					110			
	Leu	Tyr	Ser	Gly	Glu	Glu	Phe	His	Glu	Thr	Phe	Asp	Cys	Pro	Ile	Lys	
			115					120					125				
10	Ile	Ile	Ala	Val	His	Pro	His	Phe	Val	Arg	Ser	Ser	Cys	Lys	Gln	Phe	
			130					135					140				
	Val	Thr	Gly	Gly	Lys	Lys	Leu	Leu	Leu	Phe	Glu	Arg	Ser	Trp	Met	Asn	
			145			150					155					160	
15	Arg	Trp	Lys	Ser	Ala	Val	Leu	His	Glu	Gly	Glu	Gly	Asn	Ile	Arg	Ser	
					165					170					175		
	Val	Lys	Trp	Arg	Gly	His	Leu	Ile	Ala	Trp	Ala	Asn	Asn	Met	Gly	Val	
				180					185					190			
20	Lys	Ile	Phe	Asp	Ile	Ile	Ser	Lys	Gln	Arg	Ile	Thr	Asn	Val	Pro	Arg	
			195					200					205				
	Asp	Asp	Ile	Ser	Leu	Arg	Pro	Asp	Met	Tyr	Pro	Cys	Ser	Leu	Cys	Trp	
25			210				215					220					
	Lys	Asp	Asn	Val	Thr	Leu	Ile	Ile	Gly	Trp	Gly	Thr	Ser	Val	Lys	Val	
			225			230					235					240	
	Cys	Ser	Val	Lys	Glu	Arg	His	Ala	Ser	Glu	Met	Arg	Asp	Leu	Pro	Ser	
30					245					250					255		
	Arg	Tyr	Val	Glu	Ile	Val	Ser	Gln	Phe	Glu	Thr	Glu	Phe	Tyr	Ile	Ser	
				260					265					270			
	Gly	Leu	Ala	Pro	Leu	Cys	Asp	Gln	Leu	Val	Val	Leu	Ser	Tyr	Val	Lys	
35			275					280					285				
	Glu	Ile	Ser	Glu	Lys	Thr	Glu	Arg	Glu	Tyr	Cys	Ala	Arg	Pro	Arg	Leu	
			290				295					300					
	Asp	Ile	Ile	Gln	Pro	Leu	Ser	Glu	Thr	Cys	Glu	Glu	Ile	Ser	Ser	Asp	
40						310					315					320	
	Ala	Leu	Thr	Val	Arg	Gly	Phe	Gln	Glu	Asn	Glu	Cys	Arg	Asp	Tyr	His	
					325					330					335		
	Leu	Glu	Tyr	Ser	Glu	Gly	Glu	Ser	Leu	Phe	Tyr	Ile	Val	Ser	Pro	Arg	
45				340					345					350			
	Asp	Val	Val	Val	Ala	Lys	Glu	Arg	Asp	Gln	Asp	Asp	His	Ile	Asp	Trp	
				355				360					365				
	Leu	Leu	Glu	Lys	Lys	Lys	Tyr	Glu	Glu	Ala	Leu	Met	Ala	Ala	Glu	Ile	
50				370			375					380					
	Ser	Gln	Lys	Asn	Ile	Lys	Arg	His	Lys	Ile	Leu	Asp	Ile	Gly	Leu	Ala	
					385		390				395					400	
55	Tyr	Ile	Asn	His	Leu	Val	Glu	Arg	Gly	Asp	Tyr	Asp	Ile	Ala	Ala	Arg	

EP 1 284 298 A2

	405	410	415
5	Lys Cys Gln Lys Ile Leu Gly Lys Asn Ala Ala Leu Trp Glu Tyr Glu 420 425 430		
	Val Tyr Lys Phe Lys Glu Ile Gly Gln Leu Lys Ala Ile Ser Pro Tyr 435 440 445		
10	Leu Pro Arg Gly Asp Pro Val Leu Lys Pro Leu Ile Tyr Glu Met Ile 450 455 460		
	Leu His Glu Phe Leu Glu Ser Asp Tyr Glu Gly Phe Ala Thr Leu Ile 465 470 475 480		
15	Arg Glu Trp Pro Gly Asp Leu Tyr Asn Asn Ser Val Ile Val Gln Ala 485 490 495		
	Val Arg Asp His Leu Lys Lys Asp Ser Gln Asn Lys Thr Leu Leu Lys 500 505 510		
20	Thr Leu Ala Glu Leu Tyr Thr Tyr Asp Lys Asn Tyr Gly Asn Ala Leu 515 520 525		
	Glu Ile Tyr Leu Thr Leu Arg His Lys Asp Val Phe Gln Leu Ile His 530 535 540		
25	Lys His Asn Leu Phe Ser Ser Ile Lys Asp Lys Ile Val Leu Leu Met 545 550 555 560		
	Asp Phe Asp Ser Glu Lys Ala Val Asp Met Leu Leu Asp Asn Glu Asp 565 570 575		
30	Lys Ile Ser Ile Lys Lys Val Val Glu Glu Leu Glu Asp Arg Pro Glu 580 585 590		
	Leu Gln His Val Tyr Leu His Lys Leu Phe Lys Arg Asp His His Lys 595 600 605		
35	Gly Gln Arg Tyr His Glu Lys Gln Ile Ser Leu Tyr Ala Glu Tyr Asp 610 615 620		
	Arg Pro Asn Leu Leu Pro Phe Leu Arg Asp Ser Thr His Cys Pro Leu 625 630 635 640		
40	Glu Lys Ala Leu Glu Ile Cys Gln Gln Arg Asn Phe Val Glu Glu Thr 645 650 655		
	Val Tyr Leu Leu Ser Arg Met Gly Asn Ser Arg Ser Ala Leu Lys Met 660 665 670		
45	Ile Met Glu Glu Leu His Asp Val Asp Lys Ala Ile Glu Phe Ala Lys 675 680 685		
	Glu Gln Asp Asp Gly Glu Leu Trp Glu Asp Leu Ile Leu Tyr Ser Ile 690 695 700		
50	Asp Lys Pro Pro Phe Ile Thr Gly Leu Leu Asn Asn Ile Gly Thr His 705 710 715 720		
	Val Asp Pro Ile Leu Leu Ile His Arg Ile Lys Glu Gly Met Glu Ile 725 730 735		

EP 1 284 298 A2

Pro Asn Leu Arg Asp Ser Leu Val Lys Ile Leu Gln Asp Tyr Asn Leu
740 745 750

5 Gln Ile Leu Leu Arg Glu Gly Cys Lys Lys Ile Leu Val Ala Asp Ser
755 760 765

Leu Ser Leu Leu Lys Lys Met His Arg Thr Gln Met Lys Gly Val Leu
770 775 780

10 Val Asp Glu Glu Asn Ile Cys Glu Ser Cys Leu Ser Pro Ile Leu Pro
785 790 795 800

Ser Asp Ala Ala Lys Pro Phe Ser Val Val Val Phe His Cys Arg His
805 810 815

15 Met Phe His Lys Glu Cys Leu Pro Met Pro Ser Met Asn Ser Ala Ala
820 825 830

Gln Phe Cys Asn Ile Cys Ser Ala Lys Asn Arg Gly Pro Gly Ser Ala
835 840 845

20 Ile Leu Glu Met Lys Lys
850

25 <210> 10
<211> 770
<212> PRT
<213> Rattus norvegicus

<220>
<223> Git 1

30 <400> 10
Met Ser Arg Lys Gly Pro Arg Ala Glu Val Cys Ala Asp Cys Ser Ala
1 5 10 15

35 Pro Asp Pro Gly Trp Ala Ser Ile Ser Arg Gly Val Leu Val Cys Asp
20 25 30

Glu Cys Cys Ser Val His Arg Ser Leu Gly Arg His Ile Ser Ile Val
35 40 45

40 Lys His Leu Arg His Ser Ala Trp Pro Pro Thr Leu Leu Gln Met Val
50 55 60

His Thr Leu Ala Ser Asn Gly Ala Asn Ser Ile Trp Glu His Ser Leu
65 70 75 80

45 Leu Asp Pro Ala Gln Val Gln Ser Gly Arg Arg Lys Ala Asn Pro Gln
85 90 95

Asp Lys Val His Pro Ile Lys Ser Glu Phe Ile Arg Ala Lys Tyr Gln
100 105 110

50 Met Leu Ala Phe Val His Lys Leu Pro Cys Arg Asp Asp Asp Gly Val
115 120 125

Thr Ala Lys Asp Leu Ser Lys Gln Leu His Ser Ser Val Arg Thr Gly
130 135 140

55 Asn Leu Glu Thr Cys Leu Arg Leu Leu Ser Leu Gly Ala Gln Ala Asn

EP 1 284 298 A2

	145		150		155		160
	Phe Phe His Pro Glu Lys Gly Thr Thr Pro Leu His Val Ala Ala Lys						
		165			170		175
5	Ala Gly Gln Thr Leu Gln Ala Glu Leu Leu Val Val Tyr Gly Ala Asp			185		190	
		180					
	Pro Gly Ser Pro Asp Val Asn Gly Arg Thr Pro Ile Asp Tyr Ala Arg			200		205	
10		195					
	Gln Ala Gly His His Glu Leu Ala Glu Arg Leu Val Glu Cys Gln Tyr			215		220	
		210					
	Glu Leu Thr Asp Arg Leu Ala Phe Tyr Leu Cys Gly Arg Lys Pro Asp			230		235	
15							240
	His Lys Asn Gly His Tyr Ile Ile Pro Gln Met Ala Asp Arg Ser Arg			245		250	255
	Gln Lys Cys Met Ser Gln Ser Leu Asp Leu Ser Glu Leu Ala Lys Ala			260		265	270
20							
	Ala Lys Lys Lys Leu Gln Ala Leu Ser Asn Arg Leu Phe Glu Glu Leu			275		280	285
	Ala Met Asp Val Tyr Asp Glu Val Asp Arg Arg Glu Asn Asp Ala Val			290		295	300
25							
	Trp Leu Ala Thr Gln Asn His Ser Thr Leu Val Thr Glu Arg Ser Ala			305		310	315
							320
	Val Pro Phe Leu Pro Val Asn Pro Glu Tyr Ser Ala Thr Arg Asn Gln			325		330	335
30							
	Gly Arg Gln Lys Leu Ala Arg Phe Asn Ala Arg Glu Phe Ala Thr Leu			340		345	350
	Ile Ile Asp Ile Leu Ser Glu Ala Lys Arg Arg Gln Gln Gly Lys Ser			355		360	365
35							
	Leu Ser Ser Pro Thr Asp Asn Leu Glu Leu Ser Ala Arg Asn Gln Ser			370		375	380
	Asp Leu Asp Asp Gln His Asp Tyr Asp Ser Val Ala Ser Asp Glu Asp			385		390	395
40							
	Thr Asp Gln Glu Pro Leu Pro Ser Ala Gly Ala Thr Arg Asn Asn Arg			405		410	415
	Ala Arg Ser Met Asp Ser Ser Asp Leu Ser Asp Gly Ala Val Thr Leu			420		425	430
45							
	Gln Glu Tyr Leu Glu Leu Lys Lys Ala Leu Ala Thr Ser Glu Ala Lys			435		440	445
	Val Gln Gln Leu Met Lys Val Asn Ser Ser Leu Ser Asp Glu Leu Arg			450		455	460
50							
	Lys Leu Gln Arg Glu Ile His Lys Leu Gln Ala Glu Asn Leu Gln Leu			465		470	475
							480
55							

EP 1 284 298 A2

	Arg	Gln	Pro	Pro	Gly	Pro	Val	Pro	Val	Pro	Ser	Leu	Pro	Ser	Glu	Arg	
					485					490					495		
5	Ala	Glu	His	Thr	Leu	Met	Gly	Pro	Gly	Gly	Ser	Thr	His	Arg	Arg	Asp	
				500					505					510			
	Arg	Gln	Ala	Phe	Ser	Met	Tyr	Glu	Pro	Gly	Ser	Ala	Leu	Lys	Pro	Phe	
			515					520					525				
10	Gly	Gly	Ala	Pro	Gly	Asp	Glu	Leu	Ala	Thr	Arg	Leu	Gln	Pro	Phe	His	
		530					535					540					
	Ser	Thr	Glu	Leu	Glu	Asp	Asp	Ala	Ile	Tyr	Ser	Val	His	Val	Pro	Ala	
	545					550					555					560	
15	Gly	Leu	Tyr	Arg	Ile	Arg	Lys	Gly	Val	Ser	Ala	Ser	Ser	Val	Thr	Phe	
					565					570					575		
	Thr	Pro	Ser	Ser	Pro	Leu	Leu	Ser	Ser	Ser	Gln	Glu	Gly	Ser	Arg	His	
				580					585					590			
20	Ala	Ser	Lys	Leu	Ser	Arg	His	Gly	Ser	Gly	Ala	Glu	Ser	Asp	Tyr	Glu	
			595					600					605				
	Asn	Thr	Gln	Ser	Gly	Glu	Pro	Leu	Leu	Gly	Leu	Glu	Gly	Lys	Arg	Phe	
	610						615					620					
25	Leu	Glu	Leu	Ser	Lys	Glu	Asp	Glu	Leu	His	Ala	Glu	Leu	Glu	Ser	Leu	
	625					630					635					640	
	Asp	Gly	Asp	Pro	Asp	Pro	Gly	Leu	Pro	Ser	Thr	Glu	Asp	Val	Ile	Leu	
					645					650					655		
30	Lys	Thr	Glu	Gln	Val	Thr	Lys	Asn	Ile	Gln	Glu	Leu	Leu	Arg	Ala	Ala	
				660					665					670			
	Gln	Glu	Phe	Lys	His	Asp	Ser	Phe	Val	Pro	Cys	Ser	Glu	Lys	Ile	His	
			675					680					685				
35	Leu	Ala	Val	Thr	Glu	Met	Ala	Ser	Leu	Phe	Pro	Lys	Arg	Pro	Ala	Leu	
		690					695					700					
	Glu	Pro	Val	Arg	Ser	Ser	Leu	Arg	Leu	Leu	Asn	Ala	Ser	Ala	Tyr	Arg	
	705					710					715					720	
40	Leu	Gln	Ser	Glu	Cys	Arg	Lys	Thr	Val	Pro	Pro	Glu	Pro	Gly	Ala	Pro	
					725					730					735		
	Val	Asp	Phe	Gln	Leu	Leu	Thr	Gln	Gln	Val	Ile	Gln	Cys	Ala	Tyr	Asp	
				740					745					750			
45	Ile	Ala	Lys	Ala	Ala	Lys	Gln	Leu	Val	Thr	Ile	Thr	Thr	Arg	Glu	Lys	
			755					760					765				
50	Lys	Gln															
		770															
	<210> 11																
	<211> 3236																
	<212> DNA																
55	<213> Rattus norvegicus																

<220>

<223> Git 1

5

<400> 11

gcccgcgccc cccacgctgg cccagagggc tgcggccgct tcgcccgtga ggatgtcccc 60
 gaagggggccg cgagcggagg tgtgtgcgga ctgcagcgcc cctgaccctg gctggggcacc 120
 tatcagcaga ggtgtgctgg tttgtgacga gtgctgcagt gtgcaccgga gcctggggacc 180
 acacatctcc attgtcaaac accttcgcca cagcgcctgg cctcctacgc tgctacagat 240
 10 ggtgcacacg cttgccagca acggggccaa ctctatctgg gagcattccc tgctggaccc 300
 tgcacaagtg caaagtggcc ggcgcaaaagc caacccccaa gacaaagtcc accccatcaa 360
 gtcagagttc atcagggcaa agtaccagat gctggcgttt gtgcacaagc tccctgccc 420
 tgatgatgat ggggtcaccg ccaaagacct cagcaagcaa ctgcactcga gtgtgcgaac 480
 aggcaacctg gagacctgtc tgcgcctgct tccctgggt gccaggcca acttcttcca 540
 15 ccagaaaag ggcactacac ctctacacgt ggctgccaag gcagggcaga cactgcaggc 600
 tgagctgcta gtagtgtatg gggctgaccc aggtccccct gatgtcaatg gccgcacacc 660
 cattgactat gccaggcagg cggggcacca tgaactggca gaaaggctag ttgagtggca 720
 gtatgagctc actgaccggg tggccttcta cctctgtgga cggaagcctg atcacaagaa 780
 tgggcattac atcataccac agatggctga cagatctcgg caaaagtga tgtctcagag 840
 tttggatctg tctgaattgg ccaaagctgc caagaagaag ctacaagcac tcagcaaccg 900
 20 gctcttttag gagctcgcca tggatgtgta tgacgaagtg gaccggagag aaaatgatgc 960
 agtgtggcta gctaccaga atcatagcac cctggtgaca gaacgcagtg ctgtgccctt 1020
 cctgccagtc aacctgaat actcagccac tcggaatcag ggacgacaga aattggctcg 1080
 ttttaatgcc cgagagtttg ccaccttgat catcgacatc ctcagtgaag ccaaacggag 1140
 gcagcagggc aagagtctga gcagccccac agacaacctc gagctgtctg cacggaacca 1200
 25 aagtgtacctg gacgaccagc acgactacga tagtgtggct tctgacgaag acacagacca 1260
 ggagcccttg cccagtgtcg gcgccacgcy gaacaatcgt gccaggagca tggactcctc 1320
 agatctgtcg gatggggctg tgacgtgca ggagtacctg gagctgaaga aggctctggc 1380
 tacctccgag gccaaagtgc agcagctcat gaaagtcaac agcagtctga gtgacgagct 1440
 tcggaagctg cagagggaga tccacaaact gcaggcagag aacctgcagc tccggcagcc 1500
 accaggacca gtgcctgtac cctcacttcc cagtgaacgg gcagaacaca cactcatggg 1560
 30 cctgggtgga agtaccatc gcagggaccg ccaggccttc tctatgtatg agccaggctc 1620
 cgccctgaag ccttttgag gtgcacctgg ggatgagctc gccacacggc tccagccttt 1680
 ccacagcaca gagctggaag atgatgccat ctattcagta catgtccctg ctggccttta 1740
 ccggaatccg aaggggggtg ctgcctcttc tgtgacctc actccctct cccactgct 1800
 gtcaagctcc caagaaggaa gtgccatgc gagcaagctt tcacgccacg gcagtggcg 1860
 35 agagagtga ctagagaaca cacagagtgg agagcctctg ctgggacttg aagggaagcg 1920
 attcctagag ctgagcaagg aggatgagct gcacgctgag ctggagagct tagatggaga 1980
 cccagacccc gggctcccca gcacagaaga tgtatccta aagacagagc aggtcaccaa 2040
 gaacattcag gagctattgc gggcagccca ggagttcaaa catgacagct ttgtgcctg 2100
 ttcagaaaag atccatttg ctgtgactga gatggcctct ctcttcccaa agaggccagc 2160
 cctggagcct gtgcgcagt cactgcggt gctcaacgcc agcgcctacc ggctgcagag 2220
 40 tgaatgccgg aagacagtgc ctccagaacc tggcgccct gtggacttcc agctactgac 2280
 tcagcaggtg atccagtgc cctatgacat cgccaaggct gccaaagcagc tggtcaccat 2340
 caccacccga gagaagaac agtgaccact ttccctgccc ttaccacac cctgggacct 2400
 cactggccat gggagctggg ccactccaga cactaaccga cccccaacag agccactggc 2460
 acaagtgcc ttagtgccac cattctctc tggcatccag gtgcctgggt gtccacaccc 2520
 ccttaagccc caaggatggg aatgtgaggt gcaggacca tctgtcccc acattccacg 2580
 45 cccctccctc tgtacatagc atccctgccc tctgtatagc caggagcctc aaggagtccc 2640
 tcccagctct tcacctgct tccaggggccc cctcagcaaa ggggtgggaca gggacactcc 2700
 aagtggggca gccccgcta ctgcacccta tccccatgag ccagttcagc cctggggggg 2760
 cgagcagagg caccctctcc tttgtgcatt atctmtgggt gtytytgccc cgtagccagc 2820
 agccccccg ctgctcttcc atgacaaatg gccctgcca gagcacaggc cccaacttgt 2880
 gtgcagggt cccagcagc aaacactgga acgtctttct ctccctacc ccttaatttt 2940
 50 aactttgtgg taactgagtg tccctgcgtt cttacaactg agtgtgtgag cggcagtgcc 3000
 gtgccagaga cctggtccac ctggagctct gaggggcagg ggaaccagag tagtgggacc 3060
 agcattggaa gtcagcttcc ctctacccaa cctgggacgg ggactgtcag ggtcaccagc 3120
 tgtgggtccag ttgtaccctc taactgtatc cctatcttat aaacttaaaa ggaaaaccnc 3180
 ttcctcccat ctctcccat cccctgtggg aagtgtgctg accaggcaga ggacag 3236

55

EP 1 284 298 A2

<210> 12
 <211> 136
 <212> PRT
 <213> Homo sapiens
 5
 <220>
 <223> Histone H3.3
 10
 <400> 12
 Met Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly Lys Ala
 1 5 10 15
 Pro Arg Lys Gln Leu Ala Thr Lys Ala Ala Arg Lys Ser Ala Pro Ser
 20 25 30
 15
 Thr Gly Gly Val Lys Lys Pro His Arg Tyr Arg Pro Gly Thr Val Ala
 35 40 45
 Leu Arg Glu Ile Arg Arg Tyr Gln Lys Ser Thr Glu Leu Leu Ile Arg
 50 55 60
 20
 Lys Leu Pro Phe Gln Arg Leu Val Arg Glu Ile Ala Gln Asp Phe Lys
 65 70 75 80
 Thr Asp Leu Arg Phe Gln Ser Ala Ala Ile Gly Ala Leu Gln Glu Ala
 85 90 95
 25
 Ser Glu Ala Tyr Leu Val Gly Leu Phe Glu Asp Thr Asn Leu Cys Ala
 100 105 110
 Ile His Ala Lys Arg Val Thr Ile Met Pro Lys Asp Ile Gln Leu Ala
 115 120 125
 30
 Arg Arg Ile Arg Gly Glu Arg Ala
 130 135
 35
 <210> 13
 <211> 1039
 <212> DNA
 <213> Homo sapiens
 40
 <220>
 <223> Histone H3.3
 <400> 13
 45
 tgttcgcagc cgccgcgcgc cgcgcgtcgc tctccaacgc cagcgccgcc tctcgtcgc 60
 gtaagtaagg aggtctctgc gagctccagc cgaagagaag ggggtaccat ggctcgtaca 120
 aagcagactg cccgcaaadc gaccggtggg aaagcaccca ggaagcaact ggctacaaaa 180
 gccgctcgca agagtgcgcc ctctactgga ggggtgaaga aacctcatcg ttacaggcct 240
 ggtactgtgg cgctccgtga aattagacgt tatcagaagt ccactgaact tctgattcgc 300
 aaacttccct tccagcgtct ggtgcgagaa attgctcagg actttaaaac agatctgcgc 360
 ttccagagcg cagctatcgg tgctttgcag gaggcaagtg aggcctatct ggttggcctt 420
 50
 tttgaagaca ccaacctgtg tgctatccat gccaaacgtg taacaattat gccaaaagac 480
 atccagctag cagcgcgcac acgtggagaa cgtgcttaag aatccactat gatgggaaac 540
 atttcattct caaaaaaaaaa aaaaaaattt ctcttcttcc tgttattggg agttctgaac 600
 gttagatatt ttttttccat ggggtcaaag gtacctaagt atatgattgc gagtggaaaa 660
 ataggggaca gaaatcagggt attggcagtt tttccatttt catttggtg tgaattttta 720
 atataaatgc ggagacgtaa agcattaatg caagttaaaa tgtttcagtg aacaagtttc 780
 55
 agcggttcaa ctttataata attataaata aacctgttaa atttttctgg acaatgccag 840

EP 1 284 298 A2

catttggatt tctttaaacc aagtaaattt cttattgatg gcaactaaat ggtgtttgta 900
gcatttttat catacagtag attccatcca ttactataac ttttctaact gagttgtcct 960
acatgcaagt acatgttttt aatgttgtct gtcttctgtg ctgttctgtt aagtttgcta 1020
ttaaaatata ttaaactat 1039

<210> 14
<211> 520
<212> PRT
<213> Rattus norvegicus

<220>
<223> Cytosolic 3-hydroxy 3-methylglutaryl coenzyme A synthase

<400> 14
Met Pro Gly Ser Leu Pro Leu Asn Ala Glu Ala Cys Trp Pro Lys Asp
1 5 10 15
Val Gly Ile Val Ala Leu Glu Ile Tyr Phe Pro Ser Gln Tyr Val Asp
20 25 30
Gln Ala Glu Leu Glu Lys Tyr Asp Gly Val Asp Ala Gly Lys Tyr Thr
35 40 45
Ile Gly Leu Gly Gln Ala Arg Met Gly Phe Cys Thr Asp Arg Glu Asp
50 55 60
Ile Asn Ser Leu Cys Leu Thr Val Val Gln Lys Leu Met Glu Arg Asn
65 70 75 80
Ser Leu Ser Tyr Asp Cys Ile Gly Arg Leu Glu Val Gly Thr Glu Thr
85 90 95
Ile Ile Asp Lys Ser Lys Ser Val Lys Ser Asn Leu Met Gln Leu Phe
100 105 110
Glu Glu Ser Gly Asn Thr Asp Ile Glu Gly Ile Asp Thr Thr Asn Ala
115 120 125
Cys Tyr Gly Gly Thr Ala Ala Val Phe Asn Ala Val Asn Trp Ile Glu
130 135 140
Ser Ser Ser Trp Asp Gly Arg Tyr Ala Leu Val Val Ala Gly Asp Ile
145 150 155 160
Ala Ile Tyr Ala Ser Gly Asn Ala Arg Pro Thr Gly Gly Val Gly Ala
165 170 175
Val Ala Leu Leu Ile Gly Pro Asn Ala Pro Val Ile Phe Asp Arg Gly
180 185 190
Leu Arg Gly Thr His Met Gln His Ala Tyr Asp Phe Tyr Lys Pro Asp
195 200 205
Met Leu Ser Glu Tyr Pro Val Val Asp Gly Lys Leu Ser Ile Gln Cys
210 215 220
Tyr Leu Ser Ala Leu Asp Arg Cys Tyr Ser Val Tyr Arg Lys Lys Ile
225 230 235 240
Arg Ala Gln Trp Gln Lys Glu Gly Lys Asp Lys Asp Phe Thr Leu Asn

EP 1 284 298 A2

	245	250	255
5	Asp Phe Gly Phe Met Ile Phe His Ser Pro Tyr Cys Lys Leu Val Gln 260 265 270		
	Lys Ser Leu Ala Arg Met Phe Leu Asn Asp Phe Leu Asn Asp Gln Asn 275 280 285		
10	Arg Asp Lys Asn Ser Ile Tyr Ser Gly Leu Glu Ala Phe Gly Asp Val 290 295 300		
	Lys Leu Glu Asp Thr Tyr Phe Asp Arg Asp Val Glu Lys Ala Phe Met 305 310 315 320		
15	Lys Ala Ser Ala Glu Leu Phe Asn Gln Lys Thr Lys Ala Ser Leu Leu 325 330 335		
	Val Ser Asn Gln Asn Gly Asn Met Tyr Thr Ser Ser Val Tyr Gly Ser 340 345 350		
20	Leu Ala Ser Val Leu Ala Gln Tyr Ser Pro Gln Gln Leu Ala Gly Lys 355 360 365		
	Arg Ile Gly Val Phe Ser Tyr Gly Ser Gly Leu Ala Ala Thr Leu Tyr 370 375 380		
25	Scr Leu Lys Val Thr Gln Asp Ala Thr Pro Gly Ser Ala Leu Asp Lys 385 390 395 400		
	Ile Thr Ala Ser Leu Cys Asp Leu Lys Ser Arg Leu Asp Ser Arg Thr 405 410 415		
30	Cys Val Ala Pro Asp Val Phe Ala Glu Asn Met Lys Leu Arg Glu Asp 420 425 430		
	Thr His His Leu Ala Asn Tyr Ile Pro Gln Cys Ser Ile Asp Ser Leu 435 440 445		
35	Phe Glu Gly Thr Trp Tyr Leu Val Arg Val Asp Glu Lys His Arg Arg 450 455 460		
	Thr Tyr Ala Arg Arg Pro Ser Thr Asn Asp His Ser Leu Asp Glu Gly 465 470 475 480		
40	Val Gly Leu Val His Ser Asn Thr Ala Thr Glu His Ile Pro Ser Pro 485 490 495		
	Ala Lys Lys Val Pro Arg Leu Pro Ala Thr Ser Gly Glu Pro Glu Ser 500 505 510		
45	Ala Val Ile Ser Asn Gly Glu His 515 520		
50	<210> 15 <211> 3275 <212> DNA <213> Rattus norvegicus		
55	<220> <223> Cytosolic 3-hydroxy 3-methylglutaryl coenzyme A synthase		

<400> 15
 5
 10
 15
 20
 25
 30
 35
 40
 45
 50

```

cccagggtcc gatcgcggtt ggtgcctgaa ggaggaaccg gtgacagacc tggagactac 60
agttctctgt ccttcacaca gctccttcac catgcctggg tcacttcctt tgaatgcaga 120
ggcttgctgg ccaaaagatg tgggaatcgt tgcccttgaa atctactttc ctctctagta 180
tgttgatcaa gctgagttgg aaaaatacga tgggttagat gctggaaagt ataccattgg 240
cctgggccag gccaggatgg gcttctgcac ggatcgcgaa gacatcaact ctctctgcct 300
gactgtggtt cagaaaactga tggagagaaa tagcctttcc tatgactgca ttggggggct 360
ggaagtctgg acagagacaa tcatcgacaa atcaaaaatcc gtgaagtcta atttgatgca 420
gctgtttgag gagtctggga atacagatat agaaggataa gatacaacta atgcatgcta 480
tgggggcaca gccgcagtct tcaatgctgt gaactggatc gaatccagct ctggggatgg 540
acgatacgct ttggtagttg caggagacat cgctatatat gcctcaggaa acgccaggcc 600
tacagggtgga gttggagctg tggctctgct aattgggcca aatgctcctg taatttttga 660
ccgagggtct cgtgggacac acatgcagca tgccctacgac ttttacaagc ctgacagata 720
ctctgaatac cctgtggtag atggaaaact ctccatacag tgctacctca gcgcattgga 780
ccgctgctat tctgtctacc gcaaaaagat ccggggccag tggcagaaaag agggaaagga 840
taaagatttt accctgaatg attttggctt catgatcttt cactcgccat actgtaaact 900
ggtgcagaaa tctctagcta ggatgttcct gaatgacttt cttaacgata aaaacagaga 960
caaaaacagt atttacagt ggctggaagc ctttggggat gtgaaattag aagatactta 1020
cttcgacaga gatgtggaag aggcatttat gaaggctagt gctgagctat tcaaccagaa 1080
aacaaggcca tctttgcttg tatcgaatca aaatggaaac atgtacacat cctctgtata 1140
cggttccctt gcttctgttc tggcacagta ctacacctca cagttggccg ggaagaggat 1200
tggagtgttc tcttacggtt ctggcttgcc tgccacactc tactccctta aagtccacaca 1260
agatgccaca ccaggatctg ctcttgacaa aataacagca agtttatgtg accttaagtc 1320
aaggcttgac tcaagaacgt gtgtggcacc agacgtcttt gctgaaaaca tgaagctcag 1380
agaggacaca catcacttag ccaactatat tccccagtg tcaatagatt cactcttcga 1440
aggaacatgg tatctagtca gagtggatga aaagcacaga agaacttacg ccggcgctcc 1500
ctccacaaat gaccacagt tggatgaagg agtgggactt gtgcattcaa acacagctac 1560
agagcatatt ccaagcccg ctaagaaagt gccaaactt cctgcgacct cgggcgaacc 1620
tgagtccgct gtcacagta acggggagca ctgagagccg tggccttcac agaggctcgg 1680
ggctggatgg ggtatgggaa acgttagagg aatggatgtc ttgggacaat ttacagatt 1740
acgtgttgct taaaaatgta atgtaactga cacagagccc agaaaactgt tgtgtttttg 1800
gagaagtctc gctgagctcc taacacactt cctgctgtgg gctggccaat ggtgaatgta 1860
ctgcgatggg gttaagggct ctgcagaacg tcatacctcg ctgcatgttt acacgcattg 1920
gggttaggct tcaaaactcg tctgaactga gtgcttctga ctgcaaaggc agaggctactg 1980
ctgtccagtt taaaaaatg tttttttttt ttttaatgtg taagaatttt tatactaaa 2040
taaaaaaaag tacctgtagc ttttggggga aaaaaaaa cctttttcta ggttggggat 2100
tgtggaattt aaatgttaca cataaactct gcttaatggc aaggcaaaaca ttatctttt 2160
tcgaagattt ataaatcctg aagagaaaaa aagagggtat ggttctagga tctggatgaa 2220
ccatcagtga gaaagggttag tcataatcaa gtgagcagaa ggatgctggc gttgagcagg 2280
cctctgtcac agcaaccagg gctctgtggg cacagctgag ggaactttct ggccagggtg 2340
ccgtgactgc tgcctcagct cactgagatg cagtggagct gctgcacgga agcttgctgt 2400
ggtgctgaac gccttacctg cggataaagt gtaaaagtag agggatgggc agggcactat 2460
taggttacag tgttacagac ccagggtata gacttgacag ctcaaaactca ccagacacct 2520
ttttcccttt gtggtttgtg tattttttgt gttttgtttg ttttttttta tattgttcaa 2580
tttaaaaaat tttagaaaatt ttaaccttac gttttcacat agtgtgatta gcaaaaagga 2640
atttcacttc aagatctaga aatagaattc ataactttt ttctaaact ttgactttta 2700
aaacaacgaa aattaccaca tgagatgaac aagaaaattc attagaaagt tctctgggtg 2760
atttttgggt ctgaactgac atgagcctca tagactgtaa aacagaggta gttgaaacta 2820
atgtacagaa ctacattttt taattttatt tgcatttaac tctgtgaagt ttcagttatc 2880
taaaaataaac acataaacgt gtaattgttc agattgcaag gtgagatgta atgtagcatt 2940
tgtaagatat tcttgtcaat attaaactgt aggatgttga tttgtacagt ttttaattgg 3000
taaaatgata ctaatttaac atccactgct atagatgaat gatgtaagct cagatttaat 3060
gaatgggtgg gaaatgggtg atgtaatttt ttcgcaagta tcgagagttc tgtatgtttt 3120
gaaaaagaata atttaacgt tgggttgcca ggaagggggc tttccacagag tccattggcca 3180
ggcgttgggc aagcctcgca atgttggcac ggagcgttaa ccacacctta ctaatagcaa 3240
ggggaataac tttgaaataa agtttttagc aaata 3275

```

<210> 16
 <211> 353
 <212> PRT

EP 1 284 298 A2

<213> Rattus norvegicus

<220>

<223> farnesyl pyrophosphate synthetase

<400> 16

Met Asn Gly Asp Gln Lys Leu Asp Val His Asn Gln Glu Lys Gln Asn
1 5 10 15

Phe Ile Gln His Phe Ser Gln Ile Val Lys Val Leu Thr Glu Asp Glu
20 25 30

Leu Gly His Pro Glu Lys Gly Asp Ala Ile Thr Arg Ile Lys Glu Val
35 40 45

Leu Glu Tyr Asn Thr Val Gly Gly Lys Tyr Asn Arg Gly Leu Thr Val
50 55 60

Val Gln Thr Phe Gln Glu Leu Val Glu Pro Arg Lys Gln Asp Ala Glu
65 70 75 80

Ser Leu Gln Arg Ala Leu Thr Val Gly Trp Cys Val Glu Leu Leu Gln
85 90 95

Ala Phe Phe Leu Val Leu Asp Asp Ile Met Asp Ser Ser His Thr Arg
100 105 110

Arg Gly Gln Ile Cys Trp Tyr Gln Lys Pro Gly Ile Gly Leu Asp Ala
115 120 125

Ile Asn Asp Ala Leu Leu Leu Glu Ala Ala Ile Tyr Arg Leu Leu Lys
130 135 140

Phe Tyr Cys Arg Glu Gln Pro Tyr Tyr Leu Asn Leu Leu Glu Leu Phe
145 150 155 160

Leu Gln Ser Ser Tyr Gln Thr Glu Ile Gly Gln Thr Leu Asp Leu Ile
165 170 175

Thr Ala Pro Gln Gly Gln Val Asp Leu Gly Arg Tyr Thr Glu Lys Arg
180 185 190

Tyr Lys Ser Ile Val Lys Tyr Lys Thr Ala Phe Tyr Ser Phe Tyr Leu
195 200 205

Pro Ile Ala Ala Ala Met Tyr Met Ala Gly Ile Asp Gly Glu Lys Glu
210 215 220

His Ala Asn Ala Leu Lys Ile Leu Leu Glu Met Gly Glu Phe Phe Gln
225 230 235 240

Ile Gln Asp Asp Tyr Leu Asp Leu Phe Gly Asp Pro Ser Val Thr Gly
245 250 255

Lys Val Gly Thr Asp Ile Gln Asp Asn Lys Cys Ser Trp Leu Val Val
260 265 270

Gln Cys Leu Leu Arg Ala Thr Pro Gln Gln Arg Gln Ile Leu Glu Glu
275 280 285

Asn Tyr Gly Gln Lys Asp Pro Glu Lys Val Ala Arg Val Lys Ala Leu
290 295 300

EP 1 284 298 A2

Tyr Glu Glu Leu Asp Leu Arg Ser Val Phe Phe Lys Tyr Glu Glu Asp
 305 310 315 320
 5 Ser Tyr Asn Arg Leu Lys Ser Leu Ile Glu Gln Cys Ser Ala Pro Leu
 325 330 335
 Pro Pro Ser Ile Phe Leu Glu Leu Ala Asn Lys Ile Tyr Lys Arg Arg
 340 345 350
 10 Lys
 <210> 17
 15 <211> 1271
 <212> DNA
 <213> Rattus norvegicus
 <220>
 20 <223> farnesyl pyrophosphate synthetase
 <400> 17
 ttatatattg gttctgccta ctgagccggg agtctgggaa ctacaactcc cagagtgtctg 60
 agcggatgca cgctctgctt ttaggtgtaa gccgcaaaca tcttggaacc cgggagaatc 120
 cgcggtgaag cacagagcat ttagctcctc tgtcagaatg aatggggacc agaaactgga 180
 25 tgttcataac caagaaaagc agaatttcct ccagcacttc tcccagattg tcaaggtgct 240
 gactgaggat gaactgggac acccagagaa gggagatgct attaccgga tcaaagaggt 300
 cctggagtag aacactgtag gaggcaagta caatcggggt ctgacggtgg tacagacctt 360
 ccaggaactg gtggaaccaa ggaaacagga tgctgagagc ctacagcggg ccctgacggt 420
 gggctgggtg ttagaactgc tccaggcttt ctctcctctg ttagatgaca tcatggactc 480
 ttcccacact cgccgggggc agatctgctg gtatcagaag ccgggcatag gcttggatgc 540
 30 catcaacgat gctctgcttc tggaaagcgc tatctaccgc ctgcttaagt tctactgcag 600
 ggagcagccc tactacctca acctgctgga gctctttcta cagagttcct atcagactga 660
 gatcgggcag actctcgacc tcatcacagc accccagggc caagtggatc ttggtagata 720
 cactgaaaag aggtacaaat ctatcgctca gtacaagaca gctttctact ctttctacct 780
 gccatcgcg gctgccatgt acatggctgg aattgatggg gagaaggaaac acgctaagtc 840
 cctgaagatc ctgctggaga tgggagagtt cttccagatc caggacgact accttgatct 900
 35 ctttggagac ccagtggtga ccggaaaagg cggcactgac atccaggaca acaaatgcag 960
 ctggctgggtg gttcagtgct tgctacgagc cactcctcag cagcgccaga tcttagagga 1020
 gaattatggg cagaaggacc cagaaaaagt ggcgcggtg aaagcactgt acgaggagct 1080
 ggatctgcgg agtggtgtct tcaagtacga ggaagacagt tacaaccgcc tcaagagtct 1140
 catagagcag tgctccgcgc ccctgcccc atccatcttc ctggaactag caaacaagat 1200
 40 ctacaagcgg agaaagtaac ctccaattgt agaggctgcy agggaggggt ctcaataaat 1260
 tattgttcaa c 1271
 <210> 18
 45 <211> 152
 <212> PRT
 <213> Rattus norvegicus
 <220>
 <223> Bendless protein
 50 <400> 18
 Met Ala Gly Leu Pro Arg Arg Ile Ile Lys Glu Thr Gln Arg Leu Leu
 1 5 10 15
 55 Ala Glu Pro Val Pro Gly Ile Lys Ala Glu Pro Asp Glu Ser Asn Ala
 20 25 30

EP 1 284 298 A2

Arg Tyr Phe His Val Val Ile Ala Gly Pro Gln Asp Ser Pro Phe Glu
35 40 45

5 Gly Gly Thr Phe Lys Leu Glu Leu Phe Leu Pro Glu Glu Tyr Pro Met
50 55 60

Ala Ala Pro Lys Val Arg Phe Met Thr Lys Ile Tyr His Pro Asn Val
65 70 75 80

10 Asp Lys Leu Gly Arg Ile Cys Leu Asp Ile Leu Lys Asp Lys Trp Ser
85 90 95

Pro Ala Leu Gln Ile Arg Thr Val Leu Leu Ser Ile Gln Ala Leu Leu
100 105 110

15 Ser Ala Pro Asn Pro Asp Asp Pro Leu Ala Asn Asp Val Ala Glu Gln
115 120 125

Trp Lys Ser Asn Glu Ala Gln Ala Ile Glu Thr Ala Arg Ala Trp Thr
130 135 140

20 Arg Leu Tyr Ala Met Asn Asn Ile
145 150

25 <210> 19
<211> 459
<212> DNA
<213> Rattus norvegicus

30 <220>
<223> Bendless protein

<400> 19
atggcgggc tgcccgagc gatcatcaag gaaaccagc gtttgctggc agaaccagtt 60
cctggcatta aagcagaacc agatgagagc aacgcccgtt attttcatgt ggctattgct 120
35 ggtccccagg attccccctt tgaggaggagg actttttaaac ttgaactatt ccttccagaa 180
gaatacccaa tggcagcacc taaagtacgt ttcattgacca aaatttatca tcctaattga 240
gacaagttgg gaagaatatg ttagatatt ttgaaagata agtgggtccc agcactgcag 300
atccgaacag ttctgctatc aatccaggct ttgctaagtg ctccaatcc agatgatcca 360
ttagcaaatg atgtagctga gcagtggag agcaacgaag cccaagccat agaaacagca 420
40 agagcatgga ctaggctata tgccatgaat aatatttaa 459

<210> 20
<211> 2505
<212> PRT
45 <213> Rattus norvegicus

<220>
<223> Fatty acid synthase

50 <400> 20
Met Glu Glu Val Val Ile Ala Gly Met Ser Gly Lys Leu Pro Glu Ser
1 5 10 15

Glu Asn Leu Gln Glu Phe Trp Ala Asn Leu Ile Gly Gly Val Asp Met
20 25 30

55

EP 1 284 298 A2

	Val	Thr	Asp	Asp	Asp	Arg	Arg	Trp	Lys	Ala	Gly	Leu	Tyr	Gly	Leu	Pro	
			35					40					45				
5	Lys	Arg	Ser	Gly	Lys	Leu	Lys	Asp	Leu	Ser	Lys	Phe	Asp	Ala	Ser	Phe	
		50					55					60					
	Phe	Gly	Val	His	Pro	Lys	Gln	Ala	His	Thr	Met	Asp	Pro	Gln	Leu	Arg	
	65					70					75					80	
10	Leu	Leu	Leu	Glu	Val	Ser	Tyr	Glu	Ala	Ile	Val	Asp	Gly	Gly	Ile	Asn	
					85					90					95		
	Pro	Ala	Ser	Leu	Arg	Gly	Thr	Asn	Thr	Gly	Val	Trp	Val	Gly	Val	Ser	
				100				105						110			
15	Gly	Ser	Glu	Ala	Ser	Glu	Ala	Leu	Ser	Arg	Asp	Pro	Glu	Thr	Leu	Leu	
			115					120					125				
	Gly	Tyr	Ser	Met	Val	Gly	Cys	Gln	Arg	Ala	Met	Met	Ala	Asn	Arg	Leu	
	130						135					140					
20	Ser	Phe	Phe	Phe	Asp	Phe	Lys	Gly	Pro	Ser	Ile	Ala	Leu	Asp	Thr	Ala	
	145					150					155					160	
	Cys	Ser	Ser	Ser	Leu	Leu	Ala	Leu	Gln	Asn	Ala	Tyr	Gln	Ala	Ile	Arg	
					165					170					175		
25	Ser	Gly	Glu	Cys	Pro	Ala	Ala	Ile	Val	Gly	Gly	Ile	Asn	Leu	Leu	Leu	
				180					185					190			
	Lys	Pro	Asn	Thr	Ser	Val	Gln	Phe	Met	Lys	Leu	Gly	Met	Leu	Ser	Pro	
			195					200					205				
30	Asp	Gly	Thr	Cys	Arg	Ser	Phe	Asp	Asp	Ser	Gly	Asn	Gly	Tyr	Cys	Arg	
	210						215					220					
	Ala	Glu	Ala	Val	Val	Ala	Val	Leu	Leu	Thr	Lys	Lys	Ser	Leu	Ala	Arg	
35	225					230					235					240	
	Arg	Val	Tyr	Ala	Thr	Ile	Leu	Asn	Ala	Gly	Thr	Asn	Thr	Asp	Gly	Cys	
				245						250					255		
	Lys	Glu	Gln	Gly	Val	Thr	Phe	Pro	Ser	Gly	Glu	Ala	Gln	Glu	Gln	Leu	
40				260					265					270			
	Ile	Arg	Ser	Leu	Tyr	Gln	Pro	Gly	Gly	Val	Ala	Pro	Glu	Ser	Leu	Glu	
			275					280					285				
	Tyr	Ile	Glu	Ala	His	Gly	Thr	Gly	Thr	Lys	Val	Gly	Asp	Pro	Gln	Glu	
45			290				295					300					
	Leu	Asn	Gly	Ile	Thr	Arg	Ser	Leu	Cys	Ala	Phe	Arg	Gln	Ser	Pro	Leu	
	305					310					315					320	
	Leu	Ile	Gly	Ser	Thr	Lys	Ser	Asn	Met	Gly	His	Pro	Glu	Pro	Ala	Ser	
50					325					330					335		
	Gly	Leu	Ala	Ala	Leu	Thr	Lys	Val	Leu	Leu	Ser	Leu	Glu	Asn	Gly	Val	
				340					345					350			
55	Trp	Ala	Pro	Asn	Leu	His	Phe	His	Asn	Pro	Asn	Pro	Glu	Ile	Pro	Ala	
			355					360					365				

EP 1 284 298 A2

	Leu	Leu	Asp	Gly	Arg	Leu	Gln	Val	Val	Asp	Arg	Pro	Leu	Pro	Val	Arg	
	370						375					380					
5	Gly	Gly	Ile	Val	Gly	Ile	Asn	Ser	Phe	Gly	Phe	Gly	Gly	Ala	Asn	Val	
	385					390					395					400	
	His	Val	Ile	Leu	Gln	Pro	Asn	Thr	Gln	Gln	Ala	Pro	Ala	Pro	Ala	Pro	
					405					410					415		
10	His	Ala	Ala	Leu	Pro	His	Leu	Leu	His	Ala	Ser	Gly	Arg	Thr	Met	Glu	
				420					425						430		
	Ala	Val	Gln	Gly	Leu	Leu	Glu	Gln	Gly	Arg	Gln	His	Ser	Gln	Asp	Leu	
			435					440					445				
15	Ala	Phe	Val	Ser	Met	Leu	Asn	Asp	Ile	Ala	Ala	Thr	Pro	Thr	Ala	Ala	
	450						455					460					
	Met	Pro	Phe	Arg	Gly	Tyr	Thr	Val	Leu	Gly	Val	Glu	Gly	His	Val	Gln	
20	465					470					475					480	
	Glu	Val	Gln	Gln	Val	Pro	Ala	Ser	Gln	Arg	Pro	Leu	Trp	Phe	Ile	Cys	
					485					490					495		
	Ser	Gly	Met	Gly	Thr	Gln	Trp	Arg	Gly	Met	Gly	Leu	Ser	Leu	Met	Arg	
25				500					505					510			
	Leu	Asp	Ser	Phe	Arg	Glu	Ser	Ile	Leu	Arg	Ser	Asp	Glu	Ala	Leu	Lys	
			515					520					525				
	Pro	Leu	Gly	Val	Lys	Val	Ser	Asp	Leu	Leu	Leu	Ser	Thr	Asp	Glu	His	
30			530				535						540				
	Thr	Phe	Asp	Asp	Ile	Val	His	Ser	Phe	Val	Ser	Leu	Thr	Ala	Ile	Gln	
	545					550					555					560	
	Ile	Ala	Leu	Ile	Asp	Leu	Leu	Thr	Ser	Met	Gly	Leu	Lys	Pro	Asp	Gly	
35					565					570					575		
	Ile	Ile	Gly	His	Ser	Leu	Gly	Glu	Val	Ala	Cys	Gly	Tyr	Ala	Asp	Gly	
				580					585					590			
	Cys	Leu	Ser	Gln	Arg	Glu	Ala	Val	Leu	Ala	Ala	Tyr	Trp	Arg	Gly	Gln	
40			595					600					605				
	Cys	Ile	Lys	Asp	Ala	Asn	Leu	Pro	Ala	Gly	Ser	Met	Ala	Ala	Val	Gly	
		610					615					620					
45	Leu	Ser	Trp	Glu	Glu	Cys	Lys	Gln	Arg	Cys	Pro	Pro	Gly	Val	Val	Pro	
	625					630					635					640	
	Ala	Cys	His	Asn	Ser	Glu	Asp	Thr	Val	Thr	Ile	Ser	Gly	Pro	Gln	Ala	
					645					650					655		
50	Ala	Val	Asn	Glu	Phe	Val	Glu	Gln	Leu	Lys	Gln	Glu	Gly	Val	Phe	Ala	
				660					665					670			
	Lys	Glu	Val	Arg	Thr	Gly	Gly	Leu	Ala	Phe	His	Ser	Tyr	Phe	Met	Glu	
		675						680					685				
55	Gly	Ile	Ala	Pro	Thr	Leu	Leu	Gln	Ala	Leu	Lys	Lys	Val	Ile	Arg	Glu	

EP 1 284 298 A2

	690	695	700
5	Pro Arg Pro Arg Ser Ala Arg Trp Leu Ser Thr Ser Ile Pro Glu Ala 705 710 715 720		
	Gln Trp Gln Ser Ser Leu Ala Arg Thr Ser Ser Ala Glu Tyr Asn Val 725 730 735		
10	Asn Asn Leu Val Ser Pro Val Leu Phe Gln Glu Ala Leu Trp His Val 740 745 750		
	Pro Glu His Ala Val Val Leu Glu Ile Ala Pro His Ala Leu Leu Gln 755 760 765		
15	Ala Val Leu Lys Arg Gly Val Lys Pro Ser Cys Thr Ile Ile Pro Leu 770 775 780		
	Met Lys Arg Asp His Lys Asp Asn Leu Glu Phe Phe Leu Thr Asn Leu 785 790 795 800		
20	Gly Lys Val His Leu Thr Gly Ile Asp Ile Asn Pro Asn Ala Leu Phe 805 810 815		
	Pro Pro Val Glu Phe Pro Val Pro Arg Gly Thr Pro Leu Ile Ser Pro 820 825 830		
25	His Ile Lys Trp Asp His Ser Gln Thr Trp Asp Ile Pro Val Ala Glu 835 840 845		
	Asp Phe Pro Asn Gly Ser Ser Ser Ser Ser Ala Thr Val Tyr Asn Ile 850 855 860		
30	Asp Ala Ser Ser Glu Ser Ser Asp His Tyr Leu Val Asp His Cys Ile 865 870 875 880		
	Asp Gly Arg Val Leu Phe Pro Gly Thr Gly Tyr Leu Tyr Leu Val Trp 885 890 895		
35	Lys Thr Leu Ala Arg Ser Leu Ser Leu Ser Leu Glu Glu Thr Pro Val 900 905 910		
	Val Phe Glu Asn Val Thr Phe His Gln Ala Thr Ile Leu Pro Arg Thr 915 920 925		
40	Gly Thr Val Pro Leu Glu Val Arg Leu Leu Glu Ala Ser His Ala Phe 930 935 940		
	Glu Val Scr Asp Ser Gly Asn Leu Ile Val Ser Gly Lys Val Tyr Gln 945 950 955 960		
45	Trp Glu Asp Pro Asp Ser Lys Leu Phe Asp His Pro Glu Val Pro Ile 965 970 975		
	Pro Ala Glu Ser Glu Ser Val Ser Arg Leu Thr Gln Gly Glu Val Tyr 980 985 990		
50	Lys Glu Leu Arg Leu Arg Gly Tyr Asp Tyr Gly Pro His Phe Gln Gly 995 1000 1005		
	Val Tyr Glu Ala Thr Leu Glu Gly Glu Gln Gly Lys Leu Leu Trp Lys 1010 1015 1020		
55			

EP 1 284 298 A2

	Asp Asn Trp Val Thr Phe Met Asp Thr Met Leu Gln Ile Ser Ile Leu	
	1025	1030 1035 1040
5	Gly Phe Ser Lys Gln Ser Leu Gln Leu Pro Thr Arg Val Thr Ala Ile	
		1045 1050 1055
	Tyr Ile Asp Pro Ala Thr His Leu Gln Lys Val Tyr Met Leu Glu Gly	
		1060 1065 1070
10	Asp Thr Gln Val Ala Asp Val Thr Thr Ser Arg Cys Leu Gly Val Thr	
		1075 1080 1085
	Val Ser Gly Gly Val Tyr Ile Ser Arg Leu Gln Thr Thr Ala Thr Ser	
		1090 1095 1100
15	Arg Arg Gln Gln Glu Gln Leu Val Pro Thr Leu Glu Lys Phe Val Phe	
		1105 1110 1115 1120
	Thr Pro His Val Glu Pro Glu Cys Leu Ser Glu Ser Ala Ile Leu Gln	
		1125 1130 1135
20	Lys Glu Leu Gln Leu Cys Lys Gly Leu Ala Lys Ala Leu Gln Thr Lys	
		1140 1145 1150
	Ala Thr Gln Gln Gly Leu Lys Met Thr Val Pro Gly Leu Glu Asp Leu	
		1155 1160 1165
25	Pro Gln His Gly Leu Pro Arg Leu Leu Ala Ala Ala Cys Gln Leu Gln	
		1170 1175 1180
	Leu Asn Gly Asn Leu Gln Leu Glu Leu Gly Glu Val Leu Ala Arg Glu	
		1185 1190 1195 1200
30	Arg Leu Leu Leu Pro Glu Asp Pro Leu Ile Ser Gly Leu Leu Asn Ser	
		1205 1210 1215
	Gln Ala Leu Lys Ala Cys Ile Asp Thr Ala Leu Glu Asn Leu Ser Thr	
		1220 1225 1230
35	Leu Lys Met Lys Val Val Glu Val Leu Ala Gly Glu Gly His Leu Tyr	
		1235 1240 1245
	Ser His Ile Ser Ala Leu Leu Asn Thr Gln Pro Met Leu Gln Leu Glu	
		1250 1255 1260
40	Tyr Thr Ala Thr Asp Arg His Pro Gln Ala Leu Lys Asp Val Gln Thr	
		1265 1270 1275 1280
	Lys Leu Gln Gln His Asp Val Ala Gln Gly Gln Trp Asp Pro Ser Gly	
		1285 1290 1295
45	Pro Ala Pro Thr Asn Leu Gly Ala Leu Asp Leu Val Val Cys Asn Cys	
		1300 1305 1310
	Ala Leu Ala Thr Leu Gly Asp Pro Ala Leu Ala Leu Asp Asn Met Val	
		1315 1320 1325
50	Ala Ala Leu Lys Asp Gly Gly Phe Leu Leu Met His Thr Val Leu Lys	
		1330 1335 1340
	Gly His Ala Leu Gly Glu Thr Leu Ala Cys Leu Pro Ser Glu Val Gln	
		1345 1350 1355 1360
55		

EP 1 284 298 A2

Pro Gly Pro Ser Phe Leu Ser Gln Glu Glu Trp Glu Ser Leu Phe Ser
1365 1370 1375

5 Arg Lys Ala Leu His Leu Val Gly Leu Lys Lys Ser Phe Tyr Gly Thr
1380 1385 1390

Ala Leu Phe Leu Cys Arg Arg Leu Ser Pro Gln Asp Lys Pro Ile Phe
1395 1400 1405

10 Leu Pro Val Glu Asp Thr Ser Phe Gln Trp Val Asp Ser Leu Lys Ser
1410 1415 1420

Ile Leu Ala Thr Ser Ser Ser Gln Pro Val Trp Leu Thr Ala Met Asn
1425 1430 1435 1440

15 Cys Pro Thr Ser Gly Val Val Gly Leu Val Asn Cys Leu Arg Lys Glu
1445 1450 1455

Pro Gly Gly His Arg Ile Arg Cys Ile Leu Leu Ser Asn Leu Ser Ser
1460 1465 1470

20 Thr Ser His Val Pro Lys Leu Asp Pro Gly Ser Ser Glu Leu Gln Lys
1475 1480 1485

Val Leu Glu Ser Asp Leu Val Met Asn Val Tyr Arg Asp Gly Ala Trp
1490 1495 1500

25 Gly Ala Phe Arg His Phe Gln Leu Glu Gln Asp Lys Pro Glu Glu Gln
1505 1510 1515 1520

Thr Ala His Ala Phe Val Asn Val Leu Thr Arg Gly Asp Leu Ala Ser
1525 1530 1535

30 Ile Arg Trp Val Ser Ser Pro Leu Lys His Met Gln Pro Pro Ser Ser
1540 1545 1550

Ser Gly Ala Gln Leu Cys Thr Val Tyr Tyr Ala Ser Leu Asn Phe Arg
1555 1560 1565

35 Asp Ile Met Leu Ala Thr Gly Lys Leu Ser Pro Asp Ala Ile Pro Gly
1570 1575 1580

Lys Trp Ala Ser Arg Asp Cys Met Leu Gly Met Glu Phe Ser Gly Arg
1585 1590 1595 1600

Asp Lys Cys Gly Arg Arg Val Met Gly Leu Val Pro Ala Glu Gly Leu
1605 1610 1615

45 Ala Thr Ser Val Leu Leu Ser Pro Asp Phe Leu Trp Asp Val Pro Ser
1620 1625 1630

Ser Trp Thr Leu Glu Glu Ala Ala Ser Val Pro Val Val Tyr Thr Thr
1635 1640 1645

50 Ala Tyr Tyr Ser Leu Val Val Arg Gly Arg Ile Gln His Gly Glu Thr
1650 1655 1660

Val Leu Ile His Ser Gly Ser Gly Gly Val Gly Gln Ala Ala Ile Ser
1665 1670 1675 1680

55 Ile Ala Leu Ser Leu Gly Cys Arg Val Phe Thr Thr Val Gly Ser Ala

EP 1 284 298 A2

	1685	1690	1695
5	Glu Lys Arg Ala Tyr Leu Gln Ala Arg Phe Pro Gln Leu Asp Asp Thr 1700 1705 1710		
	Ser Phe Ala Asn Ser Arg Asp Thr Ser Phe Glu Gln His Val Leu Leu 1715 1720 1725		
10	His Thr Gly Gly Lys Gly Val Asp Leu Val Leu Asn Ser Leu Ala Glu 1730 1735 1740		
	Glu Lys Leu Gln Ala Ser Val Arg Cys Leu Ala Gln His Gly Arg Phe 1745 1750 1755 1760		
15	Leu Glu Ile Gly Lys Phe Asp Leu Ser Asn Asn His Pro Leu Gly Met 1765 1770 1775		
	Ala Ile Phe Leu Lys Asn Val Thr Phe His Gly Ile Leu Leu Asp Ala 1780 1785 1790		
20	Leu Phe Glu Gly Ala Asn Asp Ser Trp Arg Glu Val Ala Glu Leu Leu 1795 1800 1805		
	Lys Ala Gly Ile Arg Asp Gly Val Val Lys Pro Leu Lys Cys Thr Val 1810 1815 1820		
25	Phe Pro Lys Ala Gln Val Glu Asp Ala Phe Arg Tyr Met Ala Gln Gly 1825 1830 1835 1840		
	Lys His Ile Gly Lys Val Leu Val Gln Val Arg Glu Glu Glu Pro Glu 1845 1850 1855		
30	Ala Met Leu Pro Gly Ala Gln Pro Thr Leu Ile Ser Ala Ile Ser Lys 1860 1865 1870		
	Thr Phe Cys Pro Glu His Lys Ser Tyr Ile Ile Thr Gly Gly Leu Gly 1875 1880 1885		
35	Gly Phe Gly Leu Glu Leu Ala Arg Trp Leu Val Leu Arg Gly Ala Gln 1890 1895 1900		
	Arg Leu Val Leu Thr Ser Arg Ser Gly Ile Arg Thr Gly Tyr Gln Ala 1905 1910 1915 1920		
40	Lys His Val Arg Glu Trp Arg Arg Gln Gly Ile His Val Leu Val Ser 1925 1930 1935		
	Thr Ser Asn Val Ser Ser Leu Glu Gly Ala Arg Ala Leu Ile Ala Glu 1940 1945 1950		
45	Ala Thr Lys Leu Gly Pro Val Gly Gly Val Phe Asn Leu Ala Met Val 1955 1960 1965		
	Leu Arg Asp Ala Met Leu Glu Asn Gln Thr Pro Glu Leu Phe Gln Asp 1970 1975 1980		
50	Val Asn Lys Pro Lys Tyr Asn Gly Thr Leu Asn Leu Asp Arg Ala Thr 1985 1990 1995 2000		
	Arg Glu Ala Cys Pro Glu Leu Asp Tyr Phe Val Ala Phe Ser Ser Val 2005 2010 2015		
55			

EP 1 284 298 A2

Ser Cys Gly Arg Gly Asn Ala Gly Gln Ser Asn Tyr Gly Phe Ala Asn
 2020 2025 2030
 5 Ser Thr Met Glu Arg Ile Cys Glu Gln Arg Arg His Asp Gly Leu Pro
 2035 2040 2045
 Gly Leu Ala Val Gln Trp Gly Ala Ile Gly Asp Val Gly Ile Ile Leu
 2050 2055 2060
 10 Glu Ala Met Gly Thr Asn Asp Thr Val Val Gly Gly Thr Leu Pro Gln
 2065 2070 2075 2080
 Arg Ile Ser Ser Cys Met Glu Val Leu Asp Leu Phe Leu Asn Gln Pro
 2085 2090 2095
 15 His Ala Val Leu Ser Ser Phe Val Leu Ala Glu Lys Lys Ala Val Ala
 2100 2105 2110
 His Gly Asp Gly Glu Ala Gln Arg Asp Leu Val Lys Ala Val Ala His
 2115 2120 2125
 20 Ile Leu Gly Ile Arg Asp Leu Ala Gly Ile Asn Leu Asp Ser Ser Leu
 2130 2135 2140
 Ala Asp Leu Gly Leu Asp Ser Leu Met Gly Val Glu Val Arg Gln Ile
 2145 2150 2155 2160
 25 Leu Glu Arg Glu His Asp Leu Val Leu Pro Ile Arg Glu Val Arg Gln
 2165 2170 2175
 Leu Thr Leu Arg Lys Leu Gln Glu Met Ser Ser Lys Ala Gly Ser Asp
 2180 2185 2190
 30 Thr Glu Leu Ala Ala Pro Lys Ser Lys Asn Asp Thr Ser Leu Lys Gln
 2195 2200 2205
 Ala Gln Leu Asn Leu Ser Ile Leu Leu Val Asn Pro Glu Gly Pro Thr
 2210 2215 2220
 35 Leu Thr Arg Leu Asn Ser Val Gln Ser Ser Glu Arg Pro Leu Phe Leu
 2225 2230 2235 2240
 Val His Pro Ile Glu Gly Ser Ile Thr Val Phe His Ser Leu Ala Ala
 2245 2250 2255
 40 Lys Leu Ser Val Pro Thr Tyr Gly Leu Gln Cys Thr Gln Ala Ala Pro
 2260 2265 2270
 Leu Asp Ser Ile Pro Asn Leu Ala Ala Tyr Tyr Ile Asp Cys Ile Lys
 2275 2280 2285
 45 Gln Val Gln Pro Glu Gly Pro Tyr Arg Val Ala Gly Tyr Ser Phe Gly
 2290 2295 2300
 Ala Cys Val Ala Phe Glu Met Cys Ser Cln Leu Gln Ala Cln Gln Gly
 2305 2310 2315 2320
 50 Pro Ala Pro Ala His Asn Asn Leu Phe Leu Phe Asp Gly Ser His Thr
 2325 2330 2335
 55 Tyr Val Leu Ala Tyr Thr Gln Ser Tyr Arg Ala Lys Leu Thr Pro Gly
 2340 2345 2350

EP 1 284 298 A2

Cys Glu Ala Glu Ala Glu Ala Glu Ala Ile Cys Phe Phe Ile Lys Gln
2355 2360 2365

5 Phe Val Asp Ala Glu His Ser Lys Val Leu Glu Ala Leu Leu Pro Leu
2370 2375 2380

Lys Ser Leu Glu Asp Arg Val Ala Ala Ala Val Asp Leu Ile Thr Arg
2385 2390 2395 2400

10 Ser His Gln Ser Leu Asp Arg Arg Asp Leu Ser Phe Ala Ala Val Ser
2405 2410 2415

Phe Tyr Tyr Lys Leu Arg Ala Ala Asp Gln Tyr Lys Pro Lys Ala Lys
2420 2425 2430

15 Tyr His Gly Asn Val Ile Leu Leu Arg Ala Lys Thr Gly Gly Thr Tyr
2435 2440 2445

Gly Glu Asp Leu Gly Ala Asp Tyr Asn Leu Ser Gln Val Cys Asp Gly
2450 2455 2460

20 Lys Val Ser Val His Ile Ile Glu Gly Asp His Arg Thr Leu Leu Glu
2465 2470 2475 2480

Gly Arg Gly Leu Glu Ser Ile Ile Asn Ile Ile His Ser Ser Leu Ala
2485 2490 2495

25 Glu Pro Arg Val Ser Val Arg Glu Gly
2500 2505

30 <210> 21
<211> 9143
<212> DNA
<213> Rattus norvegicus

35 <220>
<223> Fatty acid synthase

<400> 21
agagagacgg cagcagcgct cgcgtccagtt cgcctgccgc gctcctcgct tgcgtctctgc 60
ctccagatcc cagacagaga agagccatgg aggaggtggt gatagccggt atgtccggga 120
40 aattgcccga gtcagagaaac ctgcaggagt tctggggccaa cctcattggc ggtgtggaca 180
tggtcacaga cgatgacagg aggtggaagg ctggggtcta tgggttgctt aagcgggtctg 240
gaaagctgaa ggatctgtcc aagttcgacg cctccttttt tgggggtccac cccaagcagg 300
cacacacaat ggaccgcgag ctccggctgc tgctggaagt cagctatgaa gctattgtgg 360
acggaggtat caaccgggcc tcaactccgag gaacaaacac tgggtgtctgg gtgggtgtga 420
gtgggttccga ggcgtcggag gccctgagca gagatcctga gactcttctg ggctacagca 480
45 tggtgggctg ccagagagca atgatggcca accggctctc tttcttcttc gacttcaaag 540
gacccagcat tgccctggac acagcctgct cctctagcct actggcacta cagaatgcct 600
atcaggctat ccgcagtggg gagtgccctg ctgccattgt gggcgggacg aacctgctgc 660
taaagcctaa cacctctgtg cagttcatga agctaggcat gctcagcccc gatggcacct 720
gcagatcctt tgatgattca gggaacgggt attgccgtgc tgaggctgtc gtggcagttc 780
tgctgactaa gaagtccttg gctcggcgag tctatgccac tattctgaat gccgggacga 840
50 acacagatgg ctgcaaggag caaggcgtga cattccccctc tggagaagcc caggaacaac 900
tcatccgttc tctgtatcag ccggggcggtg ttggccccga gtctcttgaa tatattgaag 960
cccatggcac gggcaccaag gtgggggacc cccaggaact gaacggcatt actcgggtccc 1020
tgtgtgcttt ccgcccagagc cctttgttaa ttgggtccac caaatccaac atgggacacc 1080
ctgagcctgc ctcggggctt gcagccctga ccaagggtgct gttatcccta gaaaatgggg 1140
tttgggcccc caacctgcat ttccacaacc ccaaccctga aatcccagca cttcttgatg 1200
55 ggcggctgca ggtggtcgat agggccctgc ctgttcgtgg tggcatcgtg ggcacatcaact 1260

	cgtttggcctt	cggaggtgcc	aatgtttcacg	tcattcctcca	gccaacacac	cagcaggccc	1320
	cagcacctgc	cccacatgct	gccctaccgc	atttgctgca	tgccagtggg	cggaccatgg	1380
	aggcagtgc	gggcctgctg	gaacagggcc	gccagcacag	tcaggacttg	gcctttgtga	1440
5	gcatgtcaa	tgacattgca	gcaacccta	cagcagccat	gcccttcaga	ggttacactg	1500
	tgttaggtgt	tgagggccat	gtccaggaag	tgacgaagt	gcctgccagc	cagcgccccc	1560
	tctggttcat	ctgctcaggg	atggggcacac	agtggcgtgg	aatggggctg	agccttatgc	1620
	gcctggacag	tttccgtgag	tccatcctgc	gctctgatga	ggctctgaag	cccttgggag	1680
	tcaaagtgtc	agacctgctg	ctgagcactg	atgagcacac	ctttgatgac	atcgtgcatt	1740
	cctttgtgag	cctcaccgcc	atccagattg	cctcatcgga	cctgctgacg	tctatggggc	1800
10	tgaacaccta	tgccatcatt	gggcactcct	tgggagaggt	tgccctgtggc	tatgcagatg	1860
	gctgtctctc	ccagagagag	gctgtgcttg	cagcctactg	gagaggccag	tgcattaaag	1920
	atgccaacct	tccggctgga	tccatggcag	ctgttggttt	gtcctgggaa	gaatgtaaac	1980
	aacgctgccc	tccgtgtgtg	gtgcctgcct	gccacaactc	tgaggacact	gtgaccatct	2040
	ctggaccta	ggctgcagtg	aatgaatttg	tggagcagct	aaagcaagag	ggcgtgtttg	2100
	ccaaggaggt	gcgaacaggt	ggcctggcct	tccactccta	cttcatggaa	ggaattgccc	2160
15	ccacgctgct	gcaggtctct	agaaggtga	tccgggagcc	acggccacgc	tcagcacgct	2220
	ggctcagcac	ctctatccct	gaggccaggt	ggcagagcag	cctggccccc	acatcttctg	2280
	ctgagtacaa	cgtaacaac	ctggtgagcc	ctgtgctctt	ccaggaagca	ctgtggcagc	2340
	tccccgagca	cgccgtgggtg	ctggagattg	caccccatgc	actgttgacg	gctgtcctga	2400
	agcgaggcgt	gaagcctagc	tgaccatca	tcccttgat	gaagagggac	cataaagata	2460
20	acttgaggtt	cttccctacc	aacctcggca	aggtgcacct	cacaggcatc	gacatcaacc	2520
	ctaattgcctt	gttcccacct	gtggaattcc	cgggtccccg	agggactcct	ctcatctccc	2580
	ctcacatcaa	gtgggaccac	agtcagactt	gggatatccc	agttgctgaa	gacttcccc	2640
	acgggtccag	ctcctcctca	gctacagtct	acaacattga	cgccagttcc	gagtcattctg	2700
	accactacct	ggtcgaccac	tgcatgacg	gccgtgtcct	cttccctggc	actggctacc	2760
	tgtacctggt	gtggaagaca	ctggctcgaa	gcctgagctt	gtccctagaa	gagaccctctg	2820
25	tggtgtttga	gaacgtgaca	tttcatcagg	ccaccatcct	gcccaggaca	ggaaccgtgc	2880
	ctctggaggt	gcggctgcta	gaggcctcac	atgcatttga	gggtcttgac	agtggaacc	2940
	tgatagttag	cgggaaagtg	taccagtggg	aagaccctga	ctccaagtta	ttcgaccacc	3000
	cagaagtccc	gatccccgcc	gagtcogagt	ctgtctcccg	cttgacgcag	ggagaagtat	3060
	acaaggagct	gcggctacgt	ggctatgact	atggccctca	tttccagggc	gtctatgagg	3120
	ccaccctcga	aggtgagcaa	ggcaagctgc	cttggaagaa	caactgggtg	accttcatgg	3180
30	acacatctga	gcagatatcc	atcctgggct	tccagcaagca	gagtcctgac	ctaccacccc	3240
	gtgtgactgc	catctatatt	gaccctgcaa	cccacctgca	gaagggtgtac	atgctggagg	3300
	gagacactca	agtggctgac	gtgaccacga	gccgctgtct	gggcgtgacc	gtctctgggtg	3360
	gtgtctacat	ttcgagacta	cagacaacag	caacctcacg	gcggcagcag	gaacagctgg	3420
	tccccaccct	ggagaagttt	gtcttcacac	cccatgtgga	gcctgagtg	ctgtctgaga	3480
35	gtgtctatcct	gcagaaagag	ctgcagctgt	gcaagggtct	ggcaaaaggct	ctgcagacca	3540
	aggccaccca	gcagggtctg	aagatgacag	tgcttgggct	agaggacctt	ccccagcatg	3600
	gactgcctcg	actcttggct	gctgcctgcc	agctgcagct	caacgggaac	ctgcaactgg	3660
	agttaggtga	ggtactggct	cgagagagcc	tcctgctgcc	agaagaccct	ctgatcagtg	3720
	gcctccttaa	ctcccaggcc	ctcaaggcct	gcatagacac	agccctggag	aacttgctcta	3780
	ctctcaagat	gaagggtggg	gaggtgctgg	ctggagaagg	ccacttggtat	ttccacatct	3840
40	cagcactgct	caacacccag	cctatgctgc	aactggagta	tacagccacc	gaccggcacc	3900
	cccaggccct	gaaggatgtt	cagaccaagc	tgacagcaga	tgatgtagca	caggggccagt	3960
	gggacccttc	tggtcctgct	cctaccaacc	tgggtgctct	tgacctgtgtg	gtgtgcaact	4020
	gtgcgttagc	caccctgggg	gatccagccc	tggccctgga	caacatggta	gctgccctca	4080
	aggatgggtg	tttcttgcta	atgcacacag	tgctcaaagg	acatgccctt	ggggagaccc	4140
	tggcctgcct	cccttctgag	gtgcagcctg	ggcccagctt	cttaagccag	gaagagtggg	4200
45	agagcctggt	ctcaaggaa	gcactgcacc	tgggtggcct	taaaaagtca	ttctacggta	4260
	ctgcctgtgt	cctgtgcgcg	cgtctcagcc	cacaggacaa	gcccactctc	ctgctctgtg	4320
	aggatactag	tttccagtgg	gtggactctc	tgaagagcat	tctggccaca	tcctcctccc	4380
	agcctgtgtg	gctaacagcc	atgaactgcc	ccacctcagg	tgtggtaggc	ttggtgaact	4440
	gtctccgaaa	agagccgggt	ggacaccgga	ttcgggtgtat	cctgctgtcc	aacctcagca	4500
50	gcacatctca	cgtccccaag	ctggaccctg	gctcttcaga	gctacagaag	gtgctagaga	4560
	gtgatctggt	gatgaacgtg	tacagggaag	gtgcctgggg	tgccctccgt	cacttccagt	4620
	tagagcagga	caagcccgag	gagcagacag	cacatgcctt	tgtaaacgtc	cttacccgag	4680
	gggaccttgc	ctccatccgc	tgggtctctt	ctccctgaa	acacatgcag	ccgccctcga	4740
	gctcaggagc	acagctctgc	actgtctact	atgcctcact	gaacttccga	gatatacatgc	4800
	tggccacggg	caagctgtcc	cctgatgcca	ttccaggtaa	atgggcccag	cgggactgca	4860
55	tgcttggcat	ggagttctca	ggcctgtgata	agtgcggccg	gcgtgtgatg	gggctgtgta	4920
	ccgcagaagg	cctggccacc	tcagtctctgt	tatcacccga	cttctctgtg	gatgtaccct	4980

	ctagctggac	cctggaggag	gcggcttctg	tgcctgttgt	ctacaccacc	gcctactact	5041
	ccttagtagt	gcgtggctgt	attcagcacg	gggaaactgt	gtcattcac	tcgggctccg	5101
	gtgggtgagg	ccaagcggcc	atttccattg	cccttagcct	gggctgccga	gtcttcacca	5161
5	ctgtgggctc	cgctgagaag	cgagcttacc	tccaggccag	attccctcag	ctggatgaca	5221
	ccagctttgc	taactctcga	gacacatcgt	ttgagcagca	tgtgttactg	cacacagggtg	5281
	gcaaaggggt	ggacctgggtc	ctcaactccc	tggcagaaga	gaagctgcag	gccagtgtgc	5341
	gggtgcttggc	tcagcatggc	cgcttcctag	agatcgga	atttgatctt	tctaacaacc	5401
	accctctggg	catggccatc	ttcttgaaga	acgtcacttt	ccatgggatc	ctgctggatg	5461
	cactttttga	ggggggccaac	gacagctggc	gggagggtggc	agagctgctg	aaggccggca	5521
10	tccgtgatgg	ggttgtgaag	cctctcaagt	gtacagtgtt	tcccaaggcc	cagggtggag	5581
	acgccttccg	atacatggct	caaggaaaac	atatttggca	agtccttgtc	cagggtacggg	5641
	aggaggagcc	cgaggctatg	ctgccagggg	ctcagccac	cctgatttcc	gccatctcca	5701
	agaccttctg	cccagagcat	aagagtaca	tcactactgg	tggcctagggt	ggctttggcc	5761
	tggaaactggc	ccggtggctt	gtgcttcgtg	gggcccaga	gcttgtacta	acttcccgat	5821
	ctgggaatccg	cacaggctac	caagccaagc	acgttcggga	gtggaggcgc	cagggtaccc	5881
15	atgtgctagt	gtcgacaagc	aatgtcagtt	cactggagggt	ggcccggtgt	ctcatcgctg	5941
	aagccacaaa	gcttggggcc	gttggagggtg	tcttcaacct	ggccatgggt	ttaagggatg	6001
	ccatgctgga	gaaccagact	ccagaactct	tccaggatgt	caacaagccc	aagtacaatg	6061
	gcaccctgaa	ccttgacagg	gcgaccggg	aagcctgtcc	tgagctggac	tactttgtgg	6121
	ccttctcctc	tgtaagctgc	ggcggtggta	atgctggcca	atccaactat	ggcttcggcca	6181
20	actctaccat	ggagcgtatt	tgcgaacagc	gccggcacga	tggcctccca	ggcttgcgg	6241
	tgcaatgggg	tgccattggg	gacgtgggca	ttatcttggg	agcgatgggt	accaatgaca	6301
	cagtcggttg	cggcacactg	ccacagcgca	tctcctcctg	catggagggtg	ctggacctct	6361
	tcttgaaatca	gccccacgca	gtcctgagca	gttttgtgct	ggctgagaag	aaagctgtgg	6421
	cccatgggtga	tgggtgaagcc	cagagggtatc	tgggtgaaagc	agtggcacac	atcctaggga	6481
	tcgcgcacct	cgcagggtat	aacctggaca	gctcgttggc	agacctgggc	ctggactcgc	6541
25	tcattgggtgt	ggaagtgcgc	cagatcctgg	aacgtgaaca	tgatctgggtg	ctacccattc	6601
	gtgaagtacg	gcaactcaca	ctgcggaagc	ttcaggaaat	gtcctccaag	gctggctcag	6661
	acactgagtt	ggcagccccc	aagtccaaga	atgatacatc	cctgaagcag	gcccagctga	6721
	atctgagtat	cctgctgggtg	aaccctgagg	gccctacctt	aacacgactc	aactcagttg	6781
	agagctctga	gcggcctctg	ttcctgggtg	acccatttga	aggttccatc	actgtgttcc	6841
	acagcctggc	tgccaagctc	agtgtgcca	cctacgggtct	gcagtgcacc	caagcggccc	6901
30	ccctggacag	cattccaaac	ctggctgcct	actacattga	ttgcatcaag	cagggtgcagc	6961
	ctgagggggcc	ctaccgagtg	gctgggtatt	ccttggagc	ttgtgtagcc	ttcgagatgt	7021
	gctcccagct	gcaggcccag	caggggcccag	cccccgcca	caacaacctc	ttcttgtttg	7081
	atgggtcaca	cacctacgta	ttggcgta	ccagagcta	ccgggcaaa	ctgaccccag	7141
	gctgtgaggc	tgagggtgaa	gctgaagcca	tatgcttctt	cattaagcag	tttgttgatg	7201
35	cagagcatag	caagggtgca	gaggccctgc	taccactgaa	gagcctggag	cacggggttg	7261
	ctgctgctgt	ggacctcctc	actagaagcc	accagagcct	ggaccgccc	gacctgagct	7321
	ttgctgccc	gtccttctac	tacaagcttc	gagccgccc	ccagtataaa	ccaaggcca	7381
	agtaccacgg	caatgtgatc	ctgctgccc	ccaagacagg	tggcacctac	ggcgaggact	7441
	tgggtgccc	ttacaacctg	tcccagggtg	gtgatgggaa	ggtgtctgtg	cacatcattg	7501
40	aggggtgacca	ccgtacgctg	ctggagggca	ggggcctgga	gtctatcatc	aacatcattc	7561
	acagctccct	ggctgagcct	cgagtgaagt	tacggggagg	ctagacctgc	ctaccatgaa	7621
	gccacgaccc	acaccggcca	ccagagatgc	tccgatcccc	accacaccct	gagtgacagg	7681
	actggggagg	gtcctgctgg	tgggaccccc	tcacccagct	ggcccagcac	cacccctctc	7741
	cctgggtggct	gctacaaaca	ggacctcac	atgtgtccca	gccacttagt	ggggttccca	7801
	yagccactga	cctggaggca	ccctgggtctg	tgaagagtca	gtggaggcca	gcaagagcca	7861
45	aactgagcct	ttcttgccaa	gtgacatttg	tcacactggg	tgtttctcca	ttaaattctc	7921
	atatttattg	cattgtctggg	aaagaccgce	cacccagagg	ttaactcatt	ccagaacccc	7981
	taaagtggga	aaagccatgt	ggggaaggct	gctggctgga	gccccctttt	gtcttagccc	8041
	tgtaccgctc	cactgcaggg	cagggtatgg	agagggtgg	ttcgcgggga	acgaggaacc	8101
	cagcagacac	tgtagcccat	ggcccttggg	ccccagcact	cccggtgca	cccatgatgc	8161
	agggcctacc	agactctgcg	gaccgcaccg	ggcactcact	gtatttgttt	tccaagattc	8221
50	aaattgctgc	ttgggttttg	aalltactyc	agctgtcagt	gtaaagaaac	atgtctgaac	8281
	tgtgtccttt	ttacaccaac	ctggtaaaaa	tgctcttgat	gctgtcccgt	tgccacaatt	8341
	aaactgcacg	tgagctctgg	cttccgttca	gtctctttcc	agtcaccagc	agtcacccc	8401
	agagcctcca	cagctcttac	agtgagaatc	aaattggccc	actccttggg	aggcgtggca	8461
	ttctgtcaga	gtaaaaggaa	agtagagltg	gctgattcac	gttcagcgtg	tggggctggc	8521
	tagagacctt	ggcactgtag	tgaacagaat	gtgtccacct	ttaagtcacc	ctgaaggcat	8581
55	caccatagct	acagcctcac	ccagggttag	agaatagtag	tgtctacttg	ctgactacct	8641
	ggcagttggg	gccagccccc	atagaggaaa	acagcagltg	gtggccactg	tyagaagcat	8701

EP 1 284 298 A2

atccctggaa acaggtgacc agagcagagg gctaacgcct acctgagtca cacaaaaactg 8760
 accaggcctg agtggtccaga agagtctatc agaaggccac agcattcagt cctatccaca 8820
 gagagcagca gactaagttg tctccttgcc agcttagaaa actgcagtgc tgggggtacag 8880
 5 gtaggggtgt caggaggtcc gggccccagt gattagtcta agactgaagc atctgggttg 8940
 ctgtgggtccc acctagaaaa ttcttaaagc tcttgtcatg tacttcctgg gaaggaccta 9000
 cccgtgtctca ataatgtctc tagctcgttg gagtctactg actcaaacat ttataaagtg 9060
 tcctagaaaag gcctgactcc cctacaaggc tgtgtgatcc ttcaaactca catatgtgag 9120
 ccaataaaac cttgagactc tag 9143

10 <210> 22
 <211> 373
 <212> PRT
 <213> Rattus norvegicus

15 <220>
 <223> Glutamine synthetase

20 <400> 22
 Met Ala Thr Ser Ala Ser Ser His Leu Asn Lys Gly Ile Lys Gln Met
 1 5 10 15
 Tyr Met Asn Leu Pro Gln Gly Glu Lys Ile Gln Leu Met Tyr Ile Trp
 20 25 30
 Val Asp Gly Thr Gly Glu Gly Leu Arg Cys Lys Thr Arg Thr Leu Asp
 25 35 40 45
 Cys Asp Pro Lys Cys Val Glu Glu Leu Pro Glu Trp Asn Phe Asp Gly
 50 55 60
 Ser Ser Thr Phe Gln Ser Glu Gly Ser Asn Ser Asp Met Tyr Leu His
 30 65 70 75 80
 Pro Val Ala Met Phe Arg Asp Pro Phe Arg Arg Asp Pro Asn Lys Leu
 85 90 95
 Val Phe Cys Glu Val Phe Lys Tyr Asn Arg Lys Pro Ala Glu Thr Asn
 35 100 105 110
 Leu Arg His Ser Cys Lys Arg Ile Met Asp Met Val Ser Ser Gln Arg
 115 120 125
 Pro Trp Phe Gly Met Glu Gln Glu Tyr Thr Leu Met Gly Thr Asp Gly
 40 130 135 140
 His Pro Phe Gly Trp Pro Ser Asn Gly Phe Pro Gly Pro Gln Gly Pro
 145 150 155 160
 Tyr Tyr Cys Gly Val Gly Ala Asp Lys Ala Tyr Gly Arg Asp Ile Val
 45 165 170 175
 Glu Ala His Tyr Arg Ala Cys Leu Tyr Ala Gly Ile Lys Ile Thr Gly
 180 185 190
 Thr Asn Ala Glu Val Met Pro Ala Gln Trp Glu Phe Gln Ile Gly Pro
 50 195 200 205
 Cys Glu Gly Ile Arg Met Gly Asp His Leu Trp Val Ala Arg Phe Ile
 210 215 220
 55 Leu His Arg Val Cys Glu Asp Phe Gly Val Ile Ala Thr Phe Asp Pro

EP 1 284 298 A2

225 230 235 240

Lys Pro Ile Pro Gly Asn Trp Asn Gly Ala Gly Cys His Thr Asn Phe
245 250 255

5 Ser Thr Lys Ala Met Arg Glu Glu Asn Gly Leu Arg Cys Ile Glu Glu
260 265 270

Ala Ile Asp Lys Leu Ser Lys Arg His Gln Tyr His Ile Arg Ala Tyr
275 280 285

10 Asp Pro Lys Gly Gly Leu Asp Asn Ala Arg Arg Leu Thr Gly Phe His
290 295 300

Glu Thr Ser Asn Ile Asn Asp Phe Ser Ala Gly Val Ala Asn Arg Ser
305 310 315 320

15 Ala Ser Ile Arg Ile Pro Arg Ile Val Gly Gln Glu Lys Lys Gly Tyr
325 330 335

Phe Glu Asp Arg Arg Pro Ser Ala Asn Cys Asp Pro Tyr Ala Val Thr
340 345 350

20 Glu Ala Ile Val Arg Thr Cys Leu Leu Asn Glu Thr Gly Asp Glu Pro
355 360 365

Phe Gln Tyr Lys Asn
370

25

<210> 23
<211> 2793
30 <212> DNA
<213> Rattus norvegicus

<220>
<223> Glutamine synthetase

35

<400> 23

acagccgaga atgggagtag ggccggagtgt ttgagcagca caccatttc ctctccgctc 60
ttcgtctcgt tctcgtggcc tgtccaccca tccatcatct gccggccacc gctctgaaca 120
ccttccacca tggccacctc agcaagttcc cacttgaaca aaggcatcaa gcagatgtac 180
40 atgaacctgc cccagggcga gaagatccaa ctcatgtata tctgggttga tggatccggg 240
gaagggctac gctgcaagac ccgtactctg gactgtgacc ccaagtgtgt agaagagtta 300
cccagtgga actttgatgg ttctagtacg ttctagtctg aaggctccaa cagcgacatg 360
tacctccatc ctgtggccat gtttcgagac cccttccgca gagaccccaa caagctggtg 420
ttctgcgaag tattcaagta taaccggaag ccgcagaga ccaacctgag gcacagctgt 480
aagcgtataa tggacatggt gagcagccag cgcctctggt ttggaatgga acaggagtat 540
45 actctcatgg gaacagacgg ccaccctttc ggctggcctt ctaatggctt ccctggaccc 600
caaggaccct attactgcgg tgtgggagct gacaaggctt atggccgaga tatcgtggag 660
gctcactacc gggcctgctt gtatgctgga atcaagatca cagggaacaa tgccgaggtt 720
atgcctgccc agtgggaatt ccagatagga ccctgcgaag ggatccgcat gggagatcat 780
ctctgggtag ccggttttat cttgcatcgg gtatgcgaag actttggggt gatagcaacc 840
tttgaccca agccatttc agggaaactgg aatggggcag gctgccacac caacttttagc 900
50 accaaggcca tgcgggagga gaatggtctg aggtgcattg aggaggccat tgataaactg 960
agcaagaggg accagtagca catcgtgcc tacgaccca aggggggcct ggacaacgcc 1020
cgccgtctga ctggattcca cgaaacctcc aacatcaacg acttttccgc tggcgttgcc 1080
aaccgcagcg ccagtatccg cattccccgg attgtcggcc aggagaagaa gggttacttt 1140
gaagaccgtc ggccttctgc caattgcgac ccctatgcgg tgacggaagc catcgtccgc 1200
acgtgtctcc tcaacgaaac tggcgacgag cccttccaat acaagaacta agcggactcg 1260
55 acttccagtg atcttgagcc cttcctagtt caccctactc ccaactgttc cctctccac 1320

EP 1 284 298 A2

	tgggtccccac	tgttaactcaa	aaggatggaa	taccaaggtc	tttttatctc	tgtcgccscag	1380
	ttaattttttg	ctcttattgg	tcagaataga	ggggtcagggt	tcttaattctc	tacacaccca	1440
	atcccttctt	tcctagctag	ctttccagtg	ggggaacggg	agggggtggg	gaagggtaac	1500
	ccaccgcttc	atctcagcgg	gaatgcatgt	cctgtaggca	tagctgtcac	aaatcgggtg	1560
5	tacttggtgt	gaggggaggac	tgggtttttt	ttctcttcag	gataattgaa	aggcgaggcc	1620
	caacagctta	gattaacatt	ttctctgtca	gtagagagct	gttatttctt	ccggtagaac	1680
	cagctttctt	tgtgaagtctg	gtgaggagtt	ggagggtggg	ctcttggtct	ccttagctta	1740
	gggaagggga	gttcaccctc	ccttcatgaa	acacagttca	cctgacaaaat	ggccctactg	1800
	taaaggaaga	aaaaagtttc	ttggtcctcc	atttataact	caaagcagag	tagtattttt	1860
	atattttaa	gttaaaaaa	aaaaagttat	atatattgggt	gtgtggatat	atatgtcttt	1920
10	tctaattgag	aaaaccatcc	tattccctgg	gtgcgaagtt	ttagtgagga	gctcgggtgta	1980
	gaagtgaggc	actcttgagg	taggggtggg	gatgcagtac	tgggaaagtt	ggttatcttg	2040
	gggggttcagc	ttcattacta	cttagggttt	ccctgcccac	tctgcagygag	cagatgttgg	2100
	acaggtagcc	agtgggatgc	cactgcttgc	cgccactgtc	ctggggctta	gtttaagggg	2160
	acgtgtatac	ctaattccca	cacgagttag	aagtatgagt	tgggtgttca	acttgaacat	2220
15	tgttcagaggc	gggtgggtgt	tagtgggggg	ttattttttg	gtgggactag	catgtcacta	2280
	aagcgggcct	tttgatatat	taaatttttt	aaagcaaaac	aagtttagat	tttaatcaag	2340
	ttcgtagggt	ttctaacttt	acagaattgc	ctgtttgttt	caatgactcc	ttccacttgg	2400
	ctcttagggg	aactgaggac	aggcctggag	ttaatacact	tgtcattctg	tgtcctagtgt	2460
	tctctttctt	ccggcagact	gtccccttcc	ttctgaaaaa	gccgatagag	tcttgtttta	2520
	tttttctttt	ataataaaca	cacccccact	ccatcccagc	ttgttgccct	gcagttttct	2580
20	ggatgtttgt	gtcggcagca	ggcagctgtg	gtttttttct	cctgccacga	tgactctaata	2640
	taccatgtat	agtatgttca	gttagataaac	tcactgtaaa	cagactgtaa	ctgagagcag	2700
	agcttgtaaa	tcaaacctaac	gtttataaga	tttctcttga	cctgtttctt	tgtggttcca	2760
	aaaaaaaaaa	aaaaaaaaaa	aacctcaaaa	act			2793

```
25      <210> 24
        <211> 514
        <212> PRT
        <213> Homo sapiens
```

30 <220>
 <223> Seryl t-RNA synthetase

		<400> 24																
35		Met	Val	Leu	Asp	Leu	Asp	Leu	Phe	Arg	Val	Asp	Lys	Gly	Gly	Asp	Pro	
		1				5					10					15		
		Ala	Leu	Ile	Arg	Glu	Thr	Gln	Glu	Lys	Arg	Phe	Lys	Asp	Pro	Gly	Leu	
					20					25					30			
40		Val	Asp	Gln	Leu	Val	Lys	Ala	Asp	Ser	Glu	Trp	Arg	Arg	Cys	Arg	Phe	
				35					40					45				
		Arg	Ala	Asp	Asn	Leu	Ser	Lys	Leu	Lys	Asn	Leu	Cys	Ser	Lys	Thr	Ile	
			50					55					60					
45		Gly	Glu	Lys	Met	Lys	Lys	Lys	Glu	Pro	Val	Gly	Asp	Asp	Glu	Ser	Val	
		65					70					75					80	
		Pro	Glu	Asn	Val	Leu	Ser	Phe	Asp	Asp	Leu	Thr	Ala	Asp	Ala	Leu	Ala	
					85						90					95		
50		Asn	Leu	Lys	Val	Ser	Gln	Ile	Lys	Lys	Val	Arg	Leu	Leu	Ile	Asp	Glu	
					100					105					110			
		Ala	Ile	Leu	Lys	Cys	Asp	Ala	Glu	Arg	Ile	Lys	Leu	Glu	Ala	Glu	Arg	
				115					120					125				
55		Phe	Glu	Asn	Leu	Arg	Glu	Ile	Gly	Asn	Leu	Leu	His	Pro	Ser	Val	Pro	

EP 1 284 298 A2

	130		135		140
	Ile Ser Asn Asp Glu Asp Val Asp Asn Lys Val Glu Arg Ile Trp Gly				
	145		150		155 160
5	Asp Cys Thr Val Arg Lys Lys Tyr Ser His Val Asp Leu Val Val Met				
		165		170	175
	Val Asp Gly Phe Glu Gly Glu Lys Gly Ala Val Val Ala Gly Ser Arg				
		180		185	190
10	Gly Tyr Phe Leu Lys Gly Val Leu Val Phe Leu Glu Gln Ala Leu Ile				
		195		200	205
	Gln Tyr Ala Leu Arg Thr Leu Gly Ser Arg Gly Tyr Ile Pro Ile Tyr				
		210		215	220
15	Thr Pro Phe Phe Met Arg Lys Glu Val Met Gln Glu Val Ala Gln Leu				
		225		230	235 240
	Ser Gln Phe Asp Glu Glu Leu Tyr Lys Val Ile Gly Lys Gly Ser Glu				
		245		250	255
20	Lys Ser Asp Asp Asn Ser Tyr Asp Glu Lys Tyr Leu Ile Ala Thr Ser				
		260		265	270
	Glu Gln Pro Ile Ala Ala Leu His Arg Asp Glu Trp Leu Arg Pro Glu				
		275		280	285
	Asp Leu Pro Ile Lys Tyr Ala Gly Leu Ser Thr Cys Phe Arg Gln Glu				
		290		295	300
30	Val Gly Ser His Gly Arg Asp Thr Arg Gly Ile Phe Arg Val His Gln				
		305		310	315 320
	Phe Glu Lys Ile Glu Gln Phe Val Tyr Ser Ser Pro His Asp Asn Lys				
		325		330	335
35	Ser Trp Glu Met Phe Glu Glu Met Ile Thr Thr Ala Glu Glu Phe Tyr				
		340		345	350
	Gln Ser Leu Gly Ile Pro Tyr His Ile Val Asn Ile Val Ser Gly Ser				
		355		360	365
40	Leu Asn His Ala Ala Ser Lys Lys Leu Asp Leu Glu Ala Trp Phe Pro				
		370		375	380
	Gly Ser Gly Ala Phe Arg Glu Leu Val Ser Cys Ser Asn Cys Thr Asp				
		385		390	395 400
45	Tyr Gln Ala Arg Arg Leu Arg Ile Arg Tyr Gly Gln Thr Lys Lys Met				
		405		410	415
	Met Asp Lys Val Glu Phe Val His Met Leu Asn Ala Thr Met Cys Ala				
		420		425	430
50	Thr Thr Arg Thr Ile Cys Ala Ile Leu Glu Asn Tyr Gln Thr Glu Lys				
		435		440	445
	Gly Ile Thr Val Pro Glu Lys Leu Lys Glu Phe Met Pro Pro Gly Leu				
		450		455	460
55					

EP 1 284 298 A2

Gln Glu Leu Ile Pro Phe Val Lys Pro Ala Pro Ile Glu Gln Glu Pro
465 470 475 480

Ser Lys Lys Gln Lys Lys Gln His Glu Gly Ser Lys Lys Lys Ala Ala
485 490 495

Ala Arg Asp Val Thr Leu Glu Asn Arg Leu Gln Asn Met Glu Val Thr
500 505 510

Asp Ala

<210> 25

<211> 1846

<212> DNA

<213> Homo sapiens

<220>

<223> Seryl t-RNA synthetase

<400> 25

```
gcagtgcggc ggtcacaggc tgagtgcctgc ggcgcgatcc ttgcttccct gagcgttggc 60
ccgggaggaa agaagatggt gctggatctg gatttggttc ggggtggataa aggaggggac 120
ccagccctca tccgagagac gcaggagaag cgcttcaagg acccgggact agtggaccag 180
ctggtgaagg cagacagcga gtggcgacga tgtagaattc gggcagacaa cttgagcaag 240
ctgaagaacc tatgcagcaa gacaatcgga gagaaaatga agaaaaaaga gccagtggga 300
gatgatgagt ctgtcccaga gaatgtgctg agtttcgatg accttactgc agacgcttta 360
gctaacctga aagtctcaca aatcaaaaaa gtccgactcc tcattgatga agccatcctg 420
aagtgtgacg cggagcggat aaagtgtgaa gcagagcggg ttgagaacct ccgagagatt 480
gggaaccttc tgcaccttc tgtacctatc agtaacgatg aggatgtgga caacaaagta 540
gagaggattt ggggcgattg tacagtcagg aagaagtact ctcatgtgga cctggtgggtg 600
atggtagatg gctttgaagg cgaaaagggg gccgtggtgg ctgggagtcg aggggtacttc 660
ttgaaggggg tcctggtggt cctggaacag gctctcatcc agtatgccct tcgcaccttg 720
ggaagtccgg gctacattcc cttttatacc ccctttttca tgaggaagga ggtcatgcag 780
gaggtggcac agctcagcca gtttgatgaa gaactttata aggtgattgg caaaggcagt 840
gaaaagtctg atgacaactc ctatgatgag aagtacctga ttgccacctc agagcagccc 900
attgctgccc tgcaccggga tgagtggctc cgcccgaggg acctgcccac caagtatgct 960
ggcctgtcta cctgcttccg tcaggagggtg ggctcccatg gccgtgacac ccgtggcatc 1020
ttccgagtec atcagtttga gaagattgaa cagtttgtgt actcatcacc ccatgacaac 1080
aagtcatggg agatgtttga agagatgatt accaccgcag aggagttcta ccagtccctg 1140
gggattccct accacattgt gaattattgt tcaggttctt tgaatcatgc tgccagtaag 1200
aagcttgacc tggaggcctg gtttccgggc tcaggagcct tccgtgagtt ggtctcctgt 1260
tctaattgca cggattacca ggctcgcggg ctccgaatcc gatatgggca aaccaagaag 1320
atgatggaca aggtggagtt tgtccatatg ctcaatgcta ccatgtgctg cactacctgt 1380
accatctgcg ccatcctgga gaactaccag acagagaagg gcatcactgt gcctgagaaa 1440
ttgaaggagt tcatgccgcc aggactgcaa gaactgatcc cctttgtgaa gcctgcgccc 1500
attgagcagg agccatcaaa gaagcagaag aagcaacatg agggcagcaa aaagaaagca 1560
gcagcaagag acgtcaccct agaaaacagg ctgcagaaca tggagggtcac cgatgcttga 1620
acattcctgc ctccctatct gccaggcttt catttctgtc tgctgagatc tcagagcctg 1680
cccaacagca gggaagccaa gcacccattc atccccctgc ccccatctga ctgcgtagct 1740
gagaggggaa cagtgccatg taccacacag atgttcctgt ctccctgcct gggcataggg 1800
accatcatt gatgactgat gaaaccatgt aataaagcat ctctgg 1846
```

<210> 26

<211> 434

<212> PRT

<213> Homo sapiens

<220>

EP 1 284 298 A2

<223> Alpha-enolase

<400> 26

5	Met	Ser	Ile	Leu	Lys	Ile	His	Ala	Arg	Glu	Ile	Phe	Asp	Ser	Arg	Gly	1	5	10	15
	Asn	Pro	Thr	Val	Glu	Val	Asp	Leu	Phe	Thr	Ser	Lys	Gly	Leu	Phe	Arg	20	25	30	
10	Ala	Ala	Val	Pro	Ser	Gly	Ala	Ser	Thr	Gly	Ile	Tyr	Glu	Ala	Leu	Glu	35	40	45	
	Leu	Arg	Asp	Asn	Asp	Lys	Thr	Arg	Tyr	Met	Gly	Lys	Gly	Val	Ser	Lys	50	55	60	
15	Ala	Val	Glu	His	Ile	Asn	Lys	Thr	Ile	Ala	Pro	Ala	Leu	Val	Ser	Lys	65	70	75	80
	Lys	Leu	Asn	Val	Thr	Glu	Gln	Glu	Lys	Ile	Asp	Lys	Leu	Met	Ile	Glu	85	90	95	
20	Met	Asp	Gly	Thr	Glu	Asn	Lys	Ser	Lys	Phe	Gly	Ala	Asn	Ala	Ile	Leu	100	105	110	
	Gly	Val	Ser	Leu	Ala	Val	Cys	Lys	Ala	Gly	Ala	Val	Glu	Lys	Gly	Val	115	120	125	
25	Pro	Leu	Tyr	Arg	His	Ile	Ala	Asp	Leu	Ala	Gly	Asn	Ser	Glu	Val	Ile	130	135	140	
	Leu	Pro	Val	Pro	Ala	Phe	Asn	Val	Ile	Asn	Gly	Gly	Ser	His	Ala	Gly	145	150	155	160
30	Asn	Lys	Leu	Ala	Met	Gln	Glu	Phe	Met	Ile	Leu	Pro	Val	Gly	Ala	Ala	165	170	175	
	Asn	Phe	Arg	Glu	Ala	Met	Arg	Ile	Gly	Ala	Glu	Val	Tyr	His	Asn	Leu	180	185	190	
35	Lys	Asn	Val	Ile	Lys	Glu	Lys	Tyr	Gly	Lys	Asp	Ala	Thr	Asn	Val	Gly	195	200	205	
	Asp	Glu	Gly	Gly	Phe	Ala	Pro	Asn	Ile	Leu	Glu	Asn	Lys	Glu	Gly	Leu	210	215	220	
40	Glu	Leu	Leu	Lys	Thr	Ala	Ile	Gly	Lys	Ala	Gly	Tyr	Thr	Asp	Lys	Val	225	230	235	240
	Val	Ile	Gly	Met	Asp	Val	Ala	Ala	Ser	Glu	Phe	Phe	Arg	Ser	Gly	Lys	245	250	255	
45	Tyr	Asp	Leu	Asp	Phe	Lys	Ser	Pro	Asp	Asp	Pro	Ser	Arg	Tyr	Ile	Ser	260	265	270	
50	Pro	Asp	Gln	Leu	Ala	Asp	Leu	Tyr	Lys	Ser	Phe	Ile	Lys	Asp	Tyr	Pro	275	280	285	
	Val	Val	Ser	Ile	Glu	Asp	Pro	Phe	Asp	Gln	Asp	Asp	Trp	Gly	Ala	Trp	290	295	300	
55	Gln	Lys	Phe	Thr	Ala	Ser	Ala	Gly	Ile	Gln	Val	Val	Gly	Asp	Asp	Leu				

EP 1 284 298 A2

305 310 315 320

Thr Val Thr Asn Pro Lys Arg Ile Ala Lys Ala Val Asn Glu Lys Ser
325 330 335

5 Cys Asn Cys Leu Leu Leu Lys Val Asn Gln Ile Gly Ser Val Thr Glu
340 345 350

Ser Leu Gln Ala Cys Lys Leu Ala Gln Ala Asn Gly Trp Gly Val Met
355 360 365

10 Val Ser His Arg Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu
370 375 380

Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
385 390 395 400

15 Ser Glu Arg Leu Ala Lys Tyr Asn Gln Leu Leu Arg Ile Glu Glu Glu
405 410 415

Leu Gly Ser Lys Ala Lys Phe Ala Gly Arg Asn Phe Arg Asn Pro Leu
420 425 430

20 Ala Lys

25 <210> 27
<211> 1755
<212> DNA
<213> Homo sapiens

30 <220>
<223> Alpha-enolase

<400> 27

35 acggagatct cgccggcttt acgttcacct cgggtgtctgc agcaccctcc gcttcctctc 60
ctaggcgacg agaccagtg gctagaagtt caccatgtct attctcaaga tccatgccag 120
ggagatcttt gactctcgcg ggaatccac tggtgaggtt gatctcttca cctcaaaagg 180
tctcttcaga gctgctgtgc ccagtgggtgc ttcaactggt atctatgagg ccctagagct 240
ccggggacaat gataagactc gctatatggg gaagggtgtc tcaaaggctg ttgagcacat 300
caataaaact attgcgcctg ccctgggttag caagaaactg aacgtcacag aacaagagaa 360
gattgacaaa ctgatgatcg agatggatgg aacagaaaat aaatctaagt ttggtgcgaa 420
40 cgccattctg ggggtgtccc ttgccgtctg caaagctggt gccgttgaga agggggtccc 480
cctgtaccgc cacatcgctg acttggctgg caactctgaa gtcacctgc cagtcccggc 540
gttcaatgtc atcaatggcg gttctcatgc tggcaacaag ctggccatgc aggagttcat 600
gatcctccca gtcggtgcag caaacttcag ggaagccatg cgcattggag cagaggttta 660
ccacaacctg aagaatgtca tcaaggagaa atatgggaaa gatgccacca atgtggggga 720
45 tgaaggcggg ttgctccca acatcctgga gaataaagaa ggcttgagc tgctgaagac 780
tgctatggg aaagctggct aactgataa ggtgggtcatc ggcatggacg tagcggcctc 840
cgagttcttc aggtctggga agtatgacct ggacttcaag tctcccgatg accccagcag 900
gtacatctcg cctgaccagc tggctgacct gtacaagtc ttcacaaagg actaccagat 960
ggtgtctatc gaagatccct ttgaccagga tgactgggga gcttggcaga agttcacagc 1020
cagtgacgga atccaggtag tgggggatga tctcacagt accaacccaa agaggatcg 1080
50 caaggcctg aacgagaagt cctgcaactg cctcctgctc aaagtcaacc agattggctc 1140
cgtgaccgag tctcttcagg cgtgcaagct ggcccaggcc aatggttggg gcgtcatggt 1200
gtctcatcgt tcgggggaga ctgaagatac ctcatcgct gacctgggtg tggggctgtg 1260
cactgggcag atcaagactg gtgccccttg ccgatctgag cgcttggcca agtacaacca 1320
gtccttcaga attgaagagg agctgggcag caaggctaag tttgccggca ggaacttcag 1380
55 aaacccttg gccaaagtaag ctgtgggcag gcaagccttc ggtcacctgt tggctacaca 1440
gaccctctcc ctcgtgtcag ctcaggcagc tcgaggcccc cgaccaacac ttgcaggggt 1500

EP 1 284 298 A2

ccctgctagt tagcgccccca ccgccgtgga gttcgtaccg cttccttaga acttctacag 1560
aagccaagct cctggagacc ctgttggcag ctctagcttt tgcagtcgtg taatgggccc 1620
aagtcattgt ttttctcgcc tcaactttcca ccaagtgtct agagtcattg gagcctcgtg 1680
tcatctccgg ggtggccaca ggctagatcc ccggtgggtt tgtgctcaaa ataaaaagcc 1740
tcagtgacct atgag 1755

<210> 28
<211> 316
<212> PRT
<213> Rattus norvegicus

<220>
<223> Aldose reductase

<400> 28
Met Ala Ser His Leu Glu Leu Asn Asn Gly Thr Lys Met Pro Thr Leu
1 5 10 15
Gly Leu Gly Thr Trp Lys Ser Pro Pro Gly Gln Val Thr Glu Ala Val
20 20 25 30
Lys Val Ala Ile Asp Met Gly Tyr Arg His Ile Asp Cys Ala Gln Val
35 40 45
Tyr Gln Asn Glu Lys Glu Val Gly Val Ala Leu Gln Glu Lys Leu Lys
25 50 55 60
Glu Gln Val Val Lys Arg Gln Asp Leu Phe Ile Val Ser Lys Leu Trp
65 70 75 80
Cys Thr Phe His Asp Gln Ser Met Val Lys Gly Ala Cys Gln Lys Thr
30 85 90 95
Leu Ser Asp Leu Gln Leu Asp Tyr Leu Asp Leu Tyr Leu Ile His Trp
100 105 110
Pro Thr Gly Phe Lys Pro Gly Pro Asp Tyr Phe Pro Leu Asp Ala Ser
35 115 120 125
Gly Asn Val Ile Pro Ser Asp Thr Asp Phe Val Asp Thr Trp Thr Ala
130 135 140
Met Glu Gln Leu Val Asp Glu Gly Leu Val Lys Ala Ile Gly Val Ser
40 145 150 155 160
Asn Phe Asn Pro Leu Gln Ile Glu Arg Ile Leu Asn Lys Pro Gly Leu
165 170 175
Lys Tyr Lys Pro Ala Val Asn Gln Ile Glu Cys His Pro Tyr Leu Thr
45 180 185 190
Gln Glu Lys Leu Ile Glu Tyr Cys His Cys Lys Gly Ile Val Val Thr
195 200 205
Ala Tyr Ser Pro Leu Gly Ser Pro Asp Arg Pro Trp Ala Lys Pro Glu
50 210 215 220
Asp Pro Ser Leu Leu Glu Asp Pro Arg Ile Lys Glu Ile Ala Ala Lys
225 230 235 240

EP 1 284 298 A2

Tyr Asn Lys Thr Thr Ala Gln Val Leu Ile Arg Phe Pro Ile Gln Arg
 245 250 255
 Asn Leu Val Val Ile Pro Lys Ser Val Thr Pro Ala Arg Ile Ala Glu
 260 265 270
 Asn Phe Lys Val Phe Asp Phe Glu Leu Ser Asn Glu Asp Met Ala Thr
 275 280 285
 Leu Leu Ser Tyr Asn Arg Asn Trp Arg Val Cys Ala Leu Met Ser Cys
 290 295 300
 Ala Lys His Lys Asp Tyr Pro Phe His Ala Glu Val
 305 310 315
 <210> 29
 <211> 1337
 <212> DNA
 <213> Rattus norvegicus
 <220>
 <223> Aldose reductase
 <400> 29
 ctcttgccggg tcgttggtgcg taacttgacg caatcatggc tagccatctg gaactcaaca 60
 acggcaccac gatgcccacc ctgggtcttg gcacctggaa gtctcctcct ggccaggtga 120
 ccgaggctgt gaagggttgct atcgacatgg ggtatcgcca cattgactgc gccaggtgt 180
 accagaatga gaaggaggtg ggggtggccc tccaggagaa gctcaaggag caggtggtga 240
 agcgccagga tctcttcatt gtcagcaagc tgtggtgcac gttccacgac cagagcatgg 300
 tgaaaggggc ctgccagaag acgtgagcg acctgcagct ggactacctg gacctctacc 360
 ttattcactg gccaaactggc ttcaagcctg ggcctgacta tttcccctg gatgcatcgg 420
 gaaacgtgat tccagtgtac accgattttg tggacacttg gacggctatg gagcaactag 480
 tggatgaagg tttggtaaaa gcaatcggag tctccaactt caaccctctt cagattgaga 540
 ggatcttgaa caaacctggc ttaaagtata agcctgctgt taaccagatc gagtggcacc 600
 catacctaac tcaggagaag ctgattgagt actgccattg caaaggcatc gtggtgactg 660
 catacagtc ccttggttct cctgacaggc cctggggcaa gcctgaggac cctctctctc 720
 tggaggatcc caggatcaag gaaattgcag ccaagtacaa taaaactaca gccaggtgc 780
 tgatccggtt ccccatccaa aggaacctgg tcgtgatccc caagtctgtg acaccagcac 840
 gtattgctga gaactttaag gtctttgact ttgagctgag caatgaggac atggccactc 900
 tactcagcta caacaggaac tggaggggtg gcgccttgat gagctgtgcc aaacacaagg 960
 attaccctt ccacgcagaa gtctgaagct gtggtggacg aatcctgctc ctccccaaagc 1020
 gacttaacac atgttctttc tgcctcatct gccttgcaa gtgtccctct gactgggtg 1080
 gcaccttgca gaccagatgg tgagagtttg ttagtttgac gtagaatgtg gagggcagta 1140
 ccagtagctg aggagtttct tcggcccttc ttggtcttct tcccacctgg aggacttta 1200
 cacgagtacc ttttccaacc aaagagaaag caagatttat agcccaagtc atgccactaa 1260
 cacttaaatt tgagtgttta gaactccagt cctatggggg tcagactttt tgctctaaat 1320
 aaaaactgct tttgtcg 1337
 <210> 30
 <211> 299
 <212> PRT
 <213> Rattus norvegicus
 <220>
 <223> Cytochrome C oxidase, subunit 1
 <400> 30
 Glu Phe Pro Phe Phe Asp Pro Ala Gly Gly Gly Asp Pro Ile Leu Tyr
 1 5 10 15

EP 1 284 298 A2

Gln His Leu Phe Trp Phe Phe Gly His Pro Glu Val Tyr Ile Leu Ile
 20 25 30
 5 Leu Pro Gly Phe Gly Ile Ile Ser His Val Val Thr Tyr Tyr Ser Gly
 35 40 45
 Lys Lys Glu Pro Phe Gly Tyr Met Gly Met Val Trp Ala Met Met Ser
 50 55 60
 10 Ile Gly Phe Leu Gly Phe Ile Val Trp Ala His His Met Phe Thr Val
 65 70 75 80
 Gly Leu Asp Val Asp Thr Arg Ala Tyr Phe Thr Ser Ala Thr Met Ile
 85 90 95
 15 Ile Ala Ile Pro Thr Gly Val Lys Val Phe Ser Trp Leu Ala Thr Leu
 100 105 110
 His Gly Gly Asn Ile Lys Trp Ser Pro Ala Met Leu Trp Ala Leu Gly
 115 120 125
 20 Phe Ile Phe Leu Phe Thr Val Gly Gly Leu Thr Gly Ile Val Leu Ser
 130 135 140
 Asn Ser Ser Leu Asp Ile Val Leu His Asp Thr Tyr Tyr Val Val Ala
 145 150 155 160
 25 His Phe His Tyr Val Leu Ser Met Gly Ala Val Phe Ala Ile Met Ala
 165 170 175
 Cys Phe Val His Trp Phe Pro Leu Phe Ser Gly Tyr Thr Leu Asn Asp
 180 185 190
 30 Thr Trp Ala Lys Ala His Phe Ala Ile Met Phe Val Gly Val Asn Met
 195 200 205
 Thr Phe Phe Pro Gln His Phe Leu Gly Leu Ala Gly Met Pro Arg Arg
 210 215 220
 35 Tyr Ser Asp Tyr Pro Asp Ala Tyr Thr Thr Trp Asn Thr Val Ser Ser
 225 230 235 240
 Met Gly Ser Phe Ile Ser Leu Thr Ala Val Leu Val Met Ile Phe Met
 245 250 255
 40 Ile Trp Glu Ala Phe Ala Ser Lys Arg Glu Val Leu Ser Ile Ser Tyr
 260 265 270
 Ser Ser Thr Asn Leu Glu Trp Leu His Gly Cys Pro Pro Pro Tyr His
 275 280 285
 45 Thr Phe Glu Glu Pro Ser Tyr Val Lys Val Lys
 290 295
 50 <210> 31
 <211> 987
 <212> DNA
 <213> Rattus norvegicus
 55 <220>
 <223> Cytochrome C oxidase, subunit 1

EP 1 284 298 A2

5 <400> 31
gaattccctt tcttcgaccc cgctggaggt ggagacccaa ttctttatca acacctattc 60
tgattcttcg gccacccaga agtgtagatc ttaattcttc cagggttttg aattatttca 120
catgtagtta cctattactc tggaaaaaaa gaacccttcg gatatatagg tatggtagta 180
gccataatat ctattggctt cctaggattt attgtatgag cacatcacat attcacagta 240
ggcctagatg tagacacccg agcctacttt acatctgcca ctataattat cgcaattcct 300
acaggcgtaa aagtattcag ctgactcgct acactacatg gaggaaatat caaatgatcc 360
10 cccgccatat tatgagcctt aggggtttatc ttcttattca cagtaggggg cctaacaggg 420
atcgtagtat ctaactcatc ccttgacatt gtacttcattg atacatacta cgtagtagct 480
cacttccact atgtcttctc tataggagca gtattcgcca tcatagcttg cttcgtccac 540
tgattcccac tattctcagg ctatacccta aatgacacat gagcaaaagc ccactttgcc 600
attatatttg taggtgtaaa cataacattt ttccctcaac acttcctagg attagcaggg 660
atacctcgtc gttactctga ttatccagat gcttatacca catgaaatac agtctcctct 720
15 ataggctcat tcatctcact tacggccgctc cttgtaatga tcttcatgat ttgagaagcc 780
ttcgcaccaa aacgagaagt gctctcaatt tcctactctt caactaacct agaagtactg 840
catggatgcc cccacacctt ccacacattc gaagaacctt cctatgtaaa agttaaataa 900
gaaaggaagg attcgaaccc cctacaactg gtttcaagcc aatttcataa ccattatgtc 960
tttctcaata aaaaaaaaaa ggaatttc 987

20
25 <210> 32
<211> 334
<212> PRT
<213> Rattus norvegicus

30 <220>
<223> LDH-B

<400> 32
Met Ala Thr Leu Lys Glu Lys Leu Ile Ala Pro Val Ala Asp Asp Glu
1 5 10 15
Thr Ala Val Pro Asn Asn Lys Ile Thr Val Val Gly Val Gly Gln Val
20 25 30
35 Gly Met Ala Cys Ala Ile Ser Ile Leu Gly Lys Ser Leu Ala Asp Glu
35 40 45
Leu Ala Leu Val Asp Val Leu Glu Asp Lys Leu Lys Gly Glu Met Met
50 55 60
40 Asp Leu Gln His Gly Ser Leu Phe Leu Gln Thr Pro Lys Ile Val Ala
65 70 75 80
Asp Lys Asp Tyr Ser Val Thr Ala Asn Ser Lys Ile Val Val Val Thr
85 90 95
45 Ala Gly Val Arg Gln Gln Glu Gly Glu Ser Arg Leu Asn Leu Val Gln
100 105 110
Arg Asn Val Asn Val Phe Lys Phe Ile Ile Pro Gln Ile Val Lys Tyr
115 120 125
50 Ser Pro Asp Cys Thr Ile Ile Val Val Ser Asn Pro Val Asp Ile Leu
130 135 140
Thr Tyr Val Thr Trp Lys Leu Ser Gly Leu Pro Lys His Arg Val Ile
145 150 155 160
55 Gly Ser Gly Cys Asn Leu Asp Ser Ala Arg Phe Arg Tyr Leu Met Ala

EP 1 284 298 A2

165 170 175
 Glu Lys Leu Gly Ile His Pro Ser Ser Cys His Gly Trp Ile Leu Gly
 180 185 190
 5 Glu His Gly Asp Ser Ser Val Ala Val Trp Ser Gly Val Asn Val Ala
 195 200 205
 Gly Val Ser Leu Gln Glu Leu Asn Pro Glu Met Gly Thr Asp Asn Asp
 210 215 220
 10 Ser Glu Asn Trp Lys Glu Val His Lys Met Val Val Asp Ser Ala Tyr
 225 230 235 240
 Glu Val Ile Lys Leu Lys Gly Tyr Thr Asn Trp Ala Ile Gly Leu Ser
 245 250 255
 15 Val Ala Asp Leu Ile Glu Ser Met Leu Lys Asn Leu Ser Arg Ile His
 260 265 270
 Pro Val Ser Thr Met Val Lys Gly Met Tyr Gly Ile Glu Asn Glu Val
 275 280 285
 Phe Leu Ser Leu Pro Cys Ile Leu Asn Ala Arg Gly Leu Thr Ser Val
 290 295 300
 25 Ile Asn Gln Lys Leu Lys Asp Asp Glu Val Ala Gln Leu Arg Lys Ser
 305 310 315 320
 Ala Asp Thr Leu Trp Asp Ile Gln Lys Asp Leu Lys Asp Leu
 325 330
 30 <210> 33
 <211> 1217
 <212> DNA
 <213> Rattus norvegicus
 35 <220>
 <223> LDH-B
 <400> 33
 40 cagagcctcc tcttgtctgg acaagatggc aacccttaag gaaaagctca ttgcgccagt 60
 cgagacgac gagactgccg tcccgaacaa caagattact gtagtaggcg ttggacaagt 120
 tggaaatggct tgtgctatca gcattctggg gaagtctctg gctgatgagc ttgccctggg 180
 ggatgtcttg gaagacaagc tcaaaggaga aatgatggat ctgcagcacg ggagcttatt 240
 tctccagact ccgaaaatcg tggctgataa agattactcc gtgacagcca attctaagat 300
 tgtggtggtg accgcggggag tccgccagca ggagggggag agtcgggtca acctggtgca 360
 gagaaacgtc aatgtattca agttcattat tcctcagatc gtcaagtaca gccccgactg 420
 45 caccatcatc gtggtttcca acccagtgga tattcttacc tatgtcacct ggaagctgag 480
 cgggctacct aagcaccgcg tgattggaag tggatgcaat ctggattctg ctcggtttcg 540
 ttacctcatg gccgaaaagc ttggtattca tcccagcagc tgccacggct ggatcctggg 600
 cgagcacggg gactccagtg tggcagtgtg gagcgggggtg aatgtggcag gagtctccct 660
 ccaggaactg aaccagagaga tgggaacgga caatgacagc gagaactgga aggaggtgca 720
 taagatggtg gtggacagtg cctatgaagt catcaagcta aaaggctaca ccaactgggc 780
 50 catcggccta agtgtggctg acctcatcga atccatgctg aaaaacctct ctcggattca 840
 ccccggtgtc acaatggtga agggaatgta cggcatcgag aacgaagtct tcctcagtct 900
 cccgtgcac cttaatgtc ggggactgac cagcgtcatc aaccagaagc tgaaggacga 960
 tgaggtcgct cagctcagga agagtgcgga caccctgtgg gatattccaga aagacctcaa 1020
 ggacctgtga ctgccaggcg ccaggctgta gaaatccaaa cctccaatgt gactaagtga 1080
 55 acctttagtc ttcggccttg tacgtaggtc acagtttgct tcttccttaa catgtgataa 1140
 tgagctcaca gatcaaaacc aggagtgttt gatgtttgca ctaggagctc ctgaacaaat 1200

aaagtttagc aattgca

1217

5 <210> 34
 <211> 86
 <212> PRT
 <213> Homo sapiens

10 <220>
 <223> Cytochrome C oxidase subunit VIb

<400> 34
 Met Ala Glu Asp Met Glu Thr Lys Ile Lys Asn Tyr Lys Thr Ala Pro
 1 5 10 15

15 Phe Asp Ser Arg Phe Pro Asn Gln Asn Gln Thr Arg Asn Cys Trp Gln
 20 25 30

Asn Tyr Leu Asp Phe His Arg Cys Gln Lys Ala Met Thr Ala Lys Gly
 35 40 45

20 Gly Asp Ile Ser Val Cys Glu Trp Tyr Gln Arg Val Tyr Gln Ser Leu
 50 55 60

Cys Pro Thr Ser Trp Val Thr Asp Trp Asp Glu Gln Arg Ala Glu Gly
 65 70 75 80

25 Thr Phe Pro Gly Lys Ile
 85

30 <210> 35
 <211> 439
 <212> DNA
 <213> Homo sapiens

<220>
 <223> Cytochrome C oxidase subunit VIb

35 <400> 35
 ttgagctgca ggttgaatcc ggggtgcctt taggattcag caccatggcg gaagacatgg 60
 agaccaaact caagaactac aagaccgccc cttttgacag ccgcttcccc aaccagaacc 120
 agactagaaa ctgctggcag aactacctgg acttccaccg ctgtcagaag gcaatgaccg 180
 40 ctaaaggagg cgatatctct gtgtgcgaat ggtaccagcg tgtgtaccag tccctctgcc 240
 ccacatcctg ggtcacagac tgggatgagc aacgggctga aggcacgttt cccgggaaga 300
 tctgaactgg ctgcatctcc ctttctctctg tcttccatcc ttctcccagg atgggtgaagg 360
 gggaccttgt acccagtgat ccccacccca ggatcctaaa tcatgactta cctgctaata 420
 aaaactcatt ggaaaagtg 439

45 <210> 36
 <211> 172
 <212> PRT
 <213> Homo sapiens

50 <220>
 <223> NADH: ubiquinone oxidoreductase PGIV subunit

<400> 36
 Met Pro Gly Ile Val Glu Leu Pro Thr Leu Glu Glu Leu Lys Val Asp
 1 5 10 15

55

EP 1 284 298 A2

Glu Val Lys Ile Ser Ser Ala Val Leu Lys Ala Ala Ala His His Tyr
20 25 30

5 Gly Ala Gln Cys Asp Lys Pro Asn Lys Glu Phe Met Leu Cys Arg Trp
35 40 45

Glu Glu Lys Asp Pro Arg Arg Cys Leu Glu Glu Gly Lys Leu Val Asn
50 55 60

10 Lys Cys Ala Leu Asp Phe Phe Arg Gln Ile Lys Arg His Cys Ala Glu
65 70 75 80

Pro Phe Thr Glu Tyr Trp Thr Cys Ile Asp Tyr Thr Gly Gln Gln Leu
85 90 95

15 Phe Arg His Cys Arg Lys Gln Gln Ala Lys Phe Asp Glu Cys Val Leu
100 105 110

Asp Lys Leu Gly Trp Val Arg Pro Asp Leu Gly Glu Leu Ser Lys Val
115 120 125

20 Thr Lys Val Lys Thr Asp Arg Pro Leu Pro Glu Asn Pro Tyr His Ser
130 135 140

Arg Pro Arg Pro Asp Pro Ser Pro Glu Ile Glu Gly Asp Leu Gln Pro
145 150 155 160

25 Ala Thr His Gly Ser Arg Phe Tyr Phe Trp Thr Lys
165 170

30 <210> 37
<211> 700
<212> DNA
<213> Homo sapiens

35 <220>
<223> NADH: ubiquinone oxidoreductase PGIV subunit

<400> 37
ggggagattca aggagacggg ggcgacgcgg ctgagggcctt ctcgtcgggg tcggggcctgc 60
agccgtcatg ccggggatag tggagctgcc cactctagag gagctgaaag tagatgaggt 120
gaaaattagt tctgtgtgct ttaaagctgc ggcccatcac tatggagctc aatgtgataa 180
40 gcccaacaag gaatttatgc tctgccgctg ggaagagaaa gatccgaggc ggtgtttaga 240
ggaaggcaaa ctggtcaaca agtgtgcttt ggacttcttt aggcagataa aacgtcactg 300
tgcagagcct ttacagaat attggacttg cattgattat actggccagc agttatttcg 360
tactgtcgc aaacagcagg caaagtttga cgagtgtgtg ctggacaaac tgggctgggt 420
gcggcctgac ctggggagaac tgtcaaaggc caccaaagtg aaaacagatc gacctttacc 480
ggagaatccc tatcactcaa gaccaagacc ggaatccagc cctgagatcg agggagatct 540
45 gcagcctgcc acacatggca gccgctttta ttctggacc aagtaaagat gggtcctggtg 600
cccacactcg gtcattgtgct cagacaacga ctgatgaaa cgcccatgcg gtttgcacg 660
actgatagtg tggtctttcc gggatcacia acattaacia 700

50 <210> 38
<211> 532
<212> PRT
<213> Mus musculus

55 <220>
<223> succinate dehydrogenase Fp subunit

EP 1 284 298 A2

<400> 38

5	Leu	Arg	Ala	Ala	Phe	Gly	Leu	Ser	Glu	Ala	Gly	Phe	Asn	Thr	Ala	Cys	1	5	10	15
	Leu	Thr	Lys	Leu	Phe	Pro	Thr	Arg	Ser	His	Thr	Val	Ala	Ala	Gln	Gly	20	25	30	
10	Gly	Ile	Asn	Ala	Ala	Leu	Gly	Asn	Met	Glu	Glu	Asp	Asn	Trp	Arg	Trp	35	40	45	
	His	Phe	Tyr	Asp	Thr	Val	Lys	Gly	Ser	Asp	Trp	Leu	Gly	Asp	Gln	Asp	50	55	60	
15	Ala	Ile	His	Tyr	Met	Thr	Glu	Gln	Ala	Pro	Ala	Ser	Val	Val	Glu	Leu	65	70	75	80
	Glu	Asn	Tyr	Gly	Met	Pro	Phe	Ser	Arg	Thr	Glu	Asp	Gly	Lys	Ile	Tyr	85	90	95	
20	Gln	Arg	Ala	Phe	Gly	Gly	Gln	Ser	Leu	Lys	Phe	Gly	Lys	Gly	Gly	Gln	100	105	110	
	Ala	His	Arg	Cys	Cys	Cys	Val	Ala	Asp	Arg	Thr	Gly	His	Ser	Leu	Leu	115	120	125	
25	His	Thr	Leu	Tyr	Gly	Arg	Ser	Leu	Arg	Tyr	Asp	Thr	Ser	Tyr	Phe	Val	130	135	140	
	Glu	Tyr	Phe	Ala	Leu	Asp	Leu	Leu	Met	Glu	Asn	Gly	Glu	Cys	Arg	Gly	145	150	155	160
30	Val	Ile	Ala	Leu	Cys	Ile	Glu	Asp	Gly	Ser	Ile	His	Arg	Ile	Arg	Ala	165	170	175	
	Lys	Asn	Thr	Val	Ile	Ala	Thr	Gly	Gly	Tyr	Gly	Arg	Thr	Tyr	Phe	Ser	180	185	190	
35	Cys	Thr	Ser	Ala	His	Thr	Ser	Thr	Gly	Asp	Gly	Thr	Ala	Met	Val	Thr	195	200	205	
	Arg	Ala	Gly	Leu	Pro	Cys	Gln	Asp	Leu	Glu	Phe	Val	Gln	Phe	His	Pro	210	215	220	
40	Thr	Gly	Ile	Tyr	Gly	Ala	Gly	Cys	Leu	Ile	Thr	Glu	Gly	Cys	Arg	Gly	225	230	235	240
	Glu	Gly	Gly	Ile	Leu	Ile	Asn	Ser	Gln	Gly	Glu	Arg	Phe	Met	Glu	Arg	245	250	255	
45	Tyr	Ala	Pro	Val	Ala	Lys	Asp	Leu	Ala	Ser	Arg	Asp	Val	Val	Ser	Arg	260	265	270	
	Ser	Met	Thr	Leu	Glu	Ile	Arg	Glu	Gly	Arg	Gly	Cys	Gly	Pro	Glu	Lys	275	280	285	
50	Asp	His	Val	Tyr	Leu	Gln	Leu	His	His	Leu	Pro	Pro	Glu	Gln	Leu	Ala	290	295	300	
55	Thr	Arg	Leu	Pro	Gly	Ile	Ser	Glu	Thr	Ala	Met	Ile	Phe	Ala	Gly	Val	305	310	315	320

EP 1 284 298 A2

Asp Val Thr Lys Glu Pro Ile Pro Val Leu Pro Thr Val His Tyr Asn
 325 330 335
 5 Met Gly Gly Ile Pro Thr Asn Tyr Lys Gly Gln Val Leu Lys His Val
 340 345 350
 Asn Gly Gln Asp Gln Ile Val Pro Gly Leu Tyr Ala Cys Gly Glu Ala
 355 360 365
 10 Ala Cys Ala Ser Val His Gly Ala Asn Arg Leu Gly Ala Asn Ser Leu
 370 375 380
 Leu Asp Leu Val Val Phe Gly Arg Ala Cys Ala Leu Ser Ile Ala Glu
 385 390 395 400
 15 Ser Cys Arg Pro Gly Asp Lys Val Pro Ser Ile Lys Ala Asn Ala Gly
 405 410 415
 Glu Glu Ser Val Met Asn Leu Asp Lys Leu Arg Phe Ala Asp Gly Ser
 420 425 430
 20 Ile Arg Thr Ser Glu Leu Arg Leu Asn Met Gln Lys Ser Met Gln Asn
 435 440 445
 His Ala Ala Val Phe Arg Val Gly Ser Val Leu Gln Glu Gly Cys Glu
 450 455 460
 25 Lys Ile Ser Gln Leu Tyr Gly Asp Leu Lys His Leu Lys Thr Phe Asp
 465 470 475 480
 Arg Gly Met Val Trp Asn Thr Asp Leu Val Glu Thr Leu Glu Leu Gln
 485 490 495
 30 Asn Leu Met Leu Cys Ala Leu Gln Thr Ile Tyr Gly Ala Glu Ala Arg
 500 505 510
 Lys Glu Ser Arg Gly Ala His Ala Arg Glu Asp Tyr Lys Val Arg Val
 515 520 525
 35 Asp Glu Tyr Asp
 530

<210> 39
 <211> 1596
 <212> DNA
 <213> Mus musculus

<220>
 <223> succinate dehydrogenase Fp subunit

<400> 39
 ttgcgagctg catttggcct ttctgaggca gggtttaata ctgcatgcct tacaaagctc 60
 ttctctaccc gatcacatac tggtgcagca caggaggta tcaatgctgc tctgggggaac 120
 atggaagagg acaactggag atggcatttc tatgacactg tgaaaggctc cgactggctg 180
 50 ggggatcagg atgccatcca ttacatgaca gagcaagctc ctgcctctgt ggttgagcta 240
 gaaaattatg gtatgccatt tagcagaact gaagatggga agatttatca gcgtgcattt 300
 ggtggacaga gcctcaagtt tgggaaaggc gggcaggctc atcgggtgtg ctgtgtggct 360
 gatcggacag gccactcact cttacacacc ttgtatggaa gatctctgcg atatgacacc 420
 agttattttg tgggaatattt tgcactggat cttctgatgg aaaaatgggga gtgccgtggt 480
 gtcattgcac tgtgcataga agatgggtcc atacaccgaa taagagcaaa aaacactggt 540
 55 attgctactg ggggctacgg gcgaacctac ttcagctgta catctgcccc taccagcaca 600

EP 1 284 298 A2

```

5      ggggacggca cagccatggt cactagggct ggtttgctt gccaggactt agaatttggt 660
      cagttccacc ccacaggtat atacgggtgt ggctgcctca tcacagaagg gtgtcgtgga 720
      gaggggggga ttctcatcaa cagtcaagggt gaaagggttca tggagagata cgcccctggt 780
      gccaaggacc tggcatcaag agatgttgtg tctcgatcca tgactcttga gatccgtgaa 840
10     ggaagaggct gtggccctga gaaagatcac gtctacctgc agttgcatca tctgcctcct 900
      gagcaactgg ccacacgtct gcccgggaatt tcagagacag ccatgatctt cgctgggtgtg 960
      gatgtcacta aggagcccat tccagtcctc cccactgtgc attacaacat ggggtgggatt 1020
      cccactaact acaagggaca ggtgctgaag catgtgaaat gccaggatca gattgtgcct 1080
      ggactgtatg cctgtgggga ggctgcctgc gcctcagtgc atggtgccaa ccggcttgga 1140
15     gcaaattctc tcttggaact tgtagtcttt ggagagcct gtgccctgag cattgcagaa 1200
      tcttgcaagg ctggagataa agttccttca attaaggcaa atgctggaga agaatcggtt 1260
      atgaatcttg acaagttgag atttgccgat ggaagtataa gaacatcaga actacgccta 1320
      aacatgcaga agtcgatgca gaacctgct gcagtgttcc gtgtggggag tgtattgcaa 1380
      gaaggctgtg aaaaaatcag tcagctctat ggagacctaa agcatctaaa gacattcgac 1440
      aggggaatgg tttggaacac agacctggtg gagaccctgg agctgcagaa tctgatgctg 1500
20     tgccgactgc agaccatata tgggtgcagaa gtcggaagg agtcccgggg agcccatgcc 1560
      aggggaagatt acaaagtgcg ggtcgatgag tatgat 1596

```

```

20     <210> 40
      <211> 453
      <212> PRT
      <213> Homo sapiens

```

```

25     <220>
      <223> Core protein II of human mitochondrial cytochrome bc-1 complex

```

```

30     <400> 40
      Met Lys Leu Leu Thr Arg Ala Gly Ser Phe Ser Arg Phe Tyr Ser Leu
          1             5             10             15

      Lys Val Ala Pro Lys Val Lys Ala Thr Ala Ala Pro Ala Gly Ala Pro
          20             25             30

      Pro Gln Pro Gln Asp Leu Glu Phe Thr Lys Leu Pro Asn Gly Leu Val
          35             40             45

35     Ile Ala Ser Leu Glu Asn Tyr Ser Pro Val Ser Arg Ile Gly Leu Phe
          50             55             60

      Ile Lys Ala Gly Ser Arg Tyr Glu Asp Phe Ser Asn Leu Gly Thr Thr
          65             70             75             80

40     His Leu Leu Arg Leu Thr Ser Ser Leu Thr Lys Gly Ala Ser Ser
          85             90             95

      Phe Lys Ile Thr Arg Gly Ile Glu Ala Val Gly Gly Lys Leu Ser Val
          100            105            110

45     Thr Ala Thr Arg Glu Asn Met Ala Tyr Thr Val Glu Cys Leu Arg Gly
          115            120            125

      Asp Val Asp Ile Leu Met Glu Phe Leu Leu Asn Val Thr Thr Ala Pro
          130            135            140

50     Glu Phe Arg Arg Trp Glu Val Ala Asp Leu Gln Pro Gln Leu Lys Ile
          145            150            155            160

      Asp Lys Ala Val Ala Phe Gln Asn Pro Gln Thr His Val Ile Glu Asn
          165            170            175

55

```

EP 1 284 298 A2

	Leu	His	Ala	Ala	Ala	Tyr	Gln	Asn	Ala	Leu	Ala	Asn	Pro	Leu	Tyr	Cys	
				180					185					190			
5	Pro	Asp	Tyr	Arg	Ile	Gly	Lys	Val	Thr	Ser	Glu	Glu	Leu	His	Tyr	Phe	
			195					200					205				
	Val	Gln	Asn	His	Phe	Thr	Ser	Ala	Arg	Met	Ala	Leu	Ile	Gly	Leu	Gly	
		210					215					220					
10	Val	Ser	His	Pro	Val	Leu	Lys	Gln	Val	Ala	Glu	Gln	Phe	Leu	Asn	Met	
	225					230					235					240	
	Arg	Gly	Gly	Leu	Gly	Leu	Ser	Gly	Ala	Lys	Ala	Asn	Tyr	Arg	Gly	Gly	
				245					250						255		
15	Glu	Ile	Arg	Glu	Gln	Asn	Gly	Asp	Ser	Leu	Val	His	Ala	Ala	Phe	Val	
				260				265							270		
	Ala	Glu	Ser	Ala	Val	Ala	Gly	Ser	Ala	Glu	Ala	Asn	Ala	Phe	Ser	Val	
			275					280					285				
20	Leu	Gln	His	Val	Leu	Gly	Ala	Gly	Pro	His	Val	Lys	Arg	Gly	Ser	Asn	
		290				295						300					
	Thr	Thr	Ser	His	Leu	His	Gln	Ala	Val	Ala	Lys	Ala	Thr	Gln	Gln	Pro	
	305				310						315					320	
25	Phe	Asp	Val	Ser	Ala	Phe	Asn	Ala	Ser	Tyr	Ser	Asp	Ser	Gly	Leu	Phe	
				325						330					335		
	Gly	Ile	Tyr	Thr	Ile	Ser	Gln	Ala	Thr	Ala	Ala	Gly	Asp	Val	Ile	Lys	
				340					345					350			
30	Ala	Ala	Tyr	Asn	Gln	Val	Lys	Arg	Ile	Ala	Gln	Gly	Asn	Leu	Ser	Asn	
			355					360					365				
	Thr	Asp	Val	Gln	Ala	Ala	Lys	Asn	Lys	Leu	Lys	Ala	Gly	Tyr	Leu	Met	
		370					375					380					
35	Ser	Val	Glu	Ser	Ser	Glu	Cys	Phe	Leu	Glu	Glu	Val	Gly	Ser	Gln	Ala	
	385					390					395					400	
	Leu	Val	Ala	Gly	Ser	Tyr	Met	Pro	Pro	Ser	Thr	Val	Leu	Gln	Gln	Ile	
				405						410					415		
40	Asp	Ser	Val	Ala	Asn	Ala	Asp	Ile	Ile	Asn	Ala	Ala	Lys	Lys	Phe	Val	
				420				425						430			
	Ser	Gly	Gln	Lys	Ser	Met	Ala	Ala	Ser	Gly	Asn	Leu	Gly	His	Thr	Pro	
		435					440						445				
45	Phe	Val	Asp	Glu	Leu												
		450															
50	<210> 41																
	<211> 1588																
	<212> DNA																
	<213> Homo sapiens																
55	<220>																
	<223> Core protein II of human mitochondrial cytochrome bc-1 complex																

<400> 41
 atcttgcttt cctttaatcc ggcagtgacc gtgtgtcaga acaatcttga atcatgaagc 60
 5 tactaaccag agccggctct ttctcgagat tttattccct caaagttgcc cccaaagtta 120
 aagccacagc tgcgcctgca ggagcaccgc cacaacctca ggaccttgag tttaaccaagt 180
 taccaaatgg cttgggtgatt gcttctttgg aaaactattc tcctgtatca agaattgggt 240
 tggttcattaa agcaggcagt agatatgagg acttcagcaa ttttaggaacc acccatttgc 300
 tgcgtcttac atccagtcgt acgacaaaag gagcttcac tttcaagata acccgtggaa 360
 ttgaagcagt tgggtggcaaa ttaagtgtga ccgcaacaag ggaaaacatg gcttatactg 420
 10 tgggaatgcct gcgggggtgat gttgatattc taatggagtt cctgctcaat gtcaccacag 480
 caccagaatt tcgtcgttgg gaagtagctg accttcagcc tcagctaaag attgacaaaag 540
 ctgtggcctt tcagaatccg cagactcatg tcattgaaaa tttgcatgca gcagcttacc 600
 agaatgcctt ggctaataccc ttgtattgtc ctgactatag gattggaaaa gtgacatcag 660
 aggagttaca ttacttcgtt cagaaccatt tcacaagtgc aagaatggct ttgattggac 720
 ttggtgtgag tcatcctgtt ctaaaagcaag ttgctgaaca gtttctcaac atgaggggtg 780
 15 ggcttgggtt atctgggtgca aaggccaact accgtggagg tgaaatccga gaacagaatg 840
 gagacagtct tgtccatgct gctttttag cagaaaagtgc tgcgcggga agtgcagagg 900
 caaatgcatt tagtggtctt cagcatgtcc tcggtgctgg gccacatgtc aagaggggca 960
 gcaacaccac cagccatctg caccaggctg ttgccaaagg aactcagcag ccatttgatg 1020
 20 tttctgcatt taatgccagt tactcagatt ctggactctt tgggatttat actatctccc 1080
 aggccacagc tgctgggat gttatcaagg ctgcctataa tcaagtaaaa agaatagtc 1140
 aaggaaacct ttccaacaca gatgtccaag ctgccaaaga caagctgaaa gctggatacc 1200
 taatgtcagt ggagtcttct gagtgttcc tggaagaagt cgggtcccag gctctagtgt 1260
 ctggttctta catgccacca tccacagtcc ttcagcagat tgattcagtg gctaatgctg 1320
 25 atatcataaa tgccggcaaa aggtttgttt ctggccagaa gtcaatggca gcaagtggaa 1380
 atttgggaca tacacctttt gttgatgagt tgtaatactg atgcacacat tacaggagag 1440
 agctgaacgt tctctcacc agagcagcaa acacatgaaa gtcagaagtc tctaataat 1500
 catttgcctt ttttccagt aggtaaaata aggcataaat gcaggttaatt attcccagct 1560
 gacctaaagt caataaaaca ttctgttt 1588

<210> 42
 <211> 358
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Stearoyl-CoA desaturase-2
 35
 <400> 42
 Met Pro Ala His Ile Leu Gln Glu Ile Ser Gly Ser Tyr Scr Ala Thr
 1 5 10 15
 40 Thr Thr Ile Thr Ala Pro Pro Ser Gly Gly Gln Gln Asn Gly Gly Glu
 20 25 30
 Lys Phe Glu Lys Asn Pro His His Trp Gly Ala Asp Val Arg Pro Glu
 35 40 45
 45 Ile Lys Asp Asp Leu Tyr Asp Pro Ser Tyr Gln Asp Glu Glu Gly Pro
 50 55 60
 Pro Pro Lys Leu Glu Tyr Val Trp Arg Asn Ile Ile Leu Met Ala Leu
 65 70 75 80
 50 Leu His Ile Gly Ala Leu Tyr Gly Ile Thr Leu Val Pro Ser Cys Lys
 85 90 95
 Val Tyr Thr Cys Leu Phe Ala Tyr Leu Tyr Tyr Val Ile Ser Ala Leu
 100 105 110
 55 Gly Ile Thr Ala Gly Ala His Arg Leu Trp Ser His Arg Thr Tyr Lys

EP 1 284 298 A2

	115		120		125	
	Ala Arg Leu Pro Leu Arg Leu Phe Leu Ile Ile Ala Asn Thr Met Ala					
	130		135		140	
5	Phe Gln Asn Asp Val Tyr Glu Trp Ala Arg Asp His Arg Ala His His					
	145		150		155	160
	Lys Phe Ser Glu Thr His Ala Asp Pro His Asn Ser Arg Arg Gly Phe					
10		165		170		175
	Phe Phe Ser His Val Gly Trp Leu Leu Val Arg Lys His Pro Ala Val					
		180		185		190
	Lys Glu Lys Gly Gly Lys Leu Asp Met Ser Asp Leu Lys Ala Glu Lys					
15		195		200		205
	Leu Val Met Phe Gln Arg Arg Tyr Tyr Lys Pro Gly Leu Leu Leu Met					
		210		215		220
	Cys Phe Ile Leu Pro Thr Leu Val Pro Trp Tyr Cys Trp Gly Glu Thr					
20		225		230		235
	Phe Val Asn Ser Leu Cys Val Ser Thr Phe Leu Arg Tyr Ala Val Val					
		245		250		255
	Leu Asn Ala Thr Trp Leu Val Asn Ser Ala Ala His Leu Tyr Gly Tyr					
25		260		265		270
	Arg Pro Tyr Asp Lys Asn Ile Ser Ser Arg Glu Asn Ile Leu Val Ser					
		275		280		285
	Met Gly Ala Val Gly Glu Gly Phe His Asn Tyr His His Ala Phe Pro					
30		290		295		300
	Tyr Asp Tyr Ser Ala Ser Glu Tyr Arg Trp His Ile Asn Phe Thr Thr					
		305		310		315
	Phe Phe Ile Asp Cys Met Ala Leu Leu Gly Leu Ala Tyr Asp Arg Lys					
35		325		330		335
	Arg Val Ser Lys Ala Ala Val Leu Ala Arg Ile Lys Arg Thr Gly Glu					
		340		345		350
40	Glu Ser Cys Lys Ser Gly					
		355				
	<210> 43					
45	<211> 5055					
	<212> DNA					
	<213> Rattus norvegicus					
	<220>					
50	<223> Stearoyl-CoA desaturase-2					
	<400> 43					
	ctgggctagg gatgggcaca atgcggtgtt ggtgtctgca gtattctact cctggacacc 60					
	ggtggcctgc aagtgcgctt ttggcgtcct ctcatcttct tctccttata tccgtccgcg 120					
	gctgccttgg ccagccagtt ttgtattttt tatctgttcc ttgatcgata caaagaacct 180					
55	aaggacatac aggacattaa taccacaactg ccagctcttg cccagggctt gtactgtgca 240					
	gcgggctggc tgcagaaact taagtcataa cactctttgt cgctgaggtc tgaagctctc 300					

	tgcaagttct	catccctggg	aacgtgaccc	cagcatccga	cgccaagatg	ccggctcaca	360
	tactgcaaga	gatctctggc	tottactcgg	ccaccaccac	aatcacagcg	ccaccttctg	420
	ggggacagca	gaatggagga	gagaagtttg	aaaagaatcc	tcaccactgg	ggagcagatg	480
5	ttcgccctga	aattaaagat	gacctatacg	accccagcta	ccaggatgag	gaggggcccc	540
	cgcccaagct	ggagtacgtc	tggaggaaca	tcattctcat	ggccctgctg	cacattggag	600
	ccctgtacgg	gatcacactg	gtcccctcct	gcaagggtcta	cacctgcctc	tttgcatatt	660
	tgtactacgt	aatcagcgcc	ctggggcatca	cagccggggc	tcacgcctg	tggagccaca	720
	ggacttacaa	ggctcggctg	cccctgaggc	tctttctcat	catcgccaac	accatggcat	780
	tccagaacga	tgtgtacgaa	tggggccggg	atcaccgcgc	ccaccacaag	ttctcagaga	840
10	cacacgccga	ccctcacaac	tcccgcctg	gctttttctt	ctctcacgtg	ggttgggtgc	900
	ttgtgcgcaa	acacccggc-	gtcaaagaga	agggcgga	gctggacatg	tctgacctga	960
	aagctgagaa	gctgggtgatg	ttccagagga	ggtattacaa	gcccggcctc	ctgctcatgt	1020
	gcttcacctc	gcccacgctg	gtgccctggt	actgctgggg	tgagacgttt	gtaaacagcc	1080
	tgtgcgtcag	cactttctta	cggtacgctg	tgggtgctcaa	cgccacctgg	ctgggtaaca	1140
	gcgccgccca	cctctatgga	tatcgcccc	acgacaagaa	catcagctct	cgggagaaca	1200
15	tcctgggtgtc	gatggggagct	gtggggcagg	gcttccacaa	ctaccatcac	gccttccctc	1260
	atgactactc	tgccagtgag	taccgctggc	acatcaactt	caccacgttc	ttcatcgact	1320
	gcattggccct	cctgggcctg	gcttatgacc	ggaagagggt	gtccaaggcc	gctgtcttag	1380
	ccaggattaa	gagaactggg	gaggagagct	gcaagagtgg	ctgagttcgg	ggcttccag	1440
	ttcctgttcc	aagagccggc	ttggcagagg	cttactgttc	tgttaattaa	ctactgagta	1500
	ttgctaccca	gatgctaaaa	tgatgaagtt	aacccattct	ggtacagtat	tgtaaaacgg	1560
20	acaaatatcg	gaagtcaaca	gctctacctt	ttgatgctaa	gctgttctcc	ccttctatct	1620
	tcttttcccg	ttgtcttttt	cttcgctttg	tcocccaatga	cctcaccctc	catcgctctc	1680
	cctaagccag	cagccactcc	gctgtagttc	agagtccacc	ttccagagcg	taccagcttt	1740
	tcaagggctc	acagtaaaag	ttcacgcccc	agccccaact	taacgttgct	ccaagttaca	1800
	gatagaagaa	aaatcttgag	aaatttctcc	tgttatttta	gtccagactt	tgccagatgg	1860
25	aatggggagaa	aaaatagttt	tatttggcag	agagcttgcg	aagtgggtaa	atcttaaggg	1920
	gccaaattca	acactcgggc	tgtgattcat	caaaattgtg	ggagaggggg	atctcctgtg	1980
	atcaggctcc	gctcctgtct	gcgaggtgc	tggcgtctct	tgacacagcg	tgccctctct	2040
	cctaattctg	attgggtgac	agccgtggaa	ctttgtgaca	ctaaaatatg	gcaacacatc	2100
	ggtatctcag	tgtacttttag	gctaaagatt	taaaaaaata	gagaagtgaa	aaacaatttg	2160
	taggaaaagt	ggtcttttct	aaaataagat	tttcttttcc	tttcataaca	aggacctggg	2220
30	gccaggcgctc	gtggcacccg	cctcaaaaaca	gttgagagga	gaggggacag	tgggtctctg	2280
	agtttgaagc	cagccagggc	tagataglga	ggccttgtct	caaatagaaa	agccaacaat	2340
	tagcaggaca	cacggagccg	ggggctcctc	tgcgaggcgt	gtctggaatc	catgagggcg	2400
	gtcgctcgtg	gtttttgagc	ttcctgtgag	ctgcaccccc	agacacttgt	aattcctgtt	2460
	cttcctgtctt	tcggatgcag	gttgcctcca	caaattcagg	atagctatgg	cgtttccatg	2520
	catcccacaa	tggaaaggagt	gtaagacttg	agcttgagtc	acagctaaaa	cccagaagac	2580
35	acaaagtcag	tctgtccttg	atcctacaaa	cactcaacga	gtgcctccct	ctggaaaaga	2640
	tgggtgaacac	cttccttcca	ctgttgggca	gtggacaggg	aagttggagg	tcgctgtagg	2700
	cagctccaag	gtttcttagg	gcaccttgcc	aggggacetc	acaacttttg	cggtctctag	2760
	tggagcaggt	taggttttag	ctcccttttg	ttcccgctgt	gctttgtggt	aagggtcttc	2820
	cctgggctgt	tgctctattc	ctcactagct	ctgtgaccag	gtaggactct	gggatacatg	2880
40	gctgaaagct	cttttgcctc	accacatctg	cctctctttc	cctacccatt	tttttgtgtt	2940
	tcgggggtggt	atttttgtgg	tgggtgtttt	gttttatttc	ttcttttctc	tttgacgttt	3000
	agtcttgctc	taggcagaaa	cgctctggat	atttacggtc	agtaaaagatg	tccgggtccca	3060
	gcagagatac	aacctctatc	tgcagtaggt	agagaaggct	gtcccttttc	gggtggctttc	3120
	agattctcca	cctctatccc	tcccaggcct	ctgatattct	ttaaacttta	aaggaaaagt	3180
	ttggccgact	ttctagaaac	atccctggct	cagagaggct	ctctgtctcc	tcgggtgttc	3240
45	taaaaacaa	ggtccgggtg	gtgtgggtgc	tggcccaaga	ctcgattcct	ctgagttagg	3300
	gcagagcatg	ctccctgcac	ctctcgggct	ctctcgggct	gatcagtgct	cctgggtgat	3360
	gctgtggtgc	ttttaggagg	aagacagtg	tggctggctg	gaaagcatga	cagttaaggt	3420
	tgtgtcttta	agtgcctcag	tttgaaagct	ttggctaggg	taggagatct	gagatgccgt	3480
	ggactttgca	gaagagattt	tgtgcagcaa	cgcagaagcc	tggctgtgtt	aagattggct	3540
	gtacaggata	gcgaatgctg	tggttggagg	gcacagtcct	cccggtgttag	ttaaatatag	3600
50	aggcttttag	acgtctctgc	gcccacttga	aggttagcctt	atccttttagc	tgttcgctaa	3660
	aatagaatcc	ttgagagatt	gacaatatat	ttgctggcct	gtcgccctat	tccttggaga	3720
	ggccttttga	atggttttaa	ttccactggt	tatccggtgc	ccacttaatc	aaatgtgaaa	3780
	aataaaaaagc	agctctcttc	ttagcctgcc	cccgtggatc	tgaggaccct	gttagatata	3840
	gctgtcggta	aggtgttacc	agctcactaa	gaaacactac	tgtcaagatt	ttaaagctca	3900
	gaccaagtga	cacgttaata	agaaactaag	atctgattga	attttctaac	agtccttgcc	3960
55	tcgtggacac	gctaaaaattc	gacttgggtg	ccttacctct	tttctaacta	gtgttactca	4020

EP 1 284 298 A2

5 tgggcctgcg ctcccttccct ctgcggattc cttagaaccg gagagcctgt aagtgtgaca 4080
 ggctcaaaac tggcctggct ggagggttag gtggactttg atctgcagtg ttccctctgg 4140
 ggtcttcggt tggggaatat ttcttggggc tgttttgctg aagtgcccggt agctgatgga 4200
 tgggtggaagt aatttgaacg tacgcgattt gtaggttttg ttatttgttt taagatttaa 4260
 aggctgggtg tagcatttaa aagtgaagc tttttcttcc tggtttgcta gtgttctgcg 4320
 tgtcttcttt agttgaaata ggtagtgga gaagttaaga aagcgggtggc cgtgttacgc 4380
 tgggtggtgaa ggccagggcc gcctacaaac tctcagtttt gttttgtttt gtttttttat 4440
 aacagtccca ctctgacaat aatgagttca ctccctggat aagggttgta atgagggaag 4500
 agcccttcag acctaatacag ctcttactgg acccagctgt caacactgtt gcattgggga 4560
 10 ttaagtttcc aaccccgta atcatgggac agactcaaac cgtagcactg ggcattgtcg 4620
 ctaacaatat aatgtgactc agtattctgt gagacatggg ataatttcc tgacctacct 4680
 ccacgggtag gtgcgagcat gagcaaatgc tctttataaa acatttgggg atcctcagca 4740
 gaggagtatt taagtcctgc acatttttat agtaaccgtc caccatggac ttgacacgtg 4800
 cctatgtccc agacgacatt gttaatctac atcattcttc tcagaggttg aatggatgca 4860
 ttagataatg tatactcatt gctatggaaa cctgcaggac tcttttctc tcttgggtg 4920
 15 ggattttttt ttcttttatt atgtgcaaca gtagctattt gtaatctaata aattttcatt 4980
 aataccaact ctgaaagtat ttctactcat ctgaggttgt gttgttcat aataaaatga 5040
 aatgatctg actgc 5055

20 <210> 44
 <211> 605
 <212> PRT
 <213> Rattus norvegicus

25 <220>
 <223> Ribophorin 1

<400> 44
 Met Glu Ala Pro Ile Val Leu Leu Leu Leu Leu Trp Leu Ala Leu Ala
 1 5 10 15
 30 Pro Thr Pro Gly Ser Ala Ser Ser Glu Ala Pro Pro Leu Val Asn Glu
 20 25 30
 Asp Val Lys Arg Thr Val Asp Leu Ser Ser His Leu Ala Lys Val Thr
 35 35 40 45
 Ala Glu Val Val Leu Ala His Pro Gly Gly Gly Ser Thr Ala Arg Ala
 50 55 60
 Ser Ser Phe Val Leu Ala Leu Glu Pro Glu Leu Glu Ser Arg Leu Ala
 65 70 75 80
 40 His Leu Gly Val Gln Val Lys Gly Glu Asp Glu Glu Asp Asn Asn Leu
 85 90 95
 Glu Val Arg Glu Thr Lys Met Lys Gly Lys Ser Gly Arg Phe Phe Thr
 100 105 110
 45 Val Lys Leu Pro Val Ala Leu Asp Pro Gly Ser Lys Ile Ser Ile Val
 115 120 125
 Val Glu Thr Val Tyr Thr His Val Leu His Pro Tyr Pro Thr Gln Ile
 130 135 140
 50 Thr Gln Ser Glu Lys Gln Phe Val Val Phe Glu Gly Asn His Tyr Phe
 145 150 155 160
 Tyr Ser Pro Tyr Pro Thr Lys Thr Gln Thr Met Arg Val Arg Leu Ala
 165 170 175
 55

EP 1 284 298 A2

	Ser	Arg	Asn	Val	Glu	Ser	His	Thr	Lys	Leu	Gly	Asn	Pro	Ser	Arg	Ser	
				180					185					190			
5	Glu	Asp	Ile	Leu	Asp	Tyr	Gly	Pro	Phe	Lys	Asp	Ile	Pro	Ala	Tyr	Ser	
			195					200					205				
	Gln	Asp	Thr	Phe	Lys	Val	His	Tyr	Glu	Asn	Asn	Ser	Pro	Phe	Leu	Thr	
			210				215					220					
10	Ile	Thr	Ser	Met	Thr	Arg	Val	Ile	Glu	Val	Ser	His	Trp	Gly	Asn	Ile	
	225					230					235					240	
	Ala	Val	Glu	Glu	Asn	Val	Asp	Leu	Lys	His	Thr	Gly	Ala	Val	Leu	Lys	
					245					250					255		
15	Gly	Pro	Phe	Ser	Arg	Tyr	Asp	Tyr	Gln	Arg	Gln	Pro	Asp	Ser	Gly	Ile	
				260					265					270			
	Ser	Ser	Ile	Arg	Ser	Phe	Lys	Thr	Ile	Leu	Pro	Ala	Ala	Ala	Gln	Asp	
			275					280					285				
20	Val	Tyr	Tyr	Arg	Asp	Glu	Ile	Gly	Asn	Val	Ser	Thr	Ser	His	Leu	Leu	
		290					295					300					
	Ile	Leu	Asp	Asp	Ser	Val	Glu	Met	Glu	Ile	Arg	Pro	Arg	Phe	Gly	Leu	
	305					310					315					320	
25	Phe	Gly	Gly	Trp	Lys	Thr	His	Tyr	Ile	Val	Gly	Tyr	Asn	Leu	Pro	Ser	
					325					330					335		
	Tyr	Glu	Tyr	Leu	Tyr	Asn	Leu	Gly	Asp	Gln	Tyr	Ala	Leu	Lys	Met	Arg	
				340					345					350			
30	Phe	Val	Asp	His	Val	Phe	Asp	Glu	Gln	Val	Ile	Asp	Ser	Leu	Thr	Val	
			355					360					365				
	Lys	Ile	Ile	Leu	Pro	Glu	Gly	Ala	Lys	Asn	Ile	Gln	Val	Asp	Ser	Pro	
		370					375					380					
35	Tyr	Asp	Ile	Ser	Arg	Ala	Pro	Asp	Glu	Leu	His	Tyr	Thr	Tyr	Leu	Asp	
	385					390					395					400	
	Thr	Phe	Gly	Arg	Pro	Val	Ile	Val	Ala	Tyr	Lys	Lys	Asn	Leu	Val	Glu	
					405					410					415		
40	Gln	His	Ile	Gln	Asp	Ile	Val	Val	His	Tyr	Thr	Phe	Asn	Lys	Val	Leu	
				420					425					430			
	Met	Leu	Gln	Glu	Pro	Leu	Leu	Val	Val	Ala	Ala	Phe	Tyr	Ile	Leu	Phe	
			435					440					445				
45	Phe	Thr	Val	Ile	Ile	Tyr	Val	Arg	Leu	Asp	Phe	Ser	Ile	Thr	Lys	Asp	
			450				455					460					
	Pro	Ala	Ala	Glu	Ala	Arg	Met	Lys	Val	Ala	Cys	Ile	Thr	Glu	Gln	Val	
	465					470					475					480	
50	Leu	Thr	Leu	Val	Asn	Lys	Arg	Leu	Gly	Leu	Tyr	Arg	His	Phe	Asp	Glu	
					485					490					495		
55	Thr	Val	Asn	Arg	Tyr	Lys	Gln	Ser	Arg	Asp	Ile	Ser	Thr	Leu	Asn	Ser	
				500					505					510			

EP 1 284 298 A2

Gly Lys Lys Ser Leu Glu Thr Glu His Lys Ala Val Thr Ser Glu Ile
 515 520 525
 5 Ala Val Leu Gln Ser Arg Leu Lys Thr Glu Gly Ser Asp Leu Cys Asp
 530 535 540
 Arg Val Ser Glu Met Gln Lys Leu Asp Ala Gln Val Lys Glu Leu Val
 545 550 555 560
 10 Leu Lys Ser Ala Val Glu Ala Glu Arg Leu Val Ala Gly Lys Leu Lys
 565 570 575
 Lys Asp Thr Tyr Ile Glu Asn Glu Lys Leu Ser Ser Gly Lys Arg Gln
 580 585 590
 15 Glu Leu Val Thr Lys Ile Asp His Ile Leu Asp Ala Leu
 595 600 605
 <210> 45
 <211> 2214
 <212> DNA
 <213> Rattus norvegicus
 <220>
 <223> Ribophorin 1
 25
 <400> 45
 tcgcggtcat ggaggcgccg atcgtcttgc tgcgtctgct atggctcgcc ttggccccga 60
 cgcctggcag cgcctcttcg gaggctccgc cgctgggtcaa cgaggacgtg aagcgcacgg 120
 tggacctgag cagccaccta gccaaaggta cggttgaggt ggtcctggcg caccggggcg 180
 30 ggcgctctac agcacgagcc agctctttcg ttctggccct ggagcccgaa ctggagtcgc 240
 gacttgacaca cctaggcggtg caggtaaagg gagaagatga ggaagacaac aacctagaag 300
 tacgagaaac caaaatgaag gggaaaagtg ggaggttttt caccgtcaag ctcccagttg 360
 ctcttgatcc tgggtccaag atctcaatcg ttgtggaac tgtctacacc catgtgtctc 420
 atccataccc gactcagata actcagtcag agaaacagtt tgtggtgttt gagggcaacc 480
 35 attacttcta ctctccctat ccaacaaaga cccagaccat gcgagtgaaga cttgcttccc 540
 gaaatgtgga gagccatacc aagctgggga acccctcaag gtctgaggac atcctggact 600
 atgggccttt taaagacatc cctgcctaca gtcaggatac tttcaaagta cattatgaga 660
 acaatagccc ttctctgacc atcaccagta tgaccgggt cattgaggt tctcactggg 720
 gcaatatgtc tgtggaagag aacgtggact tgaagcatac aggtgcggtg ctgaaggac 780
 ctttctcccg ctacgattac cagaggcagc ctgacagtgg gatctcctcc attcgttctt 840
 40 ttaagaccat ccttctgtg gctgcocagg atgtgtatta ccgggatgaa atcggtaatg 900
 tttccaccag ccacctcctt attttggatg actcctgga aatggaaatc cggcctcgat 960
 ttggtctctt tggaggggtg aagacacact acatcgttgg ttacaacctc ccaagctatg 1020
 agtacctcta taatctgggt gaccagtatg cactgaagat gcggtttgta gaccagtggt 1080
 ttgatgagca agtgatagat tctctgacag tgaagatcat ccttctgag ggagccaaga 1140
 acatccagggt agacagtccc tacgatatta gccgggcccc agatgagctg cattacacct 1200
 45 acctagacac attcggccgc ccggtgattg ttgcttaca gaagaatcta gttgaacagc 1260
 acattcagga cattgtggtg cactacacat tcaacaagggt gctcatgctg caggagcctc 1320
 tgctggttgt ggccgccttc tacatcctgt tcttcaccgt catcatctac gtccgtctag 1380
 acttttccat caccaaggac ccagcagcag aagccaggat gaaagtggcc tgtatcacag 1440
 agcaggtctt aaccctggtc aacaagaggt taggcctcta ccgtcacttt gatgagactg 1500
 tcaatagata caagcagtc cgggacatct ctaccctcaa tagtggcaag aagagcctag 1560
 50 agacagagca caaagctgtg accagtgaaga ttgctgtgct gcagtctagg ctgaagacgg 1620
 agggctctga cctgtgtgac aggggtgagc aaatgcagaa gctggacgag caggtaagg 1680
 agctgtgtact gaagtctgcg gtggaggcag agaggctgggt ggctggcaag ctcaagaagg 1740
 acacatacat cgagaatgaa aagctcagct caggaaaacg ccaggagctg gtcaccaaga 1800
 tcgaccacat cctagacgct ctgtagctct tgtctccaga gcaggcctgg gtggcctaca 1860
 55 cttctggatg gaataggtag agggaggaag ttgtgattag cctaagacct caagaaaaaa 1920
 gctgaggccc atccatggct gtgtaagaag cttgtccctt atttctgaat ggttctcttt 1980

EP 1 284 298 A2

tttacaaaaa caaaaaccta aacaaaaaatc ctgccccaaaa aacaaacttg gttgtgtttt 2040
gagcaaaagc attttgagta gttgattgct gttttgtttt gatacctggg tattttttct 2100
gtctgtaagc cctgttttat ggccttctga ttcctaattg ttgggtcttt tgtgagcgta 2160
tgcatgggtt tttaaaagtg tgtatgacca aataaaaaata aaggaggac tgtg 2214

<210> 46

<211> 284

<212> PRT

<213> Rattus norvegicus

<220>

<223> Sulfotransferase-like protein

<400> 46

Met	Ala	Glu	Ser	Glu	Ala	Glu	Thr	Pro	Gly	Thr	Pro	Gly	Glu	Phe	Glu
1				5					10					15	
Ser	Lys	Tyr	Phe	Glu	Phe	His	Gly	Val	Arg	Leu	Pro	Pro	Phe	Cys	Arg
			20					25					30		
Gly	Lys	Met	Glu	Asp	Ile	Ala	Asp	Phe	Pro	Val	Arg	Pro	Ser	Asp	Val
		35					40					45			
Trp	Ile	Val	Thr	Tyr	Pro	Lys	Ser	Gly	Thr	Ser	Leu	Leu	Gln	Glu	Val
	50					55					60				
Val	Tyr	Leu	Val	Ser	Gln	Gly	Ala	Asp	Pro	Asp	Glu	Ile	Gly	Leu	Met
65					70					75				80	
Asn	Ile	Asp	Glu	Gln	Leu	Pro	Val	Leu	Glu	Tyr	Pro	Gln	Pro	Gly	Leu
				85					90					95	
Asp	Ile	Ile	Lys	Glu	Leu	Thr	Ser	Pro	Arg	Leu	Ile	Lys	Ser	His	Leu
			100					105					110		
Pro	Tyr	Arg	Phe	Leu	Pro	Ser	Asp	Leu	His	Asn	Gly	Asp	Ser	Lys	Val
		115					120					125			
Ile	Tyr	Met	Ala	Arg	Asn	Pro	Lys	Asp	Leu	Val	Val	Ser	Tyr	Tyr	Gln
	130					135					140				
Phe	His	Arg	Ser	Leu	Arg	Thr	Met	Ser	Tyr	Arg	Gly	Thr	Phe	Gln	Glu
145					150					155				160	
Phe	Cys	Arg	Arg	Phe	Met	Asn	Asp	Lys	Leu	Gly	Tyr	Gly	Ser	Trp	Phe
				165					170					175	
Glu	His	Val	Gln	Glu	Phe	Trp	Glu	His	Arg	Met	Asp	Ala	Asn	Val	Leu
			180				185						190		
Phe	Leu	Lys	Tyr	Glu	Asp	Met	His	Arg	Asp	Leu	Val	Thr	Met	Val	Glu
		195				200						205			
Gln	Leu	Ala	Arg	Phe	Leu	Gly	Val	Ser	Cys	Asp	Lys	Ala	Gln	Leu	Glu
	210					215					220				
Ser	Leu	Ile	Glu	His	Cys	His	Gln	Leu	Val	Asp	Gln	Cys	Cys	Asn	Ala
225					230					235				240	
Glu	Ala	Leu	Pro	Val	Gly	Arg	Gly	Arg	Val	Gly	Leu	Trp	Lys	Asp	Ile
				245					250					255	

EP 1 284 298 A2

Phe Thr Val Ser Met Asn Glu Lys Phe Asp Leu Val Tyr Lys Gln Lys
260 265 270

Met Gly Lys Cys Asp Leu Thr Phe Asp Phe Tyr Leu
275 280

<210> 47
<211> 2239
<212> DNA
<213> Rattus norvegicus

<220>
<223> Sulfotransferase-like protein

<400> 47
ggcacgagcc ctggagctgc gggccggggc gggcggcagc atggcggaga gcgaagcgga 60
gaccccgggc accccgggag agttcgagag caagtacttc gaggttccatg gcgtgcggct 120
gcctcccttc tgccgaggga agatggagga catcgccgac ttcccagtgcc ggcccagcga 180
tgtgtggatc gtcacctacc ccaagtcagg tacgagcttg ctgcaagagg tggcttactt 240
ggtgagccag ggggctgacc ctgatgagat tggcctcatg aacattgacg agcagctgcc 300
agtactggag taccacacagc ccgggctgga catcatcaag gaactgacgt ctccccgcct 360
catcaagagc caccctccct accgcttccct gccctctgac ctccacaacg gggactccaa 420
ggtcatctac atggctcgca acccaaagga cctgggtggtt tcttactatc agttccaccg 480
ctcgctgcgg accatgagtt accgaggaac cttccaggag ttctgtcgga ggttcatgaa 540
cgacaaattg ggctatggct cctggtttga gcacgttcag gaattctggg aacatcgaat 600
ggacgcaaat gtgcttttcc tcaagtatga agatatgcac cgggacctgg tgaccatggt 660
ggagcagctg gccagattcc tgggtgtgtc ctgtgataag gccagctgg agtccttgat 720
cgagcactgc caccagctgg tggaccagtg ctgcaatgct gaggccctgc ctgtgggccc 780
gggaagagtc gggctgtgga aggacatctt cactgtctcc atgaacgaga agtttgatct 840
agtgtataaa cagaagatgg ggaagtgtga cctcacgttt gacttttatt tataatacca 900
gaatccgcaa acttgcatgc tcacggtccc cagacgctct actagctaaa agtcctgttt 960
gcgttcattt attccttgcg ggacactccg gaagtgtctt ggaaacagca gggggcgagc 1020
ctgggtgaga gagccgagga gtgagatgat gctgtctaca gcagccgcct ggccgtagcg 1080
tttgagtctc cactgtctgg ccataccaca cgcacgggca ggcaaatgtc tgcccctgta 1140
ccccatgtta ttcactgtat tttatagcgc ttttactga aaatcgaaat aaatatgtca 1200
accaaatgca agtccatttc caagggggag caggagcgag ctgtgccggg atgctaggaa 1260
gctctcaggg gtcactgtaa tttttatagt ctctctctta ggacacagca tcccaccttg 1320
tcccagatc aaaggacagg ttggggggag ctggagaggt ggggtgtagcc tgtggagttc 1380
agttttcttg aaccatcctg acaccaagcc aggtcctgtc ccaggctctc gagcccagta 1440
cagaatgttc tggaaggga gctggcctga ggctgcggat ggcatctgaa ggcatcagtg 1500
gtgtgtgaag cgtaccacaca gacaccagac tgcaccaaga actagtatat ctcatagcct 1560
tcacttgctc cccaaggccg tgactggcac actccaatg gcaagagaca tgacatacca 1620
tggttctgaa gtccctagtc atcgtcacgt ctgtgccacc tgtgccaagg ctctcgctcg 1680
ggagaccag tctgcaggtt gactgtcctc catgcagata ggattggcaa gccacctgt 1740
ctgagggggc acttagccct caaggatgtc tgagggagca atggcccat gtactgtcca 1800
ccctgacacc taccggctct gtcttcacgc tccaatttgg ctcaagtgat gaccagatga 1860
tgggtggacc aggagattgc tgcttgtggg gaccaactta ttctgttccct taccaggatg 1920
ggaagagtct taacgtgggtg gggggaggct ctggctgtgg aaggtgcctg ctgtgcgcca 1980
tctctgaagc aggtttggtt gtacgagcgt tacctctgtc tagaggaaaq cttgtgtggg 2040
tctggtgcat ggttctctga ggtgggcatg gcagtgcctt tctgtgtgt ctggggagga 2100
aggctgcttt ctgtgaaatt ttctttctat ttttctattt ttagtactgt acggatgttc 2160
tggaaccaca caccgtactc tgtgcttgc tgcattctta ataaaagaca cctccccctg 2220
caaaaaaaaa aaaaaaaaaa 2239

<210> 48
<211> 235
<212> PRT
<213> Rattus norvegicus

EP 1 284 298 A2

<220>

<223> F1-ATPase alpha subunit

<400> 48

```

5 Val Ala Asp Arg Gln Met Ser Leu Leu Leu Arg Arg Pro Pro Gly Arg
  1          5          10          15

Glu Ala Tyr Pro Gly Asp Val Phe Tyr Leu His Ser Arg Leu Leu Glu
          20          25          30

10 Arg Ala Ala Lys Met Asn Asp Ser Phe Gly Gly Gly Ser Leu Thr Ala
    35          40          45

Leu Pro Val Ile Glu Thr Gln Ala Gly Asp Val Ser Ala Tyr Ile Pro
    50          55          60

15 Thr Asn Val Ile Ser Ile Thr Asp Gly Gln Ile Phe Leu Glu Thr Glu
    65          70          75          80

Leu Phe Tyr Lys Gly Ile Arg Pro Ala Ile Asn Val Gly Leu Ser Val
          85          90          95

20 Ser Arg Val Gly Ser Ala Ala Gln Thr Arg Ala Met Lys Gln Val Ala
    100          105          110

Gly Thr Met Lys Leu Glu Leu Ala Gln Tyr Arg Glu Val Ala Ala Phe
    115          120          125

25 Ala Gln Phe Gly Ser Asp Leu Asp Ala Ala Thr Gln Gln Leu Leu Ser
    130          135          140

Arg Gly Val Arg Leu Thr Glu Leu Leu Lys Gln Gly Gln Tyr Ser Pro
    145          150          155          160

Met Ala Ile Glu Glu Gln Val Ala Val Ile Tyr Ala Gly Val Arg Gly
    165          170          175

30 Tyr Leu Asp Lys Leu Glu Pro Ser Lys Ile Thr Lys Phe Glu Ser Ala
    180          185          190

Phe Leu Ser His Val Val Ser Gln His Gln Ser Leu Leu Gly Asn Ile
    195          200          205

40 Arg Ser Asp Gly Lys Ile Ser Glu Gln Ser Asp Ala Lys Leu Lys Glu
    210          215          220

Ile Val Thr Asn Phe Leu Ala Gly Phe Glu Pro
    225          230          235

```

<210> 49

<211> 1066

<212> DNA

<213> Rattus norvegicus

<220>

<223> F1-ATPase alpha subunit

<400> 49

```

gtggctgacc gccagatgct tctgctgctc cgccgacccc cgggtcgaga ggcctatccc 60
ggtgatgtgt ttacctaca ctctgcctg ctggagagag cagccaagat gaacgattcc 120
tttggtggtg gctctttgac tgccttaccac gtcattgaaa cacaggctgg tgatgtgtcc 180

```

EP 1 284 298 A2

```

gcctacattc caacaaacgt tatttccatc accgatggac agatcttctt ggaaacagaa 240
ttgttctata aaggcatccg ccctgccatt aatgtgggct tgtctgtgtc ccgtgtcggg 300
tctgccgccc agaccagagc catgaagcag gtggcaggca ccatgaagct ggagttggcc 360
cagtaccggg aggtcgctgc ttttgcccag tttggttctg atctggatgc tgccactcag 420
cagctcttga gccgtggcgt gcgcctgacc gagctgctaa agcaaggaca gtactctccc 480
atggctattg aagaacaggt ggctgtcatc tatgcaggcg tccgggggta tcttgataaa 540
ctggagccca gtaagatcac aaagttcgag agtgctttct tgtctcatgt tgtgagccag 600
caccagagcc tcttgggcaa tatcaggctc gatgggaaaa tctcagaaca gtcggatgca 660
aagctgaagg aaatcgtaac aaacttcttg gctgggtttg aaccttaaag ccctgccact 720
gtcaccagac actgcttttg ttttgtcatt tattgtggta aaatcagcac catttgtaaa 780
ggtttactct tgtactccct gatgtacaga aatcacatga ataaaagttc catattgagt 840
gctagtttgt gtgggacggg ctcagatgta tcctgggact tgtggaggtc agagagcagc 900
ctgtaggagt caatgccctc ctttccctgg gaatttaact caggttatta tttaaagctc 960
gacttcaggg gttggggatt tagctcagtg gtgagcgct tgcctaggaa gcgcaaggcc 1020
ctgggttcgg tccccagctc cggaaaaaaa agaaccaacc cgaatt 1066

```

<210> 50

<211> 168

<212> PRT

<213> Rattus norvegicus

<220>

<223> F1F0 ATPase delta subunit

<400> 50

Met Leu Pro Ala Ala Leu Leu Arg His Pro Gly Leu Arg Arg Leu Val
1 5 10 15

Leu Gln Ala Arg Thr Tyr Ala Gln Ala Ala Ser Pro Ala Pro Ala
20 25 30

Ala Gly Pro Gly Gln Met Ser Phe Thr Phe Ala Ser Pro Thr Gln Val
35 40 45

Phe Phe Asp Gly Ala Asn Val Arg Gln Val Asp Val Pro Thr Leu Thr
50 55 60

Gly Ala Phe Gly Ile Leu Ala Ser His Val Pro Thr Leu Gln Val Leu
65 70 75 80

Arg Pro Gly Leu Val Met Val His Ala Glu Asp Gly Thr Thr Thr Lys
85 90 95

Tyr Phe Val Ser Ser Gly Ser Val Thr Val Asn Ala Asp Ser Ser Val
100 105 110

Gln Leu Leu Ala Glu Glu Val Val Thr Leu Asp Met Leu Asp Leu Gly
115 120 125

Ala Ala Arg Ala Asn Leu Glu Lys Ala Gln Ser Glu Leu Ser Gly Ala
130 135 140

Ala Asp Glu Ala Ala Arg Ala Glu Ile Gln Ile Arg Ile Glu Ala Asn
145 150 155 160

Glu Ala Leu Val Lys Ala Leu Glu
165

<210> 51

<211> 811

<212> DNA

<213> Rattus norvegicus

<220>

<223> F1F0 ATPase delta subunit

<400> 51

```

ggaattccgc tgctgtcgct aagctaaagt cactgacgtt tccgccacca tgctgcccgc 60
cgcatatgctt cgtcaccacag gtctgcgccg tctgggtgctc caggcgcgta cgtacgcccc 120
ggccgcgcgc tcacctgccc ccgccgctgg gcctggacag atgtccttca ccttcgcctc 180
cccgcgcag gtgttctttg atggtgccaa tgcccgcaa gtggatgtgc ctacgctgac 240
tggagccttt ggatccttg catcccatgt cccacacta caggctctac ggcctgggct 300
ggtaatgggt catgcggaag atggcaccac aactaagtat tttgtgagca gcggtcccg 360
cactgtgaat gcggactcct ctgtgcaatt actagctgaa gaagtcgtga cactggacat 420
gctggacctc ggggcagccc gggcaaacct ggagaaggcg cagtcagagc tgtcaggggc 480
agcagatgag gcagcacggg ctgagatcca aatccggatc gaggccaatg aagccctgg 540
gaaggccctg gagtaggcgt actttgtctg tcaccacag ggtaacagag gcaggtcctg 600
gggggtgaa gtcgccacca gggggcagca gtgctccggt tactggctta aagcttcct 660
ggtgctgctt gccaggtcat ggagggttc cccaggcttc cagagtctgg gatccccagg 720
atgcctctgg agagctggc ttgattgcc ctcaaagcca cccggacagt cagctggccc 780
agcctatctg cattaataac cacggaattc c
811

```

<210> 52

<211> 572

<212> PRT

<213> Homo sapiens

<220>

<223> Dihydropyrimidinase-related protein

<400> 52

```

Met Ser Tyr Gln Gly Lys Lys Asn Ile Pro Arg Ile Thr Ser Asp Arg
 1          5          10          15

Leu Leu Ile Lys Gly Gly Lys Ile Val Asn Asp Asp Gln Ser Phe Tyr
      20          25          30

Ala Asp Ile Tyr Met Glu Asp Gly Leu Ile Lys Gln Ile Gly Glu Asn
      35          40          45

Leu Ile Val Pro Gly Gly Val Lys Thr Ile Glu Ala His Ser Arg Met
      50          55          60

Val Ile Pro Gly Gly Ile Asp Val His Thr Arg Phe Gln Met Pro Asp
      65          70          75          80

Gln Gly Met Thr Ser Ala Asp Asp Phe Phe Gln Gly Thr Lys Ala Ala
      85          90          95

Leu Ala Gly Gly Thr Thr Met Ile Ile Asp His Val Val Pro Glu Pro
      100          105          110

Gly Thr Ser Leu Leu Ala Ala Phe Asp Gln Trp Arg Glu Trp Ala Asp
      115          120          125

Ser Lys Ser Cys Cys Asp Tyr Ser Leu His Val Asp Ile Ser Glu Trp
      130          135          140

His Lys Gly Ile Gln Glu Glu Met Glu Ala Leu Val Lys Asp His Gly
      145          150          155          160

```

EP 1 284 298 A2

	Val	Asn	Ser	Phe	Leu	Val	Tyr	Met	Ala	Phe	Lys	Asp	Arg	Phe	Gln	Leu	
					165					170					175		
5	Thr	Asp	Cys	Gln	Ile	Tyr	Glu	Val	Leu	Ser	Val	Ile	Arg	Asp	Ile	Gly	
				180					185					190			
	Ala	Ile	Ala	Gln	Val	His	Ala	Glu	Asn	Gly	Asp	Ile	Ile	Ala	Glu	Glu	
			195					200					205				
10	Gln	Gln	Arg	Ile	Leu	Asp	Leu	Gly	Ile	Thr	Gly	Pro	Glu	Gly	His	Val	
		210				215						220					
	Leu	Ser	Arg	Pro	Glu	Glu	Val	Glu	Ala	Glu	Ala	Val	Asn	Arg	Ala	Ile	
	225					230					235					240	
15	Thr	Ile	Ala	Asn	Gln	Thr	Asn	Cys	Pro	Leu	Tyr	Ile	Thr	Lys	Val	Met	
				245						250					255		
	Ser	Lys	Ser	Ser	Ala	Glu	Val	Ile	Ala	Gln	Ala	Arg	Lys	Lys	Gly	Thr	
				260					265					270			
20	Val	Val	Tyr	Gly	Glu	Pro	Ile	Thr	Ala	Ser	Leu	Gly	Thr	Asp	Gly	Ser	
			275					280					285				
	His	Tyr	Trp	Ser	Lys	Asn	Trp	Ala	Lys	Ala	Ala	Ala	Phe	Val	Thr	Ser	
		290					295					300					
25	Pro	Pro	Leu	Ser	Pro	Asp	Pro	Thr	Thr	Pro	Asp	Phe	Leu	Asn	Ser	Leu	
	305					310					315					320	
	Leu	Ser	Cys	Gly	Asp	Leu	Gln	Val	Thr	Gly	Ser	Ala	His	Cys	Thr	Phe	
				325						330				335			
30	Asn	Thr	Ala	Gln	Lys	Ala	Val	Gly	Lys	Asp	Asn	Phe	Thr	Leu	Ile	Pro	
				340					345					350			
	Glu	Gly	Thr	Asn	Gly	Thr	Glu	Glu	Arg	Met	Ser	Val	Ile	Trp	Asp	Lys	
			355				360						365				
35	Ala	Val	Val	Thr	Gly	Lys	Met	Asp	Glu	Asn	Gln	Phe	Val	Ala	Val	Thr	
			370				375					380					
	Ser	Thr	Asn	Ala	Ala	Lys	Val	Phe	Asn	Leu	Tyr	Pro	Arg	Lys	Gly	Arg	
	385					390					395					400	
40	Ile	Ala	Val	Gly	Ser	Asp	Ala	Asp	Leu	Val	Ile	Trp	Asp	Pro	Asp	Ser	
				405					410						415		
	Val	Lys	Thr	Ile	Ser	Ala	Lys	Thr	His	Asn	Ser	Ser	Leu	Glu	Tyr	Asn	
				420					425					430			
	Ile	Phe	Glu	Gly	Met	Glu	Cys	Arg	Gly	Ser	Pro	Leu	Val	Val	Ile	Ser	
			435					440					445				
50	Gln	Gly	Lys	Ile	Val	Leu	Glu	Asp	Gly	Thr	Leu	His	Val	Thr	Glu	Gly	
		450					455					460					
	Ser	Gly	Arg	Tyr	Ile	Pro	Arg	Lys	Pro	Phe	Pro	Asp	Phe	Val	Tyr	Lys	
	465					470					475					480	
55	Arg	Ile	Lys	Ala	Arg	Ser	Arg	Leu	Ala	Glu	Leu	Arg	Gly	Val	Pro	Arg	
				485						490					495		

EP 1 284 298 A2

Gly Leu Tyr Asp Gly Pro Val Cys Glu Val Ser Val Thr Pro Lys Thr
500 505 510

5 Val Thr Pro Ala Ser Ser Ala Lys Thr Ser Pro Ala Lys Gln Gln Ala
515 520 525

Pro Pro Val Arg Asn Leu His Gln Ser Gly Phe Ser Leu Ser Gly Ala
530 535 540

10 Gln Ile Asp Asp Asn Ile Pro Arg Arg Thr Thr Gln Arg Ile Val Ala
545 550 555 560

Pro Pro Gly Gly Arg Ala Asn Ile Thr Ser Leu Gly
565 570

15

<210> 53
<211> 4459
<212> DNA
<213> Homo sapiens

20

<220>
<223> Dihydropyrimidinase-related protein

<400> 53

25 gtttctctct ctccttctct ctctctctct ctctctcttt tttttccgcc cttagctgggg 60
ctgtgttgga ggagaggaag aaagagagac agaggattgc attcatccgt tacgttcttg 120
aaatttccta atagcaagac cagcgaagcg gttgcaccct tttcaatctt gcaaaggaaa 180
aaaacaaaac aaaacaaaaa aaacccaagt ccccttcccg gcagtttttg ccttaaagct 240
gccctcttga aattaatttt ttcccaggag agagatgtct tatcagggga agaaaaatat 300
tccacgcata acgagcgatc gtcttctgat caaaggaggt aaaattgtta atgatgacca 360
30 gtcgttctat gcagacatat acatggaaga tgggttgatc aagcaaatag gagaaaaatct 420
gattgtgcca ggaggagtga agaccatcga ggcccactcc cggatggtga tccccggagg 480
aattgacgtc cacactcgtt tccagatgcc tgatcaggga atgacgtctg ctgatgattt 540
cttccaagga accaaggcgg ccctggcttg gggaaccact atgatcattg accacgttgt 600
tcttgagcct gggacaagcc tgctcgctgc ctttgaccag tggagggaat gggccgacag 660
caagtccctg tgtgactact ctctgcattg ggacatcagc gagtggcata agggcatcca 720
35 ggaggagatg gaagcgcttg tgaaggatca cggggtaaat tccttcctcg tgtacatggc 780
tttcaaaagt cgttccagc taacggattg ccagatttat gaagtactga gtgtgatccg 840
ggatattggc gccatagccc aagtccacgc agaaaatggc gacatcattg cagaggagca 900
gcagaggatc ctggatctgg gcatcacggg ccccgaggga catgtgctga gccgacctga 960
ggaggtcgag gccgaagccg tgaatcgtgc catcaccatc gccaacaga ccaactgcc 1020
40 gctgtatata accaagggtga tgagcaaaag ctctgctgag gtcacgccc aggcacggaa 1080
gaagggaact gtggtgtatg gcgagcccat cactgccagc ttgggaacgg acggctccca 1140
ttactggagc aagaactggg ccaaggctgc tgcctttgtc acctcccac ccttgagccc 1200
tgatccaacc actccagact ttctcaactc cttgctgtcc tgtggagacc tccaggtcac 1260
gggcagtgcc cattgcacgt ttaacactgc ccagaaggct gtaggaaagg acaactcac 1320
cctgattccg gaggggacca atggcactga ggagcggatg tccgtcatct gggacaaggc 1380
45 tgtggtcact ggaagatgg atgagaacca gtttgtggct gtgaccagca ccaatgcagc 1440
caaagtcttc aacctttacc cccggaaagg ccgcattgct gtgggatccg atgccgacct 1500
ggtcatctgg gaccccgaca gcgttaaaac catctctgcc aagacacaca acagctctct 1560
cgagtacaac atctttgaag gcatggagtg ccgcggctcc cactggttg tcatcagcca 1620
ggggaagatt gtccctggag acggcacccct gcatgtcacc gaaggctctg gacgctacat 1680
50 tcccgggaag ccttccctg attttgttta caagcgtatc aaggcaagga gcaggctggc 1740
tgagctgaga ggggttcctc gtggcctgta tgacggacct gtgtgtgaag tgtctgtgac 1800
gccaagaca gtcactccag cctcctcggc caagacgtct cctgccaagc agcaggcccc 1860
acctgtccgg aacctgcacc agtctggatt cagtttgtct ggtgctcaga ttgatgacaa 1920
cattccccgc cgcaccaccc agcgtatcgt ggcgcccccc ggtggccgtg ccaacatcac 1980
cagctcgggc tagagctcct gggctgtgcy tccactgggg actggggatg ggacacctga 2040
55 ggacattctg agacttcttt ctctctctct tttttttttt ttgttttttt ttttaagagc 2100
ctgtgatagt tactgtggag cagccagttc atgggggtccc ccttgggggc ccacaccccg 2160

EP 1 284 298 A2

5 tctctcacca agagttactg attttgc tca tccacttccc tacacatcta tgggtatcac 2220
 acccaagact acccaaccaag ctcatacagg gaaccacacc caacacttag acatgcgaac 2280
 aagcagcccc cagcgagggt ctccttcgcc tccaacctcc tagtgtctgt tagcatcttc 2340
 cttttcatgg ggggagggaa gataaagtga attgccaga gctgcctttt tcttttcttt 2400
 ttaaaaattt taagaagttt tccttgtggg gctggggagg ggccggggtc agggagagtc 2460
 tttttttttt tttttttaa tactaaattg gaacatttaa ttccatatta atacaagggg 2520
 tttgaactgg acatccta at gatgcaatta cgtcatcacc cagctgattc cgggtggttg 2580
 gcaaaactcat cgtgtctgtc ctgagaggct ccacaatgcc caccgcgcat gccattctgt 2640
 agtcttcagg gtcagctgtt gataaagggg caggcttgcc ttattggcct agattttgct 2700
 10 gcagattaaa tcctttgagg attctctctt cttttaccat ttttctgcgt gctctcactc 2760
 tctctttctc tctctagctt tttaattcat gaatattttc gtgtctgtct ctctctctct 2820
 ctgtgtttcc tccagccctt gtctcggaga cgggtgtttc ctcccttgcc ccattatctt 2880
 ttcacctccc aggtctacca tttcatgggt gtcgttggtt ccgcctaaag gatttgagcg 2940
 tttgccattg caagcatagt gctgtgtcat cctgggtccat gtaggactgg tgctaaccac 3000
 ctgccatcat gaggatgtgt gctagagtgt gggaccctgg ccaagtgcag gaatgggcca 3060
 15 tgccgtctca cccacagtat cacacgtgga accgcagaca gggcccagaa gcttttagagg 3120
 tatgaggctg cagaaccgga gagattttcc tctgtgcagt gctctctggc taaagtcacg 3180
 gtcaaaccta aacaccgagc ctcattaacc caagtgaacc aaccaaagtc accagttcag 3240
 aagtgtctaa ctaataggag tctgaccgga gggcctgctg ctctctgggt aagtatcttt 3300
 tgagattcta gaacacatgg gagcttttta ttttcgggga aaaaccgtat ttttttcttg 3360
 20 tccaattatt tctaaagaca cactacatag aaagaggccc tataaactca aaaagtcatt 3420
 gggaaactta aagtctattc tactttgcaa gaggagaaat gtgttttatg aacgatagat 3480
 cacatcagaa ctctgtgtgg gaggaaacct tataaattaa acacatggcc cccttagaga 3540
 ccacaggtga tgtctgtctc catccttccc tctccttttc tgtcaccttt ccccttagct 3600
 ggctcctttg gacctacccc tgtccttgct gacttgtgtt gcattgtatt ccaaaccgtgt 3660
 ttacagggttc tcttaagcaa tgttgtattt gcaggctttt ctgaatacca aatctgcttt 3720
 25 ttgtaaagcg taaaaacatc acaaagtagg tcattccatc accacccttg tctctctaca 3780
 cattttgcct ttggggatct ggttgggttt ttgggttttt tgttgtgtgt gtttarattg 3840
 tattttaaag gtaaattgca cttttaaaa aataattggt tgacttaata tatttgcttt 3900
 ttttctcacc tgcacttaga ggaaatttga acaagtggga aaaaaacaat ttttgtttca 3960
 attctaagaa acacttgtag ctctagtatt cacttgagtc ttctgtttt tcctgtaccg 4020
 ggtcatggta atttttgggt gttttgggtt ttttcttaa aaacaagtta aaacctgacg 4080
 30 atttctgcag gctgtgtaag catgtttacc tgttggcttg ctttgtgtgt ctgttaaatg 4140
 aatgtcatat gtaaatgcta aaataaatcg acagtgtctc agaactgaat aactgcagtg 4200
 acttgatgct ctaaaacagt gtaggattta agaataagtg gtttttaac ctggaaattg 4260
 tgattgtgac ccattgagtg aggaactttc agttcctaa ctgataaagt gtgtagccag 4320
 aagagtactt tttttttgtt aacctgtgtc ttgatggcaa aataattatg gtaaaaaaca 4380
 agtctcgtgt ttattattcc ttaagaactc tgtgttatat taccatggaa cgcctaataa 4440
 35 agcaaaatgt gggtgtttc 4459

40 <210> 54
 <211> 1410
 <212> DNA
 <213> Rattus norvegicus

45 <220>
 <223> Myelin basic protein S

50 <400> 54
 ttcggcttcc gaaggcctga tgtgatggca tcacagaaga gaccctcaca gcgacacgga 60
 tccaagtact tggccacagc aagtaccatg gaccatgccc ggcattggctt cctcccaagg 120
 cacagagaca cgggcacatc tgactccatc gggcgcttct ttagecgtga cagggtgagc 180
 55 cccaagcggg gctctggcaa ggactcacac acaagaacta cccactacgg ctccctgccc 240
 cagaagtgcg agaggaccca agatgaaaac ccagtagtcc acttcttcaa gaacattgtg 300
 acacctcgta caccctctcc atcccaagga aaggggagag gcctgtccct cagcagattt 360
 agctggggag gaagagacag ccgctctgga tctcccatag caagacgctg agagcctccc 420
 tgctcagcct tcccgaatcc tgccctcggc tctctaatat aactgcctta aacgtttaat 480
 tctacttgca ccaaatagct agttagagca gaccctctct taatcccgtg gggctgtgaa 540
 55 cgcggcgggc cagcccacgg caccctgact ggctaaaact gtttgtccct ttttatttga 600
 agattgagtt tcctcgggggt cttctctgac ccgacttgct ccccgtgtac cttggctgac 660

EP 1 284 298 A2

tccggaggtt caggtgcacg gacacccttt caagttcacc cctactccat cctcagactt 720
 tcttttcacg gcgaggcgca cccctccagc ttccgtgggc actgcggata gacaggcaca 780
 ccgccaagga gccagagagc atggcgagcagg ggaactatgtg gtccagggtt cctttgtttt 840
 ctttccccta aagagctttg tttttcctga caggatcaga cagtcttga gtggcttaca 900
 5 caacgggggc ttgtggtatg tgagcacagg tcgggcagct gtgagagtcc agagtggggt 960
 ggccctgggg acgcttccag gccagcgggt ccctgcaccc caccagctga tttcgagcgt 1020
 ggccagaggga aggaaagggg cgagcgggct gggcaatgga cccgacagga aacggggact 1080
 taggggaaca cgctggagat gccatgtgtg gctgccgaag gtcaccatct ctcctcagt 1140
 ctccccagag caggtgcttt taagaacctt gtttctctc agagcctagg gagagtccaa 1200
 10 ggacatggcg catcaggaag tgggactgca ggagttctct ggtggcctcg tgctgtccct 1260
 ctggccactt ctcactttag ggtgggtcacg gcagctcgcc atggcagtg cttgtgtgca 1320
 cactaacctc atggaaaagt aaccattccc tgcctcttag aaagaactca ttcttagttt 1380
 taggaggggt cctgtcgctg aatcaagtcg 1410

 <210> 55
 <211> 698
 <212> PRT
 <213> Rattus norvegicus

 <220>
 20 <223> Transferrin

 <400> 55
 Met Arg Phe Ala Val Gly Ala Leu Leu Ala Cys Ala Ala Leu Gly Leu
 1 5 10 15
 25 Cys Leu Ala Val Pro Asp Lys Thr Val Lys Trp Cys Ala Val Ser Glu
 20 25 30
 His Glu Asn Thr Lys Cys Ile Ser Phe Arg Asp His Met Lys Thr Val
 35 40 45
 30 Leu Pro Ala Asp Gly Pro Arg Leu Ala Cys Val Lys Lys Thr Ser Tyr
 50 55 60
 Gln Asp Cys Ile Lys Ala Ile Ser Gly Gly Glu Ala Asp Ala Ile Thr
 65 70 75 80
 35 Leu Asp Gly Gly Trp Val Tyr Asp Ala Gly Leu Thr Pro Asn Asn Leu
 85 90 95
 Lys Pro Val Ala Ala Glu Phe Tyr Gly Ser Leu Glu His Pro Gln Thr
 100 105 110
 40 His Tyr Leu Ala Val Ala Val Val Lys Lys Gly Thr Asp Phe Gln Leu
 115 120 125
 Asn Gln Leu Gln Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser
 130 135 140
 45 Ala Gly Trp Ile Ile Pro Ile Gly Leu Leu Phe Cys Asn Leu Pro Glu
 145 150 155 160
 Pro Arg Lys Pro Leu Glu Lys Ala Val Ala Ser Phe Phe Ser Gly Ser
 165 170 175
 50 Cys Val Pro Cys Ala Asp Pro Val Ala Phe Pro Gln Leu Cys Gln Leu
 180 185 190
 Cys Pro Gly Cys Gly Cys Ser Pro Thr Gln Pro Phe Phe Gly Tyr Val
 195 200 205

EP 1 284 298 A2

	Gly	Ala	Phe	Lys	Cys	Leu	Arg	Asp	Gly	Gly	Gly	Asp	Val	Ala	Phe	Val	
	210						215					220					
5	Lys	His	Thr	Thr	Ile	Phe	Glu	Val	Leu	Pro	Gln	Lys	Ala	Asp	Arg	Asp	
	225					230					235					240	
	Gln	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	Asn	Thr	Arg	Lys	Pro	Val	Asp	Gln	
					245					250					255		
10	Tyr	Glu	Asp	Cys	Tyr	Leu	Ala	Arg	Ile	Pro	Ser	His	Ala	Val	Val	Ala	
				260					265					270			
	Arg	Asn	Gly	Asp	Gly	Lys	Glu	Asp	Leu	Ile	Trp	Glu	Ile	Leu	Lys	Val	
			275					280					285				
15	Ala	Gln	Glu	His	Phe	Gly	Lys	Gly	Lys	Ser	Lys	Asp	Phe	Gln	Leu	Phe	
	290						295					300					
	Gly	Ser	Pro	Leu	Gly	Lys	Asp	Leu	Leu	Phe	Lys	Asp	Ser	Ala	Phe	Gly	
	305				310						315					320	
20	Cys	Tyr	Gly	Val	Pro	Pro	Arg	Met	Asp	Tyr	Arg	Leu	Tyr	Leu	Gly	His	
					325					330					335		
	Ser	Tyr	Val	Thr	Ala	Ile	Arg	Asn	Gln	Arg	Glu	Gly	Val	Cys	Pro	Glu	
				340					345					350			
25	Ala	Ser	Ile	Asp	Ser	Ala	Pro	Val	Lys	Trp	Cys	Ala	Leu	Ser	His	Gln	
			355					360					365				
	Glu	Arg	Ala	Lys	Cys	Asp	Glu	Trp	Ser	Val	Thr	Ser	Asn	Gly	Gln	Ile	
	370						375						380				
30	Glu	Cys	Glu	Ser	Ala	Glu	Ser	Thr	Glu	Asp	Cys	Ile	Asp	Lys	Ile	Val	
	385					390					395					400	
	Asn	Gly	Glu	Ala	Asp	Ala	Met	Ser	Leu	Asp	Gly	Gly	His	Ala	Tyr	Ile	
					405					410					415		
35	Ala	Gly	Gln	Cys	Gly	Leu	Val	Pro	Val	Met	Ala	Glu	Asn	Tyr	Asp	Ile	
				420					425					430			
	Ser	Ser	Cys	Thr	Asn	Pro	Gln	Ser	Asp	Val	Phe	Pro	Lys	Gly	Tyr	Tyr	
			435					440					445				
	Ala	Val	Ala	Val	Val	Lys	Ala	Ser	Asp	Ser	Ser	Ile	Asn	Trp	Asn	Asn	
			450				455						460				
45	Leu	Lys	Gly	Lys	Lys	Ser	Cys	His	Thr	Gly	Val	Asp	Arg	Thr	Ala	Gly	
	465					470					475					480	
	Trp	Asn	Ile	Pro	Met	Gly	Leu	Leu	Phe	Ser	Arg	Ile	Asn	His	Cys	Lys	
					485					490					495		
50	Phe	Asp	Glu	Phe	Phe	Ser	Gln	Gly	Cys	Ala	Pro	Gly	Tyr	Lys	Lys	Asn	
				500					505					510			
	Ser	Thr	Leu	Cys	Asp	Leu	Cys	Ile	Gly	Pro	Ala	Lys	Cys	Ala	Pro	Asn	
			515					520					525				
55	Asn	Arg	Glu	Gly	Tyr	Asn	Gly	Tyr	Thr	Gly	Ala	Phe	Gln	Cys	Leu	Val	

EP 1 284 298 A2

	530	535	540	
5	Glu Lys Gly Asp Val Ala Phe Val Lys His Gln Thr Val Leu Glu Asn 545 550 555 560			
	Thr Asn Gly Lys Asn Thr Ala Ala Trp Ala Lys Asp Leu Lys Gln Glu 565 570 575			
10	Asp Phe Gln Leu Leu Cys Pro Asp Gly Thr Lys Lys Pro Val Thr Glu 580 585 590			
	Phe Ala Thr Cys His Leu Ala Gln Ala Pro Asn His Val Val Val Ser 595 600 605			
15	Arg Lys Glu Lys Ala Ala Arg Val Ser Thr Val Leu Thr Ala Gln Lys 610 615 620			
	Asp Leu Phe Trp Lys Gly Asp Lys Asp Cys Thr Gly Asn Phe Cys Leu 625 630 635 640			
20	Phe Arg Ser Ser Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Lys Cys 645 650 655			
	Leu Thr Lys Leu Pro Glu Gly Thr Thr Tyr Glu Glu Tyr Leu Gly Ala 660 665 670			
25	Glu Tyr Leu Gln Ala Val Gly Asn Ile Arg Lys Cys Ser Thr Ser Arg 675 680 685			
	Leu Leu Glu Ala Cys Thr Phe His Lys Ser 690 695			
30	<210> 56 <211> 2293 <212> DNA <213> Rattus norvegicus			
35	<220> <223> Transferrin			
40	<400> 56 cgctccgctcc tgcacacaca caccgagagg atgagggttcg ctgtgggtgc cctgctggct 60 tgtgcccgcc tgggactgtg tctggctgtc cctgacaaaa cgggtcaaatg gtgcgcagtg 120 tctgagcatg agaacaccaa gtgtatcagt ttccgtgacc acatgaaaac cgtccttcca 180 gctgatggcc ccgggcttgc ctgtgtgaag aaaacctcct atcaagattg catcaaggcc 240 atctctggag gtgaagctga tgccattacc ttggatgggg gttgggtgta cgatgcaggc 300 ctgactccca acaacctgaa gcctgtggca gcagagtttt atggatcact tgaacatcca 360 cagacccact acttggctgt ggccgtgtgt aagaaggga cagacttcca gctgaaccag 420 ctccagggca agaagtctg ccacactggc ctgggcagggt ctgcaggctg gattatcccc 480 attggccttac ttttctgtaa cttgccagag ccccgcaagc ctcttgagaa agctgtggcc 540 agtttcttct cgggcagttg tgtcccctgt gcagatccag tggccttccc ccagctgtgt 600 caactgtgtc caggctgtgg ctgctccccg actcaaccgt tctttggcta cgtaggcgcc 660 ttcaagtgtc tgagagatgg aggtggagat gtggcctttg tcaagcatac aaccatattt 720 gagggtcttg cacagaaggc tgacagggat caatatgagc tgctctgcct tgacaatacc 780 cgcaagccag tggatcagta tgaggactgc tacctagccc ggatcccttc tcatgctgtt 840 gtggctcgaa atggagatgg caaagaggac ttgatctggg agatcctcaa agtgggtcag 900 gaacactttg gcaaaggcaa atcaaaagac ttccaactgt tcggctctcc tcttgggaaa 960 gacctgtgtg ttaaggattc tccttttggc tggttacgggg tgccccaag gatggactac 1020 aggctgtacc tgggccacag ctatgtcact gccattcgaa atcagcggga aggcgtgtgc 1080 ccggaggcct ccacgcacag cgcgccagtg aaatggtgtg cactgagtca ccaagagaga 1140 gccaagtgtg atgagtggag cgtcacgagc aatgggcaga tagagtgtga gtcagcagag 1200			

EP 1 284 298 A2

5 agcactgagg actgcattga caagattgtg aatggagaag cagatgccat gagcttggat 1260
 ggaggtcatg cctacatagc aggccagtgt ggactagtgc ccgtcatggc agagaactat 1320
 gatactctctt cgtgtacaaa cccacaatca gatgtctttc ctaaagggtta ttatgccgtg 1380
 gctgtgggtga aggcattcaga ctccagcatc aactggaaca acctgaaagg caagaagtcc 1440
 tgccatactg gagtagacag aaccgcccgc tggaaacatcc ctatgggcct gctgttcagc 1500
 aggatcaacc actgcaagtt cgtgaattt ttccagtcaag gctgtgctcc tggctataag 1560
 aagaattcca cctctgtgta cctgtgtatt ggcccagcaa aatgtgctcc gaacaacaga 1620
 gagggatata atggttatac aggggctttc cagtgcctcg ttgagaaggg agacgtagcc 1680
 tttgtgaagc accagactgt cctggaaaac acgaacggaa agaactgc tgcattgggt 1740
 10 aaggatctga agcaggaaga ctccagctg ctgtgccctg atggtaccaa gaagcctgta 1800
 accgagttcg ccacctgcca cctggcccaa gctccaaacc atgttgtggt ctcacgaaaa 1860
 gagaaggcag cccgggttag cactgtgctg actgcccaga aggatttatt ttggaaagggt 1920
 gacaaggact gcaactggcaa tttctgtttg ttccgggtctt ccaccaagga ccttctgttc 1980
 agagatgaca ccaagtgttt gactaaactt ccagaaggta ccacatatga agagtactta 2040
 ggagcagagt acttgcaagc tgttggaac ataagggaag gttaacctc acgactccta 2100
 15 gaagcctgca ctttccacaa aagttaaaat ccaaggagtg ggtgccactg tgggtggagga 2160
 ggatgcccc gtgatccatg ggcttctcct ggctccata gccctgagcg gctggggcta 2220
 actgtgtccg tcttactgct tgggtgtgtt accacatata cagagcacia aataaaaaat 2280
 gactgttgac ttt 2293

20 <210> 57
 <211> 542
 <212> PRT
 <213> Rattus norvegicus

25 <220>
 <223> NF-L

<400> 57
 Met Ser Ser Phe Ser Tyr Glu Pro Tyr Phe Ser Thr Ser Tyr Lys Arg
 1 5 10 15
 30 Arg Tyr Val Glu Thr Pro Arg Val His Ile Ser Ser Val Arg Ser Gly
 20 25 30
 Tyr Ser Thr Ala Arg Ser Ala Tyr Ser Ser Tyr Ser Ala Pro Val Ser
 35 35 40 45
 Ser Ser Leu Ser Val Arg Arg Ser Tyr Ser Ser Ser Ser Gly Ser Leu
 50 55 60
 40 Met Pro Ser Leu Glu Asn Leu Asp Leu Ser Gln Val Ala Ala Ile Ser
 65 70 75 80
 Asn Asp Leu Lys Ser Ile Arg Thr Gln Glu Lys Ala Gln Leu Gln Asp
 85 90 95
 45 Leu Asn Asp Arg Phe Ala Ser Phe Ile Glu Arg Val His Glu Leu Glu
 100 105 110
 Gln Gln Asn Lys Val Leu Glu Ala Glu Leu Leu Val Leu Arg Gln Lys
 115 120 125
 50 His Ser Glu Pro Ser Arg Phe Arg Ala Leu Tyr Glu Gln Glu Ile Arg
 130 135 140
 Asp Leu Arg Leu Ala Ala Glu Asp Ala Thr Asn Glu Lys Gln Ala Leu
 145 150 155 160
 55 Gln Gly Glu Arg Glu Gly Leu Glu Glu Thr Leu Arg Asn Leu Gln Ala
 165 170 175

EP 1 284 298 A2

	Arg Tyr Glu Glu Glu Val Leu Ser Arg Glu Asp Ala Glu Gly Arg Leu	180	185	190
5	Met Glu Ala Arg Lys Gly Ala Asp Glu Ala Ala Leu Ala Arg Ala Glu	195	200	205
	Leu Glu Lys Arg Ile Asp Ser Leu Met Asp Glu Ile Ala Phe Leu Lys	210	215	220
10	Lys Val His Glu Glu Glu Ile Ala Glu Leu Gln Ala Gln Ile Gln Tyr	225	230	235
	Ala Gln Ile Ser Val Glu Met Asp Val Ser Ser Lys Pro Asp Leu Ser	245	250	255
15	Ala Ala Leu Lys Asp Ile Arg Ala Gln Tyr Glu Lys Leu Ala Ala Lys	260	265	270
	Asn Met Gln Asn Ala Glu Glu Trp Phe Lys Ser Arg Phe Thr Val Leu	275	280	285
20	Thr Glu Ser Ala Ala Lys Asn Thr Asp Ala Val Arg Ala Ala Lys Asp	290	295	300
	Glu Val Ser Glu Ser Arg Arg Leu Leu Lys Ala Lys Thr Leu Glu Ile	305	310	315
25	Glu Ala Cys Arg Gly Met Asn Glu Ala Leu Glu Lys Gln Leu Gln Glu	325	330	335
	Leu Glu Asp Lys Gln Asn Ala Asp Ile Ser Ala Met Gln Asp Thr Ile	340	345	350
30	Asn Lys Leu Glu Asn Glu Leu Arg Ser Thr Lys Ser Glu Met Ala Arg	355	360	365
	Tyr Leu Lys Glu Tyr Gln Asp Leu Leu Asn Val Lys Met Ala Leu Asp	370	375	380
35	Ile Glu Ile Ala Ala Tyr Arg Lys Leu Leu Glu Gly Glu Glu Thr Arg	385	390	395
	Leu Ser Phe Thr Ser Val Gly Ser Ile Thr Ser Gly Tyr Ser Gln Ser	405	410	415
40	Ser Gln Val Phe Gly Arg Ser Ala Tyr Ser Gly Leu Gln Ser Ser Ser	420	425	430
	Tyr Leu Met Ser Ala Arg Ala Phe Pro Ala Tyr Tyr Thr Ser His Val	435	440	445
45	Gln Glu Glu Gln Ser Glu Val Glu Glu Thr Ile Glu Ala Thr Lys Ala	450	455	460
	Glu Glu Ala Lys Asp Glu Pro Pro Ser Glu Gly Glu Ala Glu Glu Glu	465	470	475
50	Glu Lys Glu Lys Glu Glu Gly Glu Glu Glu Glu Gly Ala Glu Glu Glu	485	490	495
	Glu Ala Ala Lys Asp Glu Ser Glu Asp Ala Lys Glu Glu Glu Gly Gly			
55				

EP 1 284 298 A2

	500	505	510
	Glu Gly Glu Glu Glu Asp Thr Lys Glu Ser Glu Glu Glu Glu Lys Lys		
	515	520	525
5			
	Glu Glu Ser Ala Gly Glu Glu Gln Ala Ala Lys Lys Lys Asp		
	530	535	540
10	<210> 58 <211> 2032 <212> DNA <213> Rattus norvegicus		
15	<220> <223> NF-L		
20	<400> 58 gaattccccc ggttcttctc tctaggtccc ctatctccgc cccgggcctg agggggcgac 60 cgaccgccac catgagttcg ttcagctacg agccgtactt ttccagctcc tacaagcggc 120 gctacgtgga gacgccccgg gtgcacatct ccagcgtgcg cagcggctac agcacggcgc 180 gctctgcgta ctccagctac tccgcgcccg tctcctcctc tctgtcgggtg cggccgagct 240 actcatccag ctccggctct ttgatgcccc gcttgagaa cctcgatctg agccaggtag 300 ccgccatcag caacgacctc aagtctatcc gcacacagga gaaggcacag ctgcaggacc 360 tcaacgatcg cttcgccagc ttcacgcagc gcgtgcacga gctggagcag cagaacaagg 420 tcctggaagc cgagctgttg gtgctgcgcc agaagcactc agagccttcc cgcttccgcg 480 ccctgtatga gcaggagatc cgtgatctgc gactggcggc cgaagacgcc actaacgaga 540 agcaggcgct gcagggcgag cgcgagggggc tggaggagac tctgcgcaac ctgcaggctc 600 gctacgagga ggaggtgctg agccgcgagg acgcccaggg ccggtgatg gaagcccga 660 aaggcgcgga tgaggctgcg ctgcgccgag ccgagctgga gaagcgcac gacagcctga 720 tggacgagat agccttcctg aaaaagggtg acgaggaaga gatcgccgag ctgcaggctc 780 agatccagta tgctcagatc tccgtggaga tggacgtgtc ctccaagccc gacctctccg 840 ccgctctcaa ggacatccgc gctcagtacg agaagctggc cgccaagaat atgcagaatg 900 ccgaagagtg gttcaagagc cgcttcacgg tgctaaccga gagcgccgac aagaacaccg 960 acgcagtgcg cgctgccaa gacgaggtgt cggaaagccg ccgcctactt aaggctaaga 1020 ccctggagat cgaagcctgc cggggtatga acgaagctct agagaagcag ctgcaggagc 1080 tggaggacaa gcagaatgca gacatcagcg ccatgcagga cacaatcaac aaactggaga 1140 atgagctgag aagcacgaag agcgagatgg ccagggtact gaaggagtag caggacctcc 1200 tcaatgtcaa gatggcattg gacattgaga ttgcagctta caggaaactc ttggaaggcg 1260 aagaaaccag gctcagtttc accagcgtgg gtagcataac cagcggctac tctcagagct 1320 cgcaggctct tggccgttct gcttacagtg gcttgcagag cagctcctac ttgatgtctg 1380 ctgagcatt cccagcctac tataccagcc acgtccagga agagcagtc gaggtggagg 1440 agaccattga ggctacgaaa gctgaggagg ccaaggatga gccccctct gaaggagaag 1500 cagaagagga ggagaaggag aaagaggagg gggagggaaga ggaagggtgt gaggaggaag 1560 aagctgccaa ggatgagtct gaagatgcca aagaagaaga aggtggtgag ggtgaagagg 1620 aagacaccaa agagtcagaa gaggaagaga agaaagagga gagtgtctgg gaggagcaag 1680 ctgctaagaa gaaagattga gccccattcc caactatccc agggaaaaag tctcccaaaa 1740 tcaggtcaac ctcatcacca aaccaaccag ttgagttcca gatcctatac agattaagaa 1800 gtcaatatat gtataattct gagatgactt aggttggaca ttcaatgttg tgctatgact 1860 ttctctctta tgcagagtat ctgtttgctt gcagagtggc tttctggctt gctgcccaacc 1920 tgtgcatggt ccattgcttat gatttcagga tctacggcaa tgtgaatcac acagatgttt 1980 acaataataa taataaaaaa accacacata cacaacatga ataaatgaat tc 2032		
50	<210> 59 <211> 626 <212> PRT <213> Rattus norvegicus		
55	<220> <223> MAG		

EP 1 284 298 A2

<400> 59

Met Ile Phe Leu Thr Thr Leu Pro Leu Phe Trp Ile Met Ile Ser Ala
 1 5 10 15

5 Ser Arg Gly Gly His Trp Gly Ala Trp Met Pro Ser Ser Ile Ser Ala
 20 25 30

Phe Glu Gly Thr Cys Val Ser Ile Pro Cys Arg Phe Asp Phe Pro Asp
 35 40 45

10 Glu Leu Arg Pro Ala Val Val His Gly Val Trp Tyr Phe Asn Ser Pro
 50 55 60

Tyr Pro Lys Asn Tyr Pro Pro Val Val Phe Lys Ser Arg Thr Gln Val
 65 70 75 80

15 Val His Glu Ser Phe Gln Gly Arg Ser Arg Leu Leu Gly Asp Leu Gly
 85 90 95

Leu Arg Asn Cys Thr Leu Leu Leu Ser Thr Leu Ser Pro Glu Leu Gly
 100 105 110

20 Gly Lys Tyr Tyr Phe Arg Gly Asp Leu Gly Gly Tyr Asn Gln Tyr Thr
 115 120 125

Phe Ser Glu His Ser Val Leu Asp Ile Ile Asn Thr Pro Asn Ile Val
 130 135 140

25 Val Pro Pro Glu Val Val Ala Gly Thr Glu Val Glu Val Ser Cys Met
 145 150 155 160

Val Pro Asp Asn Cys Pro Glu Leu Arg Pro Glu Leu Ser Trp Leu Gly
 165 170 175

30 His Glu Gly Leu Gly Glu Pro Thr Val Leu Gly Arg Leu Arg Glu Asp
 180 185 190

Glu Gly Thr Trp Val Gln Val Ser Leu Leu His Phe Val Pro Thr Arg
 195 200 205

Glu Ala Asn Gly His Arg Leu Gly Cys Gln Ala Ala Phe Pro Asn Thr
 210 215 220

40 Thr Leu Gln Phe Glu Gly Tyr Ala Ser Leu Asp Val Lys Tyr Pro Pro
 225 230 235 240

Val Ile Val Glu Met Asn Ser Ser Val Glu Ala Ile Glu Gly Ser His
 245 250 255

45 Val Ser Leu Leu Cys Gly Ala Asp Ser Asn Pro Pro Pro Leu Leu Thr
 260 265 270

Trp Met Arg Asp Gly Met Val Leu Arg Glu Ala Val Ala Glu Ser Leu
 275 280 285

50 Tyr Leu Asp Leu Glu Glu Val Thr Pro Ala Glu Asp Gly Ile Tyr Ala
 290 295 300

Cys Leu Ala Glu Asn Ala Tyr Gly Gln Asp Asn Arg Thr Val Glu Leu
 305 310 315 320

55 Ser Val Met Tyr Ala Pro Trp Lys Pro Thr Val Asn Gly Thr Val Val

EP 1 284 298 A2

	325	330	335
5	Ala Val Glu Gly Glu Thr Val Ser Ile Leu Cys Ser Thr Gln Ser Asn 340 345 350		
	Pro Asp Pro Ile Leu Thr Ile Phe Lys Glu Lys Gln Ile Leu Ala Thr 355 360 365		
10	Val Ile Tyr Glu Ser Gln Leu Gln Leu Glu Leu Pro Ala Val Thr Pro 370 375 380		
	Glu Asp Asp Gly Glu Tyr Trp Cys Val Ala Glu Asn Gln Tyr Gly Gln 385 390 395 400		
15	Arg Ala Thr Ala Phe Asn Leu Ser Val Glu Phe Ala Pro Ile Ile Leu 405 410 415		
	Leu Glu Ser His Cys Ala Ala Ala Arg Asp Thr Val Gln Cys Leu Cys 420 425 430		
20	Val Val Lys Ser Asn Pro Glu Pro Ser Val Ala Phe Glu Leu Pro Ser 435 440 445		
	Arg Asn Val Thr Val Asn Glu Thr Glu Arg Glu Phe Val Tyr Ser Glu 450 455 460		
25	Arg Ser Gly Leu Leu Leu Thr Ser Ile Leu Thr Leu Arg Gly Gln Ala 465 470 475 480		
	Gln Ala Pro Pro Arg Val Ile Cys Thr Ser Arg Asn Leu Tyr Gly Thr 485 490 495		
30	Gln Ser Leu Glu Leu Pro Phe Gln Gly Ala His Arg Leu Met Trp Ala 500 505 510		
	Lys Ile Gly Pro Val Gly Ala Val Val Ala Phe Ala Ile Leu Ile Ala 515 520 525		
35	Ile Val Cys Tyr Ile Thr Gln Thr Arg Arg Lys Lys Asn Val Thr Glu 530 535 540		
	Ser Pro Ser Phe Ser Ala Gly Asp Asn Pro His Val Leu Tyr Ser Pro 545 550 555 560		
40	Glu Phe Arg Ile Ser Gly Ala Pro Asp Lys Tyr Glu Ser Glu Lys Arg 565 570 575		
	Leu Gly Ser Glu Arg Arg Leu Leu Gly Leu Arg Gly Glu Pro Pro Glu 580 585 590		
45	Leu Asp Leu Ser Tyr Ser His Ser Asp Leu Gly Lys Arg Pro Thr Lys 595 600 605		
	Asp Ser Tyr Thr Leu Thr Glu Glu Leu Ala Glu Tyr Ala Glu Ile Arg 610 615 620		
50	Val Lys 625		
55	<210> 60 <211> 2475		

<212> DNA
 <213> *Rattus norvegicus*

<220>
 <223> MAG

<400> 60
 cagaagccag accatccaac cttctgtatc agtgcctcctc gtcgectcac tgtacttcac 60
 ggaagagact tgggtgactg gccacttgga gcggaatcag gagacattcc caactcaggg 120
 agactgaggt gagggcccta gctcgcccac ttgctggaca agatgatatt ccttaccacc 180
 ctgcctctgt tttggataat gatttcagct tctcgagggg ggcactgggg tgcctggatg 240
 ccctcgtcca tctcagcctt cgagggcacg tgtgtctcca tcccctgccg tttcgacttc 300
 ccggatgagc tcagaccggc tgtggtacat ggcgtctggt atttcaacag tccctacccc 360
 aagaactacc cgccagtggc cttcaagtc cgcacacaag tgggccacga gagcttccat 420
 ggccgtagcc gcctgttggg agacctgggc ctacgaaact gcacctgct tctcagcacg 480
 ctgagccctg agctgggagg gaaatactat ttccgaggtg acctggggcg ctacaaccag 540
 tacaccttct cggagcacag cgtcctggac atcatcaaca ccccacat cgtgggtgcc 600
 ccagaagtgg tggcaggaac ggaagtagag gtcagctgca tgggtgccga caactgccc 660
 gagctgcgcc ctgagctgag ctggctgggc cagcaggggc taggggagcc cactgttctg 720
 ggtcggctgc yggaggatga aggcacctgg gtgcaggtgt cactgctaca cttcgtgcct 780
 actagagagg ccaacggcca ccgtctgggc tgtcaggctg ccttccccaa caccaccttg 840
 cagttcaggg gttacgccag tctggacgtc aagtaccccc cgggtgattgt ggagatgaat 900
 tcctctgttg aggccattga gggctcccat gtcagcctgc tctgtggggc tgacagcaac 960
 ccgccaccgc tgctgacttg gatgcgggat gggatggtgt tgagggaggg agttgctgag 1020
 agcctgtacc tggatctgga ggaggtgacc ccagcagagg acggcatcta tgcttgccctg 1080
 gcagagaatg cctatggcca ggacaaccgc acggtggagc tgagcgtcat gtatgcacct 1140
 tgggaagccca cagtgaatgg gacggtgggtg gcggtagagg gggagacagt ctcacacctg 1200
 tgttccacac agagcaaccg ggacctatt ctacccatct tcaaggagaa gcagatcctg 1260
 gccacggtca tctatgagag tcagctgcag ctggaactcc ctgcagtgac gcccgaggac 1320
 gatggggagt actggtgtgt agctgagaac cagtatggcc agagagccac cgcttcaac 1380
 ctgtctgttg agtttgctcc cataatcctt ctggaatcgc actgtgcagc ggccagagac 1440
 accgtgcagt gcctgtgtgt ggtaaaatcc aaccgggaac cctccgtggc ctttgagctg 1500
 ccttcccgca acgtgactgt gaacgagaca gagagggagt ttgtgtactc agagcgcagc 1560
 ggcctcctgc tcaccagcat cctcacgctc cggggtcagg cccaagcccc accccgcgctc 1620
 atttgtacct ccaggaacct ctacggcacc cagagcctcg agctgccttt ccagggagca 1680
 caccgactga tgtggggccaa aatcggccct gtgggtgctg tggtcgcctt tgccatcctg 1740
 agcttctcag cgggagacaa ccctcatgtc ctgtacagcc ccgaattccg aatctctgga 1800
 gcacctgata agtatgagag tgagaagcgc ctggggtccg agaggaggct gctgggcctt 1860
 aggggggaac cccagaaact ggacctcagt tatteccact cagacctggg gaaacgacct 1920
 accaaggaca gctacacct gacagaggag ctggctgagt acgcagaaat ccgagtcaag 2040
 tgaggaaact gggggctggc cctgtggctc acccccatc aggacctcgt cttggcccc 2100
 actggccgtg ggctcccttt ctcttgagag tggtaggggt gggggcggga agggcgggg 2160
 caggaaacag tgaggtctta gggggccggc ctccctcct tcccggclgc tctctctgc 2220
 caacatcctg cacctatgtt acagctccct ctccctcct tttaacctca gctgttgaga 2280
 ggggtgctct gtctgtccat gttatttatt gttatcctgg tctcctgtcc ccttaccggg 2340
 ccccaggacc tgtacaaaag ggacatgaaa taaatgtcct aatgacaagt gccagctag 2400
 acccatcctt tggaggaaag gggcatatta gtaatacttt tctcgttgct gtaacaaaat 2460
 actggacaaa aacac 2475

<210> 61
 <211> 845
 <212> PRT
 <213> *Rattus norvegicus*

<220>
 <223> NF-M protein

<400> 61
 Met Ser Tyr Thr Leu Asp Ser Leu Gly Asn Pro Ser Ala Tyr Arg Arg
 1 5 10 15

EP 1 284 298 A2

Val Pro Thr Glu Thr Arg Ser Ser Phe Ser Arg Val Ser Gly Ser Pro
20 25 30

5 Ser Ser Gly Phe Arg Ser Gln Ser Trp Ser Arg Gly Ser Pro Ser Thr
35 40 45

Val Ser Ser Ser Tyr Lys Arg Ser Ala Leu Ala Pro Arg Leu Ala Tyr
50 55 60

10 Ser Ser Ala Met Leu Ser Ser Ala Glu Ser Ser Leu Asp Phe Ser Gln
65 70 75 80

Ser Ser Ser Leu Leu Asn Gly Gly Ser Gly Gly Asp Tyr Lys Leu Ser
85 90 95

15 Arg Ser Asn Glu Lys Glu Gln Leu Gln Gly Leu Asn Asp Arg Phe Ala
100 105 110

Gly Tyr Ile Glu Lys Val His Tyr Leu Glu Gln Gln Asn Lys Glu Ile
115 120 125

20 Glu Ala Glu Ile His Ala Leu Arg Gln Lys Gln Ala Ser His Ala Gln
130 135 140

Leu Gly Asp Ala Tyr Asp Gln Glu Ile Arg Glu Leu Arg Ala Thr Leu
145 150 155 160

25 Glu Met Val Asn His Glu Lys Ala Gln Val Gln Leu Asp Ser Asp His
165 170 175

Leu Glu Glu Asp Ile His Arg Leu Lys Glu Arg Phe Glu Glu Glu Ala
180 185 190

30 Arg Leu Arg Asp Asp Thr Glu Ala Ala Ile Arg Ala Val Arg Lys Asp
195 200 205

Ile Glu Glu Ser Ser Met Val Lys Val Glu Leu Asp Lys Lys Val Gln
210 215 220

35 Ser Leu Gln Asp Glu Val Ala Phe Leu Arg Ser Asn His Glu Glu Glu
225 230 235 240

Val Ala Asp Leu Leu Ala Gln Ile Gln Ala Ser His Ile Thr Val Glu
245 250 255

40 Arg Lys Asp Tyr Leu Lys Thr Asp Ile Ser Thr Ala Leu Lys Glu Ile
260 265 270

Arg Ser Gln Leu Glu Cys His Ser Asp Gln Asn Met His Gln Ala Glu
275 280 285

Glu Trp Phe Lys Cys Arg Tyr Ala Lys Leu Thr Glu Ala Ala Glu Gln
290 295 300

50 Asn Lys Glu Ala Ile Arg Ser Ala Lys Glu Glu Ile Ala Glu Tyr Arg
305 310 315 320

Arg Gln Leu Gln Ser Lys Ser Ile Glu Leu Glu Ser Val Arg Gly Thr
325 330 335

55 Lys Glu Ser Leu Glu Arg Gln Leu Ser Asp Ile Glu Glu Arg His Asn

EP 1 284 298 A2

	340	345	350
5	His Asp Leu Ser Ser Tyr Gln Asp Thr Ile Gln Gln Leu Glu Asn Glu 355 360 365		
	Leu Arg Gly Thr Lys Trp Glu Met Ala Arg His Leu Arg Glu Tyr Gln 370 375 380		
10	Asp Leu Leu Asn Val Lys Met Ala Leu Asp Ile Glu Ile Ala Ala Tyr 385 390 395 400		
	Arg Lys Leu Leu Glu Gly Glu Glu Thr Arg Phe Ser Thr Phe Ser Gly 405 410 415		
15	Ser Ile Thr Gly Pro Leu Tyr Thr His Arg Gln Pro Ser Val Thr Ile 420 425 430		
	Ser Ser Lys Ile Gln Lys Thr Lys Val Glu Ala Pro Lys Leu Lys Val 435 440 445		
20	Gln His Lys Phe Val Glu Glu Ile Ile Glu Glu Thr Lys Val Glu Asp 450 455 460		
	Glu Lys Ser Glu Met Glu Asp Ala Leu Thr Val Ile Ala Glu Glu Leu 465 470 475 480		
25	Ala Ala Ser Ala Lys Glu Glu Lys Glu Glu Ala Glu Glu Lys Glu Glu 485 490 495		
	Glu Pro Glu Val Lys Ser Pro Val Lys Ser Pro Glu Ala Lys Glu Glu 500 505 510		
30	Glu Glu Gly Glu Lys Glu Glu Glu Glu Gly Gln Glu Glu Glu Glu 515 520 525		
	Glu Glu Asp Glu Gly Val Lys Ser Asp Gln Ala Glu Glu Gly Gly Ser 530 535 540		
35	Glu Lys Glu Gly Ser Ser Glu Lys Asp Glu Gly Glu Gln Glu Glu Glu 545 550 555 560		
	Gly Glu Thr Glu Ala Glu Gly Glu Gly Glu Glu Ala Glu Ala Lys Glu 565 570 575		
40	Glu Lys Lys Thr Glu Gly Lys Val Glu Glu Met Ala Ile Lys Glu Glu 580 585 590		
	Ile Lys Val Glu Lys Pro Glu Lys Ala Lys Ser Pro Val Pro Lys Ser 595 600 605		
45	Pro Val Glu Glu Val Lys Pro Lys Pro Glu Ala Lys Ala Gly Lys Asp 610 615 620		
	Glu Gln Lys Glu Glu Glu Lys Val Glu Glu Lys Lys Glu Val Ala Lys 625 630 635 640		
50	Glu Ser Pro Lys Glu Glu Lys Val Glu Lys Lys Glu Glu Lys Pro Lys 645 650 655		
	Asp Val Pro Asp Lys Lys Lys Ala Glu Ser Pro Val Lys Glu Lys Ala 660 665 670		
55			

EP 1 284 298 A2

Val Glu Glu Met Ile Thr Ile Thr Lys Ser Val Lys Val Ser Leu Glu
675 680 685

5 Lys Asp Thr Lys Glu Glu Lys Pro Gln Gln Gln Glu Lys Val Lys Glu
690 695 700

Lys Ala Glu Glu Glu Gly Gly Ser Glu Glu Glu Val Gly Asp Lys Ser
705 710 715 720

10 Pro Gln Glu Ser Lys Lys Glu Asp Ile Ala Ile Asn Gly Glu Val Glu
725 730 735

Gly Lys Glu Glu Glu Gln Glu Thr Gln Glu Lys Gly Ser Gly Gln
740 745 750

15 Glu Glu Glu Lys Gly Val Val Thr Asn Gly Leu Asp Val Ser Pro Ala
755 760 765

Glu Glu Lys Lys Gly Glu Asp Arg Ser Asp Asp Lys Val Val Val Thr
770 775 780

20 Lys Lys Val Glu Lys Ile Thr Ser Glu Gly Gly Asp Gly Ala Thr Lys
785 790 795 800

Tyr Ile Thr Lys Ser Val Thr Val Thr Gln Lys Val Glu Glu His Glu
805 810 815

25 Glu Thr Phe Glu Glu Lys Leu Val Ser Thr Lys Lys Val Glu Lys Val
820 825 830

Thr Ser His Ala Ile Val Lys Glu Val Thr Gln Gly Asp
835 840 845

30

<210> 62
<211> 2717
<212> DNA
<213> Rattus norvegicus

35

<220>
<223> NF-M protein

<400> 62

40 ggcctccaag atgagctaca cgctggactc gctgggcaac ccgtccgcct accggcgcgct 60
tccaaccgag acccggtcca gcttcagtcg tgtgagcggt tccccgtcca gcggcttccg 120
ctcgcagtcg tgggtcccgcg gctcgcgccag caccgtgtcc tcctcctaca agcgcagcgc 180
gctcgcgccg cgctcgcct acagctcggc tatgctcagc tcggccgaga gcagcctcga 240
cttcagccag tcctcttcgc tgcttaacgg cggctccggc ggcgactaca agctgtcccg 300
ctcaaaccag aaagagcagc tgcaggggct gaacgaccgt ttcgcccgtt acatcgagaa 360

45 agtgcactac ttggaacaac agaacaagga gatcgaggca gagatccacg cgctgcggca 420
gaagcaggcc tcgcacgccc agctgggtga cgcttacgac caggagatcc gagagctgcg 480
cgccaccctg gagatgggtga atcacgagaa ggctcaagtg cagctggact ctgatcactt 540
ggaggaagac atccaccggc tcaaggagcg cttcgaggag gaggcgcggc tgcgggacga 600
cacggaggct gccatccggg cggtgcgcaa agacatagag gattcgtcga tggttaaggt 660
ggagctggac aagaagggtt agtcgctgca ggatgaggtg gccttctctg ggagcaatca 720

50 cgaagaggag gtggccgacc tgctggccca gatccaggcg tcgcacatca ccgtagagcg 780
caaagactac ctgaagacag acatctccac ggcgctgaaa gagatccgct cccagctcga 840
gtgtcactcc gaccagaaca tgcaccaggc cgaagagtgg ttcaaagtgc gctacgcca 900
gctcaccgag gcggccgagc agaacaagga ggcatccgc tccgctaaag aagagatcgc 960
cgagtaccgg cgccagctgc agtccaagag cattgagctc gattcggtgc gaggcactaa 1020

55 ggagtccctg gaacggcagc tcagcgacat cgaggagcgc cacaaccacg acctcagcag 1080
ctaccaggac accatccagc agctggaaaa tgagcttcgg ggaacaaagt gggaaatggc 1140

EP 1 284 298 A2

5 tcgtcatttg cgagaataacc aggatctcct taacgtcaag atggctcttg acatcgagat 1200
 cgccgcataat aggaactac tggaggggtga agagaccaga tttagcacat tttcaggaag 1260
 catcactggg cctctgtaca cacaccgaca gccctcagtc acaatatcca gtaagattca 1320
 gaagacccaaa gtcgaggccc ccaagctcaa ggtccaacac aaatttgttg aggagatcat 1380
 tgaggagact aaagtgggaag atgagaagtc agaaatggaa gacgcctca cagtcattgc 1440
 agaggaattg gcagcctctg ccaagagga gaaagaagag gcagaagaaa aggaagagga 1500
 accggaagtg aagtcctccg tgaagtctcc tgaggctaag gaagaggagg aaggggaaaa 1560
 ggaggaagaa gaggaaggcc aagaggaaga agaggaggaa gatgaagggt tcaagtcaga 1620
 ccaggcagaa gagggaggat ctgagaagga aggtctcagt gaaaaggatg aaggtgagca 1680
 10 agaagaagaa ggggaaactg aggcagaagg tgaaggagag gaagcagaag ctaaggagga 1740
 aaagaaaaca gagggaaagg tcgaggaaat ggctatcaag gaggaaatca aggtcgagaa 1800
 gcccgagaaa gccaaagtccc ctgtgccaaa atcaccgggt gaagaagtaa agccaaaacc 1860
 agaagccaaa gccggaagg atgagcagaa ggaggaagag aaagttgagg agaagaagga 1920
 ggtagccaaag gaatcaccca aggaagagaa ggtggagaaa aaggaggaga agccaaaaga 1980
 tgtcccagat aaaaagaagg ctgagtcctc agtgaaagaa aaggccgtag aggaaatgat 2040
 15 caccattact aagtcggtaa aggtgagcct ggagaaagac accaaagagg agaagcctca 2100
 gcagcaggag aaggtgaagg agaaggcaga ggaggagggg ggtagttagg aggaagtggg 2160
 tgacaaaagc ccgcaagaat ccaagaagga agacatagct atcaatgggg aggtggaagg 2220
 aaaagaggag gaggagcagg aaactcagga gaagggcagt gggcaagagg aggagaaagg 2280
 ggtggtcact aatggcttag atgtgagccc tgcggaggaa aagaaagggg aggatagaag 2340
 20 tgatgacaaa gtggtggtga ccaagaaggt agaaaaaatc accagcgagg gaggcgatgg 2400
 tgctacccaa tacatcacca aatctgttac tgtcactcaa aaggttgaag agcatgagga 2460
 gacctttgag gagaagctgg tgtcaactaa aaaggtagaa aaggtcactt cacatgccat 2520
 agtcaaggaa gtcaccagg gtgactaaga tcggagtcca ttgcaaaagg ttaagccata 2580
 caacaatttc aaaatgcatg tgattgacag cttcaaaaca gaatgggttc tcccatgagg 2640
 25 gctccagaca ttgtattttc ctttgtgcaa tatgagggaa ctgcatgcaa gctcagggtg 2700
 cctcctcagt ccttggg 2717

<210> 63
 <211> 707
 <212> PRT
 30 <213> Rattus norvegicus

<220>
 <223> Neurodegeneration associated protein 1

35 <400> 63
 Met Ser Gln Tyr Thr Glu Lys Glu Pro Ser Val Met Asp Gln Asp Ser
 1 5 10 15
 Ser Lys Ala Ala Trp Pro Arg Ala Ala Gly Gly Tyr Gln Thr Ile Thr
 20 25 30
 40 Gly Arg Arg Tyr Gly Arg Arg His Ala Tyr Val Ser Phe Lys Pro Cys
 35 40 45
 Met Thr Arg His Glu Arg Ser Leu Gly Arg Ala Gly Asp Asp Tyr Glu
 50 55 60
 45 Val Leu Glu Leu Asp Asp Val Ala Lys Glu Asn Thr Ala Gly Ser Ser
 65 70 75 80
 Ser Leu Asp Gln Val His Pro Ser Leu Pro Ser Glu Thr Thr Val Glu
 85 90 95
 50 Lys Ser Glu Thr Glu Ile Pro Thr Cys Gly Pro Ala Leu Asn Gln Ser
 100 105 110
 Thr Glu Ser Asn Pro Ser Val Ala Thr Val Cys His Ser Glu Glu Val
 115 120 125

EP 1 284 298 A2

	Arg	Glu	Thr	Leu	Asp	Ser	Ser	Thr	Asn	Leu	Gln	Asn	His	Ala	Glu	Arg	
	130						135					140					
5	Glu	Cys	Thr	Pro	Ala	Val	Cys	Asn	Ala	Ser	Ser	Val	Gln	Asn	Gly	Ile	
	145					150					155					160	
	Val	Leu	Val	His	Thr	Asp	Ser	Tyr	Asp	Pro	Asp	Ser	Lys	His	Asp	Glu	
					165					170					175		
10	Asn	Asp	Ser	Leu	Gln	Leu	Cys	Ala	Gln	Ala	Val	Glu	Gly	Gly	Arg	Arg	
				180					185					190			
	Gln	Lys	Val	Leu	Gly	Asn	Ala	Val	Phe	Glu	Leu	Glu	Asn	Gly	Glu	Val	
			195					200					205				
15	Glu	Arg	Tyr	Ala	Asp	Leu	Cys	Pro	Ser	Val	Pro	Ser	Leu	Ser	Gly	Glu	
	210						215					220					
	Ile	Arg	Glu	Glu	Ser	Glu	Glu	Leu	Gly	Ser	Ala	Leu	Leu	Glu	Lys	Asn	
	225					230					235					240	
20	Ser	Ala	Gly	Asp	Ala	Glu	Ala	Val	His	Gln	Asp	Gly	Gln	Glu	Phe	Gln	
				245						250					255		
	Arg	Ser	Ser	Glu	Asp	Gly	Ile	Val	Arg	Lys	Arg	Arg	Gln	Asp	Asp	Thr	
				260					265					270			
25	Asp	Gln	Gly	Arg	Gln	Thr	Glu	Asn	Ser	Thr	Glu	Asp	Ala	Asp	Cys	Val	
			275					280					285				
	Pro	Gly	His	Val	Glu	Gln	Asn	Thr	Ser	Glu	Arg	Ala	Asn	His	His	Gly	
		290					295					300					
30	Ser	Ser	Pro	Glu	Gln	Val	Val	Arg	Pro	Lys	Val	Arg	Lys	Val	Ile	Ser	
	305					310					315					320	
	Ser	Ser	Gln	Val	Asp	Gln	Glu	Ser	Gly	Phe	Asn	Arg	His	Glu	Ala	Lys	
				325						330					335		
35	Gln	Arg	Ser	Val	Gln	Arg	Trp	Arg	Glu	Ala	Leu	Glu	Val	Glu	Glu	Cys	
				340					345					350			
	Ser	Ser	Asp	Asp	Pro	Ile	Ile	Lys	Cys	Asp	Asp	Tyr	Asp	Gly	Asp	His	
			355					360					365				
40	Asp	Cys	Met	Phe	Leu	Thr	Pro	Ser	Tyr	Ser	Arg	Val	Thr	Pro	Arg	Glu	
		370					375					380					
	Ala	Glu	Arg	His	Arg	Ala	Thr	Ala	Glu	Asn	Gly	Ala	Thr	Ala	Ser	Gly	
	385				390						395					400	
	Arg	Gln	Glu	Ala	Arg	Glu	Asn	Ala	Phe	Trp	Asn	Ala	Cys	Gly	Glu	Tyr	
				405						410					415		
50	Tyr	Gln	Leu	Phe	Asp	Lys	Asp	Glu	Asp	Ser	Ser	Glu	Cys	Ser	Asp	Gly	
			420					425						430			
	Glu	Trp	Ser	Ala	Ser	Leu	Pro	His	Arg	Phe	Ser	Gly	Thr	Glu	Lys	Asp	
			435				440						445				
55	Gln	Ser	Ser	Ser	Asp	Glu	Ser	Trp	Glu	Thr	Leu	Pro	Gly	Lys	Asp	Glu	
	450						455					460					

EP 1 284 298 A2

5 Asn Glu Pro Glu Leu Gln Ser Asp Ser Ser Gly Pro Glu Glu Glu Asn
 465 470 475 480
 Gln Glu Leu Ser Leu Gln Glu Gly Glu Gln Thr Ser Leu Glu Glu Gly
 485 490 495
 Glu Ile Pro Trp Leu Gln Tyr Asn Glu Val Asn Glu Ser Ser Ser Asp
 500 505 510
 10 Glu Gly Asn Glu Pro Ala Asn Glu Phe Ala Gln Pro Glu Ala Phe Met
 515 520 525
 Leu Asp Gly Asn Asn Asn Leu Glu Asp Asp Ser Ser Val Ser Glu Asp
 530 535 540
 15 Leu Asp Val Asp Trp Ser Leu Phe Asp Gly Phe Ala Asp Gly Leu Gly
 545 550 555 560
 Val Ala Glu Ala Ile Ser Tyr Val Asp Pro Gln Phe Leu Thr Tyr Met
 565 570 575
 20 Ala Leu Glu Glu Arg Leu Ala Gln Ala Met Glu Thr Ala Leu Ala His
 580 585 590
 Leu Glu Ser Leu Ala Val Asp Val Glu Val Ala Asn Pro Pro Ala Ser
 595 600 605
 25 Lys Glu Ser Ile Asp Gly Leu Pro Glu Thr Leu Val Leu Glu Asp His
 610 615 620
 Thr Ala Ile Gly Gln Glu Gln Cys Cys Pro Ile Cys Cys Ser Glu Tyr
 625 630 635 640
 Ile Lys Asp Asp Ile Ala Thr Glu Leu Pro Cys His His Phe Phe His
 645 650 655
 35 Lys Pro Cys Val Ser Ile Trp Leu Gln Lys Ser Gly Thr Cys Pro Val
 660 665 670
 Cys Arg Arg His Phe Pro Pro Ala Val Ile Asp Ala Ser Ala Ala Ala
 675 680 685
 40 Ser Ser Glu Pro Asp Leu Asp Ala Ser Pro Ala Asn Asp Asn Ala Glu
 690 695 700
 Glu Ala Pro
 705
 45 <210> 64
 <211> 4758
 <212> DNA
 <213> Rattus norvegicus
 50 <220>
 <223> Neurodegeneration associated protein 1
 <400> 64
 55 tggcgggtgg aggatcgagc gctgttctcg cctggagcc gctgcacatc tcggaatcat 60
 ttgcagctta ttactgtgt aaggaaaaac caaattacat ccataattct attgaactgg 120
 aagcatagac gctgccatat atgtcacagt atacagaaaa agaaccatca gtaatggatc 180

	aagactccag	caaggctgcg	tggcctagag	cagcaggagg	ataccagacg	attacaggca	240
	ggagggtacgg	aaggagacat	gcgtatgtca	gttttaagcc	atgtatgacc	aggcatgaac	300
	ggagcttggg	tcgggctggc	gatgactatg	aagtctctgga	actggatgac	gttgccaagg	360
	aaaacaccgc	aggttccagt	tcatgtgatc	aagtccatcc	ttctttacc	agtgaacta	420
5	cagttgaaaa	aagtgaacaa	gaaattcccta	cttgtggtcc	agcactgaat	caaagcacgg	480
	agagcaaccc	atccgttgcc	acagtgtgtc	atagttagga	agtcaggagg	accttagaca	540
	gcagtagcaa	tcttcagaat	cacgctgaga	gagagtgtac	gccagcagtt	tgtaatgcct	600
	caagtgtcca	gaatgggaatt	gtgttggttc	atactgactc	ttatgatcca	gacagcaagc	660
	atgatgagaa	tgactctctt	caacttttgtg	cccaagctgt	ggaagggtgg	agacgtcaga	720
10	aggtattagg	caatgcagtc	tttgagctgg	aaaatggaga	ggtagagaga	tatgctgac	780
	tgtgtccctc	agttccctct	ctcagtgggtg	aaataaggga	ggagtctgaa	gagctagggt	840
	cagcactctt	agagaaaaat	tctgctggcg	atgctggagg	tgctccatcag	gatgggcagg	900
	aatttcagag	gtcttctgaa	gacggcattg	ttagaaagag	gcgacaagat	galaccgatc	960
	aggggaagaca	gacagaaaaat	tcaactgaag	atgcagactg	tggtccaggc	catggtgaac	1020
	aaaataactag	tgagagagcc	aatcaccatg	gaagttctcc	tgaacaggta	gtgaggccca	1080
15	aagttagaaa	agtgtacagt	tcaagccagg	tggaccaaga	gagcggtttt	aataggcacg	1140
	aggctaagca	aagaagtgtt	cagagggtgga	gagaggctct	ggaagttgag	gaatgcagtt	1200
	cagatgaccc	tataatcaag	tgtagcagatt	atgatggaga	ccatgactgc	atgttcttaa	1260
	ccccatccta	ctcaagagtt	acgccaaggg	aagcagaacg	tcaccgtgcg	acagcagaaa	1320
	atggagccac	agcttcaggga	aggcaagagg	ctcgggaaaa	tgctttttgg	aatgcctgtg	1380
	gagagtatta	ccagctcttt	gacaaaagacg	aagacagttc	agagtgcagt	gatgggggaat	1440
20	gggtctgttc	tctgcctcac	cgattttctg	gcacagaaaa	agaccagtcc	tcaagcgatg	1500
	aaagctggga	aactctgcca	ggaaaagatg	agaatgaacc	tgagctacag	agttagagta	1560
	gtggccctga	ggaagaaaaac	caagaattgt	ctcttcaggga	gggagaacag	acgtccttgg	1620
	aggaggggga	gattccctgg	ttacagtaca	atgaggtcaa	tgagagcagc	agcgatgaag	1680
	ggaacgagcc	tgccaatgag	tttgccacaac	cagaagcttt	catgtttgat	gggaacaaca	1740
	acctggagga	cgactcgagc	gtgagtgaag	acctggatgt	ggactggagc	ctatgtgatg	1800
25	gttttgcgga	tggacttggg	gttgctgaag	ctatttcccta	cgtaggatcct	cagttcctca	1860
	cctacatggc	actagaagaa	cgcttagccc	aggctatgga	gactgcactg	gcacacttag	1920
	agtctcttgc	tgtagacgtt	gaggtggcta	acccacctgc	cagtaaggaa	agcatcgacg	1980
	gacttcagaa	aacctttgtc	ctagaagatc	acaccgctat	tggtcaggag	cagtgctgtc	2040
	ccatctgtcg	cagtgtgtac	attaaggatg	acatcgcaac	agagctgccc	tgccatcact	2100
30	tctttcataa	gccttgtgtc	tccatttggc	tacagaagtc	cggaaactgc	cctgtgtgtc	2160
	gccgccactt	cccacctgca	gtgattgacg	catctgcagc	tgcttccctc	gaaccagacc	2220
	ttgatgcctc	gcctgcaaac	gacaatgctg	aggaagcccc	gtaagccgtc	acgggggaaat	2280
	gagatcgaaa	ttctatcaca	gtaaatcctc	aaattccttc	taaatctgat	gtgcaaataa	2340
	ttatatataa	atatatttaa	aatgtctctat	atagtatatg	ccgtagttaa	gaaagagaat	2400
	attaaccttt	ctaaactgaa	tttaggtttg	cagaagatac	taaacatttt	caagctgaat	2460
35	gttgaagcag	tgcatccatt	ttcttttagtt	gaacatgggtg	tccattgtaa	cgtagtagtt	2520
	catctctgtg	gcatacgttt	ctgttttgtc	tgaagtgtctg	ccactaagag	atcgaattta	2580
	agctctcctt	tccacatcag	atgtgaaagg	agagcttaat	tctgtatctc	gtggcatacg	2640
	tttctgtttt	gtctgaagtg	ctgccactaa	gagatcagaa	ttaagctctc	ctttccacat	2700
	cagatgtgaa	aactgtgatc	acaacagtag	tacagtttgg	tttcattgaa	aataaactga	2760
	attctaaagc	atgctttttc	actggtccct	ttgcttttgc	tacttcgaga	cctcttgggt	2820
40	tatataacac	tgagggttaag	attaaagctt	ttcagaatgc	caggcaaaaga	ctagagtttt	2880
	gaccggaaca	cacacacaaa	ataaaaaaat	aaaaaataaa	ttacatctta	gatgtaaact	2940
	tcctgaaact	gtcatgtaat	aaactattca	gtgaacgttg	gatgttttaa	ggctagtaaa	3000
	gcatgtgaat	tatctgatgt	gcttcatgct	cggcacagtc	tcatgagctt	ggcctatgaa	3060
	acactgtcta	agccctcatg	cagtctgctt	ctacttggtt	aacactgaag	gtccagacca	3120
45	gtcttggcat	ctgattaaga	aattggatgt	agtttagctaa	ggtagtttgg	gttctacttt	3180
	aggagatctg	aagatttgca	catggccatg	tctgttacag	catcacccca	gattagaaag	3240
	gcacagcttt	taggttggtca	cacgagtagg	caagtctgtg	cagacgctgg	tgtgataggt	3300
	agcttacagg	tgagccctga	catcagcaca	gggacaacgg	ctcagcaggc	ccagcactgg	3360
	agcccaatccg	cgtgcacatc	tacctgccct	gtcctccag	ttcgggaata	tttctatagc	3420
	ttcccaaatc	agcttcatct	gatttgtgta	atatatctga	gtatttatag	tctttctttt	3480
50	ttctccagtc	ttaaaaataa	atgaattttc	actgttggca	catttgaggc	ttaaatataa	3540
	gaaacctaac	acttgcattc	tgatttttgc	atatattgta	aatgtggctg	gtatttacag	3600
	cgaatcctgt	gtgtcctttt	atgggtaaaa	caaaagtga	cattgcatgc	aagtaattgtg	3660
	gtgaatttgt	aatttagggg	tttcttgggg	cttctgtgac	tgtygatgct	taaatccagg	3720
	ccttaattgtt	gctctagcta	gcatgtttcc	ttctaagtga	catagtcagc	ctgtatccac	3780
	taatctctgc	ttgtcttctc	ctccgtggtc	ttcacaccgt	atccactgat	ggctcagttag	3840
55	tgtcagaggt	caccaggtt	agcatcagtt	cccatgtgtg	ccgtgaggat	tgtgagccgt	3900

EP 1 284 298 A2

```

gtggttgctt ggttggtttt cttttatgta ctttgattag ctgtggcact tactgagtaa 3960
acttacgttg ctgcagactg ctgtgtaaca agccacgttt tgtgtttagt cagtattaca 4020
cacgggacct tgttttatte ttctagatag cagctgtccc aaagaaaaata tttcttcttt 4080
gcctattaag atttagctat tatctgccag ttgttaaggg gtttgattcc aaactcaacc 4140
5 agagtgaac gtaagaaagc tgctgtactc ttgctgtcca tctgttacgt cctccgttgt 4200
tggctcctga ctacgtaccc acggctgctg aaggagactt gttttaattt gttttaaaaa 4260
ggaaaaatgaa gttttaggac tttgatgggt gggaagctga caagttcaga cccagtcctg 4320
tcatttgctc ttagcttgga tccttttgaa aagttaagaa tatatgaagg taaattagaa 4380
aaagtaaaaa tattgataaa atgtcattta tcttatgtct attttatgtt gttatttggc 4440
10 ctattaattt taattttttg aacattttct tctttatgtt aatatgaatg ccgatattta 4500
aagtttgact cacttgggtt tcttttgtgt ttcttagttg ttatctctaa gcctaactaa 4560
cttttaagat tatttgtgat atggatttat ataagctgtt aaatatatat gagctgttaa 4620
aatggaatgc aaggttttcc aaagaccagg tctaactgta atgattgggt tattgttcta 4680
caatcccagc ccggcatttt ccgtgtaa atcataacaat aaacaggata tactcagtg 4740
15 tcatttctaa aaaaaaaaaa 4758

```

<210> 65

<211> 1488

<212> DNA

<213> Rattus norvegicus

<220>

<223> Brain S-100 protein beta-subunit

<400> 65

```

aagtcacac ccagtcctct ctggaggaag aaaagggagc ttctctgtct accctcctag 60
25 tccttgga caagaagcc agaggactcc ggcggaacaa ggtgaccagg agcctccggg 120
atgtctgagc tggagaaggc catggttgcc ctcatgtatg tcttccatca gtattcaggg 180
agagaggggtg acaagcaca gctgaagaag tcagaactga aggagctcat caacaacgag 240
ctctctcact tcctggagga aatcaaagag caggaagtgg tggacaaagt gatggagacg 300
ctggacgaag atggggatgg ggagtgtgac ttccaggagt ttatggcctt cgtctccatg 360
30 gtgaccacag cctgtcatga gttctttgaa catgagttag acaaaaaaaaa aaaaaaaaaa 420
gtggctgagc cgtttccccg tggcagacat gagggccacg agaggaggca cggcagaagg 480
ctcgtgggct ggaaggagct gcgctctcta gacgcataata actaattagg aagcttgatt 540
tgcttcaggg atgaaactct gaccccgctt ccaagggctg ctttaagtta gcacttcgtt 600
tctgtcacac taggtattcc tgtgagctga atggtcccgg gaactattga taagagtcac 660
35 tgagggacga aatcaacact ctgtgggtat agcactgggt gtagaccacc atgtctcctgt 720
ggaaggggtca cctgtaagaa tcaaggcaga ctaccaatag cacctccgtt ggacagcttt 780
cttaggtgta atgtatgctg tccatgcatc tacagaccga cagctggatc cactgccacc 840
cgaagaggtt ggctcgccct tacaactgct tgtcctctgt ycaaacyaly ccccgaaaag 900
ttagacctat caccacacc ctcccaccac cccagggcca aaaggacagc ccaccaagt 960
cccccccc acagcgaatc gcggtttgtt accaagtacg tatttgacat caacagttcc 1020
40 aactggtgga acgattagat ctgcgacact aagtattagc accctaactc acgaccgaga 1080
atcaaaattc tgctcagtag acgtctcctt tcaggatgac accattgtcc ccataggaca 1140
cggacagagg agggcactgg agagagtgtc aggtcttttt ctactgtat cttcctctct 1200
ccctctgctg ccataatgt gagtgacctt ctagggtgag acttgcaggg tgagctgctg 1260
aggaatgaag ggccactgag atgtgtcctt tagctgctgg gtgtcatgtc tgacctgctg 1320
gtgcctaggg cctgcttaac actcggcaag gctgcgagcc gaggactgtg ggaagccgga 1380
45 cttgatgctt tctaactgct atatttgaat gccgaaggtc aaacaatcca agttacagat 1440
aaataaaaac cgcattgcaa gtattaaaaa gccattctag gaaaattc 1488

```

<210> 66

<211> 2364

<212> PRT

<213> Rattus norvegicus

<220>

<223> Microtubule associated protein IB

<400> 66

EP 1 284 298 A2

	Gly	Gln	Lys	Ile	Leu	His	His	Arg	Ser	Asp	Val	Leu	Glu	Thr	Val	Val	
	1				5					10					15		
5	Leu	Ile	Asn	Pro	Ser	Asp	Glu	Ala	Val	Ser	Thr	Glu	Val	Arg	Leu	Met	
			20						25					30			
	Ile	Thr	Asp	Ala	Ala	Arg	His	Lys	Leu	Leu	Val	Leu	Thr	Gly	Gln	Cys	
			35					40					45				
10	Phe	Glu	Asn	Thr	Gly	Glu	Leu	Ile	Leu	Gln	Ser	Gly	Ser	Phe	Ser	Phe	
		50					55					60					
	Gln	Asn	Phe	Ile	Glu	Ile	Phe	Thr	Asp	Gln	Glu	Ile	Gly	Glu	Leu	Leu	
		65				70					75					80	
15	Ser	Thr	Thr	His	Pro	Ala	Asn	Lys	Ala	Ser	Leu	Thr	Leu	Phe	Cys	Pro	
					85					90					95		
	Glu	Glu	Gly	Asp	Trp	Lys	Asn	Ser	Asn	Leu	Asp	Arg	His	Asn	Leu	Gln	
				100					105					110			
20	Asp	Phe	Ile	Asn	Ile	Lys	Leu	Asn	Ser	Ala	Ser	Ile	Leu	Pro	Glu	Met	
			115					120					125				
	Glu	Gly	Leu	Ser	Glu	Phe	Thr	Glu	Tyr	Leu	Ser	Glu	Ser	Val	Glu	Val	
		130					135					140					
25	Pro	Ser	Pro	Phe	Asp	Ile	Leu	Glu	Pro	Pro	Thr	Ser	Gly	Gly	Phe	Leu	
		145				150					155					160	
	Lys	Leu	Ser	Lys	Pro	Cys	Cys	Tyr	Ile	Phe	Pro	Gly	Gly	Arg	Gly	Asp	
					165					170					175		
30	Ser	Ala	Leu	Phe	Ala	Val	Asn	Gly	Phe	Asn	Met	Leu	Ile	Asn	Gly	Gly	
				180					185					190			
	Ser	Glu	Arg	Lys	Ser	Cys	Phe	Trp	Lys	Leu	Ile	Arg	His	Leu	Asp	Arg	
			195					200					205				
35	Val	Asp	Ser	Ile	Leu	Leu	Thr	His	Ile	Gly	Asp	Asp	Asn	Leu	Pro	Gly	
		210					215					220					
	Ile	Asn	Ser	Met	Leu	Gln	Arg	Lys	Ile	Ala	Glu	Leu	Glu	Glu	Glu	Ser	
		225				230					235					240	
40	Gln	Gly	Ser	Thr	Ser	Asn	Ser	Asp	Trp	Met	Lys	Asn	Leu	Ile	Ser	Pro	
					245					250					255		
	Asp	Leu	Gly	Val	Val	Phe	Leu	Asn	Val	Pro	Glu	Asn	Leu	Lys	Asn	Pro	
				260					265					270			
45	Glu	Pro	Asn	Ile	Lys	Met	Lys	Arg	Ser	Thr	Glu	Glu	Ala	Cys	Phe	Thr	
			275					280					285				
	Leu	Gln	Tyr	Leu	Asn	Lys	Leu	Ser	Met	Lys	Pro	Glu	Pro	Leu	Phe	Arg	
		290					295					300					
50	Ser	Val	Gly	Asn	Ala	Ile	Glu	Pro	Val	Ile	Leu	Phe	Gln	Lys	Met	Gly	
		305				310					315					320	
	Val	Gly	Lys	Leu	Lys	Met	Tyr	Val	Leu	Asn	Pro	Val	Lys	Ser	Ser	Lys	
					325					330					335		
55																	

EP 1 284 298 A2

	Glu Met Gln Tyr Phe Met Gln Gln Trp Thr Gly Thr Asn Lys Asp Lys	
	340	345 350
5	Ala Glu Leu Ile Leu Pro Asn Gly Gln Glu Val Asp Ile Pro Ile Ser	
	355	360 365
	Tyr Leu Ala Ser Val Ser Ser Leu Ile Val Trp His Pro Ala Asn Pro	
	370	375 380
10	Ala Glu Lys Ile Ile Arg Val Leu Phe Pro Gly Asn Ser Thr Gln Tyr	
	385	390 395 400
	Asn Ile Leu Glu Gly Leu Glu Lys Leu Lys His Leu Asp Phe Leu Lys	
	405	410 415
15	Gln Pro Leu Ala Thr Gln Lys Asp Leu Thr Gly Gln Val Ser Thr Pro	
	420	425 430
	Pro Val Lys Gln Val Lys Leu Lys Gln Arg Ala Asp Ser Arg Glu Ser	
20	435	440 445
	Leu Lys Pro Ala Thr Lys Pro Leu Ser Ser Lys Ser Val Arg Lys Glu	
	450	455 460
	Ser Lys Glu Glu Ala Pro Glu Ala Thr Lys Ala Ser Gln Val Glu Lys	
25	465	470 475 480
	Thr Pro Lys Val Glu Ser Lys Glu Lys Val Ile Val Lys Lys Asp Lys	
	485	490 495
	Pro Gly Lys Val Glu Ser Lys Pro Ser Val Thr Glu Lys Glu Val Pro	
30	500	505 510
	Ser Lys Glu Glu Gln Ser Pro Val Lys Ala Glu Val Ala Glu Lys Ala	
	515	520 525
	Ala Thr Glu Ser Lys Pro Lys Val Thr Lys Asp Lys Val Val Lys Lys	
35	530	535 540
	Glu Ile Lys Thr Lys Pro Glu Glu Lys Lys Glu Glu Lys Pro Lys Lys	
	545	550 555 560
	Glu Val Ala Lys Lys Glu Asp Lys Thr Pro Leu Lys Lys Asp Glu Lys	
40	565	570 575
	Pro Lys Lys Glu Glu Ala Lys Lys Glu Ile Lys Lys Glu Ile Lys Lys	
	580	585 590
45	Glu Glu Lys Lys Glu Leu Lys Lys Glu Val Lys Lys Glu Thr Pro Leu	
	595	600 605
	Lys Asp Ala Lys Lys Glu Val Lys Lys Asp Glu Lys Lys Glu Val Lys	
	610	615 620
50	Lys Glu Glu Lys Glu Pro Lys Lys Glu Ile Lys Lys Ile Ser Lys Asp	
	625	630 635 640
	Ile Lys Lys Ser Thr Pro Leu Ser Asp Thr Lys Lys Pro Ala Ala Leu	
	645	650 655
55	Lys Pro Lys Val Ala Lys Lys Glu Glu Pro Thr Lys Lys Glu Pro Ile	

EP 1 284 298 A2

	660	665	670
	Ala Ala Gly Lys Leu Lys Asp Lys Gly Lys Val Lys Val Ile Lys Lys		
	675	680	685
5	Glu Gly Lys Thr Thr Glu Ala Ala Ala Thr Ala Val Gly Thr Ala Ala		
	690	695	700
	Val Ala Ala Ala Ala Gly Val Ala Ala Ser Gly Pro Ala Lys Glu Leu		
10	705	710	715
	Glu Ala Glu Arg Ser Leu Met Ser Ser Pro Glu Asp Leu Thr Lys Asp		
	725	730	735
	Phe Glu Glu Leu Lys Ala Glu Glu Ile Asp Val Ala Lys Asp Ile Lys		
15	740	745	750
	Pro Gln Leu Glu Leu Ile Glu Asp Glu Glu Lys Leu Lys Glu Thr Glu		
	755	760	765
	Pro Gly Glu Ala Tyr Val Ile Gln Lys Glu Thr Glu Val Ser Lys Gly		
20	770	775	780
	Ser Ala Glu Ser Pro Asp Glu Gly Ile Thr Thr Thr Glu Gly Glu Gly		
	785	790	795
	Glu Cys Glu Gln Thr Pro Glu Glu Leu Glu Pro Val Glu Lys Gln Gly		
25	805	810	815
	Val Asp Asp Ile Glu Lys Phe Glu Asp Glu Gly Ala Gly Phe Glu Glu		
	820	825	830
	Ser Ser Glu Ala Gly Asp Tyr Glu Glu Lys Ala Glu Thr Glu Glu Ala		
30	835	840	845
	Glu Glu Pro Glu Glu Asp Gly Glu Asp Asn Val Ser Gly Ser Ala Ser		
	850	855	860
	Lys His Ser Pro Thr Glu Asp Glu Glu Ile Ala Lys Ala Glu Ala Asp		
35	865	870	875
	Val His Ile Lys Glu Lys Arg Glu Ser Val Ala Ser Gly Asp Asp Arg		
	885	890	895
	Ala Glu Glu Asp Met Asp Glu Ala Leu Glu Lys Gly Glu Ala Glu Gln		
40	900	905	910
	Ser Glu Glu Glu Gly Glu Glu Glu Glu Asp Lys Ala Glu Asp Ala Arg		
	915	920	925
	Glu Glu Asp His Glu Pro Asp Lys Thr Glu Ala Glu Asp Tyr Val Met		
45	930	935	940
	Ala Val Val Asp Lys Ala Ala Glu Ala Gly Val Thr Glu Asp Gln Tyr		
	945	950	955
	Asp Phe Leu Gly Thr Pro Ala Lys Gln Pro Gly Val Gln Ser Pro Ser		
50	965	970	975
	Arg Glu Pro Ala Ser Ser Ile His Asp Glu Thr Leu Pro Gly Gly Ser		
	980	985	990
55			

EP 1 284 298 A2

	Glu Ser Glu Ala Thr Ala Ser Asp Glu Glu Asn Arg Glu Asp Gln Pro	995	1000	1005
5	Glu Glu Phe Thr Ala Thr Ser Gly Tyr Thr Gln Ser Thr Ile Glu Ile	1010	1015	1020
	Ser Ser Glu Pro Thr Pro Met Asp Glu Met Ser Thr Pro Arg Asp Val	1025	1030	1035
10	Met Thr Asp Glu Thr Asn Asn Glu Glu Thr Glu Ser Pro Ser Gln Glu	1045	1050	1055
	Phe Val Asn Ile Thr Lys Tyr Glu Ser Ser Leu Tyr Ser Gln Glu Tyr	1060	1065	1070
15	Ser Lys Pro Val Val Ala Ser Phe Asn Gly Leu Ser Asp Gly Ser Lys	1075	1080	1085
	Thr Asp Ala Thr Asp Gly Arg Asp Tyr Asn Ala Ser Ala Ser Thr Ile	1090	1095	1100
20	Ser Pro Pro Ser Ser Met Glu Glu Asp Lys Phe Ser Lys Ser Ala Leu	1105	1110	1115
	Arg Asp Ala Tyr Arg Pro Glu Glu Thr Asp Val Lys Thr Gly Ala Glu	1125	1130	1135
25	Leu Asp Ile Lys Asp Val Ser Asp Glu Arg Leu Ser Pro Ala Lys Ser	1140	1145	1150
	Pro Ser Leu Ser Pro Ser Pro Pro Ser Pro Ile Glu Lys Thr Pro Leu	1155	1160	1165
30	Gly Glu Arg Ser Val Asn Phe Ser Leu Thr Pro Asn Glu Ile Lys Ala	1170	1175	1180
	Ser Ala Glu Gly Glu Ala Thr Ala Val Val Ser Pro Gly Val Thr Gln	1185	1190	1195
35	Ala Val Val Glu Glu His Cys Ala Ser Pro Glu Glu Lys Thr Leu Glu	1205	1210	1215
	Val Val Ser Pro Ser Gln Ser Val Thr Gly Ser Ala Gly His Thr Pro	1220	1225	1230
40	Tyr Tyr Gln Ser Pro Thr Asp Glu Lys Ser Ser His Leu Pro Thr Glu	1235	1240	1245
	Val Thr Glu Asn Ala Gln Ala Val Pro Val Ser Phe Glu Phe Thr Glu	1250	1255	1260
45	Ala Lys Asp Glu Asn Glu Arg Ser Ser Ile Ser Pro Met Asp Glu Pro	1265	1270	1275
	Val Pro Asp Ser Glu Ser Pro Ile Glu Lys Val Leu Ser Pro Leu Arg	1285	1290	1295
50	Ser Pro Pro Leu Ile Gly Ser Glu Ser Ala Tyr Glu Asp Phe Leu Ser	1300	1305	1310
	Ala Asp Asp Lys Ala Leu Gly Arg Arg Ser Glu Ser Pro Phe Glu Gly	1315	1320	1325
55				

EP 1 284 298 A2

Lys Asn Gly Lys Gln Gly Phe Ser Asp Lys Glu Ser Pro Val Ser Asp
 1330 1335 1340
 5 Leu Thr Ser Asp Leu Tyr Gln Asp Lys Gln Glu Glu Lys Arg Ala Gly
 1345 1350 1355 1360
 Phe Ile Pro Ile Lys Glu Asp Phe Ser Pro Glu Lys Lys Ala Ser Asp
 1365 1370 1375
 10 Ala Glu Ile Met Ser Ser Gln Ser Ala Leu Ala Leu Asp Glu Arg Lys
 1380 1385 1390
 Leu Gly Gly Asp Gly Ser Pro Thr Gln Val Asp Val Ser Gln Phe Gly
 1395 1400 1405
 15 Ser Phe Lys Glu Asp Thr Lys Met Ser Ile Ser Glu Gly Thr Val Ser
 1410 1415 1420
 Asp Lys Ser Ala Thr Pro Val Asp Glu Gly Ala Glu Asp Thr Tyr Ser
 1425 1430 1435 1440
 20 His Met Glu Gly Val Ala Ser Val Ser Thr Ala Ser Val Ala Thr Ser
 1445 1450 1455
 Ser Phe Pro Glu Pro Thr Thr Asp Asp Val Ser Pro Ser Leu His Ala
 1460 1465 1470
 25 Glu Val Gly Ser Pro His Ser Thr Glu Val Asp Asp Ser Leu Ser Val
 1475 1480 1485
 Ser Val Val Gln Thr Pro Thr Thr Phe Gln Glu Thr Glu Met Ser Pro
 1490 1495 1500
 30 Ser Lys Glu Glu Cys Pro Arg Pro Met Ser Ile Ser Pro Pro Asp Phe
 1505 1510 1515 1520
 Ser Pro Lys Thr Ala Lys Ser Arg Thr Pro Val Gln Asp His Arg Ser
 1525 1530 1535
 35 Glu Gln Ser Ser Met Ser Ile Glu Phe Gly Gln Glu Ser Pro Glu His
 1540 1545 1550
 Ser Leu Ala Met Asp Phe Ser Arg Gln Ser Pro Asp His Pro Thr Val
 1555 1560 1565
 Gly Ala Gly Met Leu His Ile Thr Glu Asn Gly Pro Thr Glu Val Asp
 1570 1575 1580
 45 Tyr Ser Pro Ser Asp Ile Gln Asp Ser Ser Leu Ser His Lys Ile Pro
 1585 1590 1595 1600
 Pro Thr Glu Glu Pro Ser Tyr Thr Gln Asp Asn Asp Leu Ser Glu Leu
 1605 1610 1615
 50 Ile Ser Val Ser Gln Val Glu Ala Ser Pro Ser Thr Ser Ser Ala His
 1620 1625 1630
 Thr Pro Ser Gln Ile Ala Ser Pro Leu Gln Glu Asp Thr Leu Ser Asp
 1635 1640 1645
 55 Val Val Pro Pro Arg Asp Met Ser Leu Tyr Ala Ser Leu Ala Ser Glu

EP 1 284 298 A2

	1650	1655	1660
5	Lys Val Gln Ser Leu Glu Gly Glu Lys Leu Ser Pro Lys Ser Asp Ile 1665 1670 1675 1680		
	Ser Pro Leu Thr Pro Arg Glu Ser Ser Pro Thr Tyr Ser Pro Gly Phe 1685 1690 1695		
10	Ser Asp Ser Thr Ser Gly Ala Lys Glu Ser Thr Ala Ala Tyr Gln Thr 1700 1705 1710		
	Ser Ser Ser Pro Pro Ile Asp Ala Ala Ala Glu Pro Tyr Gly Phe 1715 1720 1725		
15	Arg Ser Ser Met Leu Phe Asp Thr Met Gln His His Leu Ala Leu Ser 1730 1735 1740		
	Arg Asp Leu Thr Thr Ser Ser Val Glu Lys Asp Asn Gly Gly Lys Thr 1745 1750 1755 1760		
20	Pro Gly Asp Phe Asn Tyr Ala Tyr Gln Lys Pro Glu Ser Thr Thr Glu 1765 1770 1775		
	Ser Pro Asp Glu Glu Asp Tyr Asp Tyr Glu Ser His Glu Lys Thr Ile 1780 1785 1790		
25	Gln Ala His Asp Val Gly Gly Tyr Tyr Tyr Glu Lys Thr Glu Arg Thr 1795 1800 1805		
	Ile Lys Ser Pro Cys Asp Ser Gly Tyr Ser Tyr Glu Thr Ile Glu Lys 1810 1815 1820		
30	Thr Thr Lys Thr Pro Glu Asp Gly Gly Tyr Ser Cys Glu Ile Thr Glu 1825 1830 1835 1840		
	Lys Thr Thr Arg Thr Pro Glu Glu Gly Gly Tyr Ser Tyr Glu Ile Ser 1845 1850 1855		
35	Glu Lys Thr Thr Arg Thr Pro Glu Val Ser Gly Tyr Thr Tyr Glu Lys 1860 1865 1870		
	Thr Glu Arg Ser Arg Arg Leu Leu Asp Asp Ile Ser Asn Gly Tyr Asp 1875 1880 1885		
40	Asp Thr Glu Asp Gly Gly His Thr Leu Gly Asp Cys Ser Tyr Ser Tyr 1890 1895 1900		
	Glu Thr Thr Glu Lys Ile Thr Ser Phe Pro Glu Ser Glu Ser Tyr Ser 1905 1910 1915 1920		
45	Tyr Glu Thr Thr Thr Lys Thr Thr Arg Ser Pro Asp Thr Ser Ala Tyr 1925 1930 1935		
	Cys Tyr Glu Thr Met Glu Lys Ile Thr Lys Thr Pro Gln Ala Ser Thr 1940 1945 1950		
50	Tyr Ser Tyr Glu Thr Ser Asp Arg Cys Tyr Thr Pro Glu Arg Lys Ser 1955 1960 1965		
	Pro Ser Glu Ala Arg Gln Asp Val Asp Leu Cys Leu Val Ser Ser Cys 1970 1975 1980		
55			

EP 1 284 298 A2

Glu Phe Lys His Pro Lys Thr Glu Leu Ser Pro Ser Phe Ile Asn Pro
 1985 1990 1995 2000
 5 Asn Pro Leu Glu Trp Phe Ala Gly Glu Glu Pro Thr Glu Glu Ser Glu
 2005 2010 2015
 Arg Pro Leu Thr Gln Ser Gly Gly Ala Pro Pro Pro Ser Gly Gly Lys
 2020 2025 2030
 10 Gln Gln Gly Arg Gln Cys Asp Glu Thr Pro Pro Thr Ser Val Ser Glu
 2035 2040 2045
 Ser Ala Pro Ser Gln Thr Asp Ser Asp Val Pro Pro Glu Thr Glu Glu
 2050 2055 2060
 15 Cys Pro Ser Ile Thr Ala Asp Ala Asn Leu Asp Ser Glu Asp Glu Ser
 2065 2070 2075 2080
 Glu Thr Ile Pro Thr Asp Lys Thr Val Thr Tyr Lys His Met Asp Pro
 2085 2090 2095
 20 Pro Pro Ala Pro Met Gln Asp Arg Ser Pro Ser Pro Arg His Pro Asp
 2100 2105 2110
 Val Ser Met Val Asp Pro Glu Ala Leu Ala Ile Glu Gln Asn Leu Gly
 2115 2120 2125
 25 Lys Ala Leu Lys Lys Asp Leu Lys Glu Lys Ala Lys Thr Lys Lys Pro
 2130 2135 2140
 Gly Thr Lys Thr Lys Ser Ser Ser Pro Val Lys Lys Gly Asp Gly Lys
 2145 2150 2155 2160
 30 Ser Lys Pro Ser Ala Ala Ser Pro Lys Pro Gly Ala Leu Lys Glu Ser
 2165 2170 2175
 Ser Asp Lys Val Ser Arg Val Ala Ser Pro Lys Lys Lys Glu Ser Val
 2180 2185 2190
 35 Glu Lys Ala Met Lys Thr Thr Thr Thr Pro Glu Val Lys Ala Thr Arg
 2195 2200 2205
 Gly Glu Glu Lys Asp Lys Glu Thr Lys Asn Ala Ala Asn Ala Ser Ala
 2210 2215 2220
 40 Ser Lys Ser Val Lys Thr Ala Thr Ala Gly Pro Gly Thr Thr Lys Thr
 2225 2230 2235 2240
 Ala Lys Ser Ser Thr Val Pro Pro Gly Leu Pro Val Tyr Leu Asp Leu
 2245 2250 2255
 45 Cys Tyr Ile Pro Asn His Ser Asn Ser Lys Asn Val Asp Val Glu Phe
 2260 2265 2270
 Phe Lys Arg Val Arg Ser Ser Tyr Tyr Val Val Ser Gly Asn Asp Pro
 2275 2280 2285
 50 Ala Ala Glu Glu Pro Ser Arg Ala Val Leu Asp Ala Leu Leu Glu Gly
 2290 2295 2300
 Lys Ala Gln Trp Gly Ser Asn Met Gln Val Thr Leu Ile Pro Thr His
 2305 2310 2315 2320

EP 1 284 298 A2

Asp Ser Glu Val Met Arg Glu Trp Tyr Gln Glu Thr His Glu Lys Gln
2325 2330 2335

Gln Asp Leu Asn Ile Met Val Leu Ala Ser Ser Ser Thr Val Val Met
2340 2345 2350

Gln Asp Glu Ser Phe Pro Ala Cys Lys Ile Glu Leu
2355 2360

<210> 67
<211> 7095
<212> DNA
<213> Rattus norvegicus

<220>
<223> Microtubule associated protein IB

<400> 67
ggacaaaaga tcctccatca ccgaagtgc gtcttagaaa ctgtagttct gatcaaccct 60
tcggatgaag cagtcagcac cgaggtgcgt ttgatgatca ctgacgccgc ccgccataaa 120
ctgctgggtgc tcaccggaca gtgctttgag aacactggag agctcatcct ccagtcaggc 180
tctttctcct tccagaactt catagagatt ttcaccgacc aagagattgg ggagctccta 240
agcaccaccc atcctgcca caaagccagc ctcaccctct tctgccctga ggaaggagac 300
tggaagaact ccaaccttga cagacacaat ctccaagact tcatcaacat caagctcaac 360
tcagcttcta tcttgccaga aatggaggga ctttctgagt tcaccgagta cctctcggag 420
tctgtcgaag tcccctcccc ctttgacatc ctggagcccc cgacctcggg cggatttctg 480
aagctctcca agccttgttg ttacattttt ccgggggggc gcgggggactc tgcctgttgc 540
gcagtgaaac gattcaacat gctcattaac ggaggatcag aaagaaagtc ctgcttctgg 600
aagctcattc ggcacttgga ccgggtggac tccatcctgc tcaccacat tggggatgac 660
aacttgcccc ggatcaacag catgttgcaa cgcaagattg cagagctgga agaggagtc 720
acaggctcca ccagcaacag tgactggatg aaaaacctca tctcccctga cttgggggtt 780
gtgtttctca atgtacctga aaatctgaaa aaccacagac ccaacatcaa gatgaagaga 840
agtacagaag aagcatgctt caccctccag tacctaaca aactgtccat gaaaccagag 900
cctttattta gaagtgtagg caatgccatt gagcctgtca tcctgttcca aaaaatggga 960
tggggtaaac tgaagatgta tgtgcttaac ccagtcaaaa gcagcaagga aatgcagtat 1020
ttcatgcagc agtggactgg aaccaacaaa gacaaggctg aacttatcct gcccaatgg 1080
caagaagtag acatcccgat ttcctaccta gcttccgtct cgtctttgat tgtgtggcac 1140
ccagccaacc ctgctgagaa aatcatccgg gttctgtttc ctggaaacag caccagtag 1200
aacatcctag aagggtgga aaaactcaaa catctagact tcctaagca gccactggcc 1260
acccaaaag atctcactgg ccaggtgtcc accccccag tgaaacaggt caagttgaaa 1320
cagcgggctg acagccgaga gagtctgaag ccagccacaa aaccactttc cagtaaatca 1380
gtgaggaagg agtccaaaga ggaggcccct gaagccacaa aagccagcca agtggaaaaa 1440
acacccaaaag ttgaaagcaa agagaaagt atagtgaaga aagacaagcc aggaaggta 1500
gaaagtaagc catcggtgac ggaaaaggag gtgccagca aagaggagca gtcgcccgtc 1560
aaagctgagg tggctgagaa ggcggccacg gagagcaaac ccaaagtcac caaagacaaa 1620
gtggtaaaaa aggaataaaa gacaaaaccc gaagaaaga aagaggagaa gcccaagaa 1680
gaagtggcta aaaaggaaga caaaactccc ctcaagaaag acgagaagcc caaaaaggaa 1740
gaggcgaaga aggagatcaa gaaagaaatc aaaaaggga agaaaaagga gctgaagaaa 1800
gaggtgaaga aggaacgcc cctgaaggac gccagaagg aggtgaagaa agacgagaag 1860
aaagaagtta aaaaggaaga gaaggaaccc aaaaaggaga ttaagaagat cccaaggac 1920
ataaagaaat ccaactcctt gtcagacaca aagaaaccgg ctgcattgaa accaaaagta 1980
gcaaagaaag aagagccac caagaaggag cctattgctg ctgggaaact caaggacaag 2040
gggaagggtca aagtcattaa aaaggaaggc aagaccacag aggccgctgc cacagctgtt 2100
ggcactgctg ccgtggctgc agcagccgga gtagcggcca gcggtcctgc caaagaactt 2160
gaagctgagc ggtccctcat gtcgtccctt gaggatctaa ccaaggactt tgaggagcta 2220
aaggctgagg agatcgtatg agcgaaggac atcaagcctc agctygagct cattgaagat 2280
gaagagaac tgaaggaaac cgagccggga gaagcctacg tcattcagaa agagacggaa 2340
gtcagcaaa gttctgtga gtcacctgat gaaggatca ccaccactga yggggaaagg 2400
gagtgcgagc aaacccccga ggagctggag ccagttgaga agcaggcggt ggatgacatc 2460
gagaagttcg aggatgaagg cgtctgtttt gaagaatcct cagaggccgg agactacgaa 2520

	gagaaggcag	aaactgagga	ggccgaggag	ccggaagaag	acggggaaga	caatgtgagc	2580
	gggagcgct	cgaagcacag	ccccacagaa	gacgaagaaa	tcgctaaggc	tgaggcggac	2640
	gtacacatca	aggagaagag	ggagtctgtg	gccagcggcg	atgaccgggc	cgaagaagac	2700
	atggatgaag	cgcttgagaa	aggagaagct	gaacagtctg	aggaggagg	tgaggaggag	2760
5	gaggacaaag	cagaggacgc	cagagaggaa	gacctgagc	ccgacaaaac	tgaggctgaa	2820
	gattatgtga	tggtgtggt	tgacaaggcc	gcggaggccg	gagtcaccga	ggatcagtat	2880
	gatttctctg	ggacaccggc	caagcaacct	ggagtccagt	ctcctagccg	agaaccccg	2940
	tcttcaattc	atgatgagac	cctacccgga	ggctccgaga	gcgaggccac	tgcttcagat	3000
	gaggagaatc	gagaagacca	gcctgaggaa	ttcactgcta	cctccggata	tactcagtc	3060
10	accatcgaga	tatctagtga	gccgactcca	atggatgaga	tgtccactcc	tcgagatgtg	3120
	atgaccgacg	agaccaacaa	tgaggagaca	gagtccccgt	ctcaggagtt	cgtgaacatt	3180
	accaaatacg	agtcttcgct	gtactctcag	gagtactcca	aacctgtggt	tgcatcattc	3240
	aatggattgt	cagacgggtc	aaagacagac	gccactgacg	gtagggatta	caacgcttcc	3300
	gcctccacca	tatcaccacc	ttcgtccatg	acagaagaca	aattcagcaa	gtctgtctct	3360
	cgtgacgctt	accgcccaga	agagacggac	gtgaaaaccg	gtgccgagtt	ggacatcaaa	3420
15	gatgtttcgg	atgagagact	tagcccagcc	aagagtccat	ccctgagtc	ttctccacca	3480
	tcacccatag	agaagactcc	cctgggtgaa	cgtagcgtga	atttctctct	gacacccaac	3540
	gagatcaaag	cctctgcaga	gggagaggca	acagcagtag	tgtcccccg	agtgacccaa	3600
	gcagtgttg	aagaacactg	tgccagtcc	gaggagaaga	ccttgagggt	agtgtcaccg	3660
	tctcagtcctg	tgacaggcag	tgccggccac	acaccttact	accaatctcc	caccgacgaa	3720
	aagtccagtc	acctacctac	agaagtcact	gagaacgcgc	aggcagtcct	ggtgagcttt	3780
20	gaattcactg	aggccaaaga	tgagaacgag	aggtcgtcca	tcagcccat	ggatgaacct	3840
	gtgcctgact	cagagtctcc	tatcgagaaa	gttctgtctc	cgttacgcag	ccctccctct	3900
	attggatccg	agtcgcgata	tgaagacttc	ctgagtgcgg	atgacaaggc	tcttggcaga	3960
	cgttcagaaa	gcccctttga	agggaagaat	ggaaagcaag	gcttctcaga	caaagaaagc	4020
	ccagtttctg	acctgacttc	cgatctttac	caagacaagc	aggaagagaa	aaggcgccgc	4080
25	ttcataccga	taaagggaag	ctttagtcca	gaaaagaaa	ccagcgatgc	tgaaatcatg	4140
	agttctcaat	cagctctggc	tttggatgaa	aggaaactgg	gaggagatgg	atctccaacg	4200
	caagtagatg	tcagtcagtt	tggtctcttc	aaagaagaca	ccaagatgtc	catttcggaa	4260
	ggcaccgttt	cagacaagtc	cgccacgcct	gtggatgagg	gcgcggaaga	cacctattca	4320
	cacatggaag	gtgtggcctc	agtgtcaacg	gcctctgtgg	ctaccagctc	gtttccagag	4380
	ccaaccacag	atgacgtgtc	tccttctctc	cacgctgaag	tgggtctctc	acattccaca	4440
30	gaggtggatg	actccctgtc	ggtgtcggcg	gtgcaaacac	caactacttt	ccaggaaaca	4500
	gaaatgtctc	cgctctaaaga	agagtgccta	agaccaatgt	cgatttctct	tcctgacttc	4560
	tcccctaaga	cagccaaatc	caggacacca	gttcaagatc	accgatccga	acagtcttca	4620
	atgtctattg	aattcgggtc	ggaatcccc	gagcattctc	ttgctatgga	ctttagtcgg	4680
	cagtctccag	accaccttac	tgtgggtgct	ggtatgcttc	acatcaccca	aaatgggcca	4740
	actgaggtgg	actacagtcc	ctccgatatc	caggactcta	gtttgtcaca	taagattcct	4800
35	cctacagaag	agccatccta	caccacggat	aatgatctgt	ccgagctcat	ctctgtgtct	4860
	caggtggagg	cttccccatc	caactcttct	gtcacactc	cttctcagat	agctctctct	4920
	cttcaggaag	acactctctc	tgatgtcggt	cctcccagag	atatgtcctt	atatgcctcg	4980
	cttgcgctcg	agaaagtgc	gagcctggaa	ggagagaaac	tctctccaaa	atccgatatt	5040
	tctccgctca	cccctcgaga	gtcctcacct	acatattcac	ctggcttttc	agattctacc	5100
	tctggagcta	aagagagtac	agcgggttac	caaacctcct	cttccccacc	aatagatgca	5160
40	gcagccgcag	agccctacgg	cttccgctcc	tcaatgttat	ttgatacaat	gcagcatcac	5220
	ctggccttga	gtagagattt	gaccacatct	agtgtggaga	aggacaatgg	agggagagaa	5280
	cccggtgact	ttactatgac	ctatcaaaa	cccagagaca	ccaccgaatc	cccagatgaa	5340
	gaagattatg	actatgaatc	tcacgagaaa	accatccagg	cccacgatgt	gggtggttac	5400
	tactatgaga	agacagagag	aaccataaaa	tcccctatgt	acagtggata	ctcctatgag	5460
45	accattgaga	agaccaccaa	gaccccagaa	gatgggtggc	actcctgtga	aattaccgag	5520
	aaaaccactc	ggacccttga	agagggcggg	tactcgtatg	agatcagcga	gaagacaaca	5580
	cgaaccctcg	aagtaagtyg	ctacacctat	gagaagacgg	agaggtccag	aaggctcctc	5640
	gatgacatta	gcaatggcta	cgatgacact	gaggatgggt	gccacacact	tggcgactgt	5700
	agctattcct	acgaaaccac	tgagaaaatt	accagctttc	ctgaatctga	aagctattcc	5760
	tatgagacaa	ctacaaaaac	aacacggagt	ccagacacct	ctgcatactg	ttacgagacc	5820
50	atggagaaga	tcaccaagac	cccacaggca	tccacatact	cctatgagac	ctcagaccga	5880
	tgctacactc	cagaaaggaa	gtccccctcg	gaggcacgcc	aggatgttga	cttgtgtctg	5940
	gtgtcctcct	gtgaattcaa	gcatcccaag	accgagctct	caccttctct	cattaatcca	6000
	aacctctctg	agtgttttgc	tgggggaagag	cccactgaag	aatctgagag	gcctctcact	6060
	cagtctggag	gagccccccc	accttcagga	ggaaaacaac	agggcagaca	atgcgatgaa	6120
	actccacca	cctcagtcag	tgagtcagct	ccatcccaga	cggactctga	tgttccccca	6180
55	gagacagaag	agtgtcccctc	catcacagct	gatgccaacc	ttgactctga	agatgagtc	6240

EP 1 284 298 A2

5
10
15

```

gaaaccatcc ccacagacaa aacgggttacg taaaaacaca tggacccgcc tccagccccc 6300
atgcaagacc gaagcccttc tcctcgccac cctgatgtgt ccatggtgga tccagaggcc 6360
ttggctattg agcagaacct aggcaaggct ctgaaaaagg atctgaagga gaaggccaag 6420
accaagaaac caggcacaaa gaccaagtcc tcttcacctg tcaaaaaggg tgatggggaag 6480
tccaagcctt cagcagcttc ccccaaacca ggagccttga aggaatcctc tgacaagggtg 6540
tccagagtgg cttctcccaa gaagaaagag tctgtggaga aagctatgaa gaccaccacc 6600
actcctgagg tcaaagccac acgaggggaa gagaaggaca aggaaactaa gaatgcagcc 6660
aatgcttctg catccaagtc agtgaagact gcaacagcag gaccaggaac cactaagacg 6720
gccaagtcgt ccaccgtgcc tcccgccctc cctgtgtatt tggacctctg ctatatctcc 6780
aaccacagca acagtaagaa tgtcgtatgt gagtttttca agagagttag gtcattctac 6840
tacgtggtga gtgggaacga ccctgccgcg gaggagccca gccgggctgt cctggatgcc 6900
ttgttggaag ggaaggctca gtggggaagc aacatgcagg tgactctgat cccaacacat 6960
gactctgagg tgatgaggga gtggtaccag gagaccacg agaagcagca agacctcaac 7020
atcatgggtc tagcaagcag tagtacagtg gtcatgcaag acgagtcctt ccctgcatgc 7080
aagatagaac tgtag                                     7095

```

20
25
30
35
40
45
50
55

```

<210> 68
<211> 379
<212> PRT
<213> Rattus norvegicus

<220>
<223> cdc 37 homolog

<400> 68
Met Val Asp Tyr Ser Val Trp Asp His Ile Glu Val Ser Asp Asp Glu
 1             5             10             15

Asp Glu Thr His Pro Asn Ile Asp Thr Ala Ser Leu Phe Arg Trp Arg
          20             25             30

His Gln Ala Arg Val Glu Arg Met Glu Gln Phe Gln Lys Glu Lys Glu
          35             40             45

Glu Leu Asp Arg Gly Cys Arg Glu Cys Lys Arg Lys Val Ala Glu Phe
 50             55             60

Gln Arg Lys Leu Lys Glu Leu Glu Val Ala Glu Gly Gly Gly Gln Val
 65             70             75             80

Glu Leu Glu Arg Leu Arg Ala Glu Ala Gln Gln Leu Arg Lys Glu Glu
          85             90             95

Arg Thr Gly Ser Arg Ser Trp Arg Thr Cys Gly Lys Lys Glu Lys Asn
          100            105            110

Met Pro Trp Asn Val Asp Thr Leu Ser Lys Asp Gly Phe Ser Lys Ser
          115            120            125

Met Val Asn Thr Lys Pro Glu Lys Ala Glu Glu Asp Ser Glu Glu Ala
          130            135            140

Arg Glu Gln Lys His Lys Thr Phe Val Glu Lys Tyr Glu Lys Gln Ile
          145            150            155            160

Lys His Phe Gly Met Leu His Arg Trp Asp Asp Ser Gln Lys Tyr Leu
          165            170            175

Ser Asp Asn Val His Leu Val Cys Glu Glu Thr Ala Asn Tyr Leu Val
          180            185            190

```

EP 1 284 298 A2

Ile Trp Cys Ile Asp Leu Glu Val Glu Glu Lys Cys Ala Leu Met Glu
195 200 205

5 Gln Val Ala His Gln Thr Met Val Met Gln Phe Ile Leu Glu Leu Ala
210 215 220

Lys Ser Leu Lys Val Asp Pro Arg Ala Cys Phe Arg Gln Phe Phe Thr
225 230 235 240

10 Lys Ile Lys Thr Ala Asp Gln Gln Tyr Met Glu Gly Phe Lys Tyr Glu
245 250 255

Leu Glu Ala Phe Lys Glu Arg Val Arg Gly Arg Ala Lys Leu Arg Ile
260 265 270

15 Glu Lys Ala Met Lys Glu Tyr Glu Glu Glu Glu Arg Lys Lys Arg Leu
275 280 285

Gly Pro Gly Gly Leu Asp Pro Val Glu Val Tyr Glu Ser Leu Pro Glu
290 295 300

20 Glu Leu Gln Lys Cys Phe Asp Val Lys Asp Val Gln Met Leu Gln Asp
305 310 315 320

Ala Ile Ser Lys Met Asp Pro Thr Asp Ala Lys Tyr His Met Gln Arg
325 330 335

25 Cys Ile Asp Ser Gly Leu Trp Val Pro Asn Ser Lys Ser Gly Glu Ala
340 345 350

Lys Glu Gly Glu Glu Ala Gly Pro Gly Asp Pro Leu Leu Glu Ala Val
355 360 365

30 Pro Lys Ala Gly Phe Glu Lys Asp Ile Ser Ala
370 375

<210> 69
<211> 1604
<212> DNA
<213> Rattus norvegicus

<220>
<223> cdc 37 homolog

<400> 69
cgagcggact ctctagccct tgtgggtccc tgttcagcgc ccggccgtgt ggagacccgg 60
gagccagtcc gggcctccga ggcgaagatg gtggactaca gcgtttggga tcacatcgag 120
gtgtcggacg atgaggacga gacgcacccc aacatagaca cggccagcct gttccgctgg 180
45 cggcaccagg cccgggtgga acgcatggaa cagtttcaga aggagaaaaga agaactggac 240
cggggctgcc gggaaatgcaa gcgcaaggta gccgagttcc agcgcaagct gaaggaaactg 300
gaagtggctg aggggtgggtg ccaggtggag cttgagcggc ttcgagcggg ggcacagcag 360
ctgcgcaagg aggagcgaaac tgggagcaga agctggagga catgcggaac aaaggagaag 420
aacatgccct ggaatgtgga cacactcagc aaagatggct tcagcaagag catggtcaat 480
accaagcctg agaaggcaga ggaagactca gaggaggcaa gggagcagaa acacaagacc 540
50 ttcgttgaaa aatacgagaa acagatcaaa catttcggca tgctccaccg ctgggatgac 600
agccagaagt acctgtcaga caatgtccac ctggtgtgcy aggagacagc caactacctg 660
gttatctggt gcattgacct ggaagtgcag gagaagtgtg ccttgatgga gcaggtggct 720
caccagacca tggtcatgca gttcactctg gagttggcca agagtctgaa ggtcgacccc 780
cgggcctgct tccggcagtt tttcaccaag atcaagactg ctgaccagca gtacatggag 840
ggcttcaagt atgaactgga ggcctttaag gagcgtgtgc ggggcccgcg caagctgcga 900
55 atagagaagg ccatgaagga gtacqaggag gaggagcgca agaagaggct aggccttggt 960

EP 1 284 298 A2

5 ggccctggacc ctgtggaggt ctacgaatct ctgcctgagg agctgcagaa gtgctttgat 1020
 gtgaaggatg tacagatgct gcaagacgcc atcagcaaga tggatcctac tgatgccaag 1080
 tatcacatgc agcgttgcac cgattctggc ctctgggtcc ccaactccaa gtctgttgag 1140
 gccaaaggagg gggaggaggc gggccccggg gacccattgc tggaaagccgt ccccaaagcg 1200
 ggcttcgaga aagacatcag tgcgtgaccc ttctccagaa aaggaaaccc agccaccatg 1260
 tccctagctc ccgacttctt cacttctgct gctcctcacg tcctggccca tggcctgccc 1320
 catgtccctt ctctcccgcc ctgtccccag cactcatcag attctctgct tcgggttgag 1380
 gggctctgct gtctgcagcc cccccacccc catcagcgtt atgccaaagt cctgggggtc 1440
 tggggaggggg cagcagctgc cagggttggtc caccgggttg gggatacaca tgtcccatc 1500
 10 tgggcagggt ctgtccctat ggggtctatg tcaactgttc tcttctgtct agctttctgt 1560
 cctgcaactg gcaacaatgt ccaataaaca gttccaggtg ctgg 1604

15 <210> 70
 <211> 216
 <212> PRT
 <213> Homo sapiens

<220>
 <223> Rab5c-like protein

20 <400> 70
 Met Ala Gly Arg Gly Gly Ala Arg Arg Pro Asn Gly Pro Ala Ala Gly
 1 5 10 15
 Asn Lys Ile Cys Gln Phe Lys Leu Val Leu Leu Gly Glu Ser Ala Val
 20 25 30
 25 Gly Lys Ser Ser Leu Val Leu Arg Phe Val Lys Gly Gln Phe His Glu
 35 40 45
 Tyr Gln Glu Ser Thr Ile Gly Ala Ala Phe Leu Thr Gln Thr Val Cys
 50 55 60
 30 Leu Asp Asp Thr Thr Val Lys Phe Glu Ile Trp Asp Thr Ala Gly Gln
 65 70 75 80
 Glu Arg Tyr His Ser Leu Ala Pro Met Tyr Tyr Arg Gly Ala Gln Ala
 85 90 95
 35 Ala Ile Val Val Tyr Asp Ile Thr Asn Thr Asp Thr Phe Ala Arg Ala
 100 105 110
 Lys Asn Trp Val Lys Glu Leu Gln Arg Gln Ala Ser Pro Asn Ile Val
 115 120 125
 40 Ile Ala Leu Ala Gly Asn Lys Ala Asp Leu Ala Ser Lys Arg Ala Val
 130 135 140
 Glu Phe Gln Glu Ala Gln Ala Tyr Ala Asp Asp Asn Ser Leu Leu Phe
 145 150 155 160
 Met Glu Thr Ser Ala Lys Thr Ala Met Asn Val Asn Glu Ile Phe Met
 165 170 175
 50 Ala Ile Ala Lys Lys Leu Pro Lys Asn Glu Pro Gln Asn Ala Thr Gly
 180 185 190
 Ala Pro Gly Arg Asn Arg Gly Val Asp Leu Gln Glu Asn Asn Pro Ala
 195 200 205
 55 Ser Arg Ser Gln Cys Cys Ser Asn

EP 1 284 298 A2

210

215

5
<210> 71
<211> 1529
<212> DNA
<213> Homo sapiens

10
<220>
<223> Rab5c-like protein

<400> 71
cttacactaa gtgcctcttt gcatagcacc agtccccacc cgcacgctct ctggaccact 60
acagctggac gggcaatggc gggtcgggga ggcgcacgac gacccaatgg accagctgct 120
gggaacaaga tctgtcaatt taagctgggt ctgctggggg agtctgcggt aggcaaatcc 180
15 agcctcgtcc tccgctttgt caagggacag ttccacgagt accaggagag cacaatttga 240
gcggccttcc tcacacagac tgtctgcctg gatgacacaa cagtcaagtt tgagatctgg 300
gacacagctg gacaggagcg gtatcacagc ctggccccca tgtactatcg gggggcccag 360
gctgccatcg tggctctatga catcaccaac acagatacat ttgcacgggc caagaactgg 420
gtgaaggagc lacagaggca ggccagcccc aacatcgtca ttgcactcgc gggtaacaag 480
gcagacctgg ccagcaagag agccgtggaa ttccaggaag cacaagccta tgcagacgac 540
20 aacagtttgc tgttcatgga gacatcagca aagactgcaa tgaacgtgaa cgaaatcttc 600
atggcaatag ctaagaagct tccaagaac gagccccaga atgcaactgg tgctccaggc 660
cgaaaccgag gtgtggacct ccaggagaac aaccagcca gccggagcca gtgctgcagc 720
aactgagccc cccttgctg cccgctgccc ccgcctcctc cgcctgaatg acccgactgg 780
aatccactct aaccaatcgc acttaacgac tcggggccacc actggggggg cagggggagg 840
25 ggtccaccat gattttctcca tataattttg atcataggcc ggagtgagtc attccactg 900
cacctttctg tacaaatact aattcaattt taagtcttaa gtcacttttt taatatatat 960
gatcttctgc tcttcccact tctcccctt tctactgctc tcccattttc ccttgctggg 1020
agtagccaca tgctcttgcc ccccaaccct tgtatatggg gacagtgggg tcagtgcagc 1080
taccctttct tccctctg cgaacagcgg accagcaag agcatccaca tctcacttt 1140
gttcggagtg gtctttgggt tgggcggtgg ggcagacctt gggaaggggc ttaggaaggg 1200
30 agaggcagct ctctcttcag ctggtctca tcaggctgca gcccctccc cgctcccacc 1260
tccctgctgg gaaaccacag cattatcaca gcattattgt gacagccacg aaccattg 1320
ccacaacccc tccacctcg gtcaccccaa cctctggctc tgagccctgt tctgaccaa 1380
tcatgatgat gagtatttgg ggggtgggtg gtaagggggg gagtgggagg ggacggaacc 1440
aactttttct gtattttgta ttgtatgttt tcttcaacat gtaaccaatc agtatcttgt 1500
caatatagtc agccgatcga tcgacctca 1529

35
<210> 72
<211> 731
<212> PRT
<213> Mus musculus

40
<220>
<223> Gelsolin

<400> 72
45 Met Val Val Glu His Pro Glu Phe Leu Lys Ala Gly Lys Glu Pro Gly
1 5 10 15
Leu Gln Ile Trp Arg Val Glu Lys Phe Asp Leu Val Pro Val Pro Pro
20 25 30
50 Asn Leu Tyr Gly Asp Phe Phe Thr Gly Asp Ala Tyr Val Ile Leu Lys
35 40 45
Thr Val Gln Leu Arg Asn Gly Asn Leu Gln Tyr Asp Leu His Tyr Trp
50 55 60
55 Leu Gly Asn Glu Cys Ser Gln Asp Glu Ser Gly Ala Ala Ala Ile Phe

EP 1 284 298 A2

	65		70		75		80									
	Thr	Val	Gln	Leu	Asp	Asp	Tyr	Leu	Asn	Gly	Arg	Ala	Val	Gln	His	Arg
					85					90					95	
5	Glu	Val	Gln	Gly	Phe	Glu	Ser	Ser	Thr	Phe	Ser	Gly	Tyr	Phe	Lys	Ser
				100					105					110		
	Gly	Leu	Lys	Tyr	Lys	Lys	Gly	Gly	Val	Ala	Ser	Gly	Phe	Lys	His	Val
10			115					120					125			
	Val	Pro	Asn	Glu	Val	Val	Val	Gln	Arg	Leu	Phe	Gln	Val	Lys	Gly	Arg
		130					135					140				
	Arg	Val	Val	Arg	Ala	Thr	Glu	Val	Pro	Val	Ser	Trp	Asp	Ser	Phe	Asn
15		145				150					155					160
	Asn	Gly	Asp	Cys	Phe	Ile	Leu	Asp	Leu	Gly	Asn	Asn	Ile	Tyr	Gln	Trp
				165						170					175	
	Cys	Gly	Ser	Gly	Ser	Asn	Lys	Phe	Glu	Arg	Leu	Lys	Ala	Thr	Gln	Val
20				180					185					190		
	Ser	Lys	Gly	Ile	Arg	Asp	Asn	Glu	Arg	Ser	Gly	Arg	Ala	Gln	Val	His
			195					200					205			
	Val	Ser	Glu	Glu	Glu	Thr	Glu	Pro	Glu	Ala	Met	Leu	Gln	Val	Leu	Gly
25		210					215					220				
	Pro	Lys	Pro	Ala	Leu	Pro	Glu	Gly	Thr	Glu	Asp	Thr	Ala	Lys	Glu	Asp
		225				230					235					240
	Ala	Ala	Asn	Arg	Lys	Leu	Ala	Lys	Leu	Tyr	Lys	Val	Ser	Asn	Gly	Ala
30					245					250					255	
	Gly	Ser	Met	Ser	Val	Ser	Leu	Val	Ala	Asp	Glu	Asn	Pro	Phe	Ala	Gln
			260						265					270		
	Gly	Pro	Leu	Arg	Ser	Glu	Asp	Cys	Phe	Ile	Leu	Asp	His	Gly	Arg	Asp
35		275					280					285				
	Gly	Lys	Ile	Phe	Val	Trp	Lys	Gly	Lys	Gln	Ala	Asn	Met	Glu	Glu	Arg
		290					295					300				
	Lys	Ala	Ala	Leu	Lys	Thr	Ala	Ser	Asp	Phe	Ile	Ser	Lys	Met	Gln	Tyr
40		305				310					315					320
	Pro	Arg	Gln	Thr	Gln	Val	Ser	Val	Leu	Pro	Glu	Gly	Gly	Glu	Thr	Pro
				325						330					335	
	Leu	Phe	Lys	Gln	Phe	Phe	Lys	Asn	Trp	Arg	Asp	Pro	Asp	Gln	Thr	Asp
45			340						345					350		
	Gly	Pro	Gly	Leu	Gly	Tyr	Leu	Ser	Ser	His	Ile	Ala	Asn	Val	Glu	Arg
		355					360						365			
	Val	Pro	Phe	Asp	Ala	Gly	Thr	Leu	His	Thr	Ser	Thr	Ala	Met	Ala	Ala
50		370				375						380				
	Gln	His	Gly	Met	Asp	Asp	Asp	Gly	Thr	Gly	Gln	Lys	Gln	Ile	Trp	Arg
55		385				390					395					400

EP 1 284 298 A2

	Ile	Glu	Gly	Ser	Asn	Lys	Val	Pro	Val	Asp	Pro	Ala	Thr	Tyr	Gly	Gln	
					405					410					415		
5	Phe	Tyr	Gly	Gly	Asp	Ser	Tyr	Ile	Ile	Leu	Tyr	Asn	Tyr	Arg	His	Gly	
				420					425					430			
	Gly	Arg	Gln	Gly	Gln	Ile	Ile	Tyr	Asn	Trp	Gln	Gly	Ala	Gln	Ser	Thr	
			435					440					445				
10	Gln	Asp	Glu	Val	Ala	Ala	Ser	Ala	Ile	Leu	Thr	Ala	Gln	Leu	Asp	Glu	
		450					455					460					
	Glu	Leu	Gly	Gly	Thr	Pro	Val	Gln	Ser	Arg	Val	Val	Gln	Gly	Lys	Glu	
	465				470					475					480		
15	Pro	Ala	His	Leu	Met	Ser	Leu	Phe	Gly	Gly	Lys	Pro	Met	Ile	Ile	Tyr	
				485					490					495			
	Lys	Gly	Gly	Thr	Ser	Arg	Asp	Gly	Gly	Gln	Thr	Ala	Pro	Ala	Ser	Ile	
			500					505						510			
20	Arg	Leu	Phe	Gln	Val	Arg	Ala	Ser	Ser	Ser	Gly	Ala	Thr	Arg	Ala	Val	
		515						520					525				
	Glu	Val	Met	Pro	Lys	Ser	Gly	Ala	Leu	Asn	Ser	Asn	Asp	Ala	Phe	Val	
		530					535					540					
25	Leu	Lys	Thr	Pro	Ser	Ala	Ala	Tyr	Leu	Trp	Val	Gly	Ala	Gly	Ala	Ser	
	545				550					555						560	
	Glu	Ala	Glu	Lys	Thr	Ala	Ala	Gln	Glu	Leu	Leu	Lys	Val	Leu	Arg	Ser	
				565					570						575		
30	Gln	His	Val	Gln	Val	Glu	Glu	Gly	Ser	Glu	Pro	Asp	Gly	Phe	Trp	Glu	
			580					585						590			
	Ala	Leu	Gly	Gly	Lys	Thr	Ser	Tyr	Arg	Thr	Ser	Pro	Arg	Leu	Lys	Asp	
		595					600						605				
35	Lys	Lys	Met	Asp	Ala	His	Pro	Pro	Arg	Leu	Phe	Ala	Cys	Ser	Asn	Arg	
		610				615						620					
	Ile	Gly	Arg	Phe	Val	Ile	Glu	Glu	Val	Pro	Gly	Glu	Leu	Met	Gln	Glu	
	625				630				635						640		
40	Asp	Leu	Ala	Thr	Asp	Asp	Val	Met	Leu	Leu	Asp	Thr	Trp	Asp	Gln	Val	
				645					650						655		
	Phe	Val	Trp	Val	Gly	Lys	Asp	Ser	Gln	Glu	Glu	Glu	Lys	Thr	Glu	Ala	
			660					665						670			
45	Leu	Thr	Ser	Ala	Lys	Arg	Tyr	Ile	Glu	Thr	Asp	Pro	Ala	Asn	Arg	Asp	
		675					680						685				
	Arg	Arg	Thr	Pro	Ile	Thr	Val	Val	Arg	Gln	Gly	Phe	Glu	Pro	Pro	Ser	
		690				695						700					
50	Phe	Val	Gly	Trp	Phe	Leu	Gly	Trp	Asp	Asn	Asn	Tyr	Trp	Ser	Val	Asp	
	705				710				715						720		
55	Pro	Leu	Asp	Arg	Ala	Leu	Ala	Glu	Leu	Ala	Ala						
				725					730								

<210> 73
 <211> 2447
 <212> DNA
 <213> Mus musculus

<220>
 <223> Gelsolin

10 <400> 73
 tgagcgcggc ccagcactat ggtggtggag caccgccaat tcctgaaggc aggggaaggag 60
 cctggcctgc agatctggcg tgtggagaag tttgacctgg tgccctgtgcc ccccaacctc 120
 tatggagact tcttcacggg tgatgcctat gtcacacctga agactgtgca gctgaggaat 180
 gggaatctgc agtatgacct ccactattgg ctgggcaatg aatgcagcca ggatgagagc 240
 15 ggggctgctg ccatctttac tgtgcaactg gatgactacc tgaacggccg ggctgtgcag 300
 caccgtgagg ttcagggcct tgagtcgtcc accttctccg gctacttcaa gtctggactt 360
 aagtacaaga aaggagggtg ggcattctgga ttcaaacacg tggtaaccaa tgaggtggtg 420
 gtccagaggc tcttccaggt caaaggacgc cgtgtagtc gtgctactga ggtacctgtg 480
 tcctgggaca gtttcaacaa tggcgactgc ttcattctgg acctgggaaa caatatctat 540
 cagtgtgtg gctctggcag caacaaattt gaaaggctga aggccacaca ggtgtccaag 600
 20 ggcatccggg acaacgagag gagtggccgt gctcaagtac acgtgtctga agaggagact 660
 gagcccgagg cgatgctgca ggtgctgggc cccaagccgg ctctgcctga aggtaccgag 720
 gacacagcca aggaagatgc agccaaccgc aagctggcca agctctacaa ggtctccaac 780
 ggtgcaggta gcatgtcagt ctccctagtg gctgatgaga acccttctgc ccagggggccc 840
 ctgagatctg aggactgctt catcctggac catggcagag atgggaaaat ctttgtttgg 900
 25 aaaggcaagc aggccaaacat ggaggagcgg aaggctgccc tcaaaacagc ctctgacttc 960
 atctccaaga tgcagtaccc caggcagacc cagggtttcag ttctcccaga gggcggtgag 1020
 acccctctct ttaagcagtt cttcaagaac tggcgggacc cagaccagac agatggcccc 1080
 ggccctgggt acctctccag ccacattgcc aacgtggagc gcgtaccttt cgatgccggc 1140
 acgctgcaca cctccaccgc catggccgct cagcacggca tggatgatga tggaaactggc 1200
 cagaaacaga tctggagaat tgaaggttcc aacaagggtc cagtggaccc tgccacatac 1260
 30 ggacagttct atggaggcga cagctacatc attctgtaca actaccgcca cgggtggcgc 1320
 cagggacaga tcatctacaa ctggcagggt gctcagctca cccaggatga ggttgctgct 1380
 tctgccatcc tgactgccc a gctggatgag gagctgggag gaactcctgt ccagagccga 1440
 gtgggtccaag gcaaaagagc tgcacacctc atgagcttgt ttggcgggaa gcccatgatc 1500
 atctacaagg gtggcacctc ccgtgatggt gggcagacag ctccctgccag tatccgcctc 1560
 ttccaagtgc gtgccagcag ctctggagcc accagggtgt tggaggtgat gcctaagtct 1620
 35 ggtgctctga actccaacga tgcttttgtg ctgaaaaccc cctccgctgc ctacctgtgg 1680
 gtgggcgag gagccagtga ggcagagaag acggcgggcc aggaactctt gaaggtcctt 1740
 cgggtcccagc atgtgcaggg ggaagaaggc agtgagccag atggcttctg ggaggctctg 1800
 ggcggaaga cgtcctaccg cacatcccc aggcctaagg acaagaagat ggatgcccat 1860
 cctcctcgac tctttgcctg ctccaacagg atcggacgct ttgtgatcga agaggttcct 1920
 ggcgagctta tgcaggaaga cctggctact gatgacgtca tgctcctgga cacctgggac 1980
 40 caggctctttg tctgggttgg aaaagactcc caggaagaag aaaagacgga agccttgact 2040
 tctgctaagc ggtacatcga gacagatcca gcaaatcggg acaggcggac ccccatcaca 2100
 gtcgtttaggc agggctttga gcctccttcc ttcgtgggct ggttcctcgg ctgggacaac 2160
 aactactggt cgggtggatcc tttggaccgg gccttggctg agctggctgc ctgagtaagg 2220
 accaagccat caatgtcacc aatcagtgcc tttgagggtt gtccatctcc caaagacatc 2280
 45 atatggcaag caggaaaact atgatgtgtg cgcgcgtgtt tttgtttttg ttttttacgg 2340
 tagccaaaac aagcccttgt ggaaactcag ggtctttaca gaattgcttc aaatgtctgt 2400
 actttggaaa tgaaagccaa taaaagcttt ttgaagtga aaaaaaa 2447

<210> 74
 <211> 236
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Cd81 antigen

EP 1 284 298 A2

<400> 74
Met Gly Val Glu Gly Cys Thr Lys Cys Ile Lys Tyr Leu Leu Phe Val
1 5 10 15

5 Phe Asn Phe Val Phe Trp Leu Ala Gly Gly Val Ile Leu Gly Val Ala
20 25 30

Leu Trp Leu Arg His Asp Pro Gln Thr Thr Thr Leu Leu Tyr Leu Glu
35 40 45

10 Leu Gly Asp Lys Pro Ala Pro Ser Thr Phe Tyr Val Gly Ile Tyr Ile
50 55 60

Leu Ile Ala Val Gly Ala Val Met Met Phe Val Gly Phe Leu Gly Cys
65 70 75 80

15 Tyr Gly Ala Ile Gln Glu Ser Gln Cys Leu Leu Gly Thr Phe Phe Thr
85 90 95

Cys Leu Val Ile Leu Phe Ala Cys Glu Val Ala Ala Gly Ile Trp Gly
100 105 110

20 Phe Val Asn Lys Asp Gln Ile Ala Lys Asp Val Lys Gln Phe Tyr Asp
115 120 125

Gln Ala Leu Gln Gln Ala Val Met Asp Asp Asp Ala Asn Asn Ala Lys
130 135 140

25 Ala Val Val Lys Thr Phe His Glu Thr Leu Asn Cys Cys Gly Ser Asn
145 150 155 160

Thr Leu Thr Thr Leu Thr Thr Ala Val Leu Arg Asn Ser Leu Cys Pro
165 170 175

30 Ser Ser Ser Asn Ser Phe Thr Gln Leu Leu Lys Glu Asp Cys His Gln
180 185 190

Lys Ile Asp Glu Leu Phe Ser Gly Lys Leu Tyr Leu Ile Gly Ile Ala
195 200 205

35 Ala Ile Val Val Ala Val Ile Met Ile Phe Glu Met Ile Leu Ser Met
210 215 220

Val Leu Cys Cys Gly Ile Arg Asn Ser Ser Val Tyr
225 230 235

40

<210> 75
<211> 1303
45 <212> DNA
<213> Rattus norvegicus

<220>
<223> Cd81 antigen

50 <400> 75
gtggcggtct gagcgagcgc gcccttgctt caaagcggta gcgactctag cgcctccggc 60
taggctccaa cccttctcta ccctacgtct caatagccac accgcagtct ccggcctcaa 120
gcgacccagg ctatcttcca gtcccgggac tccgggtact gcggtcccca gaaccgccc 180
tccagggacc aacccaagtt ccgcaggccg cggcgggcgc caatgggggt ggagggctgc 240
accaaatacga tcaaatacct gctcttcgtc ttcaatttcg tcttctggct ggctggaggt 300
55 gtgatcctag gtgtagctct gtgggtgcgc catgatccac agaccaccac cttgctctac 360

EP 1 284 298 A2

```

5 ctggaactgg gagacaaacc agcacctagc accttctatg tgggcatcta cattctcatt 420
  gctgtgggag ctgtgatgat gtttgttaggc ttcctggggg gctatggggc catccaggag 480
    tcccagtgcc tgctggggac gttcttctact tgccttgtga tcctgtttgc ctgtgaggta 540
      gctgcgggca tctggggcct tgtaaacaana gaccagatcg ccaaggatgt gaagcagttc 600
        tacgaccagg cccttcagca ggctgtgatg gatgatgatg ccaacaatgc caaggcagtg 660
          gtgaagacct tccatgagac gctcaactgt tgtggctcca atacgctgac cacactgacc 720
            accgccgtgc tgaggaacag cctgtgtccc tcaagcagca actcattcac tcagcttctg 780
              aaggaagact gccatcagaa aatcgatgag ctcttttctg ggaagctgta cctcattgga 840
                attgcagcca ttgtggtagc tgtcattatg atcttcgaga tgattctgag catgggtgctg 900
                  tgctgtggca tccggaacag ctccgtgtac tgaggccctt cgcttcgcac cagaggggtcc 960
                    ctggaatgac cagagggcac cttggggggc atggcctgtg tatatactat ttctgtatta 1020
                      ctctgtaca cttagccttt ttacttttga gtcttttttg ttctgaactt ttcctgtcac 1080
                        cttttggagc cgacaccaca cataggtggc gtatgtgggg acgtagaggt ggagctggcc 1140
                          ctacgggca gggccctgta cttctgggac ccttgagag ttctgcctgc tgagccaaac 1200
                            ctctccata gctacttgtc cagagggcac atagccaagc tagaaggcca tgtccaccca 1260
                              ctctgcccac tgtgggtcac atcgctccca tctttttaat ccg 1303

```

```

20 <210> 76
    <211> 81
    <212> PRT
    <213> Rattus norvegicus

```

```

25 <220>
    <223> MOBP-81 protein

    <400> 76
    Met Ser Gln Lys Val Ala Lys Glu Gly Pro Arg Leu Ser Lys Asn Gln
      1 5 10 15
    Lys Phe Ser Glu His Phe Ser Ile His Cys Cys Pro Pro Phe Thr Phe
      20 25 30
    Leu Asn Ser Lys Arg Glu Ile Val Asp Arg Lys Tyr Ser Ile Cys Lys
      35 40 45
    Ser Gly Cys Phe Tyr Gln Lys Lys Glu Glu Asp Trp Ile Cys Cys Ala
      50 55 60
    Cys Gln Lys Thr Arg Leu Arg Arg Arg Ser Arg Ser Thr Pro Arg Lys
      65 70 75 80
    Lys

```

```

45 <210> 77
    <211> 2405
    <212> DNA
    <213> Rattus norvegicus

```

```

50 <220>
    <223> MOBP-81 protein

    <400> 77
    ctttcacagc agccaataacc tgcaggggcaa caaagaatca aatgagagcg agacaagctg 60
      ggaatgaagt cctgggttgc agatgggagc ttgaaaacac agtaagatga gtcaaaaagt 120
        ggccaaggag ggccccaggc tctccaagaa ccagaagttc tcagagcact tcagcatcca 180
          ctgtgtccca cccttcacct tctcaactc caagcgtgag atcgtggacc gcaagtacag 240
            catctgcaag agcggttgct tttaccagaa gaaggaggag gactggatct gctgtgctg 300
              ccagaagacc agattgagaa ggaggagcag gtcaacccca agaaaaaagt gaccgagaag 360
                ggacttctcg tgaatggaca gcctctgctt gtggatttac tgcttcaccg caacccatct 420

```

EP 1 284 298 A2

gcctcagac ttatctggcc tcgagtatga cgcaggggtg gacacctgct gatgtaacaa 480
ctacagatgc cctcagtcct catggtgtgg gagccttagg gcagcctgcc tggagcactt 540
ggacgatgcc actccatcac ctccctctat aaccgccgaa gaggcatctc tgtccacctt 600
5 ctgacccctcc atggttgttc agtctgaaga ttctgtgttc ttcagggatg tgcaaaacaa 660
ggtcattggtg tgcgaccatc caaatggcaa atataaaaaa gaaattgtca agtgttggcg 720
gtgacgcaag aaaaatccta gaagccacag atggggattt atacactgtc gcaacaccgt 780
tgagatgtac tctggggaca ctatcaaggc aaagtatctt aaaacctcta atcaagcgac 840
tgtaatttta ggcattccatc ctggggaaaa ctcacaccct ttagagaaa ggagaaatgc 900
cctaaatttgc ttaaaagatc gtggtttgta gtttaagagag gtagaatgag attaaccaaa 960
atgtcgggtcc acgggagagc aagagagtca atcttgggtat gtccacaaag tctaagagc 1020
10 agttaaagagc caatctgtca gacagacca tgccgagcag gtaaatctag aaagcaaac 1080
aaggactata aaagtcaagc accaggcagt aaatccagaa taagagccta tgcatacata 1140
ttgacagctc acaatcctgt actggttatt gcttacataa ggagaagcca cagatctcat 1200
tctttcttct agaattgcaat agaattttaa aatgacagca gaacaaaagg aactagaaa 1260
ttatctcttc agaaataaaa gtataagaaa taatttctgg cttgaggaaa taaccaggc 1320
15 taaaagctac acaggcctgg cttaaccata ccagcagggc atacctttgt taggagaggg 1380
tcaattcgaa gtttgtgaac agcctgggct gtttccgagg ctgcataaat cttaaacacc 1440
aaaaatgtgt gttttgaatt aactttgggt ctggtctaca gagtccggct tgtgatggct 1500
cctgacacgg gagaaaaggg gataagttaa tataaggctc tgggattttc ctttgaggaa 1560
caggcaggta ggaaaggaca ctagaatgtt ggggaatgtg gagggatgta aaacagacag 1620
20 tattatgatg gggggaaactc aggaaggaaac ggtaaggaca ccagaatggc ctctgtctgg 1680
gagccagggt ggccaagccc aggcagatgc acaaagaccc caaaggccac cattgcctca 1740
caaccagacc cagcaaatgtt cagatcaagt gcataaatgg gggtcacgtc agtggaaact 1800
gtccggagca tggagcaggg ggtgaggaag acagtcagaa ggaagcaaga gatggccttag 1860
agtgttgcac ggcagcaaga agaagcagtc caaatatcat cccaaggcag ccatggcttc 1920
ctctcccgag gacactgtgg ccctgtggaa gtgccaaggc agaggcagag gaatttaacc 1980
25 gcacacaaac tacatgcaga aactaagggtg ctaaatgaac atctacgtga caacctttct 2040
gaggaccagg ttccagttag cggcccaggg ccgttatctt cgcgatggta actgagctga 2100
gaagaatggg aaccggatag gagcacacag tagccactg gtgagacaaa tccacgggag 2160
agcctcaacc aaccactaa ggaaacttca cgccttttca tctagttttc attttgagca 2220
agcaaaagcca tctgtagtgc ttgcttctct cgccttcca cgccaccccc gagacacaga 2280
gcattgcgcac taaccagagc cgcgctaaca catgcacagc gttggacatt agcctattaa 2340
30 tgggaataac cagaaactac taaattttgt ttgtttaga aataaaacct ggggatggat 2400
caaaa 2405

<210> 78
<211> 590
35 <212> PRT
<213> Homo sapiens

<220>
<223> Syntaxin binding protein 2

40 <400> 78
Met Ala Pro Ser Gly Leu Lys Ala Val Val Gly Glu Lys Ile Leu Ser
1 5 10 15
45 Gly Val Ile Arg Ser Val Lys Lys Asp Gly Glu Trp Lys Val Leu Ile
20 25 30
Met Asp His Pro Ser Met Arg Ile Leu Ser Ser Cys Cys Lys Met Ser
35 40 45
50 Asp Ile Leu Ala Glu Gly Ile Thr Ile Val Glu Asp Ile Asn Lys Arg
50 55 60
Arg Glu Pro Ile Pro Ser Leu Glu Ala Ile Tyr Leu Leu Ser Pro Thr
65 70 75 80
55 Glu Lys Ala Leu Ile Lys Asp Phe Gln Gly Thr Pro Thr Phe Thr Tyr
85 90 95

EP 1 284 298 A2

	Lys	Ala	Ala	His	Ile	Phe	Phe	Thr	Asp	Thr	Cys	Pro	Glu	Pro	Leu	Phe	
				100					105					110			
5	Ser	Glu	Leu	Gly	Arg	Ser	Arg	Leu	Ala	Lys	Val	Val	Lys	Thr	Leu	Lys	
			115					120					125				
	Glu	Ile	His	Leu	Ala	Phe	Leu	Pro	Tyr	Glu	Ala	Gln	Val	Phe	Ser	Leu	
		130					135					140					
10	Asp	Ala	Pro	His	Ser	Thr	Tyr	Asn	Leu	Tyr	Cys	Pro	Phe	Arg	Ala	Glu	
	145					150					155					160	
	Glu	Arg	Thr	Arg	Gln	Leu	Glu	Val	Leu	Ala	Gln	Gln	Ile	Ala	Thr	Leu	
					165					170						175	
15	Cys	Ala	Thr	Leu	Gln	Glu	Tyr	Pro	Ala	Ile	Arg	Tyr	Arg	Lys	Gly	Pro	
				180					185					190			
	Glu	Asp	Thr	Ala	Gln	Leu	Ala	His	Ala	Val	Leu	Ala	Lys	Leu	Asn	Ala	
			195					200					205				
20	Phe	Lys	Ala	Asp	Thr	Pro	Ser	Leu	Gly	Glu	Gly	Pro	Glu	Lys	Thr	Arg	
		210					215					220					
	Ser	Gln	Leu	Leu	Ile	Met	Asp	Arg	Ala	Ala	Asp	Pro	Val	Ser	Pro	Leu	
25	225					230					235					240	
	Leu	His	Glu	Leu	Thr	Phe	Gln	Ala	Met	Ala	Tyr	Asp	Leu	Leu	Asp	Ile	
					245					250					255		
	Glu	Gln	Asp	Thr	Tyr	Arg	Tyr	Glu	Thr	Thr	Gly	Leu	Ser	Glu	Ala	Arg	
30				260					265					270			
	Glu	Lys	Ala	Val	Leu	Leu	Asp	Glu	Asp	Asp	Asp	Leu	Trp	Val	Glu	Leu	
			275					280					285				
	Arg	His	Met	His	Ile	Ala	Asp	Val	Ser	Lys	Lys	Val	Thr	Glu	Leu	Leu	
35			290				295					300					
	Arg	Thr	Phe	Cys	Glu	Ser	Lys	Arg	Leu	Thr	Thr	Asp	Lys	Ala	Asn	Ile	
	305					310					315					320	
	Lys	Asp	Leu	Ser	Gln	Ile	Leu	Lys	Lys	Met	Pro	Gln	Tyr	Gln	Lys	Glu	
40					325					330					335		
	Leu	Asn	Lys	Tyr	Ser	Thr	His	Leu	His	Leu	Ala	Asp	Asp	Cys	Met	Lys	
				340				345						350			
45	His	Phe	Lys	Gly	Ser	Val	Glu	Lys	Leu	Cys	Ser	Val	Glu	Gln	Asp	Leu	
			355					360					365				
	Ala	Met	Gly	Ser	Asp	Ala	Glu	Gly	Glu	Lys	Ile	Lys	Asp	Ser	Met	Lys	
		370					375					380					
50	Leu	Ile	Val	Pro	Val	Leu	Leu	Asp	Ala	Ala	Val	Pro	Ala	Tyr	Asp	Lys	
	385					390					395					400	
	Ile	Arg	Val	Leu	Leu	Leu	Tyr	Ile	Leu	Leu	Arg	Asn	Gly	Val	Ser	Glu	
					405				410						415		
55	Glu	Asn	Leu	Ala	Lys	Leu	Ile	Gln	His	Ala	Asn	Val	Gln	Ala	His	Ser	

EP 1 284 298 A2

	420	425	430
5	Ser Leu Ile Arg Asn Leu Glu Gln Leu Gly Gly Thr Val Thr Asn Pro 435 440 445		
	Gly Gly Ser Gly Thr Ser Ser Arg Leu Glu Pro Arg Glu Arg Met Glu 450 455 460		
10	Pro Thr Tyr Gln Leu Ser Arg Trp Thr Pro Val Ile Lys Asp Val Met 465 470 475 480		
	Glu Asp Ala Val Glu Asp Arg Leu Asp Arg Asn Leu Trp Pro Phe Val 485 490 495		
15	Ser Asp Pro Ala Pro Thr Ala Ser Ser Gln Ala Ala Val Ser Ala Arg 500 505 510		
	Phe Gly His Trp His Lys Asn Lys Ala Gly Ile Glu Ala Arg Ala Gly 515 520 525		
20	Pro Arg Leu Ile Val Tyr Val Met Gly Gly Val Ala Met Ser Glu Met 530 535 540		
	Arg Ala Ala Tyr Glu Val Thr Arg Ala Thr Glu Gly Lys Trp Glu Val 545 550 555 560		
25	Leu Ile Gly Ser Ser His Ile Leu Thr Pro Thr Arg Phe Leu Asp Asp 565 570 575		
	Leu Lys Ala Leu Asp Lys Lys Leu Glu Asp Ile Ala Leu Pro 580 585 590		
30	<210> 79 <211> 1888 <212> DNA <213> Homo sapiens		
35	<220> <223> Syntaxin binding protein 2		
40	<400> 79 ggcacgaggg gcggcggggc ccctcgggga agatggcgcc ctcggggctg aaggcggtgg 60 tgggggaaaa aattctgagc ggagttattc ggagtgtcaa gaaggatggg gagtggaaagg 120 tgcttatcat ggatcaccca agcatgogca tctgtgtctc ctgctgcaaa atgtcagata 180 tcctggctga gggcatcacc attgttgaag acatcaacaa acggcgggaa cccattccca 240 gtctggaggg catttatttg ctgagcccca cggagaaggc cctgatcaaa gacttccagg 300 ggaccccgac tttcacctac aaagcgggcc atattcttct caccgacacc tgccccgagc 360 ccctgttcag tgagctaggg cgctctcgtc tggcaaagggt ggtgaagacg ttgaaggaga 420 45 ttcaccttgc ctctctcccc tacgagggccc aggtgttctc cctcgatgct ccccacagca 480 cctacaacct ctactgccc ttccgggcag aggagcgac gcggcagctc gaggtgctgg 540 cccagcagat tgccacgctg tgcgccaccc tgcaggagta cccggccatc cgctaccgca 600 agggccccaga ggacacagcc cagttggccc acgccgtcct ggccaagctg aacgccttca 660 aggcagacac tcccagttct ggcgagggcc cagagaaaac ccgctcccgag ctgctgataa 720 50 tggaccgggc agctgacccc gtgtccccac tactgcatga gtcacgttc caggccatgg 780 cgatgatct gctggacata gagcaggaca catacaggta tgagaccacc gggctgagcg 840 aggcgcgggga gaaggcgtc ttgctggacg aggacgatga cttgtgggtg gagcttcgcc 900 acatgcatat cgcagatgtg tccaagaagg tcacggagct cctgaggacc ttctgtgaga 960 gcaagaggct gaccacggac aaggcgaaca tcaaagacct atcccagatc ctgaaaaaga 1020 tgccgcagta ccagaaggag ctgaataagt attctacgca cctgcatcta gcagatgatt 1080 55 gtatgaagca cttcaagggc tcggtggaga agctgtgtag tgtggagcag gacctggcca 1140 tgggctccga cgcagagggg gagaagatca aggactccat gaagctgac gttccggtgc 1200		

EP 1 284 298 A2

5
10
15
20
25
30
35
40
45
50
55

tgctggacgc ggcggtgccc gcctacgaca agatccgggt cctgctgctc tacatcctcc 1260
 ttcggaatgg tgtgagttag gagaacctgg ccaagctgat ccagcatgcc aatgtacagg 1320
 cgcacagcag cctcatccgt aacctggagc agctggggagg cactgtcacc aacccccggg 1380
 gctcggggac ctccagccgg ctggagccga gagaacgcat ggagcccacc tatcagctgt 1440
 cccgctggac cccggtcatc aaggatgtaa tggaggacgc cgtggaggac cggctggaca 1500
 ggaacctgtg gcccttcgta tccgaccccc cccccacggc cagctcccag gccgctgtca 1560
 gtgcccgttt cggctactgg cacaagaaca aggctggcat agaagcccgg gcggggcccc 1620
 ggctcatcgt gtatgtcatg gccggtgtgg ccatgtcaga gatgagggcc gcctacgagg 1680
 tgaccagggc caccgagggc aagtgggagg tgctcattgg ctccctcacac atcctcacc 1740
 cgacccgctt cctggatgac ctgaaggcac tggacaagaa gctggaggac attgccctgc 1800
 cctgaccctt ggccccgccc cctacccttc cctttccaga gaaataaaact cttcccgtcg 1860
 ctctgccaaa aaaaaaaaaa aaaaaaaaaa 1888

<210> 80
 <211> 505
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Alpha-internexin

<400> 80
 Met Ser Phe Gly Ser Glu His Tyr Leu Cys Ser Ala Ser Ser Tyr Arg
 1 5 10 15
 Lys Val Phe Gly Asp Gly Ser Arg Leu Ser Ala Arg Leu Ser Gly Pro
 20 25 30
 Gly Ala Ser Gly Ser Phe Arg Ser Gln Ser Leu Ser Arg Ser Asn Val
 35 40 45
 Ala Ser Thr Ala Ala Cys Ser Ser Ala Ser Ser Leu Gly Leu Gly Leu
 50 55 60
 Ala Tyr Arg Arg Leu Pro Ala Ser Asp Gly Leu Asp Leu Ser Gln Ala
 65 70 75 80
 Ala Ala Arg Thr Asn Glu Tyr Lys Ile Ile Arg Thr Asn Glu Lys Glu
 85 90 95
 Gln Leu Gln Gly Leu Asn Asp Arg Phe Ala Val Phe Ile Glu Lys Val
 100 105 110
 His Gln Leu Glu Thr Gln Asn Arg Ala Leu Glu Ala Glu Leu Ala Ala
 115 120 125
 Leu Arg Gln Arg His Ala Glu Pro Ser Arg Val Gly Glu Leu Phe Gln
 130 135 140
 Arg Glu Leu Arg Glu Leu Arg Ala Gln Leu Glu Glu Ala Ser Ser Ala
 145 150 155 160
 Arg Ala Gln Ala Leu Leu Glu Arg Asp Gly Leu Ala Glu Glu Val Gln
 165 170 175
 Arg Leu Arg Ala Arg Cys Glu Glu Glu Ser Arg Gly Arg Glu Gly Ala
 180 185 190
 Glu Arg Ala Leu Lys Ala Gln Gln Arg Asp Val Asp Gly Ala Thr Leu
 195 200 205

EP 1 284 298 A2

	Ala Arg Leu Asp Leu Glu Lys Lys Val Glu Ser Leu Leu Asp Glu Leu	210	215	220
5	Ala Phe Val Arg Gln Val His Asp Glu Glu Val Ala Glu Leu Leu Ala	225	230	235
	Thr Leu Gln Ala Ser Ser Gln Ala Ala Ala Glu Val Asp Val Ala Val	245	250	255
10	Ala Lys Pro Asp Leu Thr Ser Ala Leu Arg Glu Ile Arg Ala Gln Tyr	260	265	270
	Glu Ser Leu Ala Ala Lys Asn Leu Gln Ser Ala Glu Glu Trp Tyr Lys	275	280	285
15	Ser Lys Phe Ala Asn Leu Asn Glu Gln Ala Ala Arg Ser Thr Glu Ala	290	295	300
	Ile Arg Ala Ser Arg Glu Glu Ile His Glu Tyr Arg Arg Gln Leu Gln	305	310	315
20	Ala Arg Thr Ile Glu Ile Glu Gly Leu Arg Gly Ala Asn Glu Ser Leu	325	330	335
	Glu Arg Gln Ile Leu Glu Leu Glu Glu Arg His Ser Ala Glu Val Ala	340	345	350
25	Gly Tyr Gln Asp Ser Ile Gly Gln Leu Glu Ser Asp Leu Arg Asn Thr	355	360	365
	Lys Ser Glu Met Ala Arg His Leu Arg Glu Tyr Gln Asp Leu Leu Asn	370	375	380
30	Val Lys Met Ala Leu Asp Ile Glu Ile Ala Ala Tyr Arg Lys Leu Leu	385	390	395
	Glu Gly Glu Glu Thr Arg Phe Ser Thr Ser Gly Leu Ser Ile Ser Gly	405	410	415
35	Leu Asn Pro Leu Pro Asn Pro Ser Tyr Leu Leu Pro Pro Arg Ile Leu	420	425	430
	Ser Ser Thr Thr Ser Lys Val Ser Ser Ala Gly Leu Ser Leu Lys Lys	435	440	445
40	Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Gly Ala Ser Lys Glu Val	450	455	460
	Thr Lys Lys Thr Ser Lys Val Gly Glu Ser Phe Glu Glu Thr Leu Glu	465	470	475
45	Glu Thr Val Val Ser Thr Lys Lys Thr Glu Lys Ser Thr Ile Glu Glu	485	490	495
50	Ile Thr Thr Ser Ser Ser Gln Lys Met	500	505	
55	<p><210> 81 <211> 4593 <212> DNA <213> Rattus norvegicus</p>			

<220>

<223> Alpha-internexin

5 <400> 81
gaattctgaa ctacaaagca aagcgcttca catttccctg acttgtgcca taggctggaa 60
ggtaaactca gacaactgag ccatccattg ttcagggtct actctgtcct taccgggtgt 120
ggcgagggtg gccagttctg tcagccgtgc tcctgcttca ctccctggaat tgaatcaaag 180
actaatcccc acagaaaatg gttcttccat ctaattcaaa atggaatgtc aaacgcatac 240
10 agggccagac agatgaaaag acgaggtgga aagggtagct ctggagtgtc gggagctgtg 300
aggaacaccg cacttaaaaca aaggcactca ctccgccct ctgcagtcac cctaaacctt 360
ctactttcaa gagtggcagg ggctgggcat taaaagggtca aaatcaatcc agtctctttt 420
tagatgaaac ctctgacta aaaattcatt aaaaaaaaac attttgaaat ctattgtttt 480
gttggttttg gtctttttgt ttaaaccaaa gcctgcagac tcctttctac cagcctgcgg 540
tctgtggatg cgcggttgat tggagggtca gagatgaacc ctgctaattc tcaacgcttt 600
15 gctccttttc caggcctagc ctctttccct ccccgtaacc ctccgcaccc ttggaaataa 660
gcctcttgtt cttcaccaat gtccggagca tctcacgctc tctgcgaatc ctcccgttta 720
ctgtgggtgc ggagctgaga gatgctctct gaagtggacc cactttctcc gaaaaggacc 780
aggagacacc taagtccaga agataaagag gaggtgtgtt ctccccctga aaagggtggg 840
gacayggcct cacccttggg aactctggga tgcagatgag aacagagaca cctttcagaa 900
aaacctactc tccttggggg ataagcacag aaaaggaagg acaggctcta aagccatcaa 960
20 agagctgagt gctctgggct gggaagccaa ggtgtgttgg gactccctc cctccggtc 1020
attccctagg cagattcttg gggcacaggc gcagcgccca gggacggccc aggtcgggtg 1080
cgcgagctg cgggtggcact gcgcttcccc gccccgcag gcccccttc ctctccccgc 1140
tagatctgaa gatgaagctc cacccttagc gcgtcgcccc agccccgcgc cttaaaagcc 1200
ccgcacaccg ccccgccgca cccagccttg ccgcaccttc gcgtctctgc caggctccgc 1260
25 gcagccgcgc acccgggccc gacccggcca ccatgagctt cggatcagag cactactgt 1320
gtctccgctc ctctaccgc aaggtgttcg gggatggctc gcgctgtct gcgcgctgt 1380
ccgggcccgg agcgtccggc agctttcgct cgcagtcgct gtcccgagc aatgtggcct 1440
ccacggccgc ttgctcctcg gcctcgtctc tcggcctggg cctggcctac cgccgctgc 1500
cgccctccga cgggctggac ctgagccaag cagcggcgcg caccaacgag tacaagatca 1560
tccgcactaa cgagaaggag cagctgcagg gcctcaacga ccgcttcgcg gtgttcacg 1620
30 aaaagggtga ccagctggag acgcagaacc gcgcgctcga ggccgagctg gccgcgctgc 1680
gccagcgcca cgccgagccg tcgcgcgctc gcgagctctt ccagcgcgag ctgcgcgagc 1740
tgcgcgcgca gctggaggag gcgagctccg cgcgcgcgca ggccctgctg gagcgcgacg 1800
ggctggccga ggaggtgcag cgactgcggg cgcgctgcga ggaggagagc cgcgggcccg 1860
aaggcgcgga gcgcgcctg aaggcgagc agcgcgagct ggacggcgcc actctggccc 1920
gcctggatct ggagaagaag gtggagtcgc tgctggacga gctggccttc gtgcgccagg 1980
35 tgcacgacga ggaggtggcc gagctcctgg ccacgctgca ggcgtcttcg caagccgccc 2040
ccgaggtgga cgtggctgtg gctaaaccag acctgacttc ggcgctgagg gagatccgcg 2100
ccatgtatga gtcttggcc gctaagaacc tgcagtcggc cagaggagtgg tacaagtcca 2160
agttcgccaa cctgaacgag caggctgcgc gcagcacgga agccatccga gccagccgag 2220
aggagatcca cgagtaccg cgccagctcc aggtctgtac cattgagata gagggcctgc 2280
40 gcggagccaa tgaatccctg gagaggcaga tcttggaaact ggaggagcgg cacagcgctg 2340
aggtggccgg ctaccaggat agcattgggc agctggagag tgacctgagg aacaccaaga 2400
gcgagatggc ccgccacctt cgggaatacc aggaactgtt caatgtcaaa atggctcttg 2460
acattgagat agcagcttac aggaagctgc tggaaaggcg agagacacga tttagcacca 2520
gcgggttaag catctcaggg ctgaatccac ttcccaatcc cagttatttg ctccctccta 2580
gaatccttag ttctacaacc tccaaagtct catccgctgg gctgtccctg aaaaaggagg 2640
45 aggaggagga ggaggaagag gaagaagggg ctcttaagga agtcactaag aaaacatcca 2700
aggtagggga aagtttcgaa gaaacactgg aggaaacggg ggtatctacg aagaaaaccg 2760
aaaagtcaac tatagaagaa atcaccacca gttccagcca aaaaatgtaa tgctgttgct 2820
taaaaaaaaa aaacaaaaaa aggcgatgcc taagagggaa tgcacttggc ttattcacag 2880
cttactcctg aaccacacct accaccgcaa tagaatgtct tcaaggcttc aatgtcatag 2940
tctgtaccga atcctcgctc tctccagtag gaaggccact gtagctggga gcaaactgca 3000
50 gtgctggagg aggagcagga ggagctctct aagatcacag ctttctacc tacagctcag 3060
gcctcatagt gacagggtgac ccagggtgcag aggaggctca aacgaagggt ctaaatcttg 3120
tcctcgtctg ctgtgagctg aaatcgaaac ctgtttctcc accgtacccc gccagtaccc 3180
agccatagaa cctcactgta gatgtctaaa aatatacagt cactgccgag gacaagctag 3240
tgctccagac accattctcc catccccctc tgatagagct gaggcacaaa acgacggctg 3300
tctctcatgg gcagggtttc ttctctctct ttcaatcccg tattgccatt tctccacct 3360
55 gagaggaagg aacaaagttt agtgtgttat cccctcttag acacgcatag aacttacgcc 3420

EP 1 284 298 A2

5 ctttagtcct cactccgtgg gttaaattaga tgcattgtga ccattcccgt gatttgtata 3480
 acgcaccctt gtccatttca tgacctttca tgtccgtagc ttaaaaaata gaaagtgtatt 3540
 aatgataatg gcagtgattg gttttaagggt ttttcctaaa ataatactaa ttataataat 3600
 aatcataaaa gggatctcta gacttttaggc tttcagctta tccagatcca cttaattaga 3660
 gaggaaaaaa attaccttaa atgatgtagc atttcacctt aaatttagag gcacgggtgat 3720
 agttgcccta ctctgcgctt aagctgacct tagacctcgt atcgtaagta gagtgtgtga 3780
 gtgagtgtct tgaaagggaa agaacaaggt ctccctctgtg ttggtttcta tgtagtgtga 3840
 tagaatttagc tttctcatac ccttgcccta ggatctacat aattcccttc ccattagggt 3900
 agtargctat gtataggaca ttttatcacc agacacaacg ctactgcca aaagtgaata 3960
 10 acacacactt ctgggtcaatc aacaccacca gcaaataattt aaaaaaata aaaaaggag 4020
 gaagaaagaa agaaagaaag aaagaaagaa agagagagag agagagaaag agagaaagaa 4080
 agagaaagat tgattctcag agtcttttcc taacagggtt acattgtctc agttgggtga 4140
 tgtccctccc ctgaaggaaa gacagaaaca ttattcagggt tccaggagggt gtatgcacac 4200
 ttctcccca cctcaagaag gcaggctgga aagtcagctc ttcgtgcact caactgtggc 4260
 atccacatga cctgtctgcc tcgctgtgcca aacttgatgc agggtttgcc ctgtctctgc 4320
 15 tcaactccac caagctgtag aactgtctgt cctgtcccg cccacccat cgcaagctct 4380
 gtgctgataa ggacatgatg cttctactga attcacattc tagcacgtgc ttcaatatag 4440
 ctcaaggaac cggaagaca cttcgttttt cctgacccat cccctcttga cccccccc 4500
 acactgtaag acattagtaa tattaagaaa ttaaagtca ttaatcctat gtggttcttg 4560
 tctgtgtct ctatagctc tgaggtgtgc att 4593

20
 <210> 82
 <211> 320
 <212> PRT
 <213> Mus musculus

25
 <220>
 <223> Beta-sarcoglycan

<400> 82
 Met Ala Ala Ala Ala Ala Ala Ala Ala Thr Glu Gln Gln Gly Ser
 30 1 5 10 15
 Asn Gly Pro Val Lys Lys Ser Met Arg Glu Lys Ala Val Glu Arg Arg
 20 25 30
 Asn Val Asn Lys Glu His Asn Ser Asn Phe Lys Ala Gly Tyr Ile Pro
 35 35 40 45
 Ile Asp Glu Asp Arg Leu His Lys Thr Gly Leu Arg Gly Arg Lys Gly
 50 55 60
 Asn Leu Ala Ile Cys Val Ile Val Leu Leu Phe Ile Leu Ala Val Ile
 40 65 70 75 80
 Asn Leu Leu Ile Thr Leu Val Ile Trp Ala Val Ile Arg Ile Gly Pro
 85 90 95
 Asn Gly Cys Asp Ser Met Glu Phe His Glu Ser Gly Leu Leu Arg Phe
 45 100 105 110
 Lys Gln Val Ser Asp Met Gly Val Ile His Pro Leu Tyr Lys Ser Thr
 115 120 125
 Val Gly Gly Arg Arg Asn Glu Asn Leu Val Ile Thr Gly Asn Asn Gln
 50 130 135 140
 Pro Ile Val Phe Gln Gln Gly Thr Thr Lys Leu Ser Val Glu Lys Asn
 145 150 155 160
 55 Lys Thr Ser Ile Thr Ser Asp Ile Gly Met Gln Phe Phe Asp Pro Arg

EP 1 284 298 A2

		165		170		175	
		Thr His Asn Ile Leu Phe Ser Thr Asp Tyr Glu Thr His Glu Phe His					
		180		185		190	
5		Leu Pro Ser Gly Val Lys Ser Leu Asn Val Gln Lys Ala Ser Thr Glu					
		195		200		205	
		Arg Ile Thr Ser Asn Ala Thr Ser Asp Leu Asn Ile Lys Val Asp Gly					
		210		215		220	
10		Arg Ala Ile Val Arg Gly Asn Glu Gly Val Phe Ile Met Gly Lys Thr					
		225		230		235	240
		Ile Glu Phe His Met Gly Gly Asp Val Glu Leu Lys Ala Glu Asn Ser					
			245		250		255
15		Ile Ile Leu Asn Gly Thr Val Met Val Ser Pro Thr Arg Leu Pro Ser					
			260		265		270
		Ser Ser Ser Gly Asp Gln Ser Gly Ser Gly Asp Trp Val Arg Tyr Lys					
			275		280		285
20		Leu Cys Met Cys Ala Asp Gly Thr Leu Phe Lys Val Gln Val Thr Gly					
			290		295		300
		His Asn Met Gly Cys Gln Val Ser Asp Asn Pro Cys Gly Asn Thr His					
			305		310		315
							320
30		<210> 83					
		<211> 1237					
		<212> DNA					
		<213> Mus musculus					
35		<220>					
		<223> Beta-sarcoglycan					
		<400> 83					
		gagagcgcaa ggcggggctg cggcggggcca agatggcggc agcggcgggcg ggcggcgag 60					
		cgaccgagca gcaaggggtcc aacggggocag tgaagaaatc catgcgggag aaggctgtgg 120					
40		agcggaggaa tgtaataaaa gagcacaaca gcaatttcaa agctggatat atccccatcg 180					
		atgaggaccg gctccataag actgggctga gggggcgaaa gggcaactta gccatctgcg 240					
		tgatcgctct cctgtttatc ctggcgttca tcaatctact cattacactt gtcactctggg 300					
		cggtgatccg cattgggcca aatgggtgtg atagcatgga gttccacgag agcgggtctgc 360					
		tgagggttcaa gcaagtgtct gacatgggcg tcatccacc gctttataag agcacggtgg 420					
45		gaggacggcg gaatgaaaac ctggtcatca ctggcaacaa ccagccaatt gtcttccagc 480					
		aagggacgac caagctgagt gttgaaaaga acaagacctc catcaccagc gacatcgagg 540					
		tgcagttttt tgacccaagg acacacaata tcctgttcag cacggactat gagacgcacg 600					
		agtttcatct gccaaagtgg gtgaaaagtt tgaacgttca gaaagcatcg actgaaagga 660					
		ttaccagcaa tgctaccagt gacttaaaca tcaaagtcca tgggcgtgca attgtgagag 720					
		gcaacgaagg cgtcttcatc atgggcaaaa ccattgaatt tcacatggga ggagatgtgg 780					
50		agttaaaagc tgaaaacagc atcatcctca acggcacggg gatggtcagc cctacgcgcc 840					
		tgcccagttc ctccagcggg gaccagtcag ggagtggtga ctgggtgccc tacaagctct 900					
		gcatgtgtgc agatggcaca ctcttcaaag tacaagtaac aggtcacaac atgggctgcc 960					
		aggtctcaga caacccttgt gggaacactc attagacggg gcatccgcag gctcagcgcg 1020					
		ctcagatctg acttgacctt ccccttttta agaattgcag tgaaccatgt ttgtacagcg 1080					
		tttgccataa cttgtaatta ttttacctgg ggagcaccac tgtgtctatt atgtactctc 1140					
55		catatttaag ggatcttgag tgcctacatt ctaatacatt ttagtaagtt gcactgatac 1200					

tcaacagttc tctaaaacaa tgatgagaat taataaa

1237

5 <210> 84
 <211> 251
 <212> PRT
 <213> Homo sapiens

 10 <220>
 <223> CGI-78 protein

 <400> 84
 Met Gly Ala Ala Val Phe Phe Gly Cys Thr Phe Val Ala Phe Gly Pro
 1 5 10 15
 15 Ala Phe Ala Leu Phe Leu Ile Thr Val Ala Gly Asp Pro Leu Arg Val
 20 25 30
 Ile Ile Leu Val Ala Gly Ala Phe Phe Trp Leu Val Ser Leu Leu Leu
 35 40 45
 20 Ala Ser Val Val Trp Phe Ile Leu Val His Val Thr Asp Arg Ser Asp
 50 55 60
 Ala Arg Leu Gln Tyr Gly Leu Leu Ile Phe Gly Ala Ala Val Ser Val
 65 70 75 80
 25 Leu Leu Gln Glu Val Phe Arg Phe Ala Tyr Tyr Lys Leu Leu Lys Lys
 85 90 95
 Ala Asp Glu Gly Leu Ala Ser Leu Ser Glu Asp Gly Arg Ser Pro Ile
 100 105 110
 30 Ser Ile Arg Gln Met Ala Tyr Val Ser Gly Leu Ser Phe Gly Ile Ile
 115 120 125
 Ser Gly Val Phe Ser Val Ile Asn Ile Leu Ala Asp Ala Leu Gly Pro
 130 135 140
 35 Gly Val Val Gly Ile His Gly Asp Ser Pro Tyr Tyr Phe Leu Thr Ser
 145 150 155 160
 Ala Phe Leu Thr Ala Ala Ile Ile Leu Leu His Thr Phe Trp Gly Val
 165 170 175
 40 Val Phe Phe Asp Ala Cys Glu Arg Arg Arg Tyr Trp Ala Leu Gly Leu
 180 185 190
 Val Val Gly Ser His Leu Leu Thr Ser Gly Leu Thr Phe Leu Asn Pro
 195 200 205
 45 Trp Tyr Glu Ala Ser Leu Leu Pro Ile Tyr Ala Val Thr Val Ser Met
 210 215 220
 Gly Leu Trp Ala Phe Ile Thr Ala Gly Gly Ser Leu Arg Ser Ile Gln
 225 230 235 240
 50 Arg Ser Ser Cys Val Arg Thr Asp Tyr Leu Asp
 245 250

 55 <210> 85

EP 1 284 298 A2

<211> 1967
<212> DNA
<213> Homo sapiens

5 <220>
<223> CGI-78 protein

<400> 85
gtggggtcgc gttgccaccc caccgaggact cccagctgg cgcgcccctc ccatttgcct 60
gtcctgggtca ggccccacc ccccttccca cctgaccagc catgggggct gcggtgtttt 120
10 tcggctgcac tttcgtcgcg ttggcccggt ccttcgcgct tttcttgatc actgtggctg 180
gggacccgct tcgctgtatc atcctggctg caggggcatt tttctggctg gtctccctgc 240
tcctggcctc tgtgggtctg ttcattcttg tccatgtgac cgaccgggtc gatgcccggc 300
tccagtacgg cctcctgatt tttgggtgct ctgtctctgt ccttctacag gaggtgttcc 360
gctttgccta ctacaagctg cttaagaagg cagatgaggg gttagcatcg ctgagtggag 420
15 acggaagatc acccatctcc atccgccaga tggcctatgt ttctgggtct tccttcggta 480
tcatcagtggt tgtcttctct gttatcaata ttttggctga tgcacttggg ccaggtgtgg 540
ttgggatcca tggagactca cctattact tctgacttc agcctttctg acagcagcca 600
ttatcctgct ccataccttt tggggagttg tgttcttga tgcctgtgag aggagacggg 660
actgggcttt gggcctgggt gttgggagtc acctactgac atcgggactg acattcctga 720
acccctggta tgaggccagc ctgctgcccc tctatgcagt cactgtttcc atggggctct 780
20 gggccttcat cacagctgga ggttccctcc gaagtattca gcgcagctct tgtgtaagga 840
ctgactacct ggactgatcg cctgacagat cccacctgcc tgtccactgc ccatgactga 900
ggccagcccc agcccggggg catttgcccc cattctctgt ctcttctctg tcggtctacc 960
ccactacctc caggggtttt ctttgtcctt ttgtgacct tagtctctaa gctttaccag 1020
gagcagcctg ggttcagcca gtcatgact ggtgggtttg aatctgcact tatccccacc 1080
acctggggac ccccttgttg tgtccaggac tccccctgtg tcaagtgtct gctctcacc 1140
25 tgcccaagac tcacctccct tcccctctgc aggcgcagcg caggaggaca gtcgggtgat 1200
ggtgtattct gccctgcgca tcccaccgga ggactgaggg aacctagggg ggaccctgg 1260
gcctgggggt cctcctgat gtctcgcgcc tgtatttctc catctccagt tctggacagt 1320
gcaggttgcc aagaaaaggg acctagttaa gccattgccc tggagatgaa attaatggag 1380
gctcaaggat agatgagctc tgagtctctc agtactccct caagactgga catcttggtc 1440
30 tttttctcag gcctgagggg gaaccatttt tgggtgtgata aataccctaa actgcctttt 1500
tttctttttt gaggtggggg gagggaggag gtatattgga actcttctaa cctccttggg 1560
ctatatattt tctcctcgag ttgctcctca tggctgggct catttcggtc cctttctcct 1620
tggtcccaga ccttggggga aaggaaggaa gtgcattgtt gggaactggc attactggaa 1680
ctaattggtt taacctcctt aaccaccagc atccctctc tcccgaaggt gaagtggagg 1740
gtgctgtggt gagctggcca ctccagagct gcagtgccac tggaggagtc agactaccat 1800
35 gacatcgtag ggaaggaggg gagatttttt tgtagttttt aattgggggt tgggaggggg 1860
ggggagggtt tctataaact gtatcatttt ctgctgaggg tggagtgtcc catcctttta 1920
atcaagggtga ttgtgatttt gactaataaa aaagaatttg taaaaaa 1967

40 <210> 86
<211> 885
<212> PRT
<213> Homo sapiens

45 <220>
<223> KIAA0143 protein

<400> 86
Ala Gly Gly Gly Ser Cys Arg Pro Leu Gly Cys Val Thr Ala Gly Ser
1 5 10 15
50 Ala Ser Ala Pro Ser Thr Leu Arg Pro Ser Pro Phe Ala Ser Ser Arg
20 25 30
Pro Pro Arg Pro Ser Asn Gly Arg His Gly Ala Val Gly Ala Pro Cys
35 40 45
55 Ala Ala Pro Leu Ser Leu Gly Ala Ala Ala Ser Ala Val Glu Ile Ala

EP 1 284 298 A2

	50	55	60
	Met Pro Thr Arg Val Cys Cys Cys Cys Ser Ala Leu Arg Pro Arg Tyr		
	65	70	75 80
5	Lys Arg Leu Val Asp Asn Ile Phe Pro Glu Asp Pro Lys Asp Gly Leu		
		85	90 95
	Val Lys Thr Asp Met Glu Lys Leu Thr Phe Tyr Ala Val Ser Ala Pro		
		100	105 110
10	Glu Lys Leu Asp Arg Ile Gly Ser Tyr Leu Ala Glu Arg Leu Ser Arg		
		115	120 125
	Asp Val Val Arg His Arg Ser Gly Tyr Val Leu Ile Ala Met Glu Ala		
		130	135 140
15	Leu Asp Gln Leu Leu Met Ala Cys His Ser Gln Ser Ile Lys Pro Phe		
		145	150 155 160
	Val Glu Ser Phe Leu His Met Val Ala Lys Leu Leu Glu Ser Gly Glu		
		165	170 175
20	Pro Lys Leu Gln Val Leu Gly Thr Asn Ser Phe Val Lys Phe Ala Asn		
		180	185 190
	Ile Glu Glu Asp Thr Pro Ser Tyr His Arg Arg Tyr Asp Phe Phe Val		
		195	200 205
25	Ser Arg Phe Ser Ala Met Cys His Ser Cys His Ser Asp Pro Glu Ile		
		210	215 220
	Arg Thr Glu Ile Arg Ile Ala Gly Ile Arg Gly Ile Gln Gly Val Val		
		225	230 235 240
	Arg Lys Thr Val Asn Asp Glu Leu Arg Ala Thr Ile Trp Glu Pro Gln		
		245	250 255
35	His Met Asp Lys Ile Val Pro Ser Leu Leu Phe Asn Met Gln Lys Ile		
		260	265 270
	Glu Glu Val Asp Ser Arg Ile Gly Pro Pro Ser Ser Pro Ser Ala Thr		
		275	280 285
40	Asp Lys Glu Glu Asn Pro Ala Val Leu Ala Glu Asn Cys Phe Arg Glu		
		290	295 300
	Leu Leu Gly Arg Ala Thr Phe Gly Asn Met Asn Asn Ala Val Arg Pro		
		305	310 315 320
45	Val Phe Ala His Leu Asp His His Lys Leu Trp Asp Pro Asn Glu Phe		
		325	330 335
	Ala Val His Cys Phe Lys Ile Ile Met Tyr Ser Ile Gln Ala Gln Tyr		
		340	345 350
50	Ser His His Val Ile Gln Glu Ile Leu Gly His Leu Asp Ala Arg Lys		
		355	360 365
	Lys Asp Ala Pro Arg Val Arg Ala Gly Ile Ile Gln Val Leu Leu Glu		
		370	375 380
55			

EP 1 284 298 A2

	Ala Val Ala Ile Ala Ala Lys Gly Ser Ile Gly Pro Thr Val Leu Glu	385	390	395	400
5	Val Phe Asn Thr Leu Leu Lys His Leu Arg Leu Ser Val Glu Phe Glu	405	410	415	
	Ala Asn Asp Leu Gln Gly Gly Ser Val Gly Ser Val Asn Leu Asn Thr	420	425	430	
10	Ser Ser Lys Asp Asn Asp Glu Lys Ile Val Gln Asn Ala Ile Ile Gln	435	440	445	
	Thr Ile Gly Phe Phe Gly Ser Asn Leu Pro Asp Tyr Gln Arg Ser Glu	450	455	460	
15	Ile Met Met Phe Ile Met Gly Lys Val Pro Val Phe Gly Thr Ser Thr	465	470	475	480
	His Thr Leu Asp Ile Ser Gln Leu Gly Asp Leu Gly Thr Arg Arg Ile	485	490	495	
20	Gln Ile Met Leu Leu Arg Ser Leu Leu Met Val Thr Ser Gly Tyr Lys	500	505	510	
	Ala Lys Thr Ile Val Thr Ala Leu Pro Gly Ser Phe Leu Asp Pro Leu	515	520	525	
25	Leu Ser Pro Ser Leu Met Glu Asp Tyr Glu Leu Arg Gln Leu Val Leu	530	535	540	
	Glu Val Met His Asn Leu Met Asp Arg His Asp Asn Arg Ala Lys Leu	545	550	555	560
30	Arg Gly Ile Arg Ile Ile Pro Asp Val Ala Asp Leu Lys Ile Lys Arg	565	570	575	
	Glu Lys Ile Cys Arg Gln Asp Thr Ser Phe Met Lys Lys Asn Gly Gln	580	585	590	
35	Gln Leu Tyr Arg His Ile Tyr Leu Gly Cys Lys Glu Glu Asp Asn Val	595	600	605	
	Gln Lys Asn Tyr Glu Leu Leu Tyr Thr Ser Leu Ala Leu Ile Thr Ile	610	615	620	
40	Glu Leu Ala Asn Glu Glu Val Val Ile Asp Leu Ile Arg Leu Ala Ile	625	630	635	640
	Ala Leu Gln Asp Ser Ala Ile Ile Asn Glu Asp Asn Leu Pro Met Phe	645	650	655	
45	His Arg Cys Gly Ile Met Ala Leu Val Ala Ala Tyr Leu Asn Phe Val	660	665	670	
	Ser Gln Met Ile Ala Val Pro Ala Phe Cys Gln His Val Ser Lys Val	675	680	685	
50	Ile Glu Ile Arg Thr Met Glu Ala Pro Tyr Phe Leu Pro Glu His Ile	690	695	700	
	Phe Arg Asp Lys Cys Met Leu Pro Lys Ser Leu Glu Lys His Glu Lys	705	710	715	720

EP 1 284 298 A2

Asp Leu Tyr Phe Leu Thr Asn Lys Ile Ala Glu Ser Leu Gly Gly Ser
725 730 735

5 Gly Tyr Ser Val Glu Arg Leu Ser Val Pro Tyr Val Pro Gln Val Thr
740 745 750

Asp Glu Asp Arg Leu Ser Arg Arg Lys Ser Ile Val Asp Thr Val Ser
755 760 765

10 Ile Gln Val Asp Ile Leu Ser Asn Asn Val Pro Ser Asp Asp Val Val
770 775 780

Ser Asn Thr Glu Glu Ile Thr Phe Glu Ala Leu Lys Lys Ala Ile Asp
785 790 795 800

15 Thr Ser Gly Met Glu Glu Gln Glu Lys Glu Lys Arg Arg Leu Val Ile
805 810 815

Glu Lys Phe Gln Lys Ala Pro Phe Glu Glu Ile Ala Ala Gln Cys Glu
820 825 830

20 Ser Lys Ala Asn Leu Leu His Asp Arg Leu Ala Gln Ile Leu Glu Leu
835 840 845

Thr Ile Arg Pro Pro Pro Ser Pro Ser Gly Thr Leu Thr Ile Thr Ser
850 855 860

25 Gly His Ala Gln Tyr Gln Ser Val Pro Val Tyr Glu Met Lys Phe Pro
865 870 875 880

Asp Leu Cys Val Tyr
885

30

<210> 87
<211> 5286
<212> DNA
35 <213> Homo sapiens

<220>
<223> KIAA0143 protein

40

<400> 87
ggctggcggc ggtagctgtc gcccgcttgg ttgcgtgacc gcgggggtccg cgcccgctcc 60
ctccaccctt cgcccttcgc ccttcgcctc gtcccgccct ccgcgcccca gcaacggccg 120
tcatgggtgc gtccggcgctc cctgcgcggc cccgctgagc ctccggtgcgg cggcgagcgc 180
ggtcgagatc gccatgccta cccgagtatg ctgctgctgt tccgctttgc gtcctcgcta 240
45 caaacgcctg gtggacaaca tattccctga agatccaaaa gatggccttg tgaaaactga 300
tatggagaaa ttgacatttt atgcagtatc tgctccagag aaactggatc gaattgggtc 360
ttacctggca gaaagggttg gcagggatgt tgtcagacat cgttctgggt atgttttgat 420
tgctatggag gcactggacc aacttctcat ggcttgccat tctcaaagca ttaagccatt 480
tgtagaaagc tttcttcata tggtggcaaa gctgctggaa tcggggggaac caaagcttca 540
agttcttgga acaaattctt ttgtcaaatt tgcaaattat gaagaagaca caccatccta 600
50 tcacagacgt tatgactttt ttgtgtctcg attcagtgcc atgtgccatt cctgtcatag 660
tgatccagaa atacgaacag agatacgaat tgctggaatt agaggtattc aaggtgtggt 720
tcgcaaaaaca gtcaacgatg aacttcgggc caccatttgg gaacctcagc atatggataa 780
gattgttcca tccctcctgt ttaacatgca aaagatagaa gaagttgaca gtcgcatagg 840
ccctccttct tctccttctg caactgacaa agaagagaat cctgctgtgc tggctgaaaa 900
ctgtttcaga gaactgctgg gtccagcaac ttttgggaat atgaataatg ctgttagacc 960
55 agtttttgcg catttagatc atcacaaact gtgggatccc aatgaatttg cagttcactg 1020

	ctttaaatt	ataatgtatt	ccattcaggc	tcagtattct	caccatgtga	tccaggagat	1080
	tctaggacac	cttgatgctc	gtaaaaaaga	tgctccccgg	gttcgagcag	gtattattca	1140
	ggttctgtta	gaggctgttg	ccattgctgc	taaagggttc	atagggtccga	cagtgtgga	1200
5	agtcttcaat	acccttttga	aacatctgcg	tctcagcgtt	gaattcgaag	caaatgattt	1260
	acagggggga	tctgtaggca	gtgtcaactt	aaatacaagt	tccaaagaca	atgatgagaa	1320
	gattgtgcag	aatgctatca	tccaaacaat	aggatttttt	ggaagtaacc	taccagatta	1380
	tcagagggtca	gaaatcatga	tgttcattat	ggggaaagta	cctgtctttg	gaacatctac	1440
	ccatactttg	gatatcagtc	aactaggggga	tttgggaacc	aggagaattc	agataatgtt	1500
	gctgagatct	ttgcttatgg	tgacctctgg	atataaagcg	aagacgattg	ttactgcact	1560
10	gccaggggtct	ttcctggatc	ctttgttatc	accatctctc	atggaggact	acgaaactgag	1620
	acagttggtc	ttggaagtaa	tgcataatct	catggatcgt	catgacaata	gggcaaagct	1680
	tcgagggtac	agaataatac	cggatgtagc	tgacctaaag	ataaaaagag	aaaaaatttg	1740
	cagacaagac	acaagtttca	tgaaaaagaa	tgggcaacag	ctgtatcggc	acatatattt	1800
	gggttgttaa	gaggaagaca	acgttcagaa	aaactatgaa	ctactttata	cttctcttgc	1860
	tcttataaact	attgaactgg	ctaatagaaga	agtagttatt	gatctcattc	gactggccat	1920
15	tgctttacag	gacagtgcga	ttatcaatga	ggataatttg	ccaatgttcc	atcgttgtgg	1980
	aatcatggca	ctgggtgacg	catacctcaa	ctttgttaagt	cagatgatag	ctgtccctgc	2040
	atthtggcag	catgttagca	agggttattga	aatcgaact	atggaaagccc	cttattttct	2100
	accagagcat	atcttcagag	ataagtgcac	gcttccaaaa	tctttagaga	agcatgaaaa	2160
	agatttgtac	tttctgacca	acaagatttc	agagtcgcta	ggtggaagtg	gatatagtgt	2220
20	tgagagattg	tcagttccgt	atgtaccaca	agtaacagat	gaagatcgac	tttctagaag	2280
	aaaaagcatt	gtggacaccg	tatccattca	ggtggatatt	ttatccaaca	atgttctctc	2340
	tgatgatgtg	gttagtaaca	ctgaagaagt	cacttttgaa	gcattgaaga	aagcaattga	2400
	taccagtgga	atggaagaac	aggaaaagga	aaagaggcgt	cttgtgatag	agaaatttca	2460
	gaaagcacct	tttgaagaaa	tagcagcaca	gtgtgaatcc	aaagcaaatt	tgcttcatga	2520
	tagacttgcc	caaatattgg	aactcaccat	acgtcctcct	cccagtcctc	caggaaactc	2580
25	gaccattact	tctgggcatg	ccaataacca	atctgtccca	gtctatgaga	tgaagtttcc	2640
	agatctgtgt	gtgtactgat	cggcgcatga	agacctcagc	atatgatttg	taaagcctaa	2700
	aaattaaggc	caagctgagc	tttcagggtt	tacttaattgt	gtattaacat	acttcttgaa	2760
	aataatgatg	gaacatatct	ttaaccaaat	gtttggcata	ccatattaga	agttttggag	2820
	ctatatataa	tttcgagtac	tttcaaagat	agatttatgc	catgttaatt	tgctttgagg	2880
	ttcctgttgc	cttttttaagt	tgaacatgtt	ttggtttcac	tttattccac	tggttaagtag	2940
30	tatgttttaa	acttttcaca	aatgtaattgt	tttttaaaaa	gtaagccttc	agaggattga	3000
	aactgtataa	attgtttatc	tcttaaacat	ctacacagcc	gcttagatgt	agaatttttg	3060
	ttgttgtttt	ctgcaaaggc	agatacattt	aaatatattc	ctagtccttg	ggctgcaaaa	3120
	ctgttcggtg	gctttttgtc	cccattgctt	agataagctg	ggataggcac	cttgctattc	3180
	agttactata	ataatatgtg	ataggcatct	ctcatcttct	tcacaataat	aggacatctg	3240
35	ttgaatagca	ttcctcgaat	ataaccctaa	aaacgccata	ctttaaattg	tctggttctt	3300
	gtaatatgtg	gtttcctgcc	aagagtttga	ccattctgct	tgagaagtgt	agagcttact	3360
	cttggagtac	caaactgtgc	aatattttta	catcataaga	tgtattagtt	tacaggctgt	3420
	gctttgaaat	tatatagtag	ttttgtctgt	gctccattaa	ttaaatgaga	tatatattta	3480
	gtgcagaaaa	aagacattta	aaacagctat	tagttcacct	gtgaagagtc	tgtacatttt	3540
	gattttctatt	aagagcacat	ttattttacat	ttgtatatata	ttttaaatcc	tcatagtcaa	3600
40	aaaattctcc	agatggactt	ttaatttgta	agatttgaac	tgtgacttgt	atacatctgt	3660
	gtcaatttaa	ttatatattga	aaagctgcct	gtgtttttaa	agtcaagtgt	gctaaagtgt	3720
	actgacagac	ccataacatt	acatacatct	ccaagattac	agggtgactc	tacacataac	3780
	agctttcttt	gtaactcata	aaattctctt	tagtgaattc	tatcacatgg	taaaatgaac	3840
	gttctatctt	ttcagattcc	atttcttttt	acataaaaaca	gcatacatat	cctgtttata	3900
45	agcctagaat	acagtttaatt	ttttggcttt	tgtttttggt	taaaaaattg	cagtgaagaa	4020
	tgggatgttt	gtgttttatgg	ctatttgggc	acctttagta	gaaacagaca	aaagtaagga	4080
	aacgataata	ggacaagcat	acttgaataa	ttctgaatac	ttaaacaaaa	gcgcaacatc	4140
	ttgaaaacca	gtctagtcac	tgaaacctat	gaaatgacac	tgaagatcc	tgggctgctt	4200
	cttaataaag	tagatcagca	agacttggtt	cagagtgcac	gtggagtcgt	taccgctgga	4260
50	ggactaaagg	gccctgtggc	agctgtcact	ggaactttgc	ctcttgatca	ggaaaaatgc	4320
	ttcaccagtc	cgtaaagcca	agttgtatct	tttttatgtc	ccttttttcc	ttctgtatct	4380
	ttaaagaagg	atgttaattt	ttgactatat	attttaaaaa	aatctaagca	gggggacatg	4440
	caaaaaacaat	catcatccac	ttggatgtca	ttttatagat	taacactgtg	tgcttttgta	4500
	tggaaaaaaat	atatataatt	taatagtata	aaaaataaaa	tatatattca	tttgacttta	4560
	cgtgaaacac	aaactttgct	ctacaaaaat	tcgtgtttct	tagtgatttt	aaaaatgcac	4620
	tattgcatgt	aaaggaaaac	cattacaatt	aatgtttatc	acacctttat	cttgggtctt	4680
55	gttgatttgg	gttttgttgg	ggtttttgtt	actgttttta	aattacagta	ggcttctata	4740

EP 1 284 298 A2

5
10
tattcctggat ttctgaactg gtcttggtga caaggattcc caagaaatgg atcttttcac 4800
tggctgactc tcccatatct gcaagagatt ctgcaggaac tgggtgtgca cacggtgttg 4860
tagccagttc aggtactgaa tatttaggat ttggtgaagt tcactgtatt gctataatctt 4920
tgtagataaa taaaactcaa taaattgtta atcattctct ttttgctgta tagaattgct 4980
tatactactc tttctttcat gacattgggt aacatttaaa tggtcctcct gtactgtgtg 5040
tgtctgtgac cgcttataga gttttattgt tattgggtgt tacctgaata cctatgcgta 5100
cacacacaca tatttcctta atacttctga actcattatc ttttagaata ataatactac 5160
tacactttac cagcaattaa cttctcccta cccaaaatgt ttttcttct gtctgaaaat 5220
ggaacaaatt tgtcttattc gtgcttatat ctgtattaaa tgcaataaag ttagtttttg 5280
aaatgt 5286

15
<210> 88
<211> 424
<212> PRT
<213> Homo sapiens

<220>
<223> Septin 2

20
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
Thr Asp Ile Ala Arg Gln Val Gly Glu Gly Cys Arg Thr Val Pro Leu
1 5 10 15
Ala Gly His Val Gly Phe Asp Ser Leu Pro Asp Gln Leu Val Asn Lys
20 25 30
Ser Val Ser Gln Gly Phe Cys Phe Asn Ile Leu Cys Val Gly Glu Thr
35 40 45
Gly Leu Gly Lys Ser Thr Leu Met Asp Thr Leu Phe Asn Thr Lys Phe
50 55 60
Glu Gly Glu Pro Ala Thr His Thr Gln Pro Gly Val Gln Leu Gln Ser
65 70 75 80
Asn Thr Tyr Asp Leu Gln Glu Ser Asn Val Arg Leu Lys Leu Thr Ile
85 90 95
Val Ser Thr Val Gly Phe Gly Asp Gln Ile Asn Lys Glu Asp Ser Tyr
100 105 110
Lys Pro Ile Val Glu Phe Ile Asp Ala Gln Phe Glu Ala Tyr Leu Gln
115 120 125
Glu Glu Leu Lys Ile Arg Arg Val Leu His Thr Tyr His Asp Ser Arg
130 135 140
Ile His Val Cys Leu Tyr Phe Ile Ala Pro Thr Gly His Ser Leu Lys
145 150 155 160
Ser Leu Asp Leu Val Thr Met Lys Lys Leu Asp Ser Lys Val Asn Ile
165 170 175
Ile Pro Ile Ile Ala Lys Ala Asp Ala Ile Ser Lys Ser Glu Leu Thr
180 185 190
Lys Phe Lys Ile Lys Ile Thr Ser Glu Leu Val Ser Asn Gly Val Gln
195 200 205
Ile Tyr Gln Phe Pro Thr Asp Asp Glu Ser Val Ala Glu Ile Asn Gly
210 215 220

EP 1 284 298 A2

Thr Met Asn Ala His Leu Pro Phe Ala Val Ile Gly Ser Thr Glu Glu
 225 230 235 240
 5 Leu Lys Ile Gly Asn Lys Met Met Arg Ala Arg Gln Tyr Pro Trp Gly
 245 250 255
 Thr Val Gln Val Glu Asn Glu Ala His Cys Asp Phe Val Lys Leu Arg
 260 265 270
 10 Glu Met Leu Ile Arg Val Asn Met Glu Asp Leu Arg Glu Gln Thr His
 275 280 285
 Thr Arg His Tyr Glu Leu Tyr Arg Arg Cys Lys Leu Glu Glu Met Gly
 290 295 300
 15 Phe Lys Asp Thr Asp Pro Asp Ser Lys Pro Phe Ser Leu Gln Glu Thr
 305 310 315 320
 Tyr Glu Ala Lys Arg Asn Glu Phe Leu Gly Glu Leu Gln Lys Lys Glu
 325 330 335
 20 Glu Glu Met Arg Gln Met Phe Val Gln Arg Val Lys Glu Lys Glu Ala
 340 345 350
 Glu Leu Lys Glu Ala Glu Lys Glu Leu His Glu Lys Phe Asp Arg Leu
 355 360 365
 25 Lys Lys Leu His Gln Asp Glu Lys Lys Lys Leu Glu Asp Lys Lys Lys
 370 375 380
 Ser Leu Asp Asp Glu Val Asn Ala Phe Lys Gln Arg Lys Thr Ala Ala
 385 390 395 400
 30 Glu Leu Leu Gln Ser Gln Gly Ser Gln Ala Gly Gly Ser Gln Thr Leu
 405 410 415
 Lys Arg Asp Lys Glu Lys Lys Asn
 420
 35
 <210> 89
 <211> 4612
 <212> DNA
 40 <213> Homo sapiens
 <220>
 <223> Septin 2
 45 <400> 89
 cgaccgatag agctcgccag gtgggtgaag gttgccgaac tgtccccctg gctggacatg 60
 tggggllltga cagcttgccct gaccagctgg tgaataagtc cgtcagccag ggccllctgct 120
 tcaacatccct gtgcgtggga gagacaggtt tgggcaagtc caccctcatg gacaccctgt 180
 tcaacaccaa attcgaagg gagccagcca cccacacaca gccgggtgtc cagctccagt 240
 ctaataccta tgacctccaa gagagcaacg tgaggctaaa gctcacgacg gttagcacag 300
 50 ttggcttttg ggaccagatc aacaaagagg acagctacaa gcctatcgtg gaattcatcg 360
 atgcacaatt cgaggcctac ctgcaggaag agctaaagat ccgaagagtg ctacacacct 420
 accatgactc ccgaatccat gtctgcttgc atttcattgc cccacgggt cattccctga 480
 agtctctgga cctagtgc atgaagaagc tggacagtaa ggtgaacatc atccccatca 540
 ttgccaaagc agatgccatt tcgaagagtg agctaacaaa gttcaaaatc aaaatcacca 600
 gcgagcttgt cagcaacgga gtccagatct atcagtttcc tacagatgat ggtcgggtgg 660
 55 cagagatcaa tggaaccatg aacgcccacc tgccgtttgc tgcattggc agcacagaag 720

aactgaagat aggcaacaag atgatgaggg cgcggcagta tccttggggc actgtgcagg 780
 ttgaaaacga ggcccaactgc gactttgtga agctgcggga gatgctgatt cgggtcaaca 840
 tggaggatct gcgggagcag acccacacccc ggacatagta gctgtatcgc cgctgtaagc 900
 tggaggagat gggcttcaag gacaccgacc ctgacagcaa acccttcagt ttaaggaga 960
 5 catatgagggc caaaaggaac gatttcctag gggaactcca gaaaaagaa gaggagatga 1020
 gacagatgtt cgtccagcga gtcaaagaga aagaagcgga gctcaaagag gcagagaaaag 1080
 agctgcacga gaagtttgac cgtctgaaga aactgcacca ggacgagaag aagaaactgg 1140
 aggataagaa gaaatccctg gatgatgaag tgaatgcttt caagcaaaga aagacggcgg 1200
 ctgagctgct ccagtcccag ggctcccagg ctggaggctc acagactctg aagagagaca 1260
 10 aagagaagaa aaattaactc tgctgtttgc tgcattgctg atgagaccca gggctcctgtt 1320
 tgggcttccct gtagacaccc ttttctctgc caacagagct gggcctccct ttctctaatt 1380
 tcccccttaa catgcctggg gggcatataca tccaaccgc gccctctcct ctcttctctg 1440
 caaggtttat agaaacctga gaatctgagg gtgatgtctg gccgctggtc aagaagccaa 1500
 cagtcagtg gctcgcagat gcactctgca tccagctccc cctcccagca cccccagcca 1560
 tccccctgt ctccccccac atcttttgcca gaggtgtgac atggtcaggg ggcccatctg 1620
 15 ctactctttc ccaccagctc cctgtttcca gttctggttg ctgttagttt ccttgaggta 1680
 tttgcaacca ccatggctgg gtaaccaccg atcagcacag ctgtcccctt ggtctcctgt 1740
 atcccagtc ctagtctctc ctgggtccacc ccacctcat cctcaggagc cacagccatt 1800
 tcttagagg tttcaaaagg acagcctttg gcgcctttt ctcttaacct ttgagtcag 1860
 ccttttccag ttttctattc ctgcaagtaa ctgcactcaa gctgtgctca aaatcggcaa 1920
 20 cgcatttatt tacaccaagc ccttcccata aaacacaaact gctgaagaaa atagcagacg 1980
 tttccctct ctctaactct gggatatcca cagatgcaaa agggagaata aacctgaata 2040
 ttattaccag cctagagctt tgaatgatag ccttaccgaa ttcttcttgt gaggtatttc 2100
 agcatctcgg gggtaattt ccggaagggg tccatactgt cccaataagg tgaggccagt 2160
 agcaggaata ataaatccca ctttgtaggc tggaaaactg agctgtcaaa agaatacagt 2220
 gtttgggggg ttgctctgat gactcttcta gttcatttgg tgaatgtcat gatgattttt 2280
 25 aacatgcatt ttgcatgcat cccccaataa gaagagatga gactcggctg gagagaagaa 2340
 aaggccctta actttcttct caatttaagg agttgagagt ttaaaaatat tccagcccta 2400
 agtttttatt atgggtccca tctgatagtg gctttgggaa cctctgtgaa gtagagagcc 2460
 ctcccttgtc agggttatga ggcacagtg cctttgggtg ttggccagtg acagtgtgag 2520
 agatggagtt gacctggcaa tgatctgttg ctaacatgcc gtctctctgc ccttctcttg 2580
 30 cagtaatcca tggctgtgta ctgaatagta ttccccgcta cagctggact ggactccatt 2640
 tagcctttta agccgaggtt cctattttta ctgacagctt tcccttgggg tgccaggcag 2700
 cgaggccccc caccctatc ctgcccagta cttcaagctc acttcttctt tttaggttcc 2760
 gcaacttgct cctgcctccc agccccactg gcactgacca tgaccaccta ctctattttt 2820
 ttttttagag tttctttttt tgatcactta ctttcaaagc acacagtcaa acaaggttat 2880
 gccaatttc caggcctttt tgaagtattg agaaggggaa ggggatttct cacttcaatt 2940
 35 atagatcata ataggaagca aaaaagaaaa aatgaaaagc aaacatatgc acgcactttt 3000
 cttgttgaca aagcaagaat ataggtttgc tgtgtagggt tgggtgctcta ttgattgggtg 3060
 agtgaccaga gcaagtatga aggtgatgct gccaaagcac aagccttttt gaagtattga 3120
 gaaggggaag gggatttctc acttcaatta ttgttgacaa agcaagaata taggtttgct 3240
 atgaaaagca aacatatgca cgcacttttc ttgttgacaa agcaagaata taggtttgct 3240
 gtgtagggtt ggtgctctat tgattggtga gtgaccagag caagtatgaa ggtgatgctg 3300
 40 ccaaagcaca agccagttt ttgggaaaaa tcaagtlaca gtggagtatt tttttgaaga 3360
 ccatatgctt ggaggtagaa acaaaccaac gacaaaaaaa aaaaaaaa aatctgctca 3420
 gatactcagc cagtagctca gagagatgct gaggtaggct tgtcaggtct ccttgggaaa 3480
 ggcttcatat ttgcaacttt gatgattcta tgtccagctt cagagctgct tcccagaaa 3540
 ttcacgctta aacaaccaac cggtaaccac cacttcccca caccgcccgc cggtattat 3600
 ttgcattaca aaccggaggg gccctcattt gcatttgtgt acagattaac tagttaaggc 3660
 45 ttgagaagct ctgaataatt caaaaagtatt agaccacac agccttggag agaccttcag 3720
 aaactaagga ggagttttat attaggggag acatttttagt cagtaagacg atataacct 3780
 ctactccgt aaggggaaat gaaggcccag agaagggaag ggacttgacc gaggtcccac 3840
 ttctgtttcg aggcagaagc cagactaatt ttcatgcctc ctgactccca atcagtttca 3900
 caaagggatt caatctgttt atatacgta cattctgga tacgaggtct tttgatgttc 3960
 50 agagtaactg actagttagt attagaagac cctcagggtt tttttccaca gaaaaacatc 4020
 tgaagatgga ttgggtgagg gctggcaaaa cgaaggcatg ccgggcccagc tccttaaccc 4080
 aatgaccag tgatgctgca aggctggaac ggggtccagg agactgtgtg taacaggtgc 4140
 cctaggtgac ccttataatc aggggaagttt ggtgaacaaa aatcgaacc atgagtgaac 4200
 ataaattaaa aagttgatca acctattaaa atgtgtattt cattgggtag cttttctcac 4260
 ttagagacaga ttttttctt cttcaatgaa aaggctttta aattagtaca actgttacta 4320
 55 tttaaaaaaa aaatacccta agtactctgt ttacttctgg tgaacaaaaa ccagtcatta 4380
 gaaatggctc gtgcttttat tttcccagac tggagtggct tttctgaaac acacacacac 4440

EP 1 284 298 A2

acacacacac acacacacac gtacacacat cccctcacttc tcttaagcca agaagtttgc 4500
 tttccctagc tgcagtgtag atggctcttg tttttgtttt tttgttttaa tcatttggca 4560
 ttcacatgtg gctgttaata tgtgcttggt ttttaattaaa acaagaagct tt 4612

5

<210> 90
 <211> 459
 <212> PRT
 <213> Rattus norvegicus

10

<220>
 <223> Nucleobindin

15

<400> 90
 Met Pro Thr Ser Val Pro Arg Gly Ala Pro Phe Leu Leu Leu Pro Pro
 1 5 10 15

Leu Leu Met Leu Ser Ala Val Leu Ala Val Pro Val Asp Arg Ala Ala
 20 25 30

20

Pro His Gln Glu Asp Asn Gln Ala Thr Glu Thr Pro Asp Thr Gly Leu
 35 40 45

Tyr Tyr His Arg Tyr Leu Gln Glu Val Ile Asn Val Leu Glu Thr Asp
 50 55 60

25

Gly His Phe Arg Glu Lys Leu Gln Ala Ala Asn Ala Glu Asp Ile Lys
 65 70 75 80

Ser Gly Lys Leu Ser Gln Glu Leu Asp Phe Val Ser His Asn Val Arg
 85 90 95

30

Thr Lys Leu Asp Glu Leu Lys Arg Gln Glu Val Ser Arg Leu Arg Met
 100 105 110

Leu Leu Lys Ala Lys Met Asp Ala Lys Gln Glu Pro Asn Leu Gln Val
 115 120 125

35

Asp His Met Asn Leu Leu Lys Gln Phe Glu His Leu Asp Pro Gln Asn
 130 135 140

Gln His Thr Phe Glu Ala Arg Asp Leu Glu Leu Leu Ile Gln Thr Ala
 145 150 155 160

40

Thr Arg Asp Leu Ala Gln Tyr Asp Ala Ala His His Glu Glu Phe Lys
 165 170 175

Arg Tyr Glu Met Leu Lys Glu His Glu Arg Arg Arg Tyr Leu Glu Ser
 180 185 190

45

Leu Gly Glu Glu Gln Arg Lys Glu Ala Glu Arg Lys Leu Gln Glu Gln
 195 200 205

Gln Arg Arg His Arg Glu His Pro Lys Val Asn Val Pro Gly Ser Gln
 210 215 220

50

Ala Gln Leu Lys Glu Val Trp Glu Glu Leu Asp Gly Leu Asp Pro Asn
 225 230 235 240

Arg Phe Asn Pro Lys Thr Phe Phe Ile Leu His Asp Ile Asn Ser Asp
 245 250 255

55

EP 1 284 298 A2

Gly Val Leu Asp Glu Gln Glu Leu Glu Ala Leu Phe Thr Lys Glu Leu
 260 265 270
 5 Glu Lys Val Tyr Asp Pro Lys Asn Glu Glu Asp Asp Met Arg Glu Met
 275 280 285
 Glu Glu Glu Arg Leu Arg Met Arg Glu His Val Met Lys Asn Val Asp
 290 295 300
 10 Thr Asn Gln Asp Arg Leu Val Thr Leu Glu Glu Phe Leu Ala Ser Thr
 305 310 315 320
 Gln Arg Lys Glu Phe Gly Glu Thr Ala Glu Gly Trp Lys Thr Val Glu
 325 330 335
 15 Met Tyr Pro Ala Tyr Thr Glu Glu Glu Leu Lys Arg Phe Glu Glu Glu
 340 345 350
 Leu Ala Ala Arg Glu Ala Glu Leu Asn Ala Arg Ala Gln Arg Leu Ser
 355 360 365
 20 Gln Glu Thr Glu Ala Leu Gly Arg Ser Gln Asp Arg Leu Glu Ala Gln
 370 375 380
 Lys Arg Glu Leu Gln Gln Ala Val Leu Gln Met Glu Gln Arg Lys Gln
 385 390 395 400
 25 Gln Gln Gln Glu Gln Ser Ala Pro Pro Ser Gln Pro Asp Gly Gln Leu
 405 410 415
 Gln Phe Arg Ala Asp Thr Gly Asp Ala Pro Val Pro Ala Pro Ala Gly
 420 425 430
 30 Asp Gln Lys Asp Val Pro Ala Ser Glu Lys Lys Val Pro Glu Gln Pro
 435 440 445
 Pro Val Leu Pro Gln Leu Asp Ser Gln His Leu
 450 455

35

<210> 91
 <211> 2152
 <212> DNA
 <213> Rattus norvegicus

40

<220>
 <223> Nucleobindin

45

<400> 91
 ccagaaacct ggcggaggtc gcgggctggg aaaacgccct ctgcgctagg agagaccagc 60
 tacgatgcct acctctgtgc cccgcggggc gcctttcctt ctctaccac ctttactgat 120
 gctgtctgct gtgctggcag tgcctgtgga ccgcgcagca cctcatcagg aggacaacca 180
 ggccactgag accccggaca caggcctgta ctaccatcgg tacctccagg aggtcatcaa 240
 cgtgctagag acagatgggc acttccggga gaagctgcaa gctgccaacg ctgaggacat 300
 taagagtgga aagctgagtc aagagctgga cttcgtcagc cacaacgtcc gcaccaagct 360
 50 ggatgagctc aagcgacagg aggtatcaag gcttcggatg ctgctcaagg ccaagatgga 420
 tgcaaagcag gaggctaact tgcaggtgga ccacatgaac cttctgaagc agtttgaaca 480
 cctggaccct cagaaccagc acacgtttga ggctcgggac cttagagctgc tgatccagac 540
 ggccaccgga gacctcgcc agtatgacgc tgcacaccat gaagagttca aacgctacga 600
 gatgctcaag gaacatgagc gaagacgtta cctggagtct ctgggagagg agcagcggaa 660
 ggaggctgag aggaagctac aagagcagca gcgcagacac cgggaacacc ccaaagtcaa 720
 55 tgttcctggc agccaagccc agttgaagga ggtgtgggag gagctagatg gattggacc 780

EP 1 284 298 A2

5 caacaggttc aaccccaaga ccttcttcat actgcatgac atcaacagcg atgggtgtcct 840
 agatgagcaa gaactggaag ctctgtttac caaggagctg gagaagggtgt acgacccgaa 900
 gaacgaggag gacgacatga gggagatgga ggaggagcgg ctgcgcatgc gggagcatgt 960
 gatgaagaac gtggacacca accaggaccg acttgtgacc ctggaggaat tcctggcatc 1020
 cacacagagg aaggagtgtt gggaaaactgc ggagggatgg aagacagtgg aaatgtatcc 1080
 agcctacaca gaggaagagc tgaagcgttt tgaagaggag cttgctgccc gggaggctga 1140
 gctaaatgcc agagcccagc gcctcagcca ggagacagag gccctggggc gctcccagga 1200
 ccgcctagag gctcagaaga gagagctgca gcaggccgtt ctgcagatgg agcaaaggaa 1260
 gcagcaacag caagagcaga gcgctccgcc ttcccaacct gatgggcagc tgcagttccg 1320
 10 tgacagacaca ggggatgctc ctgtcccagc tccagcaggt gaccagaaag acgtgcctgc 1380
 ttctgaaaag aaggttccag agcagccccc tgtgctgcca cagctggatt ctcagcattt 1440
 ataagccctc agagatcccg gccctcaagt tcccacagac agtcatggaa gctggatgaa 1500
 gtgtccttgc agcctttctg gagaccaaag ccttcattgg ctccagggga gaacagggcc 1560
 accctgttcc tcagatgcgc ttctgcccac ttctaccagt ctgttctcac agcctctggg 1620
 tcaccagtcc gccttcttcc ctcccttccct tggcaggggac tcaactgcag gagccccctca 1680
 15 cccacactga gtgcacaccc caggccctgcc tgccttccat gctttgctct tacctgtccc 1740
 aggtcaacc ttctgtcttc ctgtacctgt cagtgggtca caggagcttg acttggtctc 1800
 tccaactctt tgccttgtga gaggccaatg atctcaattc cttttggtgg ctaggaggccg 1860
 ccacaatgtg ggggtgtccta tcagctctgc ctgggactcc tgaactccac caccacccca 1920
 ccagccttac cctaaccacc tgggcccatt acctacctga ggggtcccaga agggggccag 1980
 atatggctac accccttact gaggtccagc ctcaactcca cgtatggggg ctccctgaaaa 2040
 20 ttggttcacc cacttccctg gcttcaggcc acactgctgt gtcctgctct gtgtcccagt 2100
 ctcatccaac tatagcctgg cacaataaaa cattagatat ctgtgtgaat gt 2152

<210> 92
 <211> 160
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Myelin structural protein SR 13

30 <400> 92
 Met Leu Leu Leu Leu Leu Gly Ile Leu Phe Leu His Ile Ala Val Leu
 1 5 10 15
 35 Val Leu Leu Phe Val Ser Thr Ile Val Ser Gln Trp Leu Val Gly Asn
 20 25 30
 Gly His Arg Thr Asp Leu Trp Gln Asn Cys Thr Thr Ser Ala Leu Gly
 35 40 45
 40 Ala Val Gln His Cys Tyr Ser Ser Ser Val Ser Glu Trp Leu Gln Ser
 50 55 60
 Val Gln Ala Thr Met Ile Leu Ser Val Ile Phe Ser Val Leu Ser Leu
 65 70 75 80
 45 Phe Leu Phe Phe Cys Gln Leu Phe Thr Leu Thr Lys Gly Gly Arg Phe
 85 90 95
 Tyr Ile Thr Gly Val Phe Gln Ile Leu Ala Gly Leu Cys Val Met Ser
 100 105 110
 50 Ala Ala Ala Ile Tyr Thr Val Arg His Ser Glu Trp His Val Asn Asn
 115 120 125
 Asp Tyr Ser Tyr Gly Phe Ala Tyr Ile Leu Ala Trp Val Ala Phe Pro
 130 135 140
 55 Leu Ala Leu Leu Ser Gly Ile Ile Tyr Val Ile Leu Arg Lys Arg Glu

EP 1 284 298 A2

145

150

155

160

5

<210> 93
<211> 1736
<212> DNA
<213> Rattus norvegicus

10

<220>
<223> Myelin structural protein SR 13

<400> 93

15

```

ggggggaagcc agcaacctag aggacgcccc cgagtttgtg cctgaggcta ctccgctctg 60
agccggctgt ccctttgaac tgaaagcacc gctccaccga gcccagagccc aactccagcc 120
accatgcttc tactcttggtt ggggatcctg ttcccttcaca tcgcggtgct agtggttgctc 180
ttcgtctcca ccacgtcag ccaatggctc gtgggcaatg gacacaggac tgatctctgg 240
cagaactgta ccacatccgc cttgggagcc gtccagcact gctactcctc atctgtgagc 300
gaatggcttc agtctgtcca ggccaccatg atcctgtctg tcactcttcag cgtcctgtcc 360
ctgttcctgt tcttctgcca gctcttcact ctaccaaag gcggcgctt ttacatcact 420
ggagctcttc aaatccttgc tggctgtgtg gtgatgagtg cagcggccat ctacacagtg 480
agacacagtg agtggcatgt caacaacgac tactcctatg gctttgctta catcctggcc 540
tgggtggctt tcccgtctgg cctccttagt ggcatcatct acgtgatcct gcggaaacgc 600
gaatgaggcg cccgacgcac catccgtcta ggctctgagc gtgcataggg tacacaggga 660
gggaggaagg aaaccagaaa accaaaccaa ccaaccctaa agagctagcc cccaaaccca 720
aacgcaagcc aaaccaaaac gaacacagtt gagtggggat tgctgtcgat tgaagatgta 780
tataatatct atggtttata aaacctaatt ataacacttt ttacatacat gtacatagga 840
ttgtttgctt tttatgttga ccgtcagcct cgtgttgaat cttaaacgac tctacatcct 900
aacactataa ccaagctcag tattttcgtt ttgtttcgtt ttttcatct tttgttttg 960
ctcagacata aaaaaaaaaa aaaaatccac gtggccccct ttcatctgaa agcagatccc 1020
tccctcccat tcaacctcat aggataacca aagtgcgggg acaaacccca gatggccaga 1080
ggccttcaca ctatgggtga cccagtgaat ttagcaggaa taatccgctg cccgaatcaa 1140
tgtgtgaagc cctaagcact cacagacgaa acgccttgac cagagccctc tgcgaaacca 1200
atagctgggtg gctgcggaac acttgaccct gaaggcggag tactggggca catgtttaa 1260
tgagacgtca gagacaagca atctgtgaaa tgggtctata gatttaccat tccttggtat 1320
tactaatcat ttaaacact cactggaaac tcaattaaca gttttatgac ctacagcaga 1380
acagagaccc gatacaaacg gttcgttaact gcttcgttac atagctaggg tgttggtatt 1440
actacaataa ataaatctca aagccttcgt cactcccaca gttttctcac ggtcggagca 1500
tcaggacgag ggtctagacc cttgggacta gcaaattccc tggctttctg ggtctagagt 1560
gttctgtgcc tccaaggact gtctagcgat gacttgtatt ggccaccaac tgtagatgta 1620
tatacgtgtg ccttctgatg ctaagactcc agacctttct tggttttgct ggctttttct 1680
gattttatac caactgtgtg gactaagatg cattaataa aacatcagag taactc 1736

```

40

<210> 94
<211> 375
<212> PRT
<213> Rattus norvegicus

45

<220>
<223> Cytoplasmic beta-actin

<400> 94

50

```

Met Asp Asp Asp Ile Ala Ala Leu Val Val Asp Asn Gly Ser Gly Met
  1             5             10             15

Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg Ala Val Phe Pro
      20             25             30

Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met Val Gly Met Gly

```

55

EP 1 284 298 A2

	35		40		45
	Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala Gln Ser Lys Arg Gly Ile				
	50		55		60
5	Leu Thr Leu Lys Tyr Pro Ile Glu His Gly Ile Val Thr Asn Trp Asp				
	65		70		75
	Asp Met Glu Lys Ile Trp His His Thr Phe Tyr Asn Glu Leu Arg Val				
10		85		90	95
	Ala Pro Glu Glu His Pro Val Leu Leu Thr Glu Ala Pro Leu Asn Pro				
		100		105	110
	Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe Glu Thr Phe Asn				
15		115		120	125
	Thr Pro Ala Met Tyr Val Ala Ile Gln Ala Val Leu Ser Leu Tyr Ala				
		130		135	140
	Ser Gly Arg Thr Thr Gly Ile Val Met Asp Ser Gly Asp Gly Val Thr				
20			150		155
	His Thr Val Pro Ile Tyr Glu Gly Tyr Ala Leu Pro His Ala Ile Leu				
			165		170
	Arg Leu Asp Leu Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met Lys Ile				
25		180		185	190
	Leu Thr Glu Arg Gly Tyr Ser Phe Thr Thr Thr Ala Glu Arg Glu Ile				
		195		200	205
	Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp Phe Glu				
30		210		215	220
	Gln Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys Ser Tyr				
			230		235
	Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly Asn Glu Arg Phe Arg				
35			245		250
	Cys Pro Glu Ala Leu Phe Gln Pro Ser Phe Leu Gly Met Glu Ser Cys				
		260		265	270
	Gly Ile His Glu Thr Thr Phe Asn Ser Ile Met Lys Cys Asp Val Asp				
40		275		280	285
	Ile Arg Lys Asp Leu Tyr Ala Asn Thr Val Leu Ser Gly Gly Thr Thr				
		290		295	300
	Met Tyr Pro Gly Ile Ala Asp Arg Met Gln Lys Glu Ile Thr Ala Leu				
45			310		315
	Ala Pro Ser Thr Met Lys Ile Lys Ile Ile Ala Pro Pro Glu Arg Lys				
		325		330	335
	Tyr Ser Val Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Ser Thr Phe				
50		340		345	350
	Gln Gln Met Trp Ile Ser Lys Gln Glu Tyr Asp Glu Ser Gly Pro Ser				
55		355		360	365

Ile Val His Arg Lys Cys Phe
370 375

5 <210> 95
<211> 4100
<212> DNA
<213> Rattus norvegicus

10 <220>
<221> misc_feature
<222> 3859
<223> n is a or g or c or t

15 <220>
<223> Cytoplasmic beta-actin

<400> 95
acctcttctt caactcactt ctctctactc tcactttttt ttttcttctt cttttttttt 60
tttttttttt tttttttttt tgcaaaagaa gggggtataa aaatgctgca ctgtcgggcg 120
aggccgggtga gtgagcgagc cggagccaat cagcgcccg cgttccgaaa ttgcctttta 180
tggtctcgagt ggccgctgtg gcgtcctata aaaccggcg gcgcaacgag cgccactgtc 240
gagtcgcggt ccaccgcgga gtacaacctc ctgagctc ctccgtcccg gtccacaccc 300
gccaccagggt aagcagggac gtcggggcca gcggggccca actttacctt ggccactacc 360
tcgctgcagg atcgtgagga aactcagaa gggacaccgt agaggggtgg agcgtggtac 420
cgggcccggg agcagctggc aaagcttaac ttcccgggc cctaggggtgt agagtgtttg 480
cagtcgtatt cccgcggtgt ggacactcgt gggtagctc ctgcttgggtg cgcggggctt 540
ggggacacac tagagtcgag gtgtgggcat ttggagagcc ggtgcggctg cgggtgttaa 600
gccgcatctg tccaccttga ggggcaacag tattggggtc aggcgttaca atcacgcttt 660
gatggcctat ggggtcttgt ccaaaccggg ttgtccattc ggcttggcgg gcgcgccggg 720
gccgctcggc cgggtggggg ctgggatgcc attgcgcgtg cgcgctctat cactgggcat 780
tggggcccgtg cgcgctgggg agggaaactc tcctctcccc ctcttccgag ttaagagtgt 840
cgcgctgcgtg cgcgctgggg agggaaactc gcccggggtt gggcgaggggc gggccgtcca 900
30 ccggaagggg cggggtcgta gcggctaggg gcctgctcgc gcttctcgtt ggggtgtgtc 960
gcctcccgcg cgcgcactag ccgcccgtcg cctcagtgta ggcgggcttg tgcccgtttg 1020
gggagggggc gaggcctggc ttctgcccgt ggggtccgct ccgggcccagc gtttgccctt 1080
tatggttaata atgaggctgt cctgcgcttc cttgtcccc tgagcttggg cgcgcccctg 1140
gcggctcgag gccgcggctc gccggaagtg ggcagggcg cagcggtgct tcttggcggc 1200
35 tccgcggtga ccatagccct ctttgtgccc ttgatagttc gccatggatg acgatatcgc 1260
tgcgctcgtc gtcgacaacg gtcccggcat gtgcaaggcc ggcttcgagg gcgacgatgc 1320
tccccggggc gtcttcccct ccacgtgagg ccgcccctag caccaggtaa gtgacctt 1380
actttgggag tggcagccct aggtttttct tgggggtcga tgccagtgtc gagaacgttg 1440
ttctcctccg cagggtgtga tgggtgggtat gggtcagaag gactcctacg tgggcgacga 1500
40 ggcccagagc aagagaggca tcctgacccct gaagtacccc attgaacacg gcattgtaac 1560
caactgggac gatattggaga agatttggca ccacactttc tacaatgagc tgcgtgtggc 1620
ccctgaggag caccctgtgc tgcacaccga ggcccctctg aaccctaagg ccaaccgtga 1680
aaagatgacc caggtcagta tcctgggtga cctcccccct cttattgggt caacttctca 1740
gcacgcccct ctctaattgt ctttcttctg ccatgtccca taggactctc ttctatgagc 1800
tgagtctccc ttggaacttt gcagtttctg ctctttccca gatgaggtct tttttttctc 1860
45 tcgatgcgct ttctgactag gtgtttttaa cccctacagt gctgtgggtg taggtactaa 1920
caatggctcg tgtgacaaag ctaatgaggc ttgtgataaa tggccttggg gtgtgtattc 1980
agtagatgac agtaggtcta aatggagccc ctgtcctgat actcccagca cacttaactt 2040
agctgtgttc ttgccctctt tgcatgtctc actcaaatct atccttacag tctcacctgc 2100
cctgagtggt tcttgtggct ttaggagctt gacaatactg tattccttct tctacagatc 2160
atgtttgaga ctttcaaac cccagccatg tacgtagcca tccaggctgt gttgtcccctg 2220
50 tatgcctctg gtcgtaccac tggcattgtg atggactccg gagacggggt caccacact 2280
gtgcccatct atgagggtta cgcgctcccct catgccatcc tgcgtctgga cctggctggc 2340
cgggacctga cagactacct catgaagatc ctgaccgagc gtggctacag cttcaccacc 2400
acagctgaga gggaaatcgt gcgtgacatt aaagagaagc tgtgctatgt tgccctagac 2460
ttcgagcaag agatggccac tgccgcatcc tcttctccc tggagaagag ctatgagctg 2520
cctgacggtc aggtcatcac tatcggaat gagcggttcc gatgccccga ggctctcttc 2580
55 cagccttctt tcctgggtaa gttgtagtct cgtcccttct ccatctaaag gtgaccaatg 2640

EP 1 284 298 A2

5 ctggaggcca cactgtaact ctgatctctt gcttttccctt tcagggtatgg aatcctgtgg 2700
 catccatgaa actacattca attccatcat gaagtgtgac gttgacatcc gtaaagacct 2760
 ctatgccaac acagtgtgtg ctggtggcac caccatgtac ccaggcatcg ctgacaggat 2820
 gcagaaggag attactgccc tggctcctag caccatgaag atcaaggtaa gcagccttag 2880
 cctggaccce tagtgggggtg tggtcagccc tgtagtgtga gccaaactctc ttggcttaag 2940
 gaacaaccce gcatccagaa tgctcacaat cactgtcttg ctttcttcag atcattgtctc 3000
 ctccctgagcg caagtactct gtgtggattg gtggctctat cctggcctca ctgtccacct 3060
 tccagcagat gtggatcagc aagcaggagt acgatgagtc cggccccctcc atcgtgcacc 3120
 gcaaatgctt ctaggcggac tgttactgag ctgctgttta caccctttct ttgacaaaac 3180
 10 ctaacttgcg cagaaaaaaa aaatgagaca tttggcatgg ctttattgtt tttttgtttt 3240
 ttgtttttgt tttttttaa tttttttttt aaaaaggttt tttttttttg tttttgtttt 3300
 gcgtttttga ctcaaggatt taaaaactgg aacggtgaag gcgaccgcag ttggttggag 3360
 caaacatccc ccaaagttct acaatgtggc tgaggacttt gattgtacat tgttttttgt 3420
 ttttggtttt ttttaatagc actccaagta tccacggcat agatgggtac aggaagtccc 3480
 15 tcaccctccc aaaagccacc cccaaactct aagggggagga tggctgcac catgccctga 3540
 gtccacaccg ggaaggtgac agcattgctt ctgtgtaaat tatgtacttg caaacatttt 3600
 tttaaatctt ccgccttaat acttcatttt tgtttttaat ttctgaatgg tcagccattc 3660
 gtggcctgcc cctttttttt gtccccccaa cttgatgtat gaaggctttg gtctccctgg 3720
 gagtggtttg aggtgttgag gcgccagggc tggcctgtac actgacgtga gaccgtttta 3780
 ataaaagtgc acaccttaca aacaagtttg tggctctgtg gcttctactg ggtgtgggga 3840
 gcaggctggg tgggtgtgna actccacgtg ggggaggggc aatttagggg gggctggcct 3900
 20 tgctgatag ctagtgggag ggctaaagga tcatgatctt taatgaggtc tcataaatatc 3960
 cccaccttcg gtcttgaggg aggggtgagga gttgggaagg tatctccctg acacctggcc 4020
 aagctggcct catcaaccct actttcctca gccaggggga ggtccacatc ctcccacctg 4080
 catagcttgc gtctagaggc 4100

25 <210> 96
 <211> 116
 <212> PRT
 <213> Mus musculus

30 <220>
 <223> Ly6/neurotoxin homolog

<400> 96
 Met Thr His Leu Leu Thr Val Phe Leu Val Ala Leu Met Gly Leu Pro
 1 5 10 15
 35 Val Ala Gln Ala Leu Glu Cys His Val Cys Ala Tyr Asn Gly Asp Asn
 20 25 30
 Cys Phe Lys Pro Met Arg Cys Pro Ala Met Ala Thr Tyr Cys Met Thr
 35 40 45
 Thr Arg Thr Tyr Phe Thr Pro Tyr Arg Met Lys Val Arg Lys Ser Cys
 50 55 60
 Val Pro Ser Cys Phe Glu Thr Val Tyr Asp Gly Tyr Ser Lys His Ala
 65 70 75 80
 45 Ser Ala Thr Ser Cys Cys Gln Tyr Tyr Leu Cys Asn Gly Ala Gly Phe
 85 90 95
 Ala Thr Pro Val Thr Leu Ala Leu Val Pro Ala Leu Leu Ala Thr Phe
 100 105 110
 50 Trp Ser Leu Leu
 115

55 <210> 97

<211> 3925
 <212> DNA
 <213> Mus musculus

<220>
 <223> Ly6/neurotoxin homolog

<400> 97
 taccaaacacc gcacgaagtg tgtacagatt cccagttaga cagcaggagg gacctgggag 60
 cgGCCagggg gatgttttat ctctaagaga ccaagagctc aggcagggct tctgtgccct 120
 gcttcctccc tggcttgagc tggatcctgg accagctgct gacctcctgt tcactctggc 180
 actgccctca cgtctccgtc atgacccatc tgctcacagt gttcctgggtg gccctgatgg 240
 gcctgcctgt ggcccaggct ctggagtggc acgtgtgylgc ctacaatgga gacaactgct 300
 tcaaaccat gcgctgcccc gccatggcca cctactgtat gaccacacga acttacttca 360
 ccccataccg gatgaagggt aggaagtcct gtgtccccag ctgctttgaa accgtgtacg 420
 atggctattc caagcatgca tctgccacct cctgttgcca gtactacctc tgcaacgggtg 480
 ctggctttgc taccocgggt accttggccc tgggtcccagc actcctagct accttctgga 540
 gcttgcctga aagctcgggt ccccaagcca gatccactca aacgcaacac tctcaaaaaa 600
 cacagtttcc ctctctctcc caattcactc caccacacgc tcttcttctt gacactcctc 660
 aactaccacg aggtcccatg gctacctacg aaagaactga tggcatccag atacctcact 720
 ccaaggatcat ttccagaagg ctgacatgtg gacctgtaat gtgccccacc atgggtgggg 780
 caggctgggc ttctctctca cccaagatca ggggcatctg ggagaatggt tatggaggag 840
 gggcatcac tcaagtcagg gacactgat ttgatagaat tagtagccaa actccacctt 900
 cagaaccctg cctcagtcta cccagtagag gatgggtctg cttagagtgga ggggaggaga 960
 ggggaggaga ataacgagct ggctagaagc agagaaagac tcagcagggc tgtctccgaa 1020
 gatcagcgcg gcttgccaga gcaaatgtga tgtggaagcc atgtgaggaa gccctttgtc 1080
 atttccactt atctgaggaa ctctgccaga cctgatgttg ggatagccat tggccaaggg 1140
 ttcttagcaa cggcgtcatt tccataggcc actgaaatcc ctccagcccc agctcagcag 1200
 gcccttgac ctccactaca gtcttctatt cacacaccag ctgctgggccc ttgaagttag 1260
 cagggacttg ggagcagggt acccatgcta ttttttgtct ggctgttat tctgggcatg 1320
 gcaagaaggg atcagacgca ggtcagagca gggcagtagg ggcactgaga cagggaaca 1380
 gacttcagcc agtggcttcc aggtcccgat aggcagctcc tacatccttc agtctcttgt 1440
 tacattcccg ggagacaaat atacaggggag ccaagccgag tgctaggtga tgactgcctg 1500
 tgaagtctat tgtggccaca gactgctggg taccaagtct caggagaacc cagcctagat 1560
 ttagggagca cagatctgcc tttcatgcag tgtagctgtc cttgggagcc ttaccatgct 1620
 ctctaactag ttctcaact cacatgtcac tgaggaaacc cctaacactg gccagcccc 1680
 ggggtcggga tgcctggcaa tgtccatgga gtgggactac cctggagag tcttgggtc 1740
 atcacatcac aaatgtttta ttccaacctc ccagtgggtga gagctcggga cacaagggtc 1800
 catcctgggg accttcttcc tgggtctagg cagacctgaa ctctgtctgc tgctagagct 1860
 gatgtggttt tccgcctcag ttctctctcc cggggatagg ccaccggagg atttggagg 1920
 gtggggaggg catcctgctg atgggctcgc cagggttctc aggaacagga acgggagggg 1980
 ctttagtaca cagggtgagtt ggggtgggaac tggcccgag ctgaggagac actgactggg 2040
 cagagggaag atgagtctca agggagggca ggaaaaggga gggggagcgc gcatgcacat 2100
 gtgcactcag tgcaggctac agagcccaaa aggcagcact ggctgtggtg tcccctgagg 2160
 cccagggaag atgctaggag gaagccaatg ctgccccac ctgagctcac atggaacatg 2220
 cacaccacca gcagcagcag caagcattga gactgacctg tggacgccat agggcactgg 2280
 caaggagggt cagaggcggg tccctgactc agtgggtgag gcccgggaaa cattatcctg 2340
 ttaccctcgc tgtgcaagat cattgtcccc agctagatgg cgtcctcaac caaaactgag 2400
 aggagcccca gttcaggctc tccctcttac cacaaggggg tgggtgtggag gaggcttgat 2460
 tgcccttgga gaagcaccgg tactgcagag ctgggggcca gcttctttca tctgtgtcta 2520
 gacaccgacc agataggccc cacagtggca acactgccac acagtcttac aagaagccct 2580
 gtgcctagct agcacagagc cccaaaagggt gctcaattaa tacaggggcca agcctgccag 2640
 tgggggggat gcagattagg ggaacagacc cagatggcct gtcctgaacc ctgtctgggg 2700
 tgggtgtgatg agcatctgtc tagccactg cagggtggctc tacacactcc acaacagttc 2760
 tgcaaaaagt tatgaggtgg tcattactgc gccctctca caggtaaagg cactgaggca 2820
 cggaggagtg aggcacttca ttttctctgg ccattcaact ttccaggacc aacacattca 2880
 actatgggta ctactccaat agctggggtt cttttaggct gggccccctg aagatgatag 2940
 tggcttctac aaccagagaa ttctcagagt cagtgttgta ggagcctatg aacctgaaat 3000
 gtcagaactg gaggtttgag gggctgagg gttagccagg ggtgtctggc ccttltgltg 3060
 gagacagaga gagagggaac atgggatggg gtagtagaga gaagtgcaaa ggagcgtcag 3120
 cctttctcag ggctaagtct gtcagggacg agggctcaag cctgtgagtg tttctcact 3180
 gtgataaaca gtggccctc aacacagacg gtgtccagag tggccggcag tggttatcta 3240

5 gagttgcaat ctggaagcct cttggtagtc actggagaga ggccgcttga tgggacagca 3300
 ccaaagtgtgt gtgcttctgt gggatgtgag gaagctgggt cagcgcatga agccaaagcg 3360
 tccttcagag cagaggggtg gctgggtctag tccaccagag acaagctatc cagtggagagt 3420
 catactctgt caccgtctct gtgattacct taccctcaag cagacgggga cgggatgcag 3480
 agcacccgtg tcttcattct ctgcggcaag cacgtgagtt cacattctga aactctagaa 3540
 agatttccag gagtgggggtg tgcctttgct ttggtgcatg gttacttcct ggcaagcacc 3600
 gtggcatccc gcagcactga gtgacctggg ctccctcaagc catctcattg gtgaaatgac 3660
 agtgccagta ccctctcagc tggctcttgg aggcctgtgc atgggggtctg cacagaggag 3720
 gcccccaaac tatgcatgga cggacacgtg atgcctagca cttcccttgg ttgtgtctct 3780
 10 gccaaaccca ggctctcacc cagcaaggaa atgaaatcca cttttatgac acatctccct 3840
 cccccagcca gctccattca cctatatgcc aggggtgtcc ctttcaatgt ctgtccccc 3900
 ttggatgaat aaacaagcga aggac 3925

15 <210> 98
 <211> 130
 <212> PRT
 <213> Rattus norvegicus

20 <220>
 <223> Astrocytic phosphoprotein
 <400> 98
 Met Ala Glu Tyr Gly Thr Leu Leu Gln Asp Leu Thr Asn Asn Ile Thr
 1 5 10 15
 25 Leu Glu Asp Leu Glu Gln Leu Lys Ser Ala Cys Lys Glu Asp Ile Pro
 20 25 30
 Ser Glu Lys Ser Glu Glu Ile Thr Gly Ser Ala Trp Phe Ser Phe
 35 40 45
 30 Leu Glu Ser His Asn Lys Leu Asp Lys Asp Asn Leu Ser Tyr Ile Glu
 50 55 60
 His Ile Phe Glu Ile Ser Arg Arg Pro Asp Leu Leu Thr Met Val Val
 65 70 75 80
 35 Asp Tyr Arg Thr Arg Val Leu Lys Ile Ser Glu Glu Asp Glu Leu Asp
 85 90 95
 Thr Lys Leu Thr Arg Ile Pro Ser Ala Lys Lys Tyr Lys Asp Ile Ile
 100 105 110
 40 Arg Gln Pro Ser Glu Glu Glu Ile Ile Lys Leu Ala Pro Pro Pro Lys
 115 120 125
 Lys Ala
 130

45 <210> 99
 <211> 2341
 <212> DNA
 <213> Rattus norvegicus

50 <220>
 <223> Astrocytic phosphoprotein
 <400> 99
 55 gcggaagagg cggcggcggc aggatcggcg gcagcgggtgg ccggagccaa ggagcaggct 60
 ccagacgctg cttaggaacc ggggatccgg gagtggccgc accctgagct ctcagctccg 120

EP 1 284 298 A2

5 gaggcgtcat ggcagagtac gggactctcc ttcaggacct gaccaacaac atcacccttg 180
 aagatctgga acagctcaag tcagcctgca aggaggacat cccagtgag aagagtgaag 240
 agatcactac aggcagtgcc tgggttagct tcctggagag ccacaacaag ctggacaaag 300
 5 acaacctctc ctacattgag cacatctttg agatctcccg ccgtcctgac ctactcacga 360
 tgggtggtga ctacagaacc cgtgtgctga agatctctga ggaggatgag ctggacacca 420
 agctaaccgg tatccccagc gccaaagaagt acaaagacat tatccggcag ccctctgagg 480
 aagaaatcat caaattggct cccccaccaa agaaggcctg agcaaggggg aggaagagga 540
 ggaagggttg atcttcatca gaccactccc ttcccatccc tcaatgggag gggctagggc 600
 aacaccctgc tccgtaccca cttactaact tggtcctaac cttactatg cgcgtgtgtg 660
 10 tgcgtgtgcg cacgctctgg ctgtctgtct gtctagctca tctagttcct cctcctcatg 720
 aggggatttg agtcaaggga ggggggctta gctgccccca ctgtaagggg aggtggacgc 780
 tttttctatg taaacagaaa ctggcacact cctcctcctc tcctctcctc cactcttccc 840
 cacatcttta aagtatggaa gcagaaaggg cctgcgtttt cccacactga ggagctatgg 900
 tgaaaaatgag glatggcgga aatgattaga tctaaagaaa accagtgggg aaggaagggtc 960
 aagaggctac ccaacctoca cctgaagggg cctctgagtg ccagcggggc ctcctttatg 1020
 15 cccttggttac gggcctggga tgtggataag cagagatcct aatgagaaga ccactagctc 1080
 ctttcttagg tcccagatc aaaccccagt ggagaagcca gcttttgatg tccccactt 1140
 ctgctctgga gagactatgc tgggaccatg cactgctgag cctgagccag ggatgcaggc 1200
 agagacaggc ccactctcgc tcctcagttt ctgatacag actggtggga tatactgacc 1260
 cggagcctag gaattgggga atgagatccc ttaggtttta accgcaacct gcagagtccc 1320
 20 aaaatgggta ttgtaggcaa cttttccact ttccagttcg gaattctcca agcaagagat 1380
 aagttaacga cagtgtttcc tttgactga ctaccacccc attcaatcca ggaagggact 1440
 ggtcaccttt ctcatgtggg tttgtgaatg ccacacagcc aagccactag agtacagtga 1500
 gtgaaccctag cctcctccct gtcccaagat gcccttcccc atcttgaccg tgctaactgt 1560
 gtgtacatat atattctaca tatatgtata ttaaaccgca actgccatgt ctgccctttt 1620
 25 ttgtggtttt tagcattaac ttattgtcta ggccagagcg ggagtgggag gggaatgcca 1680
 cagtaaaagg agtggcagay ccaaattgct aagttagtca aaacagaaaa catttccaac 1740
 caatcacaaac aaacattgca ttacatttg agctaagaga caatttagag aaagttgaag 1800
 gtaggagctt ttaggatgtg gggcagaaaac ttcacaggga agggaggacc agctgtcaga 1860
 agagggctct tgaagccaga ctggctagag caccctcact tcctagctga gccagtttg 1920
 cccatctcct ctggccactg ctgcagacac ctgccttaac acacacacct ctaagactoc 1980
 agttttgcct taaaggccct tcctaagtct ccctagtcct gcctggcatc tcctttgaga 2040
 30 caagaaatcc ttgtacaact gggagaaagg aactatgggc aacatccttc catctggggg 2100
 gttacgtgag agcaggagtt aagacggagg ctttccctat gaagacacag gagagagaga 2160
 ggggtgcttct cagcagtttc tctgtaaggc aaaaaacaca aaccttaaac acactaacct 2220
 gccctaatac actcacctac cctgctaccc tcgtgtgtgt gtgaggttgc ccctagcctg 2280
 gtgtcctctg tctgcagcgt gcacggcctt gttctaaccg tggaataaag gtgactgact 2340
 35 g 2341

<210> 100

<211> 582

<212> PRT

<213> Mus musculus

<220>

<223> PLIC-1

<400> 100

Met Ala Glu Ser Ala Glu Ser Gly Gly Pro Pro Gly Ala Gln Asp Ser
 1 5 10 15

Ala Ala Asp Ser Gly Pro Ala Glu Pro Lys Ile Met Lys Val Thr Val
 20 25 30

Lys Thr Pro Lys Glu Lys Glu Glu Phe Ala Val Pro Glu Asn Ser Ser
 35 40 45

Val Gln Gln Phe Lys Glu Glu Ile Ser Lys Arg Phe Lys Ser His Ile
 50 55 60

Asp Gln Leu Val Leu Ile Phe Ala Gly Lys Ile Leu Lys Asp Gln Asp

EP 1 284 298 A2

	65		70		75		80									
	Thr	Leu	Ser	Gln	His	Gly	Ile	His	Asp	Gly	Leu	Thr	Val	His	Leu	Val
				85					90						95	
5	Ile	Lys	Thr	Gln	Asn	Arg	Pro	Gln	Asp	Asn	Ser	Ala	Gln	Gln	Thr	Asn
				100					105					110		
	Thr	Thr	Gly	Asn	Ser	Val	Thr	Ser	Ser	Pro	Ala	Pro	Asp	Ser	Asn	Pro
10			115					120					125			
	Thr	Ser	Gly	Pro	Ala	Ala	Asn	Ser	Ser	Phe	Gly	Leu	Gly	Gly	Leu	Gly
			130				135					140				
	Gly	Leu	Ala	Gly	Leu	Ser	Ser	Leu	Gly	Leu	Asn	Thr	Thr	Asn	Phe	Phe
15	145					150				155						160
	Glu	Leu	Gln	Ser	Gln	Met	Gln	Arg	Gln	Leu	Leu	Ser	Asn	Pro	Glu	Met
					165					170					175	
	Met	Val	Gln	Ile	Met	Glu	Asn	Pro	Phe	Val	Gln	Ser	Met	Leu	Ser	Asn
20				180					185					190		
	Pro	Asp	Leu	Met	Arg	Gln	Leu	Ile	Met	Ala	Asn	Pro	Gln	Met	Gln	Gln
			195					200					205			
	Leu	Ile	Gln	Arg	Asp	Pro	Glu	Ile	Ser	His	Met	Leu	Asn	Asn	Pro	Asp
25			210				215					220				
	Ile	Met	Gly	Gln	Thr	Leu	Glu	Leu	Ala	Arg	Asn	Pro	Ala	Met	Met	Gln
	225					230				235						240
	Glu	Met	Met	Arg	Asn	Gln	Asp	Arg	Ala	Leu	Ser	Asn	Val	Glu	Ser	Ile
30				245						250					255	
	Arg	Gly	Gly	Tyr	Asn	Ala	Leu	Arg	Arg	Met	Tyr	Thr	Asp	Ile	Gln	Glu
				260				265						270		
	Pro	Met	Ile	Asn	Ala	Ala	Gln	Glu	Gln	Phe	Gly	Gly	Asn	Pro	Phe	Gly
35			275					280					285			
	Ser	Leu	Val	Ser	Ser	Pro	Ser	Ser	Ala	Glu	Gly	Thr	Gln	Pro	Ser	Arg
			290				295					300				
	Thr	Glu	Asn	Arg	Asp	Pro	Leu	Pro	Asn	Pro	Trp	Ala	Pro	Gln	Thr	Pro
40	305					310					315					320
	Gln	Ser	Ser	Pro	Ala	Tyr	Gly	Ser	Ser	Gly	Ser	Thr	Asn	Asn	Thr	Val
				325						330					335	
45	Ser	Thr	Ser	Gly	Gly	Asn	Ala	Thr	Ser	Thr	Pro	Ala	Gly	Gln	Gly	Thr
				340				345						350		
	Ser	Gly	Pro	Lys	Leu	Val	Pro	Gly	Ala	Gly	Gly	Ser	Met	Phe	Asn	Thr
			355					360					365			
50	Pro	Gly	Met	Gln	Ser	Leu	Leu	Gln	Gln	Ile	Thr	Glu	Asn	Pro	Gln	Leu
			370				375					380				
	Met	Gln	Asn	Met	Leu	Ser	Ala	Pro	Tyr	Met	Arg	Ser	Met	Leu	Gln	Ser
55	385					390					395					400

EP 1 284 298 A2

Leu Ser Gln Asn Pro Asp Leu Ala Ala Gln Met Met Leu Asn Asp Pro
405 410 415

5 Leu Phe Ala Gly Asn Pro Gln Leu Gln Glu Gln Met Arg Gln Gln Leu
420 425 430

Pro Thr Phe Leu Gln Gln Met Gln Asn Pro Asp Thr Leu Ser Ala Met
435 440 445

10 Ser Asn Pro Arg Thr Met Gln Ala Leu Leu Gln Ile Gln Gln Gly Leu
450 455 460

Gln Thr Leu Ala Thr Glu Ala Pro Gly Leu Ile Pro Gly Phe Thr Pro
465 470 475 480

15 Gly Leu Ala Ala Gly Asn Ser Gly Gly Pro Ala Gly Thr Thr Ala Pro
485 490 495

Ser Thr Ala Pro Gly Glu Asp Thr Asn Pro Gln Gly Gly Ala Ala Glu
500 505 510

20 Pro Gly His Gln Gln Phe Ile Gln Gln Met Leu Gln Ala Leu Ala Gly
515 520 525

Val Asn Pro Gln Leu Gln Ser Pro Glu Val Arg Phe Gln Gln Gln Leu
530 535 540

25 Glu Gln Leu Ser Ala Met Gly Phe Leu Lys Arg Glu Pro Asn Leu Gln
545 550 555 560

Ala Leu Ile Ala Thr Gly Gly Asp Ile Asn Ala Ala Ile Glu Arg Leu
565 570 575

30 Leu Gly Ser Gln Pro Ser
580

35 <210> 101
<211> 1843
<212> DNA
<213> Mus musculus

40 <220>
<223> PLIC-1

45 <400> 101
ccatggccga gagcgagag agcggcgcc caccgggccc tcaggacagt gcggccgaca 60
gcggccccc agagcccaag atcatgaagg tcacgggtgaa gacgcctaaa gagaaggaag 120
agttcgctgt gcccgagaac agctcggtcc agcagttcaa agaggaaatc tcaaaacgtt 180
tcaaattcca tattgaccaa cttgtgttga tatttgctgg aaaaatttta aaagatcaag 240
atactttgag tcagcatggg attcatgatg gacttacggg tcaccttgct atcaaaaccc 300
aaaacaggcc gcaagataat tcagctcagc aaacaaatac cactggaaac agtgtgacca 360
gttcaccagc tcctgacagt aaccccaagt ctgggcctgc tgctaacagc tcctttggtt 420
taggtggact tggaggactt gcaggcttta gtagcttggg tttaaatacc accaacttct 480
ttgaactaca gagccaaatg cagcggaac tttgtctaa ccctgaaatg atgggtccaga 540
tcatggaaaa cccctttgtg cagagcatgc tctcaaacc tgacctgatg cggcagctga 600
tcatggccaa cccacagatg cagcagctga tacagagaga cccagagatc agtcatatgc 660
ttaataaccc agatataatg ggacagacat tggaacttgc cagaaaccca gcgatgatgc 720
aggaaatgat gagaaaccag gaccgagcct tgagcaacgt agaaagtatc cgtggagggt 780
acaacgcctt acggcgcatg tacacagata ttacaggagcc catgataaac gctgcgcaag 840
agcagtttgg tggtaatcca tttggttcct tagtgagcag tccgtcctca gcagaaggga 900
55 ctcagccttc tcgaacagaa aatagggatc cgctaccta cccttgggct ccacagactc 960

EP 1 284 298 A2

5 cccagagctc tccagcctat ggcagcagtg gcagcaccaa taacacagtg agcacctctg 1020
 gtggcaatgc caccagtacc cgggcgggac agggcacctc agggcccaag cttgtgcctg 1080
 gagcaggagg tagtatgttc aacacccccg gaatgcagag cctgctgcag cagataactg 1140
 agaaccacaca gctcatgcag aacatgctgt ctgccccata catgaggagc atgctgcagt 1200
 ccctgagcca gaaccccgac cttgctgcgc agatgatgct gaatgacccc ctatttgctg 1260
 ggaaccctca gcttcaagag caaatgagac aacagctccc aacgttcctc caacaaatgc 1320
 agaacccccga cacattgtca gccatgtcga accctagaac catgcaggcc ctgctgcaaa 1380
 tccagcaggg cttgcagacg ttggccacag aagctcccgg cctcatocca gggtttactc 1440
 ctggcttggc agcgggcaat tctggaggcc ctgcaggaac cactgcacct agcactgcac 1500
 10 ctggtgagga tacgaacccc caagggggcg ctgctgagcc agggccaccag cagtttatcc 1560
 agcaaatgct gcaggccctc gccgggggtga accctcagct gcagagtcca gaagtccagat 1620
 ttcaacagca actggaacag ctcagtgcga tgggattcct gaagcgtgaa ccaaaattac 1680
 aagcactgat agcaacaggg ggcgacatca atgcggccat tgaaagggtg ctgggtlccc 1740
 agccgtcata gcagcatttc tgtatcctga aaaaatgtaa tttatttttg ataacggctc 1800
 ttaaatcttt aaaataacct gctttatttc attgggattc tgt 1843

15
 <210> 102
 <211> 618
 <212> PRT
 <213> Rattus norvegicus

20
 <220>
 <223> Nfxl

25 <400> 102
 Met Ala Asp Glu Gly Lys Ser Tyr Asn Glu His Asp Asp Arg Val Ser
 1 5 10 15
 Phe Pro Gln Arg Arg Lys Lys Gly Arg Gly Pro Phe Arg Trp Lys Cys
 20 25 30
 30 Gly Val Gly Asn Arg Arg Ser Gly Arg Gly Gly Ser Gly Ile Arg Ser
 35 40 45
 Ser Arg Phe Glu Glu Asp Asp Gly Asp Val Ala Met Asn Asp Pro Gln
 50 55 60
 35 Asp Gly Pro Arg Val Arg Phe Asn Pro Tyr Thr Thr Arg Pro Asn Arg
 65 70 75 80
 Arg Arg Asp Thr Trp His Asp Arg Asp Arg Ile His Val Thr Val Arg
 85 90 95
 40 Arg Asp Arg Ala Pro Gln Glu Arg Gly Gly Ala Gly Thr Ser Gln Asp
 100 105 110
 Gly Thr Thr Lys Asn Trp Phe Lys Ile Thr Ile Pro Tyr Gly Lys Lys
 115 120 125
 45 Tyr Asp Lys Met Trp Leu Leu Ser Met Ile Gln Ser Lys Cys Ser Val
 130 135 140
 Pro Phe Asn Pro Ile Glu Phe His Tyr Glu Asn Thr Arg Ala His Phe
 145 150 155 160
 50 Phe Val Glu Asn Ala Thr Thr Ala Ser Ala Leu Lys Ala Val Asn Tyr
 165 170 175
 Lys Ile Gln Asp Arg Glu Asn Gly Arg Ile Ser Ile Ile Ile Asn Ser
 180 185 190

EP 1 284 298 A2

	Ser	Ala	Pro	Pro	Tyr	Ile	Val	Gln	Asn	Glu	Leu	Lys	Pro	Glu	Gln	Val	
			195					200					205				
5	Glu	Gln	Leu	Lys	Leu	Ile	Met	Ser	Lys	Arg	Tyr	Asp	Gly	Ser	Gln	Gln	
		210					215					220					
	Ala	Leu	Asp	Leu	Lys	Gly	Leu	Arg	Ser	Asp	Pro	Asp	Leu	Val	Ala	Gln	
	225					230					235					240	
10	Asn	Ile	Asp	Val	Val	Leu	Asn	Arg	Arg	Gly	Cys	Met	Ala	Ala	Ala	Leu	
					245					250					255		
	Arg	Ile	Ile	Glu	Glu	Asn	Ile	Pro	Glu	Leu	Leu	Ser	Leu	Asn	Leu	Ser	
				260					265					270			
15	Asn	Asn	Arg	Leu	Tyr	Lys	Leu	Asp	Asp	Met	Ser	Ser	Ile	Val	Gln	Lys	
			275					280					285				
	Ala	Pro	Asn	Leu	Lys	Ile	Leu	Asn	Leu	Ser	Gly	Asn	Glu	Leu	Lys	Ser	
		290					295					300					
20	Glu	Trp	Glu	Leu	Asp	Lys	Ile	Lys	Gly	Leu	Lys	Leu	Glu	Glu	Leu	Trp	
	305					310					315					320	
	Leu	Asp	Arg	Asn	Pro	Met	Cys	Asp	Thr	Phe	Leu	Asp	Gln	Ser	Thr	Tyr	
					325					330					335		
25	Ile	Ser	Thr	Ile	Arg	Glu	Arg	Phe	Pro	Lys	Leu	Leu	Arg	Leu	Asp	Gly	
				340					345					350			
	His	Glu	Leu	Pro	Pro	Pro	Ile	Ala	Phe	Asp	Val	Glu	Ala	Pro	Thr	Met	
			355					360					365				
30	Leu	Pro	Pro	Cys	Lys	Gly	Ser	Tyr	Phe	Gly	Thr	Glu	Asn	Leu	Lys	Ser	
		370					375					380					
	Leu	Val	Leu	His	Phe	Leu	Gln	Gln	Tyr	Tyr	Ala	Ile	Tyr	Asp	Ser	Gly	
	385					390					395					400	
35	Asp	Arg	Gln	Gly	Leu	Leu	Asp	Ala	Tyr	His	Asp	Gly	Ala	Cys	Cys	Ser	
					405					410					415		
	Leu	Ser	Thr	Pro	Ser	Asn	Pro	Gln	Asn	Pro	Val	Arg	His	Asn	Leu	Ala	
				420					425					430			
40	Lys	Tyr	Phe	Asn	Asp	Ser	Arg	Asn	Val	Lys	Lys	Ile	Lys	Asp	Thr	Thr	
			435					440					445				
	Thr	Arg	Phe	Arg	Leu	Leu	Lys	His	Thr	Arg	Leu	Asn	Val	Val	Ala	Phe	
		450					455					460					
45	Leu	Asn	Glu	Leu	Pro	Lys	Thr	His	His	Asp	Val	Asn	Ser	Phe	Val	Val	
	465					470				475						480	
	Asp	Ile	Ser	Ala	Gln	Thr	Ser	Thr	Leu	Leu	Cys	Phe	Ser	Val	Asn	Gly	
					485					490					495		
50	Val	Phe	Lys	Glu	Val	Asp	Gly	Lys	Ser	Arg	Asp	Ser	Leu	Arg	Ala	Phe	
				500					505					510			
	Thr	Arg	Thr	Phe	Ile	Ala	Val	Pro	Ala	Ser	Asn	Ser	Gly	Leu	Cys	Ile	
			515					520					525				

EP 1 284 298 A2

Val Asn Asp Glu Leu Phe Val Arg Asn Ala Ser Pro Glu Glu Ile Gln
530 535 540

5 Arg Ala Phe Ala Met Pro Ala Pro Thr Pro Ser Ser Ser Pro Val Pro
545 550 555 560

Thr Leu Ser Gln Glu Gln Asp Met Leu Gln Ala Phe Ser Thr Gln
565 570 575

10 Ser Gly Met Asn Leu Glu Trp Ser Gln Lys Cys Leu Gln Asp Asn Asn
580 585 590

Trp Asp Tyr Thr Arg Ser Ala Gln Ala Phe Thr His Leu Lys Ala Lys
595 600 605

15 Gly Glu Ile Pro Glu Val Ala Phe Met Lys
610 615

<210> 103
20 <211> 2304
<212> DNA
<213> Rattus norvegicus

<220>
25 <223> Nfx1

<400> 103
attccatcct aatacgactc actatagggc tcgagcggcc gcccgggcag gtccaaggcg 60
tccgggtgtt tgggtggcgc aggtttctgcg cctgagcccg cccctgtacc tgcctgtgccc 120
atggcggacg aagggaagtc atacaacgaa catgatgacc gtgttagttt cccacaaaaga 180
30 agaaaagaaa gtcggggggcc tttccgatgg aagtgtggtg tggggaatcg taggtctgga 240
agaggtggtt ctggtatacg gtcttcccgg tttgaggaag atgatggaga tgtggcaatg 300
aatgatcccc aggatggccc ccgagtgaga ttcaaccctt ataccacccg acctaacctg 360
cggagagata cttggcatga tcgagatcgg attcatgtta ctgtacggag agacagagct 420
cctcaagaaa gaggaggtgc tggcaccagt caagatggga ccaccaagaa ctggttcaag 480
attacaattc cttatggcaa aaagtatgat aaaatgtggc ttctgagcat gattcaaagc 540
35 aagtgcagtg tccccctcaa ccccatgtag ttctactatg aaaatacacg ggccccattt 600
tttgtggaaa atgccactac cgcttctgca ttaaaggctg tcaactataa gattcaggat 660
cgagaaaacg gaaggatata tcatcatc acactctctg ctccacccta tattgtacag 720
aatgaactga agcctgaaca agtagagcag ctcaagctga tcatgagcaa acgatatgat 780
ggctcccagc aagcacttga cctcaagggc ctccgctcag acccagattt ggtggcccag 840
aacatcgatg ttgttctaaa ccgtagaggc tgtatggcag ccgcccctgag gatcattgaa 900
40 gagaacattc ctgagctatt gtctttgaac ttgagtaaca acaggctgta caagcttgat 960
gacatgtcca gcattgtaca gaaggacca aacttaaaga tcctgaatct ctctggaaac 1020
gaattgaagt ccgagtggga attagacaag ataaaagggc tgaagctgga agagctgtgg 1080
cttgacagaa accccatgtg tgacaccttc ctgaccaggt ccacctatat cagcaccatt 1140
cgcgaacgat ttcccaagtt attacgcctg gatggccatg agctaccccc tccaattgccc 1200
45 tttgatgtcg aagcccctac tatgttacca cctgcaagg gaagctattt tggaaacagag 1260
aacctaaaga gtctgttcct gcacttcttg cagcagtact atgcaattta tgactcagga 1320
gaccgccagg gtcttcttga tgcctaccat gatggcgctt gttgctcgct aagcactcct 1380
tccaaccctc agaaccctgt ccgacacaac tttagccaat acttcaatga cagcagaaat 1440
gtgaagaaga ttaaagatac caccacgcgg ttccggctat taaagcatac acgtcttaat 1500
50 gtrgttgcct tcttcaatga gttacctaaa actcaccatg acgttaactc ctttgtggta 1560
gatataagtg cccaaacaag cacattgttg tgtttttctg tcaatggagt cttcaaggaa 1620
gtggacggga agtctcgaga ttctttacgt gctttcacga gaacgttcat tgcgtgttcc 1680
gccagcaatt cagggtctatg tttgttaaatt gacgaattat ttgtgcgga cgcagccct 1740
gaagaaatcc aaagagcctt gccatgcct gcaccacac cttcttcag ccagtaccc 1800
acactctccc aagaacagca ggatatgtta caagcathtt ctaccagtc tggcatgaac 1860
ctcgagtggg ctcaagaagt ccttcaagac aataactggg actacaccag atctgcccag 1920
55 gccttcactc atctcaaggc caaggagag attccagaag tagcgtttat gaaatgatct 1980

EP 1 284 298 A2

5 caagaaaagt ccccttgtaa atagcccttg gataatattg tctggctgtc atctgaggac 2040
 tcctgtccag cccgaggcca cmctgtaact gtgactgggg aggaagggct gcytcacck 2100
 tcctcaccta ccttctggaa gmcttagcag aagacttccg gaagattgag cctctatggt 2160
 gccaggaagc caaagcttac tttgtagagc tdgacrcata attaccggaa ggacttaggt 2220
 gctctgtgta cttaacccca gsattccctt tactttttaa gataaagagt gatattgtag 2280
 tgtgtgtccc aaaaaaaaaa aaaa 2304

10 <210> 104
 <211> 175
 <212> PRT
 <213> Rattus norvegicus

15 <220>
 <223> Alpha B-crystallin

15 <400> 104
 Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro
 1 5 10 15
 20 Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu
 20 25 30
 Leu Glu Ser Asp Leu Phe Ser Thr Ala Thr Ser Leu Ser Pro Phe Tyr
 35 40 45
 25 Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Ile Asp Thr Gly
 50 55 60
 Leu Ser Glu Met Arg Met Glu Lys Asp Arg Phe Ser Val Asn Leu Asp
 65 70 75 80
 30 Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp
 85 90 95
 Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly
 100 105 110
 35 Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val
 115 120 125
 Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr
 130 135 140
 40 Val Asn Gly Pro Arg Lys Gln Ala Ser Gly Pro Glu Arg Thr Ile Pro
 145 150 155 160
 Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys
 165 170 175

45 <210> 105
 <211> 6806
 <212> DNA
 <213> Rattus norvegicus

50 <220>
 <223> Alpha B-crystallin

55 <400> 105
 gggaagagca gcctatgact ttctgccac acggagccca ttcggctctac caggttacag 60
 acaggagcag cacaacaag gccctagat tttggtttat ttagcctcac ccagaattaa 120

	atcgaaggct	acgatttcac	aagggaccaa	accatacact	gtggaccatg	cacctatccc	180
	atctcccagg	aatgctgctc	cctctggggg	gtgggtggatt	tctggaatca	ccacggggagg	240
	tagacagggg	attcaccggg	tctctgggtct	ggcagtcagg	gttcaactct	ggctacctct	300
	tcctcttctc	cgggggtcagg	aggtgacagg	agcagggaga	tgtagacctc	attgacttcc	360
5	gtgtccagat	gccggccacc	ccgcggtgcc	tccaagttaa	ggatgccatc	atgggagaga	420
	gcagctctga	cccggccagg	gtccacatct	gcaggcagga	catagggttg	gacagaactc	480
	tcgggacacg	aagccgtggc	gtccagacgt	tgggggtgtc	gggcagacac	tctagcaggt	540
	tgccacagct	cctcacgggt	acctcatctg	gggtaaagtg	gctcacatcc	agaaatgcct	600
	ggaacttgcc	ttcactgagc	ctgagctctg	aggcccctgc	cctgccgccc	ccccagctc	660
	ctggcgccc	ggggccgaac	atagtagcca	tggtagaggg	tgggggtcag	gatctcttct	720
10	ggcaggaggc	ctgggagcag	agaaagaaag	agaaggcaag	aggcaggatg	aggaagaatg	780
	cagcgggcac	agacagggct	gaaaggcgat	atctggagat	atgggctaga	agagcaggtg	840
	ggaaactgta	gaggggctgg	gaaaggagag	gagatgggtta	cggaaaaagc	gagctggaac	900
	tggaggacag	aagcaaaacc	agaaaatact	ctgaagcgtg	caaggcccgg	acaccgaaag	960
	ccctgcccgat	ctaaagtctg	gtcctgaagt	ctgttagcaa	gaccagagag	agtcttgctt	1020
15	gaggggggag	tctgggtggg	gagatggctc	acctcaggag	ttcacttaag	ccccaggtag	1080
	agtggaggcc	agtgaagctg	ggcagtgagc	ccagaaattc	cggaggtggg	ggtagggaagc	1140
	atctgagcca	taccttctcc	gaagcgtctg	tcgcccagg	cggctagggt	tggcaaattc	1200
	gtactcggca	gtggctgggt	gggcgtgtgg	cactgtgcgg	cccgcacatg	ctgctgttgc	1260
	gactagtagc	cctgatccca	agtgtagccc	caacaagatc	aaggcgaccc	ctccagcttc	1320
	agagggagag	ccaggactca	gtcagagtgg	gggcgggggtc	tacaccaccc	aaaatagtcg	1380
20	agagcgtctg	ggggatgggg	gaggggtggg	agcctaagtc	tagagtgcag	ctatgagggt	1440
	gtgatcagcg	ctgcctggac	ccccaaagtc	ccctcctctg	tatacccttc	agctgtcgca	1500
	taggcctgga	agaacagctg	agggctcctg	tcctagagta	agctgggaag	agaaactggt	1560
	gcgtcgcagg	agggcaaggga	gagggcctgt	tgggcccctc	accaattgta	cattccacat	1620
	caccctttgt	ccttatcagt	ctcaggcact	gagcacatta	cttagaaaaa	aaaaaaaaaa	1680
25	gacaatgttc	tatgagccac	atgaacgtca	aaatacaaga	aacattttct	gtctttttta	1740
	tgtcagggtc	ttctgaacct	agatcaactc	gggggtccag	tcagacacct	agtctctgac	1800
	tattggtggg	cacagctctc	ctctgggact	ccacaagag	ttaatgtccc	tgggctcagc	1860
	ccaggaagat	tccagcctct	gcccaggccc	aagatagttg	ctggctcaat	tcccctggca	1920
	tgcaagactg	gagaggagga	ggggcccacc	agcagctgct	tgggattcca	gaccctgtcc	1980
	tggctccaga	gaacaaggat	gggggtgggtg	ggtgccacta	ggtgtggaca	gagagctagt	2040
30	gaaacaagac	cgtgacaagt	caccggccag	ctcagccctg	ccccgtgttt	ctcttttctt	2100
	agctcagtg	gtactgggta	tgtgtcaccc	tgccaaatcc	ctgatcaca	gtcccctatg	2160
	actgtcgggg	agctgggata	ataaaacccc	tgacatcacc	gttccagaag	cttcacaaga	2220
	ctgcataat	aaggggcagg	ctgtagcagc	ggctgaagga	gttgaccggc	taaccgactc	2280
	tacactcatc	tagccatcat	ggacatagcc	atccaccacc	cctggatccg	gcgtcccttc	2340
	tttcttttcc	actccccaag	ccgcctcttt	gaccagttct	tcggagagca	cctgttggag	2400
35	tctgacctct	tctctacagc	cacttccctg	agcccttctt	accttcggcc	acctccttc	2460
	ctgcgggcac	ctagctggat	tgacactggg	ctctcagagg	taagtctccc	ttgtgccagg	2520
	gcaggaaatac	gtatccttcc	tggctctctc	attcctttgc	cctttcaccc	tgcctaagtc	2580
	atlttaggca	tgtgcgtgtg	caaaggta	gagaaatgag	gttactgttc	tcttctctgt	2640
	gcacctgttc	tgttgatgct	cctgttctct	gtccattttc	tgtgcatggt	gcctctttct	2700
	cctctttcaa	ctcctttacc	cacctcttta	atagtccag	tcttggcaga	ttttatcatc	2760
40	tcaaaactgta	gagatcagat	agaaaaccac	tattctctgg	cttttctctg	cttctttcct	2820
	ccccacttcc	ttttgatgga	gctggataca	tcaatcaata	ttctctctct	ctctctctct	2880
	ctctctctct	ctctctctct	ctctctcttc	cttggcctat	gactttccgg	gttctctcgg	2940
	gctgagacag	tgcattgact	tcagtccatg	ccttaagagg	accgctcttg	ggaagccctg	3000
	acttcttata	tcagcagcgt	gggagataag	attaacagag	gttgctcacag	ataaactgt	3060
45	ggtttaaaaa	tattcgcgtg	tgaggaaaca	ggagctgagt	gagcaagggc	tgttgaagga	3120
	cagaacattc	cagatcgagt	gggttggaaa	cttggcaggc	aactgaacaa	gaaaaagggg	3180
	gcttttgttt	tatagacaaa	tgacaaagcc	agcactgggt	agagaggcag	cagatgccat	3240
	ccccagaccc	attcttgtga	ctagtctcct	actgaccgt	cttcttccct	gtgcctctcg	3300
	gtaaaagtttg	ggactgatgg	atgactaaga	ggtgcttttt	gggtatcacc	atgggtggctc	3360
	acataataca	gtgtcactag	tcaataagag	gatttttccc	ccagcagcca	ggtagaggat	3420
50	ggattaccag	ggcagggaag	aaatctcctg	gacgatgagc	cttctccagc	ttaatggaca	3480
	ttctaccatc	ttttctcttc	cgcccccttg	ttattctaga	tgcgtatgga	gaaggacagg	3540
	ttctctgtga	acctggacgt	gaagcacttc	tctccagagg	aactcaaaag	caaggttctg	3600
	ggagacgtga	ttgaggtgca	cggcaagcac	gaagagcgcc	aggtgtgtgg	acctttctgc	3660
	cttctcttgt	gaattcattt	agtgcctctg	tggatgccag	ggactgccgc	caccagcctc	3720
	tgaggctggc	agaattccag	tccccaaaca	taagactaga	tcaggagtta	tagatcaatg	3780
55	gctgggaaac	aagttagggc	tagatctgct	gttagtggtg	tggctgtgct	gagagaactt	3840

tccccctggat gttcccttttg attgccttgt cttgtccagt gacgtcagaa tagcagaaga 3900
 attctcaaca tttcccaacc tcagcacatc ctaggccaat tgaatctgaa gtttttaggga 3960
 catagctcag gcatcaacct ttaaacaaac aaacaaacaa actcactcct tgggtacttt 4020
 ctgtacccca aactggcagc cattgtctta ggcacagtgt gctgtacata atggctctgc 4080
 5 gaaatgacag tcaccacgga gtcgaaggca ataaaatctg tggccttttga atgttcagga 4140
 ttccatgcct cttctgtctca gtttaatgct atgctacttg gtttgtctgc ttttcagagc 4200
 ttcaggctta tggctgtgag gaagttaatt gagatttgtt tgtgtggatg cttgggggtac 4260
 ttgggattca ataggtaaca ggattagcat ccacaattcc tcttgcatth ttagcatttt 4320
 tttttcttga cttcctaaaa aggtgttatg attgcttctt aaaaattaat gacttggggg 4380
 10 gctggggatt tagctcagtg gtagagcgct tacctaggaa gcgcaaggte ctgggttcgg 4440
 tccccagctc cgaaaaaaaaa gaacaaaaaa aaaaaaattt aatgacttgg ggttggggat 4500
 ttagctcagc ggtagagcgt ttgcctagca agcgcaaggc cctgggttca gtccccagct 4560
 ccgaaaaaaaa gaaaagaaaa aaaaattaat gacttagggc ctggagagat ggctcagcag 4620
 ttaaaagcac tgaccgctct tccagaggct ctgcatacaa tttccagcaa ccacatgggtg 4680
 gctcacaacc atctgtaatg ggatccaatg cctcttctcg gcatgcaggt gtacatgcag 4740
 15 atagagtgtc catacataaa attaaaaaaa tcttaacaaa aaataactca gctgtgacct 4800
 ggtggtgcat gcctttaatc ccaacatttg ggaggcagag gtagacagat ctaagttaga 4860
 ggccagctta gactacagaa tgagttccag gagagcagga gctcaacaga gaaacctac 4920
 ttatctcaaa caaaacaaaa aacaaaaatc aatacctcgg ttttgcctat gatttaggac 4980
 tggaccacag tgtcactgat agggtcacct tatataatat cagcaatatt atactagaaa 5040
 cattctgaga cattcctgag caattagaac aatttatggg cttcctataa gatacagaca 5100
 20 tactcggggg tggggatttg gctcagtggt agagcgtttg cctagggaagc gcaaggctcc 5160
 ggggttcggtc ccagccctg aaaaaaagaa aaaagaaaaa aaaaaagat acagacatac 5220
 tcaatgccaa agtgggagtc taaattccat ggtccagtc aatggattc attcctttgt 5280
 ggaaatgccc tgaattgtag ttgtgtctcc gaatatgaag atctatgaaa ttcggggctg 5340
 tttcagattt cctacactct gattggtagg tgtgtccatc tggacagttt attctagcct 5400
 25 taaacctgga caaacagctc tggacttagc tatctgcata tttacagttt tggaggtgaa 5460
 ctcaggcctt t.cactactag actgaatccc cagctccaga tattttttcc ccccttaggg 5520
 ccttttgttc taacccaagg gcaggggatg tctagagtct ggggcaagtg gtggtatttc 5580
 ctgctcttat ttctctccct tgccttcat tctctcggat taggacgaac atggcttcat 5640
 ctccagggag ttccacagga agtaccggat cccagccgac gtggatcctc tcaccattac 5700
 30 ttcttccctg tcatcggatg gagtctcac tgtgaatgga ccaaggaaac aggcctctgg 5760
 ccttgagcgc accattccca tcaccctgta agagaagcct gctgtcactg cagccctaa 5820
 gaagttagatt ccttttctc gttgcatttt ttaagacaag gaagtttccc atcagcgaat 5880
 gaacatctgt gactagtgc gaagcttact aatgctaagg gctggcccag attattaagc 5940
 taataaaaaa tatcgttcag caacagacct gcctcgtctt tgcaaaccga gtgtgcttta 6000
 35 aaccaatctg caaacatagc agatctgtct atccccaccc tgtgattcag ggggctccga 6060
 ggatacgttt ggtcagagtg attggctcca gaactttgta cagtacaaac ccagggaaaa 6120
 ccattcactc tcttggtatt ccagttctca gtttataaca cactgtactg gttaggacag 6180
 agtcttagga gtagactaag aaggggagaaa tggtagcgtc ccagcagggt catgatgaat 6240
 cagctctggc taactccaca taaaagactt cagtgcatth ctgaagatta attacttcac 6300
 caggggggaca cgggtggcctt ggtgttattt gaagagtgtc ctcagctaatt tcacaggaca 6360
 gtaaatagct cgtgggtggg gactgtcgaa cgagagagcc tctcgggaat ggcacagagt 6420
 40 aatcaacaga taccttttaa accgagacca ttctctacca aacatgaaaa tgacaataaa 6480
 ggggtccagca aaaaaacaaa accaaaaatc agaagaacat cttcctccta aagttactaa 6540
 cccctggggg gggggggaag ccacacaaaa tagaaacccc ccaaaaacct ctctccattt 6600
 taatgggtct agacatagtt tctgtcagat tacactgagc cctgctaccc gatattctggc 6660
 aagcctgtag caccagttct catctctcct gtgttaactt taggttcaat tgaggatgtg 6720
 45 ccttttgaag atttttttta tttagtaatt attatttttt tataaaactt gataaaaaat 6780
 agtatttcca actgtacagt cactag 6806

<210> 106

<211> 646

<212> PRT

<213> Rattus norvegicus

<220>

<223> Heat shock cognate protein 70

<400> 106

Met Ser Lys Gly Pro Ala Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser

EP 1 284 298 A2

	1	5	10	15
	Cys Val Gly Val Phe Gln His Gly Lys Val Glu Ile Ile Ala Asn Asp	20	25	30
5	Gln Gly Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu	35	40	45
	Arg Leu Ile Gly Asp Ala Ala Lys Asn Gln Val Ala Met Asn Pro Thr	50	55	60
10	Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Arg Phe Asp Asp	65	70	75
	Ala Val Val Gln Ser Asp Met Lys His Trp Pro Phe Met Val Val Asn	85	90	95
15	Asp Ala Gly Arg Pro Lys Val Gln Val Glu Tyr Lys Gly Glu Thr Lys	100	105	110
	Ser Phe Tyr Pro Glu Glu Val Ser Ser Met Val Leu Thr Lys Met Lys	115	120	125
20	Glu Ile Ala Glu Ala Tyr Leu Gly Lys Thr Val Thr Asn Ala Val Val	130	135	140
	Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln Ala Ala Lys Asp	145	150	155
25	Ala Gly Thr Ile Ala Gly Leu Asn Val Leu Arg Ile Ile Asn Glu Pro	165	170	175
	Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Lys Lys Val Arg Ala Glu	180	185	190
30	Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser	195	200	205
	Ile Leu Thr Thr Glu Asp Gly Ile Phe Glu Val Lys Ser Thr Ala Gly	210	215	220
35	Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Met Val Asn His	225	230	235
	Phe Ile Ala Glu Phe Lys Arg Lys His Lys Lys Asp Ile Ser Glu Asn	245	250	255
40	Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu Arg Ala Lys Arg	260	265	270
	Thr Leu Ser Ser Ser Thr Gln Ala Ser Ile Glu Ile Asp Ser Leu Tyr	275	280	285
45	Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala Arg Phe Glu Glu	290	295	300
	Leu Asn Ala Asp Leu Phe Arg Gly Thr Leu Asp Pro Val Glu Lys Ala	305	310	315
50	Leu Arg Asp Ala Lys Leu Asp Lys Ser Gln Ile His Asp Ile Val Leu	325	330	335
55				

EP 1 284 298 A2

Val Gly Gly Ser Thr Arg Ile Pro Lys Ile Gln Lys Leu Leu Gln Asp
340 345 350

5 Phe Phe Asn Gly Lys Glu Leu Asn Lys Ser Ile Asn Pro Asp Glu Ala
355 360 365

Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu Ser Gly Asp Lys
370 375 380

10 Ser Glu Asn Val Gln Asp Leu Leu Leu Leu Asp Val Thr Pro Leu Ser
385 390 395 400

Leu Gly Ile Glu Thr Ala Gly Gly Val Met Thr Val Leu Ile Lys Arg
405 410 415

15 Asn Thr Thr Ile Pro Thr Lys Gln Thr Gln Thr Phe Thr Thr Tyr Ser
420 425 430

Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu Gly Glu Arg Ala
435 440 445

20 Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu Leu Thr Gly Ile
450 455 460

Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Asp Ile
465 470 475 480

25 Asp Ala Asn Gly Ile Leu Asn Val Ser Ala Val Asp Lys Ser Thr Gly
485 490 495

Lys Glu Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly Arg Leu Ser Lys
500 505 510

30 Glu Asp Ile Glu Arg Met Val Gln Glu Ala Glu Lys Tyr Lys Ala Glu
515 520 525

Asp Glu Lys Gln Arg Asp Lys Val Ser Ser Lys Asn Ser Leu Glu Ser
530 535 540

35 Tyr Ala Phe Asn Met Lys Ala Thr Val Glu Asp Glu Lys Leu Gln Gly
545 550 555 560

Lys Ile Asn Asp Glu Asp Lys Gln Lys Ile Leu Asp Lys Cys Asn Glu
565 570 575

40 Ile Ile Ser Trp Leu Asp Lys Asn Gln Thr Ala Glu Lys Glu Glu Phe
580 585 590

Glu His Gln Gln Lys Glu Leu Glu Lys Val Cys Asn Pro Ile Ile Thr
595 600 605

45 Lys Leu Tyr Gln Ser Ala Gly Gly Met Pro Gly Gly Met Pro Gly Gly
610 615 620

Phe Pro Gly Gly Gly Ala Pro Pro Ser Gly Gly Ala Ser Ser Gly Pro
625 630 635 640

50 Thr Ile Glu Glu Val Asp
645

55 <210> 107

<211> 2242
 <212> DNA
 <213> Rattus norvegicus

<220>
 <223> Heat shock cognate protein 70

<400> 107
 atgcactttc aaagtagtga gaaaattttg atgttttcta atacatagaa atgatatcat 60
 taaaaggcag atgtggctca ttgaacgcag agccagctct cgggggtctc tgtgtggtct 120
 cgatcatcagc acagctgggc ctacacgcaa gcaaccatgt ctaagggacc tgcagttggc 180
 attgatcttg gcaccaccta ctctgtgtg ggtgtcttcc agcatggaaa ggtggaaaata 240
 attgccaatg accagggtaa ccgcaccacg ccgagctatg ttgctttcac cgacacagaa 300
 cgattaattg gggatgcggc caagaatcag gttgcaatga accccaccaa cacagttttt 360
 gatgccaaac gtctgatcgg acgtagggtc gatgatgctg ttgttcagtc tgacatgaag 420
 cactggccct tcatggtggt gaacgatgca ggcaggccca aggtccaagt cgaatacaaa 480
 ggggagacaa aaagtttcta tcctgaggaa gtgtcttcaa tggttctgac aaaaatgaag 540
 gaaattgcag aagcttacct tggaaagact gttaccaatg ccgtgggtcac cgtgccagct 600
 tacttcaatg actctcagcg acaggcagca aaagatgctg gaactattgc tggcctcaac 660
 gtacttcgaa ttatcaatga gccaaactgct gctgctattg cctatggcct agataagaag 720
 gtcagggctg aaaggaatgt gctcattttt gacttgggag gtggcacttt tgatgtgtca 780
 attctgacta ctgaggatgg aatttttgaa gtcaaatcaa cagctggaga caccacttg 840
 ggcggagaag actttgacaa ccgaatggtc aaccatttca ttgctgagtt taagcgaaa 900
 cacaagaagg acatcagtga gaacaagaga gctgtcaggc gtctccgcac tgcctgtgag 960
 cgggccaagc gcaccctctc ctccagcacc caggccagta ttgagattga ttctctctat 1020
 gagggaattg acttctacac ctccattacc cgtgctcgat ttgaggagtt gaatgctgac 1080
 ctgttccgtg gcacactgga cctgtagag aaggcccttc gagatgccaa actagacaag 1140
 tcacagatcc atgatattgt cctgggtgggt ggttctacca gaatcccaa gatccagaaa 1200
 cttctgcaag acttcttcaa tggaaaagag ctgaataaga gcattaaccc cgatgaagct 1260
 gttgcctatg gtgcagctgt ccaggcagcc attctatctg gagacaagtc tgagaatggt 1320
 caggatttgc tgctcttgga tgtcactcct ctttcccttg ggattgaaac tgcgtggtgga 1380
 gtcatgactg tcctcatcaa ggcgaatacc accattccca ccaagcagac ccagactttc 1440
 accacctact ctgacaacca gccagggtgta ctcattccagg tgtatgaagg tgaaaaggcc 1500
 atgaccaagg acaacaacct gcttgggaag tttgagctca caggcatacc tccagcacc 1560
 cgtgggggtc ctgagattga ggttactttt gacattgatg ccaatggcat cctcaatggt 1620
 tctgctgtag ataagagcac aggaaaggag aacaagatca ccatcaccaa tgacaagggc 1680
 cgcttgagta aggaggatat tgagcgcagc gtccaagaag ctgagaagta caaagctgag 1740
 gatgagaagc agagagataa ggtttcctct aagaactcgc tggagtctta tgccttcaac 1800
 atgaaaacaa ctgttgagga tgagaaactt caaggcaaga tcaatgatga agacaaacag 1860
 aagattcttg acaagtgcga cgaaatcatc agctggctgg ataagaacca gactgcggag 1920
 aaggaagaat ttgagcatca gcagaaagaa ctggagaagg tctgcaaccc tatcatcacc 1980
 aagctgtacc agagtgtctg tggcatgcct ggagggaatgc ctgggtggctt ccctgggtgga 2040
 ggagctctc catctggttg tgcttcttca ggccccacca ttgaagaggt cgattaagtc 2100
 aaagtagagg gtgtagcatt gttccacagg gacccaaaac aagtaacatg gaataa-aaa 2160
 actattttaa ttggcacaaa aaaaaaaaaa aaaacggaga tgtggtgact cagctgtaat 2220
 cccggcactt aggaagctga gg 2242

<210> 108
 <211> 374
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Tau microtubule associated protein

<400> 108
 Met Ala Glu Pro Arg Gln Glu Phe Asp Thr Met Glu Asp Gln Ala Gly
 1 5 10 15
 Asp Tyr Thr Met Leu Gln Asp Gln Glu Gly Asp Met Asp His Gly Leu
 20 25 30

EP 1 284 298 A2

Lys Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro Asn Met Glu Asp Gln
 35 40 45
 5 Ala Ala Gly His Val Thr Gln Ala Arg Val Ala Gly Val Ser Lys Asp
 50 55 60
 Arg Thr Gly Asn Asp Glu Lys Lys Ala Lys Gly Ala Asp Gly Lys Thr
 65 70 75 80
 10 Gly Ala Lys Ile Ala Thr Pro Arg Gly Ala Ala Thr Pro Gly Gln Lys
 85 90 95
 Gly Thr Ser Asn Ala Thr Arg Ile Pro Ala Lys Thr Thr Pro Ser Pro
 100 105 110
 15 Lys Thr Pro Pro Gly Ser Gly Glu Pro Pro Lys Ser Gly Glu Arg Ser
 115 120 125
 Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg
 130 135 140
 20 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala
 145 150 155 160
 Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ala Ser Lys Ser Arg Leu
 165 170 175
 25 Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Arg Ser Lys
 180 185 190
 Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val
 195 200 205
 30 Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys
 210 215 220
 Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln
 225 230 235 240
 35 Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly
 245 250 255
 Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val
 260 265 270
 40 Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly
 275 280 285
 Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile
 290 295 300
 45 Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp
 305 310 315 320
 50 His Gly Ala Glu Ile Val His Lys Ser Pro Val Val Ser Gly Asp Thr
 325 330 335
 Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met
 340 345 350
 55 Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser Ala Ser

355

360

365

Leu Ala Lys Gln Gly Leu
370

5

<210> 109
<211> 5240
<212> DNA
<213> Rattus norvegicus

10

<220>
<223> Tau microtubule associated protein

15

20

25

30

35

40

45

50

55

```

<400> 109
cctccccctgg ggaggttctgc gttccccgtgg ctgcgcctg ctgcccgcgg gcctcgagaa 60
cgcgctctct cggccgcggc gctcacagtc tccgccaccc accagctcca gcaccagcag 120
cagcgccggc gccaccgccc accttctgct gtcgcccgg ccacaaccac ctccccctcc 180
gctgtcctct tctgtcctcg cctcctgtcg attatcaggc tttgaagcag catggctgaa 240
ccccgccagg agtttgacac aatggaagac caggccggag attacactat gctccaagac 300
caagaaggag acatggacca tggcttaaaa gctgaagaag caggcatcgg agacaccccg 360
aacatggagg acaagctgc tgggcatgtg actcaagctc gagtggccgg cgtaaagcaa 420
gacaggacag gaaatgacga gaagaaagcg aaggggggccg atggcaaaac gggggcgagg 480
atcgccacac ctccggggagc agccactccg ggccagaaag gcacatccaa tgccaccagg 540
atccagacca agaccacacc cagcccaaaag actcctccag gatcagggtga accacaaaaa 600
tccggagaac gaagcggcta cagcagcccc ggctcgcggc gaaccctgg cagtgcgtcc 660
cgtaccccat ccctaccaac gccgccacc cgagagccca aaaagggtggc agtggttcgc 720
actcccccta agtcaccgtc tgccagtaag agcgcctac agactgccc tgtgcccattg 780
ccagacctaa agaacgtcag gtccaagatt ggctccactg agaacctgaa gcaccagccg 840
ggagggcgga aggtgcagat aattaataag aagctggatc ttagcaacgt ccagtccaag 900
tgtggtctaa aggacaatat caaacacgtc ccgggcggag gcagtgtgca aatagtctac 960
aagccagtggt acctgagcaa ggtgacctcc aagtgtggtt ccttagggaa catccatcac 1020
aagccaggag gtggccaggt agaagtaaaa tcagagaagc tggacttcaa ggatagagtc 1080
cagtogaaga ttggctcctt ggataacatc acccatgtcc ctggaggagg gaataagaag 1140
attgaaaccc acaagctgac cttcaggggag aatgccaaag ccaagacaga ccatggagca 1200
gaaatcgtgc acaagtcacc tgtggtgtct ggggacacat ctccacggca cctcagcaac 1260
gtctcctcca cgggcagcat cgacatggtg gactctccac agcttgccac gttagccgat 1320
gaagtgtccg cctctttggc caagcagggg ttgtgatcag gcccctgggg ccgtcactga 1380
tcattggagag aagagagagt gagagtgtgg aaaaaaaaaa aaaaagaatg acctggcccc 1440
tcacctcttg cctccccgcg tgctcctcat agacaggctg accagcttgt cacctaacct 1500
gcttttgtgg ctccgggttg gctcgggact tcaaaatcag tgatgggaaa aagtaaat 1560
catctttcca aattgatttg tgggctagta ataaaatatt ttaagggaag gaaaaaaaaa 1620
acacgtaaaa ccatggccaa acaaaaccca acatttccct ggcaattgtt attgacccc 1680
ccccccctc tgagttttag aggtggaagg aggctttgga tagaggctgc ttctggggat 1740
tggctgaggg actagggcaa ctaattgccc acagcccat cttaggggca tcagggacag 1800
cggcagacat gaaagacttg ggacttggtg tgtttgtgga gccgtaaggc gtatgttaac 1860
tttgtgtggg tttaggggag gactgtgata gtgaaggctg agagatgggt gggctgggag 1920
tcagaggaga gaggtgagga agacagggtt ggagaggggg cattgctgtc ttgccaagga 1980
gcttggaag cacaggtagc cctgggtgca gcagtcttag ctagcacaga tgcctgcctg 2040
agaaagcaca gtgggttaca gtgggtgtgt gtgccccttc tgaagggcag cccatgggag 2100
aagggttatt gggcagaagg aaggtaggcc ccagaagggt gcaccttgta gattggttct 2160
ctgaaggctg accttgccat cccagggcac tgctccacc ctccaggagg aggtctgagc 2220
tgaggagctt ccttttcgat ctacaggaa aacctgtgtt actgagttct gaagtttgga 2280
actacagcca tgattttggc caccatacag acctgggact ttagggttaa ccagttcttt 2340
gtaaggactt gtgcctcttg cgggaacatc tgcctgttct caagcctggt cctctggcac 2400
ttctgcagtg gtgagggatg ggggtgggat tctgggatgt ggggtcccagg cctcccatcc 2460
ctcgacagc cactgtatcc cctctacctg tcctatcatg cccacgtctg ccacgagagc 2520
cagtcactgc cgtccgtaca tcacgtctca cgtcctgag tgcccagcct ccaagccca 2580
atccctggac cctgggtag ttatggccaa tctgctctac actaggggtt ggagtccagg 2640
gaaggcaaa atttgggcct tggctcttag tcctacgttg ccagaatcca accagtgtgc 2700
ctcccacaag gaaccttaca acctgtttg gtttgcctca tcaggcggtt ggcgccatcg 2760
tggatggagt ccgtgtgtgc ctggagatta ccctggacac ctctgctttt ttttttttta 2820

```

```

ctttagcgggt tgcctcctag gcctgactcc ttcccatggt gaactggagg cagccaagtt 2880
agggtgtcaat gtcctggcat cagtatgaac agtcagtagt cccagggcag ggccacactt 2940
ctcccatctt ctgcttccac cccagcttgt gattgctagc ctcccagagc tcagccgcca 3000
ttaagtcccc atgcacgtaa tcagcccttc catacccca tttggggaac atacccttg 3060
5 attgaaatgt ttccctcca gtcctatgga agcggtgctg cctgcctgct ggagcagcca 3120
gccatctcag agacgcagcc ctttctctcc tgtccgcacc ctgctgcgct gtagtcggat 3180
tcgtctgttt gtctgggttc accagagtga ctatgatagt gaaaaaaaa agaaaaagaa 3240
aaaaaagaaaa agaaaaaaa aaaaggacgc atgttatctt gaaatatttg tcaaaaggtt 3300
gtagccacc gcagggattg gagggcctga tattccttgt cttcttcgtg acttaggtcc 3360
10 aggcgggtcg agtgctaccc tgctggacat cccatgtttt gaagggtttc ttcttcatct 3420
gggacccctg cagacactgg attgtgacat tggaggtcta tacattggcc aaggctgaag 3480
cacaggaccc gttagaggca gcaggctccg actgtcaggg agagcttgtg gctggcctgt 3540
ttctctgagt gaagatggtc ctctctaate caaactcaa gtcccacagc agccctggca 3600
gacatctaag aactcctgca tcacaagaga aaaggacact agtaccagca gggagagctg 3660
tgcccttaga aattccatga ctctccacta ctatccgtgg gtcctttcca agccttgcc 3720
15 cgtcaccaag ggcttgggat ggactgcccc actgatgaaa gggacatctt tggagacccc 3780
cttggtttcc aaggcgtcag ccccttgacc ttgcatgacc tcctacagct gaaggatgag 3840
gcctttaaag attaggaacc tcaggcccag gtccggccact ttgggcttgg gtacagttag 3900
ggacgatgcy gtagaaggag gtggccaacc tttccatata agagtctgt gtgcccagag 3960
ctaccctatt gtgagctccc cactgctgat ggacttttag tgccttaga agtgaagagt 4020
ccaacggagg aaaaaggaagt gtggtttgat ggtctgtggt ccttctcatca tggttacctg 4080
20 ttgtggtttt ctctgtatcc cccattttac ccattcctga gttcctgtcc ttgaataggg 4140
gtgggggtac tctgcatat ctctttagg cagtcagccc ccaagtcata gtttggagtg 4200
atctggtcag tgctaatagg cagtttataa ggaattctgg cttgttactt cagttaggac 4260
aatccccaag ggccctggca cctgtcctgt ctttccatgg ctctccactg cagagccaat 4320
gtctttgggt gggctagata ggggtgtaca tttgcctgga acctccaagc tcttaatcca 4380
25 ctttatcaat agttccattt aaattgactt caatataaga gtgtatccat ttgagattgc 4440
ttgtgtgtg gggtaaaagg gggaggagga acatgttaag ataattgaca tgggcaaggg 4500
gaagtcttga agtgtagcag ttaaaccatc ttgtagcccc attcatgatg ttgaccactt 4560
gctagagaga agaggtgcca taaggctaga acctagaggc ttggctgtcc accaacaggc 4620
aggcttttgc aaggcagagg cagccagcta ggtccctgac ttcccagcca ggtgcagctc 4680
taagaactgc tcttgccctg tgccttcttg tgggtgtccag agcccacagc caatgcctcc 4740
30 tcaaaaccct ggcttccctc cttctaatec actggcacat cagcatcacc tccggattga 4800
cttcagatcc acagcctaca ctactagcag tgggtaagac cacttccctt gtccttgtct 4860
gttctccaga aaagtgggca tggaggcggg gtaataact ataggctgtg ggctttatga 4920
gccttcaaac ttctctctag cttctgaaag ggttactttt gggcagttat gcagtctcac 4980
cctccgatgg ctgtagcctg tgcagttgct gtactgggca tgatctccag tgcttgcaag 5040
tcccatgatt tctttggtgt tttgaggggt gggggaggga catgaatcat cttagcttag 5100
35 ctctctgtct gtgaatgtcc atatagtgt ctgtgtttta acaaacgatt tacactgact 5160
gttgctgtac aagtgaattt ggaaataaag ttattactct gattaaacaa aaaaaaaaaa 5220
aaaaaaaaa aaaaaaaaaa 5240

```

```

<210> 110
<211> 248
<212> PRT
<213> Rattus norvegicus

```

```

<220>
<223> Schwann cell peripheral myelin

```

```

<400> 110
Met Ala Pro Gly Ala Pro Ser Ser Ser Pro Ser Pro Ile Leu Ala Ala
1 5 10 15
50 Leu Leu Phe Ser Ser Leu Val Leu Ser Pro Thr Leu Ala Ile Val Val
20 25 30
Tyr Thr Asp Arg Glu Val Tyr Gly Ala Val Arg Ser Gln Val Thr Leu
35 40 45
55 His Cys Ser Phe Trp Ser Ser Glu Trp Val Ser Asp Asp Ile Ser Phe

```

EP 1 284 298 A2

	50		55		60	
	Thr Trp Arg Tyr Gln Pro Glu Gly Gly Arg Asp Ala Ile Ser Ile Phe					
	65		70		75	80
5	His Tyr Ala Lys Gly Gln Pro Tyr Ile Asp Glu Val Gly Thr Phe Lys					
		85		90		95
	Glu Arg Ile Gln Trp Val Gly Asp Pro Ser Trp Lys Asp Gly Ser Ile					
10		100		105		110
	Val Ile His Asn Leu Asp Tyr Ser Asp Asn Gly Thr Phe Thr Cys Asp					
		115		120		125
	Val Lys Asn Pro Pro Asp Ile Val Gly Lys Thr Ser Gln Val Thr Leu					
15		130		135		140
	Tyr Val Phe Glu Lys Val Pro Thr Arg Tyr Gly Val Val Leu Gly Ala					
	145		150		155	160
	Val Ile Gly Gly Ile Leu Gly Val Val Leu Leu Leu Leu Leu Phe					
20		165		170		175
	Tyr Leu Ile Arg Tyr Cys Trp Leu Arg Arg Gln Ala Ala Leu Gln Arg					
		180		185		190
	Arg Leu Ser Ala Met Glu Lys Gly Lys Phe His Lys Ser Ser Lys Asp					
25		195		200		205
	Ser Ser Lys Arg Gly Arg Gln Thr Pro Val Leu Tyr Ala Met Leu Asp					
		210		215		220
	His Ser Arg Ser Thr Lys Ala Ala Ser Glu Lys Lys Ser Lys Gly Leu					
30		225		230		235
						240
	Gly Glu Ser Arg Lys Asp Lys Lys					
		245				
35						
	<210> 111					
	<211> 1029					
	<212> DNA					
	<213> Rattus norvegicus					
40						
	<220>					
	<223> Schwann cell peripheral myelin					
	<400> 111					
45	attcgggtgg gcccttgccc ctacccacgc tatggctcct ggggctccct catccagccc	60				
	cagccctatc ctggctgccc tgctcttctc ttctttgggtg ctgtccccaa ccctggccat	120				
	tgtggtttac acggacaggg aagtctatgg tgctgtgcgc tcccagggtca ccctgcactg	180				
	ctccttctgg tccagtgaat gggctctcaga tgacatctct tttacctggc gctaccagcc	240				
	tgaaggaggc cgagatgcca tttcaatctt ccactatgcc aagggtcaac cttacatcga	300				
	tgagggtggg accttcaagg agcgcaccca gtgggtaggg gaccctagct ggaaggatgg	360				
	ctccattgtc atacacaacc tagactacag tgacaacggc actttcacat gtgatgtcaa	420				
50	aaacccaccg gacatagtgg gcaagacgtc tcagggtcacg ctctatgtct ttgaaaaagt	480				
	gccactagg tatgggggtgg tggtgggagc cgtgatcggg ggcacccctcg ggggtggtgct	540				
	ggtgtgctg ttgctcttct acctgatccg gtactgctgg ctgctgcaggc aggcctgcct	600				
	gcagaggagg ctcatgcca tggagaaggg gaaatttcac aagtcttcta aggactcctc	660				
	gaagcgcggg cggcagacgc cagtgtctgta tgccatgctg gaccacagcc gaagcaccaa	720				
	agctgccagt gagaagaaat ctaaagggtc gggggagtct cgcaaggata agaaatagcg	780				
55	gttagcgggc cgggcggggg gtcgggggtc tgcgatggag tcttccaaag gctctcagg	840				

EP 1 284 298 A2

gggtggtcatc gagatggagc ttgcaaaaga tgagcagagc tcggagcccc ggcttgagct 900
 caaatccccc agtagaacca gcctcaagaa cgccctcaag aacatgatgg gcctggactc 960
 gaacaagtga ccgtcacctc caggctctgt cagagcaggg gacctaggct cctctttttc 1020
 ccagtctag 1029

<210> 112
 <211> 444
 <212> PRT
 <213> Rattus norvegicus

<220>
 <223> Class 1 beta tubulin

<400> 112
 Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile
 1 5 10 15
 Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp Pro
 20 25 30
 Thr Gly Thr Tyr His Gly Asp Ser Asp Leu Gln Leu Asp Arg Ile Ser
 35 40 45
 Val Tyr Tyr Asn Glu Ala Thr Gly Gly Lys Tyr Val Pro Arg Ala Ile
 50 55 60
 Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ser Gly Pro
 65 70 75 80
 Phe Gly Gln Ile Phe Arg Pro Asp Asn Phe Val Phe Gly Gln Ser Gly
 85 90 95
 Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu
 100 105 110
 Val Asp Ser Val Leu Asp Val Val Arg Lys Glu Ala Glu Ser Cys Asp
 115 120 125
 Cys Leu Gln Gly Phe Gln Leu Thr His Ser Leu Gly Gly Gly Thr Gly
 130 135 140
 Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Ile Arg Glu Glu Tyr Pro
 145 150 155 160
 Asp Arg Ile Met Asn Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser
 165 170 175
 Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Val His Gln Leu
 180 185 190
 Val Glu Asn Thr Asp Glu Thr Tyr Cys Ile Asp Asn Glu Ala Leu Tyr
 195 200 205
 Asp Ile Cys Phe Arg Thr Leu Lys Leu Thr Thr Pro Thr Tyr Gly Asp
 210 215 220
 Leu Asn His Leu Val Ser Ala Thr Met Ser Gly Val Thr Thr Cys Leu
 225 230 235 240
 Arg Phe Pro Gly Gln Leu Asn Ala Asp Leu Arg Lys Leu Ala Val Asn
 245 250 255

EP 1 284 298 A2

Met Val Pro Phe Pro Arg Leu His Phe Phe Met Pro Gly Phe Ala Pro
260 265 270

5 Leu Thr Ser Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu
275 280 285

Leu Thr Gln Gln Val Phe Asp Ala Lys Asn Met Met Ala Ala Cys Asp
290 295 300

10 Pro Arg His Gly Arg Tyr Leu Thr Val Ala Ala Val Phe Arg Gly Arg
305 310 315 320

Met Ser Met Lys Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys
325 330 335

15 Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Lys Thr Ala
340 345 350

Val Cys Asp Ile Pro Pro Arg Gly Leu Lys Met Ala Val Thr Phe Ile
355 360 365

20 Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Ser Glu Gln
370 375 380

Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly
385 390 395 400

25 Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn
405 410 415

Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu
420 425 430

30 Glu Glu Asp Phe Gly Glu Glu Ala Glu Glu Glu Ala
435 440

35 <210> 113
<211> 2346
<212> DNA
<213> Rattus norvegicus

40 <220>
<223> Class 1 beta tubulin

<400> 113
ctcgcacatctc tctgcagcag cctccggggc tacgttccat cctatcagtc tgagaccagc 60
ccagaagaaa aaaacaaaa atccttaatt atcttctttt gctcgggtacc tacattggga 120
ccatcaaaaa aaaattatta cagtaaaccg tagccatgag ggaaatcgtg cacatccagg 180
ccggacagtg tggcaaccag atcgggtgcta agttctggga ggtgataagc gatgaacacg 240
gcatcgaccc caccggcacc taccacggag acagcgactt gcagctggac cgaatctctg 300
tgtactacaa tgaagctaca ggtggcaagt atgtccctcg agctatctta gtggatctag 360
aaccggggac tatggactcc gttcgctcag gtcccttttg ccagatcttc agaccggaca 420
actttgtttt tggtcagtct ggggcaggca acaactgggc taagggtcac tacacagagg 480
gagctgagct ggttgactct gtcttgatg tgggtcggaa ggaggcggag agctgtgact 540
gcctgcaagg ctttcagctg acccactcgc tgggtggagg cacgggctct ggcatgggca 600
ccctgctcat cagcaagatt cgagaagaat accccgaccg catcatgaac accttcagcg 660
tggtagccctc acccaaagt tctgacaccg tgggtgagcc ctacaacgcc accctgtccg 720
tccaccagtt ggtagagaac acagatgaga cctactgcac tgacaacgag gctctctacg 780
acatctgctt ccgtaccctt aagctcacca cgccaaccta cggagacctg aaccatctcg 840
55 tctctgccac catgagcggg gtcaccacct gcctccggtt cccggggccag ctgaacgccg 900

5 accttcggaa gctggctgtc aacatgggtgc ccttcccgcg tctccacttc ttcattgacctg 960
 gctttgcccc tctcaccagc cgtggaagcc agcagtagcc ggccctcact gtgcctgaac 1020
 tccccagca ggtcttcgac gccaaagaaca tgatggccgc ctgtgacca cgccacggcc 1080
 ggtacctcac ggttgccggt gtcttccgtg gacggatgtc catgaaggag gtagatgagc 1140
 aaatgctcaa cgtgcagaat aagaatagca gctacttcgt ggaatggatc cccaacaacg 1200
 tcaagacggc tgtctgtgac atcccaccgc gaggcctcaa gatggcagtc accttcacgt 1260
 gaaacagcac ggccatccag gagctcttca agcgcattct tgagcagttt acggcaatgt 1320
 tccgtcggaa ggctttcctc cactggtaca cgggtgaggg catggacgag atggagtcca 1380
 ccgaagctga gagcaacatg aatgacctcg tctctgagta tcagcagtag caggacgcca 1440
 ccgcagaaga ggaagaggat ttccggagagg aggcagaaga agagggcctaa ggcggaagcc 1500
 10 ctgcgtcacc tcaggctgct tagttccctt agcttttttc caactgccct ttgtttcttt 1560
 ctgctgcctc tgtcctgttt ttgttccgtt ttgttttctc attggggggg aaacgggtgcc 1620
 tggcacgtgg caggcgctca ataaatattt ctttgtggaa tgtctccttt ctctttccga 1680
 tctgacattc tgagcggtta ccctgtgctt cctcctggta cccatttctt tattatgact 1740
 gtccagttta tattcttcca atatttctc caggaaaccag cgttcggctc cagaccggg 1800
 15 gtagaaccaca gccagttctt aagaactcaa gagagtagcc accatcttaa agcaaagtag 1860
 cgggtgggga aaaggtgggt agaggagatg ctacttaggg ggtgggattt tccagtcagg 1920
 gccatttaga cacgggaatc gctggggctt tcagtcgatg gggctttctt ttttccctgc 1980
 ttcattctct ggccctcagg gaggtattaa cagtattatc accatttata tcttagctgt 2040
 cctgagccaa atctgccatt ggaggtgtct tccccgtgtt tggttctcca agggacgttg 2100
 20 tatggggatt tgtgggggca gggcagcaag gccttgttct ctaaatgtcc agaaacactc 2160
 taattaccat ttccacctgg gtgcctcaca cactccccag agggggaggta acatctctgc 2220
 cccatttcca tctgtttcct tggcttgggtc attccctacc tttctatttt ctgttaaact 2280
 tggctttttt tttttcatat tgaaaagatg acattgcccc gagagccaaa aataaatggg 2340
 aattgg 2346

25 <210> 114
 <211> 724
 <212> PRT
 <213> Rattus norvegicus

30 <220>
 <223> Heat shock protein 90

<400> 114
 Met Pro Glu Glu Val His His Gly Glu Glu Glu Val Glu Thr Phe Ala
 1 5 10 15
 35 Phe Gln Ala Glu Ile Ala Gln Leu Met Ser Leu Ile Ile Asn Thr Phe
 20 25 30
 Tyr Ser Asn Lys Glu Ile Phe Leu Arg Glu Leu Ile Ser Asn Ala Ser
 35 40 45
 40 Asp Ala Leu Asp Lys Ile Arg Tyr Glu Ser Leu Thr Asp Pro Ser Lys
 50 55 60
 Leu Asp Ser Gly Lys Glu Leu Lys Ile Asp Ile Ile Pro Asn Pro Gln
 65 70 75 80
 45 Glu Ala Thr Leu Thr Leu Val Asp Thr Gly Ile Gly Met Thr Lys Ala
 85 90 95
 Asp Leu Ile Asn Asn Leu Gly Thr Ile Ala Lys Ser Gly Thr Lys Ala
 100 105 110
 50 Phe Met Glu Ala Leu Gln Ala Gly Ala Asp Ile Ser Met Ile Gly Gln
 115 120 125
 Phe Gly Val Gly Phe Tyr Ser Ala Tyr Leu Val Ala Glu Lys Val Val
 130 135 140
 55

EP 1 284 298 A2

	Val	Ile	Thr	Lys	His	Asn	Asp	Asp	Glu	Gln	Tyr	Ala	Trp	Glu	Ser	Ser	145	150	155	160
5	Ala	Gly	Gly	Ser	Phe	Thr	Val	Arg	Ala	Asp	His	Gly	Glu	Pro	Ile	Gly		165	170	175
	Arg	Gly	Thr	Lys	Val	Ile	Leu	His	Leu	Lys	Glu	Asp	Gln	Thr	Glu	Tyr	180	185	190	
10	Leu	Glu	Glu	Arg	Arg	Val	Lys	Glu	Val	Val	Lys	Lys	His	Ser	Gln	Phe	195	200	205	
	Ile	Gly	Tyr	Pro	Ile	Thr	Leu	Tyr	Leu	Glu	Lys	Glu	Arg	Glu	Lys	Glu	210	215	220	
15	Ile	Ser	Asp	Asp	Glu	Ala	Glu	Glu	Glu	Lys	Gly	Glu	Lys	Glu	Glu	Glu	225	230	235	240
	Asp	Lys	Glu	Asp	Glu	Glu	Lys	Pro	Lys	Ile	Glu	Asp	Val	Gly	Ser	Asp	245	250	255	
20	Glu	Glu	Asp	Asp	Ser	Gly	Lys	Asp	Lys	Lys	Lys	Lys	Thr	Lys	Lys	Ile	260	265	270	
	Lys	Glu	Lys	Tyr	Ile	Asp	Gln	Glu	Glu	Leu	Asn	Lys	Thr	Lys	Pro	Ile	275	280	285	
25	Trp	Thr	Arg	Asn	Pro	Asp	Asp	Ile	Thr	Gln	Glu	Glu	Tyr	Gly	Glu	Phe	290	295	300	
	Tyr	Lys	Ser	Leu	Thr	Asn	Asp	Trp	Glu	Asp	His	Leu	Ala	Val	Lys	His	305	310	315	320
30	Phe	Ser	Val	Glu	Gly	Gln	Leu	Glu	Phe	Arg	Ala	Leu	Leu	Phe	Ile	Pro	325	330	335	
	Arg	Arg	Ala	Pro	Phe	Asp	Leu	Phe	Glu	Asn	Lys	Lys	Lys	Lys	Asn	Asn	340	345	350	
35	Ile	Lys	Leu	Tyr	Val	Arg	Arg	Val	Phe	Ile	Met	Asp	Ser	Cys	Asp	Asp	355	360	365	
	Leu	Ile	Pro	Glu	Tyr	Leu	Asn	Phe	Ile	Arg	Gly	Val	Val	Asp	Ser	Glu	370	375	380	
40	Asp	Leu	Pro	Leu	Asn	Ile	Ser	Arg	Glu	Met	Leu	Gln	Gln	Ser	Lys	Ile	385	390	395	400
	Leu	Lys	Val	Ile	Arg	Lys	Asn	Ile	Val	Lys	Lys	Cys	Leu	Glu	Leu	Phe	405	410	415	
45	Ser	Glu	Leu	Ala	Glu	Asp	Lys	Glu	Asn	Tyr	Lys	Lys	Phe	Tyr	Glu	Ala	420	425	430	
50	Phe	Ser	Lys	Asn	Leu	Lys	Leu	Gly	Ile	His	Glu	Asp	Ser	Thr	Asn	Arg	435	440	445	
	Arg	Arg	Leu	Ser	Glu	Leu	Leu	Arg	Tyr	His	Thr	Ser	Gln	Ser	Gly	Asp	450	455	460	
55	Glu	Met	Thr	Ser	Leu	Ser	Glu	Tyr	Val	Ser	Arg	Met	Lys	Glu	Thr	Gln				

EP 1 284 298 A2

	465		470		475		480
	Lys Ser Ile Tyr	Tyr Ile Thr Gly Glu Ser Lys Glu Gln Val Ala Asn					
5		485		490		495	
	Ser Ala Phe Val	Glu Arg Val Arg Lys Arg Gly Phe Glu Val Val Tyr					
		500		505		510	
	Met Thr Glu Pro	Ile Asp Glu Tyr Cys Val Gln Gln Leu Lys Glu Phe					
10		515		520		525	
	Asp Gly Lys Ser	Leu Val Ser Val Thr Lys Glu Gly Leu Glu Leu Pro					
		530		535		540	
	Glu Asp Glu Glu	Glu Lys Lys Lys Met Glu Glu Ser Lys Ala Arg Phe					
15		545		550		555	
	Glu Asn Leu Cys	Lys Leu Met Lys Glu Ile Leu Asp Lys Lys Val Glu					
		565		570		575	
	Lys Val Thr Ile	Ser Asn Arg Leu Val Ser Ser Pro Cys Cys Ile Val					
20		580		585		590	
	Thr Ser Thr Tyr	Gly Trp Thr Ala Asn Met Glu Arg Ile Met Lys Ala					
		595		600		605	
	Gln Ala Leu Arg	Asp Asn Ser Thr Met Gly Tyr Met Met Ala Lys Lys					
25		610		615		620	
	His Leu Glu Ile	Asn Pro Asp His Pro Ile Val Glu Thr Leu Arg Gln					
		625		630		635	
	Lys Ala Glu Ala	Asp Lys Asn Asp Lys Ala Val Lys Asp Leu Val Val					
30		645		650		655	
	Leu Leu Phe Glu	Thr Ala Leu Ser Ser Leu Ala Ser His Phe Arg Arg					
		660		665		670	
	Pro Lys Thr His	Ser Asn Arg Ile Tyr Arg Met Ile Lys Leu Gly Leu					
35		675		680		685	
	Gly Ile Asp Glu	Asp Glu Val Thr Ala Glu Glu Pro Ser Ala Ala Val					
		690		695		700	
	Pro Asp Glu Ile	Pro Pro Leu Glu Gly Asp Glu Asp Ala Ser Arg Met					
40		705		710		715	
	Glu Glu Val Asp						
45							
	<210>	115					
	<211>	2524					
	<212>	DNA					
	<213>	Rattus norvegicus					
50							
	<220>						
	<223>	Heat shock protein 90					
	<400>	115					
55	ggcctaggct	tgcctgtcga	gtcggacgtg	gtccgggccc	accctgctct	gtactactac	60
	tcggctttct	cgtcaagatg	cctgaggaag	tgacccatgg	agaggaagag	gtggagacct	120

EP 1 284 298 A2

tcgcctttca ggcagaaatt gccagctga tgtccctcat catcaacact ttttactcaa 180
 acaaagagat tttcctccgg gagttgatct ctaatgcttc tgatgccttg gacaagattc 240
 ggtatgagag cctgactgac ccttccaagt tggacagcgg gaaagagctg aagattgaca 300
 tcatccccc aa cctcaggaa gccacgctga ctttgggtgga cacaggcatt ggcatgacca 360
 5 aggtgacct cataaataac ttgggaacca ttgctaagtc tggtacaaag gcgttcattgg 420
 aggtctccca ggctgggtgca gacatctcca tgattgggca gtttgggtgtc ggcttctact 480
 ctgcctacct ggtggcagag aaagtgggtg tgatcacgaa gcacaacgat gatgagcagt 540
 atgcctggga gtcttctgct ggtggatcct tcaactgtccg tgcagaccac ggtgagccca 600
 ttggccgggg taccaaagt atccttcacc tcaaagaaga ccagacagag tacttagagg 660
 10 agaggagggt caaggagggt gtgaagaaac actcacagtt cataggctac cccatcaccc 720
 tctatctgga gaaggaacgc gagaaggaga tcagtgatga tgaggcagag gaagagaaaag 780
 gggagaagga ggaggaagat aaggaggatg aggagaagcc taagattgag gatgtgggat 840
 ctgatgagga ggtgacagc ggcaagata agaaaaagaa aacaaagaag atcaaggaga 900
 agtacattga ccaggaagag ctgaataaga cgaagcccat ctggaccaga aatcctgatg 960
 acatcactca agaggaatat ggtgaattct acaagagcct caccaatgac tgggaagacc 1020
 15 acttggcagt caagcacttc tctgtagaag ggcagttgga attcagggca ttgctcttca 1080
 ttcccggcg agtccctttt gacctctttt agaacaagaa gaagaagaac aacatcaaat 1140
 tgtatgtccg tcgtgtgttc atcatggaca gctgtgatga cctgatactc gactaccta 1200
 acttcatccg tgggtgtggtt gattccgagg acctgcctct gaacatctcc cgagaaatgc 1260
 tccagcagag caagatcctg aaagtcatcc gcaaaaacat tgtgaagaag tgccttgagc 1320
 20 tcttctctga gttggctgaa gacaaagaga actacaagaa attttatgag gcattctcta 1380
 agaatttaaa gcttggaatc catgaggatt ccactaaccg tcgccgcctc tctgagctcc 1440
 ttcgctacca tacctctcag tctggagatg agatgacttc cctgtcagag tatgtgtctc 1500
 gcatgaagga gacacagaag tccatctact atatcactgg tgagagcaaa gagcaggtgg 1560
 ccaactctgc ctctgtggag cgtgtgcgga aacggggcctt tgaggtggta tacatgactg 1620
 agcccattga tgagtactgc gtacagcagc tcaaggagtt cgatggcaag agcctggtct 1680
 25 ccgtgaccaaa ggagggcctg gagctaccag aggatgagga agagaagaaa aaaatggagg 1740
 agagcaaggc aaggtttgag aatctctgca agctcatgaa ggagatcttg gacaagaagg 1800
 ttgaaaaagt gactatctcc aataggcttg tgtcttcccc ctgctgcatt gtgaccagca 1860
 cctacggctg gacagccaac atggaacgga ttatgaaggc ccaggcactg cgggacaact 1920
 cgacaatggg ctacatgatg gccaagaaac acctagagat caaccctgac caccctattg 1980
 tggagactct gcggcagaag gctgaggcag acaaaaacga caaagctgtc aaagacctgg 2040
 30 tgggtgctgct gtttgagact gctctgtctt ctctcgcttc tcaactttagg agggccaaaa 2100
 cccactccaa ccgcatctac cgcatgatta aactaggcct gggcattgat gaagatgagg 2160
 tcaactgcaga agagccagat gctgctgttc ccgatgagat ccccccactg gaggggtgat 2220
 aggatgcctc tcgcatggaa gaagtggatt aaaggctcct gggaagcccc cgccctctgt 2280
 atagtatccc tgtggctccc ccaacagcct tgactggccc tgaccacct gggctctctc 2340
 35 tgctcatgto tacaagaato tcttctatcc tgtccttgtg ccttaaggca ggaagatccc 2400
 ctcccacaga tagcagggtt ggggtgtgtg tattgtgttt ttttgtttgt tttatattgt 2460
 tctgaaatta aaagtatgca aaataaagat gatgcagttt taaaaaaaaa aaaaaaaaaa 2520
 aagg 2524

40 <210> 116
 <211> 541
 <212> PRT
 <213> Homo sapiens
 45 <220>
 <223> Putative ribonuclease III

<400> 116
 Met Arg Arg Glu Val Thr Val Glu Leu Ser Ser Gln Gly Phe Trp Lys
 1 5 10 15
 50 Thr Gly Ile Arg Ser Asp Val Cys Gln His Ala Met Met Leu Pro Val
 20 25 30
 Leu Thr His His Ile Arg Tyr His Gln Cys Leu Met His Leu Asp Lys
 35 40 45
 Leu Ile Gly Tyr Thr Phe Gln Asp Arg Cys Leu Leu Gln Leu Ala Met
 50 55 60

EP 1 284 298 A2

	Thr	His	Pro	Ser	His	His	Leu	Asn	Phe	Gly	Met	Asn	Pro	Asp	His	Ala
	65					70					75				80	
	Arg	Asn	Ser	Leu	Ser	Asn	Cys	Gly	Ile	Arg	Gln	Pro	Lys	Tyr	Gly	Asp
				85						90					95	
5	Arg	Lys	Val	His	Met	His	Met	Arg	Lys	Lys	Gly	Ile	Asn	Thr	Leu	
				100					105					110		
	Ile	Asn	Ile	Met	Ser	Arg	Leu	Gly	Gln	Asp	Asp	Pro	Thr	Pro	Ser	Arg
				115					120					125		
	Ile	Asn	His	Asn	Glu	Arg	Leu	Glu	Phe	Leu	Gly	Asp	Ala	Val	Val	Glu
				130					135				140			
10	Phe	Leu	Thr	Ser	Val	His	Leu	Tyr	Tyr	Leu	Phe	Pro	Ser	Leu	Glu	Glu
	145					150					155				160	
	Gly	Gly	Leu	Ala	Thr	Tyr	Arg	Thr	Ala	Ile	Val	Gln	Asn	Gln	His	Leu
					165					170					175	
	Ala	Met	Leu	Ala	Lys	Lys	Leu	Glu	Leu	Asp	Arg	Phe	Met	Leu	Tyr	Ala
				180					185					190		
15	His	Gly	Pro	Asp	Leu	Cys	Arg	Glu	Ser	Asp	Leu	Arg	His	Ala	Met	Ala
				195					200					205		
	Asn	Cys	Phe	Glu	Ala	Leu	Ile	Gly	Ala	Val	Tyr	Leu	Glu	Gly	Ser	Leu
				210					215					220		
20	Glu	Glu	Ala	Lys	Gln	Leu	Phe	Gly	Arg	Leu	Leu	Phe	Asn	Asp	Pro	Asp
	225					230					235				240	
	Leu	Arg	Glu	Val	Trp	Leu	Asn	Tyr	Pro	Leu	His	Pro	Leu	Gln	Leu	Gln
				245						250					255	
	Glu	Pro	Asn	Thr	Asp	Arg	Gln	Leu	Ile	Glu	Thr	Ser	Pro	Val	Leu	Gln
				260					265					270		
25	Lys	Leu	Thr	Glu	Phe	Glu	Glu	Ala	Ile	Gly	Val	Ile	Phe	Thr	His	Val
				275					280					285		
	Arg	Leu	Leu	Ala	Arg	Ala	Phe	Thr	Leu	Arg	Thr	Val	Gly	Phe	Asn	His
				290				295				300				
	Leu	Thr	Leu	Gly	His	Asn	Gln	Arg	Met	Glu	Phe	Leu	Gly	Asp	Ser	Ile
	305					310					315				320	
30	Met	Gln	Leu	Val	Ala	Thr	Glu	Tyr	Leu	Phe	Ile	His	Phe	Pro	Asp	His
				325						330					335	
	His	Glu	Gly	His	Leu	Thr	Leu	Leu	Arg	Ser	Ser	Leu	Val	Asn	Asn	Arg
				340					345					350		
	Thr	Gln	Ala	Lys	Val	Ala	Glu	Glu	Leu	Gly	Met	Gln	Glu	Tyr	Ala	Ile
				355					360					365		
35	Thr	Asn	Asp	Lys	Thr	Lys	Arg	Pro	Val	Ala	Leu	Arg	Thr	Lys	Thr	Leu
				370				375				380				
	Ala	Asp	Leu	Leu	Glu	Ser	Phe	Ile	Ala	Ala	Leu	Tyr	Ile	Asp	Lys	Asp
				385			390				395				400	
	Leu	Glu	Tyr	Val	His	Thr	Phe	Met	Asn	Val	Cys	Phe	Phe	Pro	Arg	Leu
				405						410					415	
40	Lys	Glu	Phe	Ile	Leu	Asn	Gln	Asp	Trp	Asn	Asp	Pro	Lys	Ser	Gln	Leu
				420					425					430		
	Gln	Gln	Cys	Cys	Leu	Thr	Leu	Arg	Thr	Glu	Gly	Lys	Glu	Pro	Asp	Ile
				435				440					445			
	Pro	Leu	Tyr	Lys	Thr	Leu	Gln	Thr	Val	Gly	Pro	Ser	His	Ala	Arg	Thr
				450				455				460				
45	Tyr	Thr	Val	Ala	Val	Tyr	Phe	Lys	Gly	Glu	Arg	Ile	Gly	Cys	Gly	Lys
				465			470				475				480	
	Gly	Pro	Ser	Ile	Gln	Gln	Ala	Glu	Met	Gly	Ala	Ala	Met	Asp	Ala	Leu
				485					490					495		
	Glu	Lys	Tyr	Asn	Phe	Pro	Gln	Met	Ala	His	Gln	Lys	Arg	Phe	Ile	Glu
				500					505					510		
50	Arg	Lys	Tyr	Arg	Gln	Glu	Leu	Lys	Glu	Met	Arg	Trp	Glu	Arg	Glu	His
				515				520					525			
	Gln	Glu	Arg	Glu	Pro	Asp	Glu	Thr	Glu	Asp	Ile	Lys	Lys			
				530				535				540				

<210> 117
 <211> 1626
 <212> PNA
 <213> Homo sapiens

<220>
 <223> Putative ribonuclease III

<400> 117
 atgagacgag aagtaacggt ggagctaagt agccaaggat tctggaaaac tggcatccgt 60
 tctgatgtct gtcagcatgc aatgatgcta cctgttctga cccatcatat ccgctaccac 120
 caatgcctaa tgcatttgga caagttgata ggatatactt tccaagatcg ttgtctgttg 180
 cagctggcca tgactcatcc aagtcacatc ttaaattttg gaatgaatcc tgatcatgcc 240
 aggaattcat tatctaactg tgggaattcgg cagcccaaat acggagacag aaaagttcat 300
 cacatgcaca tgcggaagaa agggattaac accttgataa atatcatgtc acgccttggc 360
 caagatgacc caactccctc gaggattaac cacaatgaac ggttggaatt cctgggtgat 420
 gctgttggtg aattttctgac cagcgtccat ttgtactatt tgtttcctag tctggaagaa 480
 ggaggattag caacctatcg gactgccatt gttcagaatc agcaccttgc catgctagca 540
 aagaaacttg aactggatcg atttatgctg tatgtcacg ggcctgacct ttgtagagaa 600
 tcggaccttc gacatgcaat ggccaattgt tttgaagcgt taataggagc tgtttacttg 660
 gaggaagcc tggaggaagc caagcagtta tttggacgct tgctctttaa tgatccggac 720
 ctgcgcaag tctggctcaa ttatcctctc caccactcc aactacaaga gccaaatact 780
 gatcgacaac ttattgaaac ttctccggtt ctacaaaaac ttactgagtt tgaagaagca 840
 attggagtaa tttttactca tgttcgactt ctggcaaggg cattcacatt gagaactgtg 900
 ggatttaacc atctgaccct aggcacaaat cagagaatgg aattcctagg tgactccata 960
 atgcaactgg tagccacaga gtacttatcc attcatttcc cagatcatca tgaaggacac 1020
 ttaactttgt tgcgaagctc tttggtgaat aatagaactc aggcgaaggt agcggaggag 1080
 ctgggcatgc aggagtacgc cataaccaac gacaagacca agaggcctgt ggcgcttcgc 1140
 accaagacct tggcggacct tttggaatca tttattgcag cgctgtacat tgataaggat 1200
 ttggaatatg ttcatacttt catgaatgtc tgcttcttcc cagcattgaa agagtccatt 1260
 ttgaatcagg attggaatga ccccaaatac cagcttcagc agtggtgctt gacacttagg 1320
 acagaaggaa aagagccaga cattcctctg tacaagactc tgcagacagt gggcccatcc 1380
 catgcccga cctacactgt ggctgtttat ttcaagggag aaagaatagg ctgtgggaaa 1440
 ggaccaagta ttcagcaagc ggaaatggga gcagcaatgg atgcgcttga aaaatataat 1500
 tttccccaga tggcccatca gaagcggttc atcgaaacgga agtacagaca agagttaaaa 1560
 gaaatgaggt gggaaagaga gcatcaagag agagagccag atgagactga agacatcaag 1620
 aaataa

Claims

1. Use of:

- (a) an isolated gene sequence that is down-regulated in the spinal cord of a mammal in response to mechanically distinct first and second models of neuropathic or central sensitization pain;
- (b) an isolated gene sequence comprising a nucleic acid sequence of any of Tables I to VI;
- (c) an isolated gene sequence having at least 80% sequence identity with a nucleic acid sequence of any of Tables I to VI;
- (d) an isolated nucleic acid sequence that is hybridizable to any of the gene sequences according to (a), (b) or (c) under stringent hybridisation conditions;
- (e) a recombinant vector comprising a gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (f) a host cell containing the vector according to (e);
- (g) a non-human animal having in its genome an introduced gene sequence or nucleic acid sequence or a removed or down-regulated gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (h) an isolated polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence encoded by a nucleotide sequence according to any one of (a) to (d), or a polypeptide variant thereof

with sequential amino acid deletions from the C terminus and/or the N-terminus;

(i) an isolated polypeptide encoded by a nucleotide sequence according to any one of (a) to (d); or

(j) an isolated antibody that binds specifically to a polypeptide according to (h) or (i);

in the screening of compounds for the treatment of pain, or for the diagnosis of pain.

2. Use according to claim 1, wherein the isolated gene sequence is down-regulated both in response to streptozocin-induced diabetes and in response to surgical injury of a nerve leading to the spine.

3. Use according to claim 1 or 2 wherein the isolated gene sequence encodes a kinase.

4. Use according to claim 1, 2 or 3, wherein the isolated gene sequence encodes an expression product or fragment thereof of pyruvate kinase, M1 and M2 subunits (M24359; X97047; X56494).

5. Use according to claim 1 or 2, wherein the isolated gene sequence encodes an expression product or fragment thereof of a receptor.

6. Use according to claim 1, 2 or 5, wherein the isolated gene sequence encodes dopamine receptor D.sub.1 (I58000).

7. Use according to claim 1 or 2, wherein the isolated gene sequence encodes a transporter.

8. Use according to claim 1, 2 or 7, wherein the isolated gene sequence encodes differentiation-associated Na⁺-dependent inorganic phosphate cotransporter (AF271235) or putative vacuolar assembly protein VSP41 gene (U87309).

9. Use according to claim 1 or 2, wherein the isolated gene sequence encodes a G-protein coupled receptor protein.

10. Use according to claim 1, 2 or 9, wherein the isolated gene sequence encodes Glt1 (G-protein-coupled receptor kinase-interactor 1; GPCR kinase-associated ADP-ribosylation factor) (AF085693).

11. Use according to claim 1 or 2, wherein the isolated gene sequence encodes a DNA-binding protein.

12. Use according to claim 1, 2 or 11, wherein the isolated gene sequence encodes putative histone H3.3A (X91866; M11354).

13. Use according to claim 1 or 2, wherein the isolated gene sequence encodes a ligase.

14. Use according to claim 1, 2 or 13, wherein the isolated gene sequence encodes 3-Hydroxy 3-methylglutaryl coenzyme A synthase, cytosolic (X52625), acyl-CoA synthetase II, brain (D360666) farnesyl diphosphate synthase (M34477), bendless protein (AB032739; E12457), fatty acid synthase (X62888), glutamine synthetase (EC 6.3.1.2) (M91652), or putative seryl-tRNA synthetase (X91257).

15. Use according to claim 1 or 2, wherein the isolated gene sequence encodes a lyase.

16. Use according to claim 1, 2 or 15, wherein the lyase is enolase, alpha alpha, non-neuronal (NNE) (X02610; X52379; M14328).

17. Use according to claim 1 or 2, wherein the isolated gene sequence encodes an oxidoreductase.

18. Use according to claim 1, 2 or 17, wherein the isolated gene sequence encodes aldose reductase, lens (AREC 11.1.21) (X05884) cytochrome-c oxidase I, mitochondrial (S79304), lactate dehydrogenase-B (LDH-B) (U07181; X51905; Y00711), putative cytochrome c oxidase VIB (EC 1.9.3.1) (X13923), putative NADH: ubiquinone oxidoreductase PGIV subunit (AF044953), putative succinate dehydrogenase flavoprotein (AF095938; AF171022), putative ubiquinol-cytochrome-c reductase (EC 1.10.2.2) core protein II (J04973) or stearyl-coA desaturase 2 (AB032243; M26270).

19. Use according to claim 1 or 2, wherein the isolated sequence encodes a transferase.

20. Use according to claim 1, 2 or 19, wherein the isolated sequence encodes ribophorin I (X05300) or sulfotransferase-like protein (AF188699).

21. Use according to claim 1 or 2, wherein the isolated sequence encodes a hydrolase.

22. Use according to claim 1, 2 or 21, wherein the isolated sequence encodes ATP synthase, H⁺, alpha subunit, mitochondrial (EC 3.6.1.34) (X56133), F1F0 ATPase delta subunit (U00926), putative dihydropyrimidinase related protein (D78013), heat shock protein 90 (S45392; M18186; M16660), or putative ribonuclease III (AF116910).

23. Use according to claim 1 or 2, wherein the isolated sequence encodes myelin basic protein S (MBP S) (K00512), transferring (D38380), neurofilament, light molecular weight (NF-L) (AF031880), myelin-associated glycoprotein (MAG) (M16800; M31811), NF-M middle molecular weight neurofilament protein (M18628) neuro-degeneration associated- protein 1 (D32249), S-100 protein β -subunit (X01090), microtubule-associated protein 1b (Map 1b) (X60370; L06237), putative cdc 37 homolog (D26564), putative ras-related protein Rab-5c (U11293), putative gelsolin (J04953), Cd81 antigen (target of antiproliferative antibody 1) (U19894; X59047; M33680), Mobp81 (Myelin-associated/Oligo-dendrocytic basic protein 81) (X87900), syntaxin binding protein n-secl, sec1 homolog, A-internexin (M73049), putative β -sarcoglycan A3b (AB024921), CGI-78 protein (AF151835), KIAA0143 (D63477), septin 2 (D50918), Nucleobindin (Z36277), myelin protein SR13 (M69139; S55427), B-Actin, cytoplasmic (V01217; X03672), ly6/neurotoxin (Lynx1) homolog (AD141377), astrocytic phosphoprotein ; PFA 15 gene (AJ243949; X86694), PLIC-1 (AF177345), Nfx1 (tip associating protein (TAP) gene) (AF093139; AF093140), A-Crystallin B (U04320; M73741 ; M28638), heat shock-like protein 70 kD (X70065; U73744; Y00371), tau microtubule-associated protein (X79321), myelin, Schwann cell, Perioheral (P-0) (K03242), B-Tubulin class 1 (AB011679; X04663; AF14139), putative long-chain polyunsaturated fatty acid elongation enzyme (Helo1) or peptidylglycine alpha-amidating monooxygenase 1.

24. A non-human animal having in its genome an introduced gene sequence or a removed or down-regulated gene sequence, said sequence being down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitisation pain.

25. A non-human animal according to claim 24, wherein said gene sequence becomes down regulated both in response to streptozocin induced diabetes and in response to chronic constriction injury.

26. A non-human animal according to claim 24 or 25, wherein the introduced gene sequence is according to any of claims 1 to 23.

27. A non-human animal according to any one of claims 24 to 26 which is *C. elegans*.

28. A kit comprising;

(a) affinity peptide and/or ligand and/or substrate for an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal in response to a mechanistically distinct first and second models of neuropathic or central sensitization pain ; and

(b) a defined quantity of an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal both in response to first and second models of neuropathic or central sensitization pain, for simultaneous, separate or sequential use in detecting and/or quantifying down-regulation of a gene sequence in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain.

29. A kit according to claim 28, wherein the gene sequence is defined in any one of claims 1 to 23.

30. A kit comprising:

(a) nucleic acid sequences capable of hybridization to a nucleic acid sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain; and
(b) a defined quantity of one or more nucleic acid sequences capable of hybridization to a nucleic acid sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain,

for simultaneous, separate or sequential use in detecting and/or quantifying down-regulation of a gene sequence in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain.

- 5 31. The kit of claim 30, wherein the gene sequence is according to any of claims 1 to 23.
32. A compound that modulates the action of an expression product of a gene sequence that is down-regulated in the spinal cord of a mammal in response to first and second models of neuropathic or central sensitization pain.
- 10 33. A compound according to claim 32 wherein the gene sequence is listed in Tables I to VI.
34. A compound according to claim 32 or 33 wherein the nucleotide sequence is according to any one of claims 1 to 23.
35. A compound according to any one of claims 32 to 34 for use as a medicament.
- 15 36. A compound according to any one of claims 32 to 35 for the treatment or diagnosis of pain.
37. A pharmaceutical composition comprising a compound according to any one of claims 32 to 36 and a pharmaceutically acceptable carrier or diluent.
- 20 38. Use of a compound according to any one of claims 32 to 36 in the manufacture of a medicament for the treatment or diagnosis of pain.
39. Use of a compound according to any one of claims 32 to 36 in the manufacture of a medicament for the treatment or diagnosis of chronic pain.
- 25 40. A method of treatment of pain, which comprises administering to a patient an effective amount of a compound according to any one of claims 32 to 36.

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 284 298 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
26.05.2004 Bulletin 2004/22

(51) Int Cl.7: **C12Q 1/68**, **C07K 14/47**,
C12N 5/10, **C12N 15/85**

(43) Date of publication A2:
19.02.2003 Bulletin 2003/08

(21) Application number: **02255229.3**

(22) Date of filing: **26.07.2002**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **27.07.2001 GB 0118354**
07.02.2002 GB 0202883

(71) Applicant: **Warner-Lambert Company LLC**
Morris Plains, New Jersey 07950 (US)

(72) Inventors:
• **Brooksbank, Robert Alan**
Cambridgeshire, CB1 3AW (GB)

- **Dixon, Alistair Kerr,**
Cambridgeshire, CB1 2LL (GB)
- **Lee, Kevin, c/o Pfizer Limited UK**
Sandwich, Kent CT13 9NJ (GB)
- **Pinnock, Robert Denham,**
Pfizer Global Res. and Dev
Ann Arbor, MI 48105 (US)

(74) Representative: **Hayles, James Richard et al**
UK Patents Department,
Pfizer Limited,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Identification and use of molecules implicated in pain**

(57) The invention relates to the use of:

- (a) an isolated gene sequence that is down-regulated in the spinal cord of a mammal in response to mechanistically distinct first and second models of neuropathic or central sensitization pain;
- (b) an isolated gene sequence comprising a nucleic acid sequence of any of Tables I to VI;
- (c) an isolated gene sequence having at least 80% sequence identity with a nucleic acid sequence of any of Tables I to VI;
- (d) an isolated nucleic acid sequence that is hybridizable to any of the gene sequences according to (a), (b) or (c) under stringent hybridisation conditions;
- (e) a recombinant vector comprising a gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (f) a host cell containing the vector according to (e);
- (g) a non-human animal having in its genome an introduced gene sequence or nucleic acid sequence or a removed or down-regulated gene sequence or nucleic acid sequence according to any one of (a) to (d);
- (h) an isolated polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence encoded by a nucleotide sequence ac-

cording to any one of (a) to (d), or a variant polypeptide thereof with sequential amino acid deletions from the C terminus and/or the N-terminus;
(i) an isolated polypeptide encoded by a nucleotide sequence according to any one of (a) to (d); or
(j) an isolated antibody that binds specifically to a polypeptide according to (h) or (i);

in the screening of compounds for the treatment of pain, or for the diagnosis of pain.

The invention also relates to the use of naturally occurring compounds such as peptide ligands of the expression products of the above gene sequences and their associated signal transduction pathways for use in the treatment of pain.

EP 1 284 298 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 02 25 5229
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	SHAH B ET AL: "Beta3, An auxiliary subunit of the voltage gated sodium channel is upr" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 26, no. 1-2, 4 November 2000 (2000-11-04), page 938, ABSTRACTN03526, XP009020087 ISSN: 0190-5295 * the whole document *	1-3, 24-31	C12Q1/68 C07K14/47 C12N5/10 C12N15/85
Y	BITAR MILAD S ET AL: "Attenuation of IGF-1 antinociceptive action and a reduction in spinal cord gene expression of its receptor in experimental diabetes" PAIN, vol. 75, no. 1, March 1998 (1998-03), pages 69-74, XP002262337 ISSN: 0304-3959 * the whole document *	1-3, 24-31	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q C07K C12N
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
Munich		3 December 2003	Hermann, P
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/02 (P04/C37)



European Patent
Office

INCOMPLETE SEARCH SHEET C

Application Number

EP 02 25 5229

The following comments apply to the invention for which a search has been performed - i.e. claims 1, 2, 24-40 (in part) and 3-4 (in full) relating to the first invention of the application.

The applicant should therefore bear in mind that, should he pay additional search fees, further objections leading to incomplete search might as well arise during the search phase of the further inventions.

Claim(s) searched completely:
2-4, 26

Claim(s) searched incompletely:
1, 24, 25, 27-31

Claim(s) not searched:
32-40

Reason for the limitation of the search:

a) Article 52 (4) EPC - Method for treatment of the human or animal body by therapy (claim 40).

Although claim 40 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search could have been carried out and based on the alleged effects of the compound/composition. However, in view of the lack of clarity of said claim (see item (f) hereinbelow) no search has been carried out.

b) The isolated gene sequence of part (a) of claim 1 is only defined by a result achieved in special conditions, and the description is silent as to any other characteristic features pertaining to said isolated gene sequence. Claim 1 therefore lacks clarity (Article 84 EPC), and could only be searched as it relates to the isolated gene sequences of table I encoding a kinase, and derivative thereof as listed in parts (c)-(j) of claim 1, all relating to kinase encoding nucleic acid sequences.

c) The non-human animal of present claims 24 or 25 or the *C. elegans* of claim 27 is defined by reference to the following parameter:

- the modification of the presence or expression of a gene sequence which is downregulated in the spinal cord of a mammal in response to two models of neuropathic pain and claim 25, as for it, limits those two models to the streptozocin induced-diabetes and the chronic constriction injury.

The use of that parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 84 EPC (see also Guidelines C-III, 4.7a). For the same reasons as those hereinabove under item (b), the search for claims 24, 25 and 27 has been restricted to



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 02 25 5229

non-human animal wherein the introduced gene sequence is one of the sequences listed in Table I, encoding a kinase.

d) The expression product of a gene sequence and the nucleic acid sequence of the kits of claims 28-31 are only defined by a parameter - i.e. the expression product of said gene sequence or the nucleic acid sequence that is downregulated in the spinal cord of a mammal in response to two models of neuropathic pain. The use of that parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 84 EPC (see also Guidelines C-III, 4.7a). For the same reasons as those hereinabove under item (b), the search for claims 28-31 has been restricted respectively to the product of the gene sequences given in Table I and to the sequences given in Table I themselves.

e) Moreover in independent claim 28 none of the characteristic features of the "affinity peptide", "ligand" and "substrate" for the expression product are given in said claim, and the description is also silent as to said eventual characteristics. Therefore the skilled person would not clearly understand which compounds are falling under the scope of said claim. Said claim therefore lacks clarity (Article 84 EPC) to such an extent that a meaningful search on its entire scope could not be performed. Said search has been restricted to substrates known for the kinases encoded by the gene sequences listed in table I.

f) Claims 32-36 relate to compounds only defined by the result to be achieved and the claims as well as the description do not relate to any features which would allow the skilled person to clearly understand which compounds are falling under the scope of said claims. Said claims therefore lack clarity (Article 84 EPC) to such an extent that no meaningful search could be performed.

As claims 37-40 are depending upon one or more of claims 32-36, said claims therefore lack clarity (Article 84 EPC) and could not be searched either.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 25 5229

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	BLACKBURN-MUNRO G ET AL: "The sodium channel auxiliary subunits beta1 and beta2 are differentially expressed in the spinal cord of neuropathic rats" NEUROSCIENCE, vol. 90, no. 1, April 1999 (1999-04), pages 153-164, XP002262713 ISSN: 0306-4522 * the whole document *	1-3, 24-31	
A	NAKAMURA JIRO ET AL: "A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats" DIABETES, vol. 48, no. 10, October 1999 (1999-10), pages 2090-2095, XP002260473 ISSN: 0012-1797 * the whole document *	1-3, 24-31	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	LUO Z DAVID ET AL: "Neuronal nitric oxide synthase mRNA upregulation in rat sensory neurons after spinal nerve ligation: Lack of a role in allodynia development" JOURNAL OF NEUROSCIENCE, vol. 19, no. 21, 1 November 1999 (1999-11-01), pages 9201-9208, XP002262714 ISSN: 0270-6474 * the whole document *	1-3, 24-31	
	----- -/--		

EPO FORM 1503 03.02 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 25 5229

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	FOX ALYSON ET AL: "Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat" PAIN, vol. 81, no. 3, June 1999 (1999-06), pages 307-316, XP002260439 ISSN: 0304-3959 * the whole document *	1-3, 24-31	
A	COURTEIX C ET AL: "Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain" PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 53, no. 1, 1993, pages 81-88, XP009020332 ISSN: 0304-3959 * the whole document *	1-3, 24-31	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	MALMBERG ANNIKA B ET AL: "Preserved acute pain and reduced neuropathic pain in mice lacking PKC-gamma" SCIENCE (WASHINGTON D C), vol. 278, no. 5336, 1997, pages 279-283, XP002260438 ISSN: 0036-8075 * the whole document *	1-3, 24-31	
A	WO 00/63427 A (CUVILLIER GWLADYS ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLATTEEUW) 26 October 2000 (2000-10-26) * the whole document *	1-3, 24-31	
	-/--		

EPO FORM 1503 03.82 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 25 5229

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	TAO Y -X ET AL: "Expression and action of cyclic GMP-dependent protein kinase Ialpha in inflammatory hyperalgesia in rat spinal cord" NEUROSCIENCE, vol. 95, no. 2, 1 December 2000 (2000-12-01), pages 525-533, XP002260437 ISSN: 0306-4522 * the whole document *	1-3, 24-31	
A	BRIDGES D ET AL: "MECHANISMS OF NEUROPATHIC PAIN" BRITISH JOURNAL OF ANAESTHESIA, BJM PUBLISHING GROUP, LONDON, GB, vol. 87, no. 1, 2001, pages 12-26, XP001068882 ISSN: 0007-0912 * the whole document *	1-3, 24-31	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
T	CIRUELA A ET AL: "Identification of MEK1 as a novel target for the treatment of neuropathic pain." BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 5, March 2003 (2003-03), pages 751-756, XP002260445 ISSN: 0007-1188 (ISSN print) * the whole document *	1-3, 24-31	

EPO FORM 1503 01.82 (P04C10)



European Patent
Office

Application Number

EP 02 25 5229

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1, 2, 24-40 (in part) 3-4 (in full)



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 02 25 5229

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Invention 1: 1, 2, 24-40 (in part) 3-4 (in full)

Invention 1 relates to: i) the use of an isolated gene sequence encoding a kinase according to Table I, or derivative thereof such as recombinant vector, host cells or non-human animal comprising said isolated gene sequence, or isolated polypeptide encoded by, or comprising an isolated polypeptide encoded by said isolated gene sequence or isolated antibody directed against the above cited polypeptides, in the screening of compounds for the treatment of pain, or for the diagnosis of pain; ii) a non-human animal having introduced in its genome, said isolated gene sequence; iii) kits comprising either the expression product of said isolated gene sequence and its substrate, ligand or affinity peptide; iv) a compound that modulates the action of the expression product of said selected gene sequence; v) a pharmaceutical composition comprising said compound; vi) the use of said compound for the treatment or the diagnosis of pain; and vii) a method of treatment of pain which comprises administering to a patient an effective amount of said compound.

Invention 2: 1, 2, 24-40 (in part) 5-6 (in full)

Invention 2 is equivalent to invention 1 for an isolated gene sequence encoding an expression product or a fragment thereof of a receptor according to Table II.

Invention 3: 1, 2, 24-40 (in part) 7-8 (in full)

Invention 3 is equivalent to invention 1 for an isolated gene sequence encoding a transporter according to Table III.

Invention 4: 1, 2, 24-40 (in part) 9-10 (in full)

Invention 4 is equivalent to invention 1 for an isolated gene sequence encoding a G-protein coupled receptor protein according to Table IV.

Invention 5: 1, 2, 24-40 (in part) 11-12 (in full)

Invention 5 is equivalent to invention 1 for an isolated gene sequence encoding a DNA-binding protein according to Table V.

Invention 6: 1, 2, 24-40 (in part) 13-14 (in full)



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 02 25 5229

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Invention 6 is equivalent to invention 1 for an isolated gene sequence encoding a ligase according to rows 1-7 of Table VI.

Invention 7: 1, 2, 24-40 (in part) 15-16 (in full)

Invention 7 is equivalent to invention 1 for an isolated gene sequence encoding a lyase according to row 8 of Table VI.

Invention 8: 1, 2, 24-40 (in part) 17-18 (in full)

Invention 8 is equivalent to invention 1 for an isolated gene sequence encoding an oxido-reductase according to rows 9-16 of Table VI.

Invention 9: 1, 2, 24-40 (in part) 19-20 (in full)

Invention 9 is equivalent to invention 1 for an isolated gene sequence encoding a transferase according to rows 17-18 of Table VI.

Invention 10: 1, 2, 24-40 (in part) 21-22 (in full)

Invention 10 is equivalent to invention 1 for an isolated gene sequence encoding a hydrolase according to rows 19-21 and 54 of Table VI.

Invention 11: 1, 2, 23-40 (in part)

Invention 11 is equivalent to invention 1 for an isolated gene sequence encoding a protein according to 23rd row of Table VI.

Inventions 12-41: 1, 2, 23-40 (in part)

Inventions 12-41 are equivalent to invention 1 for an isolated gene sequences encoding a protein according to the 24th-53rd rows of Table VI respectively.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 02 25 5229

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-12-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0063427	A	26-10-2000	AU 3984700 A	02-11-2000
			AU 4137600 A	02-11-2000
			CA 2365707 A1	26-10-2000
			CA 2369478 A1	26-10-2000
			EP 1171628 A2	16-01-2002
			EP 1175506 A2	30-01-2002
			GB 2351151 A ,B	20-12-2000
			GB 2349217 A ,B	25-10-2000
			GB 2359358 A ,B	22-08-2001
			GB 2359359 A ,B	22-08-2001
			GB 2359626 A ,B	29-08-2001
			GB 2359627 A ,B	29-08-2001
			GB 2359360 A ,B	22-08-2001
			GB 2359361 A ,B	22-08-2001
			HK 1029376 A1	07-09-2001
			HK 1030047 A1	02-11-2001
			HU 0201142 A2	28-08-2002
			WO 0063426 A2	26-10-2000
			WO 0063427 A2	26-10-2000
			JP 2002541859 T	10-12-2002
			JP 2002542466 T	10-12-2002
			PL 351432 A1	22-04-2003
			US 2003154501 A1	14-08-2003
			US 2003149995 A1	07-08-2003
			US 6540996 B1	01-04-2003

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82